<SEC-DOCUMENT>0001701541-22-000018.txt : 20220511
<SEC-HEADER>0001701541-22-000018.hdr.sgml : 20220511
<ACCEPTANCE-DATETIME>20220511161723
ACCESSION NUMBER:		0001701541-22-000018
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220511
DATE AS OF CHANGE:		20220511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Black Diamond Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001701541
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39200
		FILM NUMBER:		22913951

	BUSINESS ADDRESS:	
		STREET 1:		ONE MAIN STREET, 14TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-417-5868

	MAIL ADDRESS:	
		STREET 1:		ONE MAIN STREET, 14TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Aset Therapeutics, Inc.
		DATE OF NAME CHANGE:	20170321
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>bdtx-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:674e53d2-18f0-47df-b195-3621df688bf3,g:abed15df-df65-4b1b-8a1f-1c79fbf06613,d:9b58afd7c815450f9ef9acc3673fe027--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:bdtx="http://www.blackdiamondtherapeutics.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bdtx-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180L2ZyYWc6MGNkOTlhNjRlZWU2NDI5MTgzOWY1NDUzMWVhMjYxODUvdGFibGU6ZmZhZjQ3NWQ3NzlkNDA1ZmEzNmJmMzNiMDhhNzgwN2EvdGFibGVyYW5nZTpmZmFmNDc1ZDc3OWQ0MDVmYTM2YmYzM2IwOGE3ODA3YV8yLTEtMS0xLTE1NDY4_8476db90-5f90-4638-9c53-10863ce31522">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180L2ZyYWc6MGNkOTlhNjRlZWU2NDI5MTgzOWY1NDUzMWVhMjYxODUvdGFibGU6ZmZhZjQ3NWQ3NzlkNDA1ZmEzNmJmMzNiMDhhNzgwN2EvdGFibGVyYW5nZTpmZmFmNDc1ZDc3OWQ0MDVmYTM2YmYzM2IwOGE3ODA3YV8zLTEtMS0xLTE1NDY4_157228a1-d6c9-41d6-bf6a-6c08fd8723a4">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180L2ZyYWc6MGNkOTlhNjRlZWU2NDI5MTgzOWY1NDUzMWVhMjYxODUvdGFibGU6ZmZhZjQ3NWQ3NzlkNDA1ZmEzNmJmMzNiMDhhNzgwN2EvdGFibGVyYW5nZTpmZmFmNDc1ZDc3OWQ0MDVmYTM2YmYzM2IwOGE3ODA3YV80LTEtMS0xLTE1NDY4_baf795ae-d18b-4957-83c3-6805f7dc1d84">2022</ix:nonNumeric><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180L2ZyYWc6MGNkOTlhNjRlZWU2NDI5MTgzOWY1NDUzMWVhMjYxODUvdGFibGU6ZmZhZjQ3NWQ3NzlkNDA1ZmEzNmJmMzNiMDhhNzgwN2EvdGFibGVyYW5nZTpmZmFmNDc1ZDc3OWQ0MDVmYTM2YmYzM2IwOGE3ODA3YV81LTEtMS0xLTE1NDY4_72e1512a-216f-424c-8058-b7d007a42398">0001701541</ix:nonNumeric><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180L2ZyYWc6MGNkOTlhNjRlZWU2NDI5MTgzOWY1NDUzMWVhMjYxODUvdGFibGU6ZmZhZjQ3NWQ3NzlkNDA1ZmEzNmJmMzNiMDhhNzgwN2EvdGFibGVyYW5nZTpmZmFmNDc1ZDc3OWQ0MDVmYTM2YmYzM2IwOGE3ODA3YV82LTEtMS0xLTE1NDY4_1c26091b-30a1-4de6-b0fc-cc837d12b144">12-31</ix:nonNumeric><ix:nonNumeric contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfNS0wLTEtMS0xNTQ2OA_c195240d-53ce-44bf-b8a4-8e123e896ff6">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfNS0wLTEtMS0xNTQ2OA_fcf82e1a-149c-4590-8cc4-cc8f47ea4618">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i698d38b82399483e9b66aecdbb49ea01_I20200731" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfNTgy_c161a703-7086-4d07-92a4-b87f9bfb15b3">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="i2fb5e46658e2428a9f4d40e61ba2085a_I20190228" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfMTM1MQ_fb0605bf-86e1-4515-94ea-01a6d35b03a5">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i54692e00a6974fcd89b396554614c7ad_I20201231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfMTc1MA_0ef0df9a-0a44-47d0-a64e-d0e4a8dda2cf">P5Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bdtx-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f9b46b909e84ad2acd8f6c5f14d4eee_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:FormerAddressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f21bf96360a419d92cafe6f85c6447b_I20220502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f7c42ccd5d04f12b8291c60dcbafea1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c8a085e141b45ee84f490448563d1f1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9079e499652941b491fb8e9ed7ce1958_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12c39deff1194b6c92a7c1abee14df8a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0888b6dac5434cacbd33596c1adace82_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibffb8b6ab6ec42548e3a66555c649c15_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida279286734543b991ef4eed0ef6046e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c596ceb5049485884e7b2a68aa5916c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a11083af40b47cfa476274d297e6503_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaede1a9af65846df94f23afe6ee659b3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24cb741f3e52499f82800136848ddbcf_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67ed168c54f645c2b002a94645f0df0a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaf43c36cb8d458fa8fcfb47211264db_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6d7e79d27124e3bb23e6b0101055ce0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3c688356e134568b5de6825391deaf1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fdd5c7e07db40b08c5a1dcde0c1ffd2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ca47029fd60490abe151e708b67878e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i691561fefea149049b9e700257b2dd11_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i534d154d73254bb5a34550cf1b283ddb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc707991eeb0410f91d59567f375b8b4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib55e7da72d944e7b8a9e91f5cb12ecdf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcc979a9141648ffb26ccb55a5e51ebc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddf6f9051d0a4be3a16017e93ce7ab16_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1326edc9009d45a49158855eb54f6574_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19221d9ccdb34fd994d9ee776e4585b5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id201833d4a114834a06d053bfa018915_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i377d263c6d38493ca25e90aa73fd3701_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdtx:OpenMarketSaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7586d8f4b304a96a89edaf4e92faa9f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i962aa1bfb86e483894de2bb2442985bc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d10b8beeaca440785de2cdb3d8eaf14_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42a51dbd5f584d6aa6a0cb3330f1fe5c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icadf51cb52294253943e014823f06afb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62ae75982324469693df81b6e1fc8c23_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i460915c867d24b099b0bf69feb2da59a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc6ba9d6b5064ee7aec84d28bbd1751d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34580173a0a9454eb268a5b3ec8b34eb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64edc7a1a2174b968d823d315842481f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i900b221b23fd4104a7f93150e16b1981_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ba3f44f3b104a51b92654a9c905ece2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83fb07b4cc0046609fb9c5c6324001ef_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cde33f4aa9549d797693a4f207e3ba3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cb17e460b95429b88a840c5224dd92a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29ce9fe315284e5abf314fcd5ed28b78_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fa4d5d4ec21402bb7f85adb8fb71d6a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0e121bb40fd49258c14401a29e70859_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie054d218517947ee8d0e864d31140ce8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76fdf0838e4546cd851611fb3634158c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62c67ae3c8ed44d39ed202dc3a02814d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6469b9255c64b428aceb5e576c835e6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21a15014f6814669b4a982787c14c8ed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6ef99d5dd434984929935c0f6dd1e3e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6472a833e63467aa7a16b853fed7648_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i421912da66f44fe09b19b8944d07a70d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bf4c7e984404a6f86e23661b62cf071_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd344bc37522487781fced407afc94fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c3b0ba2c8154adaaceee5c961ea1e9e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e34a2b0b44e4081b6b378a6828ca51b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15df054aa48340d4a776ceb4901608d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68881d5b14084f3c8c973338e687dea2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i131b634efed14bc78fcdf71e68e8a71e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d2f217ac6a64e4788118680cfa194b3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21ff474829e8485d8a14024ec03a39f1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4941a960ea32475eb80b88d7de07c5ba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib85e10885b3a4e9b8fb2f090569d6271_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8310139017c4117a15d446bef048a12_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd98783dea56424ba1c71b4e834b425a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c17159b04ab4338b714552e7330de6e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib197786787854aa08e044a89989c79be_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i592581da0c5c4d148c499857a0970854_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia34f847e770542fbb1c0526bcd0521db_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cf6dcdd2d6846acbcfd0f4697fbbd29_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c3fc5df5cff491cb5578febfa6291bf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icee8d91286f54b40b3f46d39ea9f5b62_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a5f439d7d2246559ccab58abf38d308_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b03f59264e74ddaa03048707c7f0deb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fa0e12ae93a4ef0b5f7c326a00d7970_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae9953ec0cd04a469a57c8508f2c84ef_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i601e1559c5444c6aadd65a73f7aba8dd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5aee93ec0e6140c1967b90030b644693_I20200114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i121d14ec620443948bfb2446cf6369a8_D20220101-20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c5c649da96f4bf6a852cad3b98671b5_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73e473532efc4938a233763c7ef748f4_I20200114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib84b1455b06c44f2b4f0df628ece6347_D20220101-20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ced07d6335641afa9f14288d1f7a2e1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e9380f128ab4b63b1d6e7a850a44abd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia65875741ae542c78ed7dd0c432423a4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id260c31e9c0140f3a78bffba8953b169_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f5c3ddf78054fd0ba9932327695ba3c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdtx:OtherAwardTypeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibde6c6664ee5474ea71ce7b63f837206_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdtx:OtherAwardTypeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83ac7265af3c4a80b9a2081786c15aec_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife37765db49e41bf81afa44e8728613a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab8781eeec934caf84183887064bbbca_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdd9e72b3a7b4336a10b4ac7dea8e88c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7445afb88fcd42778b16246f068e465b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id953a840a46b432da2c79d8a575bc2a7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3281f5219574c05b5edcdfcb8708b8f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0604fd99be6c400cb46383e020232cc3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfb5ec15550c48b5ba40e04db8d95d68_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9607feb9fa2e47abb53ba9ad7befeaf9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bed481b20eb42c4b7b7f8e7b60c3743_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdtx:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3cbdfd3eaf5479f8e2be722e19d3d35_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdtx:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96258d5fc0c3444cbbfc78ce061c9bef_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f60a8da3d204a1d84243bb405682e2e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9100305f99b146729261bbdc162cb093_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe1143b3d4d645b7b96eb90d189b5d47_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff2984996ead4b0a9658704d11ad854b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41ea06ffd4224202a713d2f339bde058_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dcd8e4f8ad5440c98fd9db5a027ce37_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a5f037265fe4d04a7f18d30566bb541_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b57788e875c480ba8c662e821360cb1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icda07b5a5283444f941929ded278868b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11c8ad192542472fae54a22841a0002f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="contract"><xbrli:measure>bdtx:contract</xbrli:measure></xbrli:unit><xbrli:context id="i698d38b82399483e9b66aecdbb49ea01_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">bdtx:OperatingLeasePrincipalOfficeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i2fb5e46658e2428a9f4d40e61ba2085a_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">bdtx:OperatingLeasePrincipalOfficeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1bcd124beab438caab6f8c9006bed30_D20210615-20210615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-15</xbrli:startDate><xbrli:endDate>2021-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54692e00a6974fcd89b396554614c7ad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">bdtx:OperatingLeaseOfficeAndLaboratorySpaceNYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i9b58afd7c815450f9ef9acc3673fe027_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">___________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGV4dHJlZ2lvbjoyMzhjZThkNzE5NTg0ZTY2YWE4ZmMwNjBmNTFmMDFiOF8xMjY_d4c99af4-a693-41af-bf8e-b2e466c273dd">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">___________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6ZTIxNmM3YjEyOGJhNGQxM2JlMjRmZjRjODQ5ZmU5NTEvdGFibGVyYW5nZTplMjE2YzdiMTI4YmE0ZDEzYmUyNGZmNGM4NDlmZTk1MV8wLTAtMS0xLTE1NDY4_f748eacd-eebc-4c7a-8e3c-c7d6719f0ee9">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">FOR THE QUARTERLY PERIOD ENDED <ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGV4dHJlZ2lvbjoyMzhjZThkNzE5NTg0ZTY2YWE4ZmMwNjBmNTFmMDFiOF8yMDU_b29fc52c-8d0e-4623-bb34-747d26124597">March&#160;31, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6MmQ5OWY2YTNmNmJmNGE0M2I1ZjZkNWIzYjkyYTk4NjMvdGFibGVyYW5nZToyZDk5ZjZhM2Y2YmY0YTQzYjVmNmQ1YjNiOTJhOTg2M18wLTAtMS0xLTE1NDY4_5a712f15-687e-48bf-ac3e-5ff2d14a845b">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FOR THE TRANSITION PERIOD FROM _ TO _</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COMMISSION FILE NUMBER <ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGV4dHJlZ2lvbjoyMzhjZThkNzE5NTg0ZTY2YWE4ZmMwNjBmNTFmMDFiOF8yNzM_9262d1a0-0729-45ee-95c7-e5d4d85cfe16">001-38501</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">___________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGV4dHJlZ2lvbjoyMzhjZThkNzE5NTg0ZTY2YWE4ZmMwNjBmNTFmMDFiOF8zMjA_24911250-648d-4080-9a7f-72fa0ebef7a8">BLACK DIAMOND THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"> ________________________________________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6YjRjNGFjM2IxZGUyNDc0NTkyYjBiM2E3OWM5YTY2ODgvdGFibGVyYW5nZTpiNGM0YWMzYjFkZTI0NzQ1OTJiMGIzYTc5YzlhNjY4OF8wLTAtMS0xLTE1NDY4_50414233-60ed-4a40-b8bc-dd9aa6df0f4a">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6YjRjNGFjM2IxZGUyNDc0NTkyYjBiM2E3OWM5YTY2ODgvdGFibGVyYW5nZTpiNGM0YWMzYjFkZTI0NzQ1OTJiMGIzYTc5YzlhNjY4OF8wLTEtMS0xLTE1NDY4_d7ff35fb-bd70-4189-babc-44754eafaaf2">81-4254660</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:139%">(State or other jurisdiction</span></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:139%">of incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:139%">(I.R.S. Employer</span></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:139%">Identification No.)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%"><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6YjRjNGFjM2IxZGUyNDc0NTkyYjBiM2E3OWM5YTY2ODgvdGFibGVyYW5nZTpiNGM0YWMzYjFkZTI0NzQ1OTJiMGIzYTc5YzlhNjY4OF8yLTAtMS0xLTE1NDY4L3RleHRyZWdpb246MjkxNDJiMDAyZjA3NDAwM2E2ZTJiNmY1YjIxNzk3MjJfNQ_54048cad-940a-4cc1-9858-3786399277a7">One Main Street, 14th Floor</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%"><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6YjRjNGFjM2IxZGUyNDc0NTkyYjBiM2E3OWM5YTY2ODgvdGFibGVyYW5nZTpiNGM0YWMzYjFkZTI0NzQ1OTJiMGIzYTc5YzlhNjY4OF8yLTAtMS0xLTE1NDY4L3RleHRyZWdpb246MjkxNDJiMDAyZjA3NDAwM2E2ZTJiNmY1YjIxNzk3MjJfOQ_57c7b87d-ee2b-4769-ae7a-56f99994cc6e">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6YjRjNGFjM2IxZGUyNDc0NTkyYjBiM2E3OWM5YTY2ODgvdGFibGVyYW5nZTpiNGM0YWMzYjFkZTI0NzQ1OTJiMGIzYTc5YzlhNjY4OF8yLTAtMS0xLTE1NDY4L3RleHRyZWdpb246MjkxNDJiMDAyZjA3NDAwM2E2ZTJiNmY1YjIxNzk3MjJfMTM_f7d85824-3b02-4ccb-8338-c6d3f5559a3e">Massachusetts</ix:nonNumeric></span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:139%">(Address of principal executive offices)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%"><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6YjRjNGFjM2IxZGUyNDc0NTkyYjBiM2E3OWM5YTY2ODgvdGFibGVyYW5nZTpiNGM0YWMzYjFkZTI0NzQ1OTJiMGIzYTc5YzlhNjY4OF8yLTEtMS0xLTE1NDY4L3RleHRyZWdpb246NzYwOGVjMDMwYWUyNGE3OTg5YmIyOGIyMmNhZTE5MjVfNQ_386fde0d-955c-4475-add5-b952c374dbda">02142</ix:nonNumeric></span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:139%">(Zip Code)</span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%"><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6YjRjNGFjM2IxZGUyNDc0NTkyYjBiM2E3OWM5YTY2ODgvdGFibGVyYW5nZTpiNGM0YWMzYjFkZTI0NzQ1OTJiMGIzYTc5YzlhNjY4OF8zLTAtMS0xLTE1NDY4L3RleHRyZWdpb246Y2Y0NGIwYzk1OGE1NDM4NTk0YTMyNjkwMzc3NTM3MGFfNQ_642c91a9-bb81-4e70-a179-6124d0e4c07b">(617)</ix:nonNumeric> <ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6YjRjNGFjM2IxZGUyNDc0NTkyYjBiM2E3OWM5YTY2ODgvdGFibGVyYW5nZTpiNGM0YWMzYjFkZTI0NzQ1OTJiMGIzYTc5YzlhNjY4OF8zLTAtMS0xLTE1NDY4L3RleHRyZWdpb246Y2Y0NGIwYzk1OGE1NDM4NTk0YTMyNjkwMzc3NTM3MGFfOA_35375a0f-6343-4491-b56e-647708c48c7a">252-0848</ix:nonNumeric></span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:139%">(Registrant&#8217;s telephone number, including area code)</span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i3f9b46b909e84ad2acd8f6c5f14d4eee_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6YjRjNGFjM2IxZGUyNDc0NTkyYjBiM2E3OWM5YTY2ODgvdGFibGVyYW5nZTpiNGM0YWMzYjFkZTI0NzQ1OTJiMGIzYTc5YzlhNjY4OF80LTAtMS0xLTE4MzUzL3RleHRyZWdpb246NmM5YzIyMDQ2OTI1NDM5ZGFhNjQzOTQ1MmNjMWQ1YmVfMTA5OTUxMTYyODkxNw_a14cb85b-3235-446f-b302-683b0012f46f">One Main Street, 10th Floor</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i3f9b46b909e84ad2acd8f6c5f14d4eee_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6YjRjNGFjM2IxZGUyNDc0NTkyYjBiM2E3OWM5YTY2ODgvdGFibGVyYW5nZTpiNGM0YWMzYjFkZTI0NzQ1OTJiMGIzYTc5YzlhNjY4OF80LTAtMS0xLTE4MzUzL3RleHRyZWdpb246NmM5YzIyMDQ2OTI1NDM5ZGFhNjQzOTQ1MmNjMWQ1YmVfMTA5OTUxMTYyODkyNA_babc4996-5599-4bce-9e21-e4a71f291182">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="i3f9b46b909e84ad2acd8f6c5f14d4eee_D20220101-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6YjRjNGFjM2IxZGUyNDc0NTkyYjBiM2E3OWM5YTY2ODgvdGFibGVyYW5nZTpiNGM0YWMzYjFkZTI0NzQ1OTJiMGIzYTc5YzlhNjY4OF80LTAtMS0xLTE4MzUzL3RleHRyZWdpb246NmM5YzIyMDQ2OTI1NDM5ZGFhNjQzOTQ1MmNjMWQ1YmVfMTA5OTUxMTYyODkyOQ_b3efb528-478d-4697-86f3-4d85a9485286">Massachusetts</ix:nonNumeric> <ix:nonNumeric contextRef="i3f9b46b909e84ad2acd8f6c5f14d4eee_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6YjRjNGFjM2IxZGUyNDc0NTkyYjBiM2E3OWM5YTY2ODgvdGFibGVyYW5nZTpiNGM0YWMzYjFkZTI0NzQ1OTJiMGIzYTc5YzlhNjY4OF80LTAtMS0xLTE4MzUzL3RleHRyZWdpb246NmM5YzIyMDQ2OTI1NDM5ZGFhNjQzOTQ1MmNjMWQ1YmVfMTA5OTUxMTYyODkzMw_89b9a44f-0fc3-4ec2-a0d1-8c7d62cfaebb">02142</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(Former name, former address and former fiscal year, if changed since last report)</span></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.871%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6NzJjYThkNTU4ZWI4NGEyMGJjMzY4ZTVjZTU5MGNmMDUvdGFibGVyYW5nZTo3MmNhOGQ1NThlYjg0YTIwYmMzNjhlNWNlNTkwY2YwNV8xLTAtMS0xLTE1NDY4_23a9d3c1-54e3-471f-943f-266b5c5ce479">Common stock, par value $0.0001</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6NzJjYThkNTU4ZWI4NGEyMGJjMzY4ZTVjZTU5MGNmMDUvdGFibGVyYW5nZTo3MmNhOGQ1NThlYjg0YTIwYmMzNjhlNWNlNTkwY2YwNV8xLTEtMS0xLTE1NDY4_a8e485f4-d120-49f2-92be-1872d8260122">BDTX</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6NzJjYThkNTU4ZWI4NGEyMGJjMzY4ZTVjZTU5MGNmMDUvdGFibGVyYW5nZTo3MmNhOGQ1NThlYjg0YTIwYmMzNjhlNWNlNTkwY2YwNV8xLTItMS0xLTE1NDY4_7eef223c-db03-493e-ad1c-fcb5d2bfb190">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr><tr style="height:9pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGV4dHJlZ2lvbjoyMzhjZThkNzE5NTg0ZTY2YWE4ZmMwNjBmNTFmMDFiOF84NzE_e16fe7cb-fd29-42a1-8c32-bd9b1623c2f8">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGV4dHJlZ2lvbjoyMzhjZThkNzE5NTg0ZTY2YWE4ZmMwNjBmNTFmMDFiOF8xMTk4_fd4e8f14-d706-4130-99e6-9eafe94c89f6">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.675%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">Large&#160;accelerated&#160;filer</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6ODRlZjczNGU5ODE0NDBmOGIwZjM3ZmUzNjU5YzIxOTkvdGFibGVyYW5nZTo4NGVmNzM0ZTk4MTQ0MGY4YjBmMzdmZTM2NTljMjE5OV8yLTAtMS0xLTE1NDY4_ea8761d6-32e1-4e59-91af-41d8999e067c">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6ODRlZjczNGU5ODE0NDBmOGIwZjM3ZmUzNjU5YzIxOTkvdGFibGVyYW5nZTo4NGVmNzM0ZTk4MTQ0MGY4YjBmMzdmZTM2NTljMjE5OV8yLTMtMS0xLTE1NDY4_4ac1e271-4d43-4507-b77c-9e823dec6726">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6ODRlZjczNGU5ODE0NDBmOGIwZjM3ZmUzNjU5YzIxOTkvdGFibGVyYW5nZTo4NGVmNzM0ZTk4MTQ0MGY4YjBmMzdmZTM2NTljMjE5OV80LTMtMS0xLTE1NDY4_070ae3b1-fba6-4283-a29f-f6fe886e8234">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGV4dHJlZ2lvbjoyMzhjZThkNzE5NTg0ZTY2YWE4ZmMwNjBmNTFmMDFiOF8xODEz_37e36721-7ade-42b4-9db3-d9676be0fe19">&#9744;</ix:nonNumeric></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGV4dHJlZ2lvbjoyMzhjZThkNzE5NTg0ZTY2YWE4ZmMwNjBmNTFmMDFiOF8xOTM3_cdd2efd4-371f-4d9d-b3b3-daee643d7385">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May&#160;2, 2022, the registrant had <ix:nonFraction unitRef="shares" contextRef="i8f21bf96360a419d92cafe6f85c6447b_I20220502" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGV4dHJlZ2lvbjoyMzhjZThkNzE5NTg0ZTY2YWE4ZmMwNjBmNTFmMDFiOF8xOTc4_9ae60953-c10b-4fae-a3cd-07d06b11f172">36,290,901</ix:nonFraction> shares of common stock, $0.0001 par value per share, outstanding. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div></div></div><div id="i9b58afd7c815450f9ef9acc3673fe027_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q (this &#8220;Quarterly Report&#8221;), contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;may&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;expects&#8221;, &#8220;intends&#8221;, &#8220;plans&#8221;, &#8220;anticipates&#8221;, &#8220;believes&#8221;, &#8220;estimates&#8221;, &#8220;predicts&#8221;, &#8220;potential&#8221;, &#8220;continue&#8221; or the negative of these terms or other comparable terminology. These statements are not guarantees of future results or performance and involve substantial risks and uncertainties. Forward-looking statements in this Quarterly Report include, but are not limited to, statements about:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the progress, timing and success of preclinical studies and our clinical trials of BDTX-1535, BDTX-4933 and any other product candidates, including the availability, timing and announcement of data and results of such studies and trials; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical trials and Investigational New Drug, or IND, applications and other regulatory submissions; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the continued development and advancement of our FGFR program and the timing for nominating a development candidate; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to obtain and maintain regulatory approval for BDTX-1535 and BDTX-4933 or any of our other current or future product candidates that we may identify or develop; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">our need to raise additional funding before we can expect to generate any revenues from product sales; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to identify future product candidates for treatment of additional disease indications; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to develop our current product candidates for the treatment of various cancers; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the rate and degree of market acceptance and clinical utility for any current or future product candidates we may develop; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the effects of competition with respect to BDTX-1535, BDTX-4933 or any of our other current or future product candidates, as well as innovations by current and future competitors in our industry; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the implementation of our strategic plans for our business, any product candidates we may develop and our MAP drug discovery engine; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to successfully develop companion diagnostics for use with our current or future product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">our intellectual property position, including the scope of protection we are able to establish, maintain and enforce for intellectual property rights covering our product candidates and MAP drug discovery engine; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to obtain additional funding for our operations, when needed, including funding necessary to complete further development and commercialization of our product candidates, if approved, and to further expand our MAP drug discovery engine;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">our financial performance and our ability to effectively manage our anticipated growth; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">our estimates regarding the market opportunities for our product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">our expectations regarding the period during which we will remain an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;); </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to maintain an effective system of internal controls; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the ultimate impact of the ongoing coronavirus, or COVID-19 pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events and with respect to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those described under Part I, Item 1A, &#8220;Risk Factors&#8221; and elsewhere in our most recent Annual Report on Form 10-K for the year ended December 31, 2021 (the &#8220;Annual Report&#8221;) and in other SEC filings. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All of our forward-looking statements are as of the date of this Quarterly Report only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of or any material adverse change in one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the Securities and Exchange Commission, (the &#8220;SEC&#8221;), could materially and adversely affect our business, prospects, financial condition and results of operations. Some of these risks and uncertainties may in the future be amplified by the ongoing COVID-19 pandemic, including as a result of the emergence of new variants, and there may be additional risks that we consider immaterial or which are unknown. It is not possible to predict or identify all such risks. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Quarterly Report, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Quarterly Report that modify or impact any of the forward-looking statements contained in this Quarterly Report will be deemed to modify or supersede such statements in this Quarterly Report. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Quarterly Report contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed as exhibits to this Quarterly Report. In this Quarterly Report, the terms &#8220;Black Diamond Therapeutics,&#8221; &#8220;Black Diamond,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar designations refer to Black Diamond Therapeutics, Inc. and, where appropriate, our subsidiaries. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We may from time to time provide estimates, projections and other information concerning our industry, the general business environment, and the markets for certain diseases, including estimates regarding the potential size of those markets and the estimated incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events, circumstances or numbers, including actual disease prevalence rates and market size, may differ materially from the information reflected in this Quarterly Report. Unless otherwise expressly stated, we obtained this industry, business information, market data, prevalence information and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources, in some cases applying our own assumptions and analysis that may, in the future, prove not to have been accurate.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">4</span></div></div></div><div id="i9b58afd7c815450f9ef9acc3673fe027_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.147%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.653%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_13">PART I</a> - FINANCIAL INFORMATION</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_13">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_13">Item 1. Condensed Consolidated Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_13">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:60pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_16">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:60pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_19">Condensed Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_19">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:60pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_22">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_22">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:60pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_25">Condensed Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_25">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:60pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_28">Notes to Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_28">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_70">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_70">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_100">Item 3. Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_100">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_103">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_103">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_106">PART II</a> - OTHER INFORMATION</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_106">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_109">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_109">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_112">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_112">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_115">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_115">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_118">Item 3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_118">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_121">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_121">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_124">Item 5. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_124">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_127">Item 6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_127">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:66pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_130">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9b58afd7c815450f9ef9acc3673fe027_130">35</a></span></div></td></tr></table></div><div style="margin-top:21pt"><span><br/></span></div><div style="margin-top:21pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We have applied for various trademarks that we use in connection with the operation of our business. This Quarterly Report may also contain trademarks, service marks and trade names of third parties, which are the property of their respective owners. Our use or display of third parties&#8217; trademarks, service marks, trade names or products in this Quarterly Report is not intended to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks, service marks and trade names referred to in this Quarterly Report may appear without the &#174;, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> symbols, but the omission of such references is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner of these trademarks, service marks and trade names will not assert, to the fullest extent under applicable law, its rights.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">From time to time, we may use our website or our LinkedIn profile at www.linkedin.com/company/black-diamond-therapeutics to distribute material information. Our financial and other material information is routinely posted to and accessible on the Investors section of our website, available at www.blackdiamondtherapeutics.com. Investors are encouraged to review the Investors section of our website because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through our website or our LinkedIn page is not incorporated into, and does not form a part of, this Quarterly Report.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div></div><div id="i9b58afd7c815450f9ef9acc3673fe027_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Part I - FINANCIAL INFORMATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item I. Condensed Consolidated Financial Statements (Unaudited)</span></div><div id="i9b58afd7c815450f9ef9acc3673fe027_16"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Black Diamond Therapeutics, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfNC0xLTEtMS0xNTQ2OA_3be49587-ebc2-486e-bfeb-fbb15efa6f1b">54,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfNC0zLTEtMS0xNTQ2OA_b526dc33-be1d-486e-82bf-446f4366b04e">65,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfNS0xLTEtMS0xNTQ2OA_b444b08a-bc52-4bf7-b022-5b01cd990a5f">125,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfNS0zLTEtMS0xNTQ2OA_d1695ad7-f54c-44aa-ba06-a5965a98bf02">143,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfNi0xLTEtMS0xNTQ2OA_bbccbc55-6f3a-44a2-ab3a-7964f649d488">8,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfNi0zLTEtMS0xNTQ2OA_f4531ccb-efa9-43f2-9acf-4e3104be8a24">5,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfNy0xLTEtMS0xNTQ2OA_11269885-a7b3-4ab3-81ec-721200a19e2c">188,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfNy0zLTEtMS0xNTQ2OA_8a98641b-17e7-4128-82ea-17c00c5e4ef8">215,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfOC0xLTEtMS0xNTQ2OA_3839aa0f-1b2f-4d34-906a-6e68ce152dd4">2,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfOC0zLTEtMS0xNTQ2OA_389d4083-d989-4ac7-90de-66e8836da08f">3,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfOS0xLTEtMS0xNTQ2OA_8ae732fd-075f-4a02-ac7d-f001eb3de680">1,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfOS0zLTEtMS0xNTQ2OA_08527ad1-f824-42ee-a8f7-9281cfb74533">1,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMTAtMS0xLTEtMTU0Njg_83f306ad-650e-4b60-afe2-68df32000c94">27,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMTAtMy0xLTEtMTU0Njg_f4b50986-5395-47e7-92ca-aeab9527ed5c">27,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMTEtMS0xLTEtMTU0Njg_301a9b23-facb-4271-bf99-6d8c28f1a010">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMTEtMy0xLTEtMTU0Njg_ff0152e2-6d98-43d3-8c84-bd167c5afc3c">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMTItMS0xLTEtMTU0Njg_09bc6d8e-a901-49cc-a5bb-cda30771e5b2">219,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMTItMy0xLTEtMTU0Njg_68a1cea1-b142-491d-bf85-923ba321eed7">247,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMTUtMS0xLTEtMTU0Njg_ef86b178-a2e5-4296-a97c-89abeb079571">1,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMTUtMy0xLTEtMTU0Njg_c3a3eebe-3bf3-4d52-9db2-1605d2c2c746">4,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMTctMS0xLTEtMTU0Njg_af20ce20-cd8a-4f15-818c-be8ae291dd88">17,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMTctMy0xLTEtMTU0Njg_67b481b6-d885-498a-9fe5-4012519ac7f5">19,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMTgtMS0xLTEtMTU0Njg_71e0f653-df90-49ae-929c-53e42c75c176">19,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMTgtMy0xLTEtMTU0Njg_432f68ef-b7fb-4e8a-80c1-9ec6ce8b8d39">23,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Non-current operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMTktMS0xLTEtMTU0Njg_e37c4459-cffd-4fa2-8ff7-88a8809d7a6f">27,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMTktMy0xLTEtMTU0Njg_f1ef2400-326a-46d3-ac7d-744505aa4683">28,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjAtMS0xLTEtMTU0Njg_a24f3512-c36a-4bd0-8996-bdd0676b6753">46,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjAtMy0xLTEtMTU0Njg_3dc3f270-16bb-4f95-b2b6-22b7abda0866">51,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commitments and contingencies (Note&#160;10)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:CommitmentsAndContingencies" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjEtMS0xLTEtMTU0Njg_585c151c-ba23-4d3b-9743-cd8105a968c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:CommitmentsAndContingencies" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjEtMy0xLTEtMTU0Njg_18db38e1-7c46-46cc-857b-ef814e6afded">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="4" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjQtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjpjNjg0ZmQyZDNmYjQ0NzVjOWZkNzMyZGRlOTk0Zjc5YV8yMQ_442287c1-4448-4042-9acf-2ad84b719dd2"><ix:nonFraction unitRef="usdPerShare" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="4" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjQtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjpjNjg0ZmQyZDNmYjQ0NzVjOWZkNzMyZGRlOTk0Zjc5YV8yMQ_83baa4f7-827e-4cd0-a64b-86a81ea9fb99">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="0" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjQtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjpjNjg0ZmQyZDNmYjQ0NzVjOWZkNzMyZGRlOTk0Zjc5YV8zNQ_25c22e2c-2420-46f1-a9d0-ff154d4c24b9">10,000,000</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="0" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjQtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjpjNjg0ZmQyZDNmYjQ0NzVjOWZkNzMyZGRlOTk0Zjc5YV80OQ_238bfc70-24e1-4580-a1ba-045566940e32">10,000,000</ix:nonFraction> shares authorized at March&#160;31, 2022 and December&#160;31, 2021, respectively; <ix:nonFraction unitRef="shares" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="0" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjQtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjpjNjg0ZmQyZDNmYjQ0NzVjOWZkNzMyZGRlOTk0Zjc5YV85OA_3e991182-1761-46bd-b651-81f034748360"><ix:nonFraction unitRef="shares" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="0" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjQtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjpjNjg0ZmQyZDNmYjQ0NzVjOWZkNzMyZGRlOTk0Zjc5YV85OA_6968b0d4-942b-4c23-b89b-529338ac4e82"><ix:nonFraction unitRef="shares" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="0" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjQtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjpjNjg0ZmQyZDNmYjQ0NzVjOWZkNzMyZGRlOTk0Zjc5YV85OA_d81b90ca-ebcb-45ad-b533-981a531748b2"><ix:nonFraction unitRef="shares" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="0" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjQtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjpjNjg0ZmQyZDNmYjQ0NzVjOWZkNzMyZGRlOTk0Zjc5YV85OA_ee5dcb40-f147-4f03-adfb-a7a75998e70d">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding at March&#160;31, 2022 and December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjQtMS0xLTEtMTU0Njg_e18b64eb-048a-46e3-a11c-16da2d5ea1a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjQtMy0xLTEtMTU0Njg_0bfd10ec-6205-4efb-8291-1b14164c2b7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Common stock; $<ix:nonFraction unitRef="usdPerShare" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjUtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjoxM2M1NWQyYTk1MmM0ZTYyYWE1YmVhMTRhODYwMDBjN18xOQ_5ce29aa3-0752-4a5c-88ce-4fad21518d0a"><ix:nonFraction unitRef="usdPerShare" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjUtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjoxM2M1NWQyYTk1MmM0ZTYyYWE1YmVhMTRhODYwMDBjN18xOQ_9d0953bf-b77c-4d5f-ab25-2f6db1eeb786">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjUtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjoxM2M1NWQyYTk1MmM0ZTYyYWE1YmVhMTRhODYwMDBjN18zMw_b2f9e1ea-417f-4e21-b155-620c3ad684a5">500,000,000</ix:nonFraction> shares authorized at March&#160;31, 2022 and <ix:nonFraction unitRef="shares" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjUtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjoxM2M1NWQyYTk1MmM0ZTYyYWE1YmVhMTRhODYwMDBjN182NA_696e1bca-4838-4b81-badf-cdc24e1621de">500,000,000</ix:nonFraction> shares authorized at December&#160;31, 2021; <ix:nonFraction unitRef="shares" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjUtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjoxM2M1NWQyYTk1MmM0ZTYyYWE1YmVhMTRhODYwMDBjN185Mg_353ab3ea-308b-4264-b7b2-84742e555e78"><ix:nonFraction unitRef="shares" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjUtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjoxM2M1NWQyYTk1MmM0ZTYyYWE1YmVhMTRhODYwMDBjN185Mg_8bb420e0-baa1-4b21-800d-451144485157">36,287,568</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2022 and <ix:nonFraction unitRef="shares" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjUtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjoxM2M1NWQyYTk1MmM0ZTYyYWE1YmVhMTRhODYwMDBjN18xMzU_64b67a46-e501-4cf6-809d-bf8a023e6a56"><ix:nonFraction unitRef="shares" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjUtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjoxM2M1NWQyYTk1MmM0ZTYyYWE1YmVhMTRhODYwMDBjN18xMzU_c976414f-3754-4433-9d00-365aa9e0f384">36,234,624</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjUtMS0xLTEtMTU0Njg_5834ca4f-3e17-44ae-94c8-0253ce4cdfb3">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjUtMy0xLTEtMTU0Njg_9c3c8048-6b41-4a66-831f-88fa6611b150">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjYtMS0xLTEtMTU0Njg_57de1235-8bee-4315-a62e-c8b204c9157f">443,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjYtMy0xLTEtMTU0Njg_f5008bed-88dc-4e09-94ef-320950b25c7c">440,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjctMS0xLTEtMTU0Njg_567dd7ca-d123-40fc-b581-a6d3a5813f6e">1,775</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjctMy0xLTEtMTU0Njg_28af77f2-cabb-45c3-b5ee-e2a17d53cd12">414</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjgtMS0xLTEtMTU0Njg_ba89f107-675a-4f64-a9a0-b98607009bab">269,327</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjgtMy0xLTEtMTU0Njg_fbe74ff3-3fee-4da6-a7af-47baaf2d8115">243,820</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjktMS0xLTEtMTU0Njg_35757498-4732-4ffe-8f59-5ba025b521b6">172,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjktMy0xLTEtMTU0Njg_7dbc694f-e0fa-44a1-996c-b04eb1af81f5">195,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total liabilities and stockholders' equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMzAtMS0xLTEtMTU0Njg_a82ce5eb-8f15-4a51-93ac-56e7a4383155">219,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMzAtMy0xLTEtMTU0Njg_9f6db4dc-c9a6-46d3-97fb-57fb259a411a">247,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">6</span></div></div></div><div id="i9b58afd7c815450f9ef9acc3673fe027_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Black Diamond Therapeutics, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.313%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.405%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.408%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMy01LTEtMS0xNTQ2OA_87a210dc-cf25-4721-88d6-25318895f8fb">17,786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMy03LTEtMS0xNTQ2OA_c3cc7a38-62a7-4518-b511-73d7e81f10f3">22,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfNC01LTEtMS0xNTQ2OA_151b41f9-7c06-4a7e-9bfa-eff1758aa33a">7,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfNC03LTEtMS0xNTQ2OA_2f5f79c3-38c1-4ba8-b3dd-183f9c3d545a">7,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfNS01LTEtMS0xNTQ2OA_5e8aab2c-a463-48ad-8f81-db257a8ee17b">25,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfNS03LTEtMS0xNTQ2OA_13a0ba46-8f41-481f-94c4-0a27d247bc3d">30,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfNi01LTEtMS0xNTQ2OA_620de64c-4525-4aad-bb48-2568995ce7a7">25,679</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfNi03LTEtMS0xNTQ2OA_fed8f9be-4342-4907-b3ae-05ea99e3b0b5">30,713</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other income (expense):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" name="us-gaap:InvestmentIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfOS01LTEtMS0xNTQ2OA_40859f53-9529-4d3d-840b-e6ce4d3adcd0">406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" name="us-gaap:InvestmentIncomeNonoperating" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfOS03LTEtMS0xNTQ2OA_22e08ded-b96c-46be-bebb-6fa421cd94ed">1,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other (expense) income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTEtNS0xLTEtMTU0Njg_64ba0c23-5e91-4f69-ba2c-7d1136e5d9d1">234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTEtNy0xLTEtMTU0Njg_213aaaf9-c89c-44ed-b526-eba66a67b89c">740</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total other income (expense), net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTItNS0xLTEtMTU0Njg_2c4e390d-e73f-4b4c-8a8f-5a976a240782">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTItNy0xLTEtMTU0Njg_adecc92b-adb8-400c-a21b-1f453926c82d">412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTMtNS0xLTEtMTU0Njg_35b81f3a-c78d-4dfb-80bb-3e319d83fd51">25,507</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTMtNy0xLTEtMTU0Njg_96d5c7b1-0a0d-47df-8572-723d2392430e">30,301</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTQtNS0xLTEtMTU0Njg_41a1cb10-27ea-48ae-b424-65ab7ab2637f"><ix:nonFraction unitRef="usdPerShare" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTQtNS0xLTEtMTU0Njg_8494290c-1bca-4650-baec-2d7bb1f50df7">0.70</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTQtNy0xLTEtMTU0Njg_ac42aac7-437e-4a85-8aad-f7e3e8eb57bd"><ix:nonFraction unitRef="usdPerShare" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTQtNy0xLTEtMTU0Njg_c74e8559-2670-4eae-a50a-1c496cd78f90">0.84</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTUtNS0xLTEtMTU0Njg_6436e7e3-8d8e-4273-bae4-5c8b1150ab11"><ix:nonFraction unitRef="shares" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTUtNS0xLTEtMTU0Njg_84d4b623-0ee0-40c0-84b5-2b7a9b16317a">36,271,291</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTUtNy0xLTEtMTU0Njg_42f90b35-0caa-4969-b8d5-4a99982d9b4b"><ix:nonFraction unitRef="shares" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTUtNy0xLTEtMTU0Njg_74068b27-7934-44fd-b073-c579b4156379">36,123,014</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Comprehensive loss:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTgtNS0xLTEtMTU0Njg_3e8ea98c-a892-4cb0-bfa9-be79ed5e65c4">25,507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTgtNy0xLTEtMTU0Njg_d5e163f4-cb27-4f71-973d-eeb6a67aa6d0">30,301</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other comprehensive income:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Change in unrealized loss on investments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMjAtNS0xLTEtMTU0Njg_b217c118-b19c-47ec-8e16-86bbeb7119e0">1,361</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMjAtNy0xLTEtMTU0Njg_fdde9f6f-387a-40d9-ba32-08ce3163f084">279</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMjEtNS0xLTEtMTU0Njg_eb22104d-3f46-4ea9-8577-a02944ade041">26,868</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMjEtNy0xLTEtMTU0Njg_e7026c3a-7898-430b-b9e2-83b5539d634e">30,580</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">7</span></div></div></div><div id="i9b58afd7c815450f9ef9acc3673fe027_22"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Black Diamond Therapeutics, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(in thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:73.102%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.508%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.511%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMy0xLTEtMS0xNTQ2OA_c2563c73-177a-4b3b-8ef0-c0d6cc66e8ff">25,507</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMy0zLTEtMS0xNTQ2OA_1c7a8241-1230-44dd-96ba-95e66b668e99">30,301</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Adjustment to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfNS0xLTEtMS0xNTQ2OA_11a03bcc-c007-4a3a-8be0-338bcc1c2e25">3,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfNS0zLTEtMS0xNTQ2OA_af4eedf6-db4b-47e1-b1f8-0b0a92f70c62">3,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfNi0xLTEtMS0xNTQ2OA_e040cdbd-faba-447e-8cdd-57f0a43e890d">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfNi0zLTEtMS0xNTQ2OA_cf1d74fc-7f88-4ae3-bfd7-e92769966813">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Amortization of premium on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfOC0xLTEtMS0xNTQ2OA_fe0fd9fd-74e6-434b-84df-c9dc8ba42d54">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfOC0zLTEtMS0xNTQ2OA_8754726b-d692-4653-ab40-8ef5c05989f1">720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Noncash rent expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" name="bdtx:RentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfOS0xLTEtMS0xNTQ2OA_256c35c1-29a9-4ea0-9951-170e18a90d0d">686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" name="bdtx:RentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfOS0zLTEtMS0xNTQ2OA_8364c217-d607-4eac-b4f0-562352e6ff4c">321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other non-cash items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMTAtMS0xLTEtMTU0Njg_d6a59ef3-f142-47a8-9a23-434ca60fd22b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMTAtMy0xLTEtMTU0Njg_a1e579b0-c0ff-4d5d-851f-4030dc07d859">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Changes in current assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMTItMS0xLTEtMTU0Njg_01fe4408-4d8e-45e7-9929-c8acb970c037">2,648</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMTItMy0xLTEtMTU0Njg_d404cffb-d46a-4b18-86b2-637ff670bfcb">2,805</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMTMtMS0xLTEtMTU0Njg_05b96fe9-58e0-477b-97f8-519dfe162fa0">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMTMtMy0xLTEtMTU0Njg_d4bfc969-56a6-43f6-9e9f-b85b47913f66">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMTQtMS0xLTEtMTU0Njg_1b2e8be7-0ec9-46fa-ba78-a20ca6527e47">2,224</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMTQtMy0xLTEtMTU0Njg_9fb93ce4-f352-4994-adec-c92ba671c313">1,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMTYtMS0xLTEtMTU0Njg_33973fb6-dfed-4459-a6e2-6c669f9ff14f">1,958</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMTYtMy0xLTEtMTU0Njg_e67e4041-667a-44f2-bea3-94e63b064e7b">2,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Non-current operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" sign="-" name="bdtx:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMTctMS0xLTEtMTU0Njg_0e918450-04c6-4646-aced-3fc188dec1f9">687</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" sign="-" name="bdtx:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMTctMy0xLTEtMTU0Njg_64a1a759-c72c-4065-9425-a3dddc0c0833">335</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMTgtMS0xLTEtMTU0Njg_1fbb6ecd-0ea6-4d89-944c-0c418ed9252b">28,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMTgtMy0xLTEtMTU0Njg_544cea47-c521-44c3-b5a9-9329a8ff8c67">24,455</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Purchases of equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMjEtMS0xLTEtMTU0Njg_94c40f5f-f792-4c38-b1b5-533365a79fc7">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMjEtMy0xLTEtMTU0Njg_17b5ce72-3e6b-40ca-8995-93e9264e5381">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Proceeds from sales and maturities of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMjItMS0xLTEtMTU0Njg_8bd7d903-e5e2-4d38-a65c-010e0fdec318">37,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMjItMy0xLTEtMTU0Njg_b0e8b203-4bfb-4e3e-8689-6fc59c51e442">45,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMjMtMS0xLTEtMTU0Njg_24e29372-9cdb-4d5f-bf1a-549e452d6817">20,504</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMjMtMy0xLTEtMTU0Njg_2ac2d27a-9468-4c8d-9aef-c0ccb1a300bb">41,526</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMjQtMS0xLTEtMTU0Njg_24b6ee73-185e-49c5-bd06-74a552ffe600">16,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMjQtMy0xLTEtMTU0Njg_0e3e3e7f-6a97-43ad-b364-2b41d8736036">3,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Proceeds from exercise of common stock options and ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMjctMS0xLTEtMTU0Njg_15194a39-1f69-45b7-afd2-4194f3fdc0bf">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMjctMy0xLTEtMTU0Njg_5053af92-10be-424c-a610-6e70ff94d1c7">481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMzAtMS0xLTEtMTU0Njg_b1606443-d4cf-4e55-bde5-f47db40da08f">153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMzAtMy0xLTEtMTU0Njg_4e282c84-2393-4133-88ac-250a47df317b">481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net decrease in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMzEtMS0xLTEtMTU0Njg_3f255857-9c13-4a0f-89b7-3d15debd7e2b">11,718</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMzEtMy0xLTEtMTU0Njg_bd847532-ae66-4861-954b-81eba83580d5">20,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMzItMS0xLTEtMTU0Njg_6c841ae7-1f02-4cf2-b9f0-8bb8a9a2e269">67,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3f7c42ccd5d04f12b8291c60dcbafea1_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMzItMy0xLTEtMTU0Njg_9a10b7d6-4c69-4470-8344-7f4650c2a17c">35,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash, cash equivalents and restricted cash, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMzMtMS0xLTEtMTU0Njg_6a1a0323-d031-4a91-a93e-8da841e72c6e">55,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5c8a085e141b45ee84f490448563d1f1_I20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMzMtMy0xLTEtMTU0Njg_bd889f6c-c706-4154-a8e0-78d0f9100d6e">15,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash and cash equivalents, end of period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMzUtMS0xLTEtMTU0Njg_ddb27de9-da45-4b84-b3ac-5b04e8761d22">54,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5c8a085e141b45ee84f490448563d1f1_I20210331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMzUtMy0xLTEtMTU0Njg_dce863b1-b408-4291-8508-72c323c4b0c8">14,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Restricted cash, end of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMzYtMS0xLTEtMTU0Njg_dabca7f1-e557-42da-9134-a1f0f879b926">1,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5c8a085e141b45ee84f490448563d1f1_I20210331" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMzYtMy0xLTEtMTU0Njg_ebe6aa41-ebff-4c55-a258-a1771ab1ab40">1,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash, cash equivalents and restricted cash, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMzctMS0xLTEtMTU0Njg_a1df4f6b-56bc-42fe-a604-45b7ab43c210">55,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5c8a085e141b45ee84f490448563d1f1_I20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMzctMy0xLTEtMTU0Njg_3ebe5009-9c91-43f2-b658-989eedcee927">15,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Supplemental disclosure of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Purchases of equipment included in accounts payable and accrued expenses </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfNDAtMS0xLTEtMTU0Njg_cf1625e8-a34d-4a9c-81da-c43db2fa9a9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfNDAtMy0xLTEtMTU0Njg_ddb36799-18f9-4b53-9dc0-b05c2f61e62e">385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for operating lease obligation </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfNDMtMS0xLTEtMTU0Njg_7ef48664-9f8f-4b16-80cd-41b5ee630ab0">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfNDMtMy0xLTEtMTU0Njg_f128dca7-f394-455e-a1b5-2841b52a4569">5,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:20.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">8</span></div></div></div><div id="i9b58afd7c815450f9ef9acc3673fe027_25"></div><hr style="page-break-after:always"/><div style="min-height:29.25pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.064%"><tr><td style="width:1.0%"></td><td style="width:44.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Black Diamond Therapeutics, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(in thousands, except share data)</span></div></td></tr><tr style="height:36pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common stock</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Additional</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">paid-in capital</span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">stockholders&#8217;</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">equity (deficit)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Par Value</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BALANCE - December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9079e499652941b491fb8e9ed7ce1958_I20201231" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMy0xLTEtMS0xNTQ2OA_627e2682-4061-47a6-bbf1-8e4b3e6b5ae4">36,078,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9079e499652941b491fb8e9ed7ce1958_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMy0zLTEtMS0xNTQ2OA_b4d84063-5d62-43be-810b-bcec3865106b">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i12c39deff1194b6c92a7c1abee14df8a_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMy01LTEtMS0xNTQ2OA_18f6a568-a6d4-4c5f-95cb-2aba10f81666">425,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0888b6dac5434cacbd33596c1adace82_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMy03LTEtMS0xNTQ2OA_022c4abc-ca31-455c-98d3-3ed1ce882a62">614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibffb8b6ab6ec42548e3a66555c649c15_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMy05LTEtMS0xNTQ2OA_f1b36998-aa8b-4b31-9632-0f81a97a6b30">118,224</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3f7c42ccd5d04f12b8291c60dcbafea1_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMy0xMS0xLTEtMTU0Njg_07fe9177-de32-4ce3-b8d3-519277b0debf">307,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise of common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ida279286734543b991ef4eed0ef6046e_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfNC0xLTEtMS0xNTQ2OA_e6e5a227-91ed-40e7-8b0f-dbd8c3eb25c3">62,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5c596ceb5049485884e7b2a68aa5916c_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfNC01LTEtMS0xNTQ2OA_39c8848d-c280-4006-a123-bb78d94c35c2">481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfNC0xMS0xLTEtMTU0Njg_aa030c79-41d6-4a21-b643-a41c68d94b83">481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ida279286734543b991ef4eed0ef6046e_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfNS0xLTEtMS0xNTQ2OA_25dde64f-e53d-4e31-9808-6ac30b693d2b">4,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ida279286734543b991ef4eed0ef6046e_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfNi0xLTEtMS0xNTQ2OA_cfd4018a-1a34-4532-b4aa-4f107a602879">1,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5c596ceb5049485884e7b2a68aa5916c_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfNi01LTEtMS0xNTQ2OA_8aa58560-20c4-450d-bb24-66c399ff98c6">3,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfNi0xMS0xLTEtMTU0Njg_e24ae0e2-a668-41ef-a28e-754ff8df43f8">3,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3a11083af40b47cfa476274d297e6503_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfNy03LTEtMS0xNTQ2OA_a662122f-d4f7-41b6-915b-c4ecdd2d6af6">279</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfNy0xMS0xLTEtMTU0Njg_db921bd2-05cb-48f3-af44-7cb0ef0ae10b">279</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iaede1a9af65846df94f23afe6ee659b3_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfOC05LTEtMS0xNTQ2OA_236ac9c2-df78-4e55-a4d5-a3e58e171818">30,301</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfOC0xMS0xLTEtMTU0Njg_ac7cf7cb-c1b0-4d36-bfb9-1e6b8928299c">30,301</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BALANCE - March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i24cb741f3e52499f82800136848ddbcf_I20210331" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfOS0xLTEtMS0xNTQ2OA_920986d4-911b-48d1-a13f-c8e430f66707">36,147,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i24cb741f3e52499f82800136848ddbcf_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfOS0zLTEtMS0xNTQ2OA_a40d031a-6b00-4dfa-9618-0de3f40ff6d2">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i67ed168c54f645c2b002a94645f0df0a_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfOS01LTEtMS0xNTQ2OA_07b85f0c-7d24-4095-ac84-a8783fa1ffec">428,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idaf43c36cb8d458fa8fcfb47211264db_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfOS03LTEtMS0xNTQ2OA_79aeeacc-39b1-4435-8ba6-d0732c8c22f1">335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if6d7e79d27124e3bb23e6b0101055ce0_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfOS05LTEtMS0xNTQ2OA_6fb86528-7f37-4cb4-bc95-f713dd15e53c">148,525</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5c8a085e141b45ee84f490448563d1f1_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfOS0xMS0xLTEtMTU0Njg_8ddd068a-44c8-4bce-a004-a4a847a1f67c">280,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="36" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BALANCE - December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic3c688356e134568b5de6825391deaf1_I20211231" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjMtMS0xLTEtMTU0Njg_d0bbe45a-dfdd-4d64-8a4f-987da72f7e83">36,234,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic3c688356e134568b5de6825391deaf1_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjMtMy0xLTEtMTU0Njg_b29e58c1-acda-44c4-a1c5-f11bfbb6a50b">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0fdd5c7e07db40b08c5a1dcde0c1ffd2_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjMtNS0xLTEtMTU0Njg_7ef86c73-fd78-49a8-af48-8123bffc4232">440,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1ca47029fd60490abe151e708b67878e_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjMtNy0xLTEtMTU0Njg_afbdfe93-f371-43c7-a012-6d07a559df99">414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i691561fefea149049b9e700257b2dd11_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjMtOS0xLTEtMTU0Njg_5058c661-a157-488b-bdc6-26c467a56f1b">243,820</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjMtMTEtMS0xLTE1NDY4_ddc8fea3-5141-465e-a799-5860455dc17b">195,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise of common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i534d154d73254bb5a34550cf1b283ddb_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjQtMS0xLTEtMTU0Njg_f74b3c58-0058-4094-91ea-29a9c7968ad2">3,565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idc707991eeb0410f91d59567f375b8b4_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjQtNS0xLTEtMTU0Njg_410702f1-7c43-4eca-b357-ce3e9a5f3b3e">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjQtMTEtMS0xLTE1NDY4_5a85fcc6-d52e-4c57-838e-7b2f06f63438">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i534d154d73254bb5a34550cf1b283ddb_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjUtMS0xLTEtMTU0Njg_6f54787f-8c83-47e2-ab1c-b1c3fd3a1f91">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of common stock related to ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i534d154d73254bb5a34550cf1b283ddb_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjktMS0xLTEtMTU3ODU_486a314c-3bef-42e0-99d0-72ed3c3af97a">31,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idc707991eeb0410f91d59567f375b8b4_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjktNS0xLTEtMTU3ODU_70e22599-bc99-47d0-861e-a0bf372c8608">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjktMTEtMS0xLTE1Nzg1_25466986-55dc-4217-8ee2-bad5f4516b86">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i534d154d73254bb5a34550cf1b283ddb_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjYtMS0xLTEtMTU0Njg_04a07df4-e2d1-49c8-8187-9bc38927f606">13,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idc707991eeb0410f91d59567f375b8b4_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjYtNS0xLTEtMTU0Njg_7aa8a198-dacf-4427-a460-819591872a39">3,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjYtMTEtMS0xLTE1NDY4_1ff188bf-2797-4314-a264-505d1ce4d22c">3,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib55e7da72d944e7b8a9e91f5cb12ecdf_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjctNy0xLTEtMTU0Njg_96d9cb57-a7be-4e5c-8e71-47520b539b3b">1,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjctMTEtMS0xLTE1NDY4_d3366e12-f252-41ba-8be3-620bfe9e8eee">1,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibcc979a9141648ffb26ccb55a5e51ebc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjgtOS0xLTEtMTU0Njg_6c21aeb4-3098-4aee-a748-26a25da4f113">25,507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjgtMTEtMS0xLTE1NDY4_9e1c6177-2126-4756-bd9c-8a53ba056ac3">25,507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BALANCE - March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iddf6f9051d0a4be3a16017e93ce7ab16_I20220331" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjktMS0xLTEtMTU0Njg_4cff16f4-dc84-46d3-b8f2-223c79f8bcfc">36,287,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iddf6f9051d0a4be3a16017e93ce7ab16_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjktMy0xLTEtMTU0Njg_7f20a540-93b8-40d1-a664-68f10d6faca9">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1326edc9009d45a49158855eb54f6574_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjktNS0xLTEtMTU0Njg_283cba56-96fb-465d-b41b-5fdf1e88378b">443,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i19221d9ccdb34fd994d9ee776e4585b5_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjktNy0xLTEtMTU0Njg_42f2fabe-27ea-48ef-9108-96728205a35a">1,775</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id201833d4a114834a06d053bfa018915_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjktOS0xLTEtMTU0Njg_71088426-0f19-415b-b9b8-94ecd7cf483b">269,327</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjktMTEtMS0xLTE1NDY4_d00c15ca-0364-44a3-a7be-5ee41e3acd11">172,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">9</span></div></div></div><div id="i9b58afd7c815450f9ef9acc3673fe027_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Black Diamond Therapeutics, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</span></div><div id="i9b58afd7c815450f9ef9acc3673fe027_31"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zMS9mcmFnOmM1MWM0NWFhMDNmYzRiMjJiMDMxYzgxMzFlMDEzOGE0L3RleHRyZWdpb246YzUxYzQ1YWEwM2ZjNGIyMmIwMzFjODEzMWUwMTM4YTRfODkxMw_4aec33d3-9d4c-4fa3-b1d6-41ad7b45f2c5" continuedAt="i6da641e1a2dd4a6881e798323b9a772d" escape="true">NATURE OF BUSINESS AND BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="i6da641e1a2dd4a6881e798323b9a772d" continuedAt="i583130aaec3642bf8e81efda1d341833"><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zMS9mcmFnOmM1MWM0NWFhMDNmYzRiMjJiMDMxYzgxMzFlMDEzOGE0L3RleHRyZWdpb246YzUxYzQ1YWEwM2ZjNGIyMmIwMzFjODEzMWUwMTM4YTRfODkxNA_2818e8e4-0905-46c3-b69d-cc8df870a80a" continuedAt="i0fd096dca7d14873af01892de0d6ae05" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Black Diamond Therapeutics, Inc. (the &#8220;Company&#8221;) is a precision oncology medicine company pioneering the discovery and development of MasterKey therapies. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing, and incurring research and development costs related to the development of its mutation, allostery, and pharmacology computational and drug discovery engine. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On February 1, 2021, the Company filed a shelf registration statement on Form S-3 ASR (the &#8220;Shelf&#8221;), with the Securities and Exchange Commission (the &#8220;SEC&#8221;), which covers the offering, issuance and sale of the Company&#8217;s common stock, preferred stock, debt securities, warrants and/or units of any combination thereof. The Company simultaneously entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with Jefferies LLC, as sales agent, to provide for the issuance and sale by the Company of up to $<ix:nonFraction unitRef="usd" contextRef="i377d263c6d38493ca25e90aa73fd3701_D20220401-20220630" decimals="-6" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zMS9mcmFnOmM1MWM0NWFhMDNmYzRiMjJiMDMxYzgxMzFlMDEzOGE0L3RleHRyZWdpb246YzUxYzQ1YWEwM2ZjNGIyMmIwMzFjODEzMWUwMTM4YTRfMzQwNg_d1127bec-bdf1-4b7d-b22b-141c4ae8a010">150</ix:nonFraction> million of its common stock from time to time through Jefferies as its sales agent (the &#8220;ATM Program&#8221;). The Shelf became automatically effective upon filing on February 1, 2021. As of March&#160;31, 2022, no sales have been made pursuant to the ATM Program.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. Historically, the Company has funded its operations primarily with proceeds from the sale of preferred and common stock. The Company expects to continue to generate operating losses for the foreseeable future. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of May&#160;11, 2022, the issuance date of the condensed consolidated financial statements, the Company expects that its cash, cash equivalents and investments will be sufficient to fund its currently planned operations for at least the next 12 months from the filing date of these unaudited interim condensed consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company may seek additional funding through private or public equity financings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><ix:continuation id="i583130aaec3642bf8e81efda1d341833"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The ongoing COVID-19 pandemic is evolving, and to date has led to the implementation of various responses, including government-imposed quarantines, travel restrictions, and other public health safety measures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has been closely monitoring the impact of the ongoing COVID-19 pandemic on all aspects of the Company&#8217;s business, including how it has impacted and may continue to impact the Company&#8217;s operations and the operations of its suppliers, vendors and business partners, and may take further precautionary and preemptive actions as may be required by federal, state or local authorities. In addition, the Company has taken steps to minimize the current environment&#8217;s impact on its business and strategy, including devising contingency plans and securing additional resources from third party service providers. Furthermore, for the safety of the Company&#8217;s employees and families, the Company has introduced enhanced safety measures for scientists to be present in its labs and increased the use of third party service providers for the conduct of certain experiments and studies for research programs. Certain of the Company&#8217;s third party service providers have also experienced shutdowns or other business disruptions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The extent to which COVID-19 ultimately impacts the Company&#8217;s business, results of operations or financial condition will depend on future developments, which, despite progress in vaccination efforts, remain highly uncertain and cannot be predicted with confidence, such as the duration of the COVID-19 pandemic, new strains of the virus, including any future variants that may emerge, which may impact rates of infection and vaccination efforts, developments or perceptions regarding the safety of vaccines, new information that may emerge concerning the severity of COVID-19, and any additional preventative and protective actions taken to contain the pandemic or treat its impact, among others. The Company does not yet know the full extent of potential delays or impacts on the Company&#8217;s business, clinical trials, research programs, healthcare systems or the global economy and cannot presently predict the scope and severity of any potential business shutdowns or disruptions but if we or any of the third parties with whom we engage were to experience prolonged business shutdowns or other disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on our business, results of operations and financial condition. The estimates of the impact on our business may change based on new information that may emerge concerning COVID-19 and the actions to contain it or treat its impact and the economic impact on local, regional, national and international markets.</span></div></ix:continuation><div id="i9b58afd7c815450f9ef9acc3673fe027_34"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNC9mcmFnOjEzODYyYzc5NmEyZjQxODI4NThhMDZmYTFkNGZkNzhiL3RleHRyZWdpb246MTM4NjJjNzk2YTJmNDE4Mjg1OGEwNmZhMWQ0ZmQ3OGJfNjgwMw_70808e93-90a6-42e3-8445-dc76e324a881" continuedAt="i87ab126c09aa47b38f538d0fb0abcd00" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i87ab126c09aa47b38f538d0fb0abcd00" continuedAt="i9f32aa0b3f8e4c8aa38d83570017b435"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following is a summary of significant accounting policies followed in the preparation of these condensed consolidated financial statements.</span></div><ix:continuation id="i0fd096dca7d14873af01892de0d6ae05"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNC9mcmFnOjEzODYyYzc5NmEyZjQxODI4NThhMDZmYTFkNGZkNzhiL3RleHRyZWdpb246MTM4NjJjNzk2YTJmNDE4Mjg1OGEwNmZhMWQ0ZmQ3OGJfNjgwNw_3b9e21e5-2ac5-4e5e-8a65-781a1acd44d4" continuedAt="ie4b24b767f294aceb5558d0ddc4ca5fd" escape="true">Principles of consolidation </ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:continuation id="ie4b24b767f294aceb5558d0ddc4ca5fd">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions.</ix:continuation> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Unaudited interim financial information</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company&#8217;s Annual Report. In the opinion of the Company&#8217;s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Contents</a></span></div></div><ix:continuation id="i9f32aa0b3f8e4c8aa38d83570017b435"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNC9mcmFnOjEzODYyYzc5NmEyZjQxODI4NThhMDZmYTFkNGZkNzhiL3RleHRyZWdpb246MTM4NjJjNzk2YTJmNDE4Mjg1OGEwNmZhMWQ0ZmQ3OGJfNjgwNQ_7c10910a-7703-43c9-b157-e9784be3855c" continuedAt="ia83dbc9a68c24f19a8badcf8261ced6e" escape="true">Use of estimates </ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:continuation id="ia83dbc9a68c24f19a8badcf8261ced6e">The preparation of the Company&#8217;s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.</ix:continuation> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The full extent to which the ongoing COVID-19 pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including expenses, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered the impact of COVID-19 on estimates within its financial statements and there may be changes to those estimates in future periods. As of the date of issuance of these consolidated financial statements, the Company has not experienced material business disruptions or incurred impairment losses in the carrying value of its assets as a result of the pandemic and is not aware of any specific related event or circumstance that would require it to update its estimates.</span></div><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNC9mcmFnOjEzODYyYzc5NmEyZjQxODI4NThhMDZmYTFkNGZkNzhiL3RleHRyZWdpb246MTM4NjJjNzk2YTJmNDE4Mjg1OGEwNmZhMWQ0ZmQ3OGJfMjc0ODc3OTA4NTQ5Ng_11f67497-b9af-49e1-b5a1-ba311a3dc1fe" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company believes that no recently issued accounting standards will have a material impact on its consolidated financial statements, or apply to its operations.</span></div></ix:nonNumeric></ix:continuation><div id="i9b58afd7c815450f9ef9acc3673fe027_37"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RleHRyZWdpb246YzcxMTc0ZWE1NTMxNDgxM2I4NDA3Zjc2MzY1ZDkzNGZfMTIwMQ_e23f73b3-5aa0-48d0-8040-7dd0dc5c5ff5" continuedAt="i99100d6a3e634961aaca887842e45aae" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><div style="margin-top:12pt"><ix:continuation id="i99100d6a3e634961aaca887842e45aae" continuedAt="iba59262cbae74f479540ffd78780e684"><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RleHRyZWdpb246YzcxMTc0ZWE1NTMxNDgxM2I4NDA3Zjc2MzY1ZDkzNGZfMTIwMg_4f19b1f6-3aa9-4b82-a3f9-d8bbabe853d5" continuedAt="i15e0e97c75d54a54b8fd9e345a132654" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value measurements at March 31, 2022 using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic7586d8f4b304a96a89edaf4e92faa9f_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfNC0xLTEtMS0xNTQ2OA_238f7be6-563b-48a2-a792-a727c5c60b0f">52,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i962aa1bfb86e483894de2bb2442985bc_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfNC0zLTEtMS0xNTQ2OA_654845b7-b729-4578-9a13-160bcfc8cfc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d10b8beeaca440785de2cdb3d8eaf14_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfNC01LTEtMS0xNTQ2OA_d5c2baf8-5173-4b4f-ab64-d4ebca7405e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i42a51dbd5f584d6aa6a0cb3330f1fe5c_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfNC03LTEtMS0xNTQ2OA_eb025307-7050-4dff-8da9-042b5ca96f29">52,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icadf51cb52294253943e014823f06afb_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfNi0xLTEtMS0xNTQ2OA_a4a96283-db17-49fa-bf07-141e7af82a79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i62ae75982324469693df81b6e1fc8c23_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfNi0zLTEtMS0xNTQ2OA_8fbb1faa-fff3-4b6e-b47c-0509f6be78de">20,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i460915c867d24b099b0bf69feb2da59a_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfNi01LTEtMS0xNTQ2OA_91f386f3-09f0-4776-bb35-f875871d7bee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc6ba9d6b5064ee7aec84d28bbd1751d_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfNi03LTEtMS0xNTQ2OA_6e73652c-cea6-4efd-b2d1-65a247b0294a">20,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i34580173a0a9454eb268a5b3ec8b34eb_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfNy0xLTEtMS0xNTQ2OA_e0328e1c-93aa-442c-bc6b-36ab20fdfa20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i64edc7a1a2174b968d823d315842481f_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfNy0zLTEtMS0xNTQ2OA_1c96709c-a871-4a60-badd-fd2b9861680e">65,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i900b221b23fd4104a7f93150e16b1981_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfNy01LTEtMS0xNTQ2OA_a10e2651-188e-488b-86ce-5811b21a5cab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3ba3f44f3b104a51b92654a9c905ece2_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfNy03LTEtMS0xNTQ2OA_1910ed5b-d129-4b60-b7c9-cc53e380e540">65,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i83fb07b4cc0046609fb9c5c6324001ef_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfOC0xLTEtMS0xNTQ2OA_64b764d5-3bdc-4f95-a2a7-e9a81f7a707f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1cde33f4aa9549d797693a4f207e3ba3_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfOC0zLTEtMS0xNTQ2OA_cba38f05-dbaf-4545-af81-17c2e205593a">39,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2cb17e460b95429b88a840c5224dd92a_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfOC01LTEtMS0xNTQ2OA_b694d8d1-5f3f-4b53-bf17-cf8f301a95dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i29ce9fe315284e5abf314fcd5ed28b78_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfOC03LTEtMS0xNTQ2OA_163436cc-01ad-4aeb-9863-e27f3a1e3dd3">39,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8fa4d5d4ec21402bb7f85adb8fb71d6a_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfOS0xLTEtMS0xNTQ2OA_9cdff07d-7f3d-44a4-9e82-6f262b653509">52,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0e121bb40fd49258c14401a29e70859_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfOS0zLTEtMS0xNTQ2OA_b876d000-1380-4367-835c-df83409c3fe5">125,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie054d218517947ee8d0e864d31140ce8_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfOS01LTEtMS0xNTQ2OA_4062d8f7-469f-4aaa-a513-20818e6164ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i76fdf0838e4546cd851611fb3634158c_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfOS03LTEtMS0xNTQ2OA_51c39fd7-6d0e-4557-a8e6-1bc66f9ef9d5">177,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><ix:continuation id="iba59262cbae74f479540ffd78780e684"><div style="margin-top:12pt"><ix:continuation id="i15e0e97c75d54a54b8fd9e345a132654"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value measurements at December 31, 2021 using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i62c67ae3c8ed44d39ed202dc3a02814d_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfNC0xLTEtMS0xNTQ2OA_9cf440f7-8e09-4e0b-a489-b49b23c38a7e">63,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6469b9255c64b428aceb5e576c835e6_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfNC0zLTEtMS0xNTQ2OA_f69b462c-29d0-4064-9a10-55a4573229cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21a15014f6814669b4a982787c14c8ed_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfNC01LTEtMS0xNTQ2OA_e62b6112-c4b5-4870-a5ba-64a35f569ca2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id6ef99d5dd434984929935c0f6dd1e3e_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfNC03LTEtMS0xNTQ2OA_fb21d03e-676d-44b5-8162-008b31db40bb">63,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib6472a833e63467aa7a16b853fed7648_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfNy0xLTEtMS0xNTQ2OA_44970fb9-7449-4625-823f-8fc0e8871550">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i421912da66f44fe09b19b8944d07a70d_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfNy0zLTEtMS0xNTQ2OA_0e53ec4f-741a-4052-b1de-895e90d245d2">104,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9bf4c7e984404a6f86e23661b62cf071_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfNy01LTEtMS0xNTQ2OA_7db3bf09-83c4-4fe9-928b-c3eaf9f5a000">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifd344bc37522487781fced407afc94fd_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfNy03LTEtMS0xNTQ2OA_9a83ae59-7823-41be-9be7-dbf21f715b36">104,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6c3b0ba2c8154adaaceee5c961ea1e9e_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfOC0xLTEtMS0xNTQ2OA_3c8c31cc-2c27-4e19-bc7e-5c5d77a27591">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7e34a2b0b44e4081b6b378a6828ca51b_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfOC0zLTEtMS0xNTQ2OA_0de7df77-588e-43c7-8bb9-8c26c6caddde">39,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i15df054aa48340d4a776ceb4901608d1_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfOC01LTEtMS0xNTQ2OA_ce7d2fb1-1fe8-4f21-b58b-d90ed2421b9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i68881d5b14084f3c8c973338e687dea2_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfOC03LTEtMS0xNTQ2OA_32bd507a-6948-49fe-9c97-e3d358323568">39,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i131b634efed14bc78fcdf71e68e8a71e_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfOS0xLTEtMS0xNTQ2OA_25476f48-0a10-44b3-97fe-218491959abc">63,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9d2f217ac6a64e4788118680cfa194b3_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfOS0zLTEtMS0xNTQ2OA_552615ea-fa56-4ed2-9b3e-adac135352c9">143,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21ff474829e8485d8a14024ec03a39f1_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfOS01LTEtMS0xNTQ2OA_280af784-efbd-45d5-9dc3-7d2302947181">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4941a960ea32475eb80b88d7de07c5ba_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfOS03LTEtMS0xNTQ2OA_fa6922d3-f905-4591-afca-d2addd409943">207,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">When developing fair value estimates, the Company maximizes the use of observable inputs and minimizes the use of unobservable inputs. When available, the Company uses quoted market prices to measure fair value. The valuation technique used to measure fair value for the Company's Level 1 and Level 2 assets is a market approach, using prices and other relevant information generated by market transactions involving identical or comparable assets. If market prices are not available, the fair value measurement is based on models that use primarily market-based parameters including yield curves, volatilities, credit ratings and currency rates. In certain cases where market rate assumptions are not available, the Company is required to make judgments about assumptions market participants would use to estimate the fair value of a financial instrument. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There were no transfers in or out of Level 3 categories in the periods presented.</span></div></ix:continuation><div id="i9b58afd7c815450f9ef9acc3673fe027_40"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RleHRyZWdpb246OTBlZGMxZGIyYTc0NDA4MDllNTE1YjRjMjRjZGU2NjlfNDYy_9ef9f0a3-a3d8-4b70-be0d-eebffe106b41" continuedAt="idff6b7f29505425b9b7027fded40ad8e" escape="true">INVESTMENTS</ix:nonNumeric></span></div><ix:continuation id="idff6b7f29505425b9b7027fded40ad8e" continuedAt="i71dc6cd4201445cd95f91e31ed8f8020"><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RleHRyZWdpb246OTBlZGMxZGIyYTc0NDA4MDllNTE1YjRjMjRjZGU2NjlfNDY0_48b1e06f-a437-4980-8b21-4fa961494b09" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, investments were comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.398%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib85e10885b3a4e9b8fb2f090569d6271_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfMS0xLTEtMS0xNTQ2OA_bb1489e3-4771-4a7f-88f1-7af9b76b29d8">20,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib85e10885b3a4e9b8fb2f090569d6271_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfMS0zLTEtMS0xNTQ2OA_aca88031-40a6-40e5-9707-aa4eef80afc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib85e10885b3a4e9b8fb2f090569d6271_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfMS01LTEtMS0xNTQ2OA_e19fcd95-fa0d-4533-bb4c-d8aabf4f3b6c">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib85e10885b3a4e9b8fb2f090569d6271_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfMS03LTEtMS0xNTQ2OA_9fa07776-994b-419d-b0d1-ce531d37ddf0">20,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic8310139017c4117a15d446bef048a12_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfMi0xLTEtMS0xNTQ2OA_62353423-db14-46aa-8f52-75e4ac25af47">66,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic8310139017c4117a15d446bef048a12_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfMi0zLTEtMS0xNTQ2OA_22a1e34b-3bcc-4b2e-b9cb-10f00dd38518">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic8310139017c4117a15d446bef048a12_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfMi01LTEtMS0xNTQ2OA_c2de8a6c-2706-4ce9-8a66-a542d8e48922">903</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic8310139017c4117a15d446bef048a12_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfMi03LTEtMS0xNTQ2OA_62f71680-dd98-410f-8e34-21b44c14f3f0">65,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icd98783dea56424ba1c71b4e834b425a_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfMy0xLTEtMS0xNTQ2OA_88d5a54d-c8f0-4148-82c7-3259cb9d0a24">40,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icd98783dea56424ba1c71b4e834b425a_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfMy0zLTEtMS0xNTQ2OA_ed66b528-006b-487b-8fd7-cb150089aa74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icd98783dea56424ba1c71b4e834b425a_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfMy01LTEtMS0xNTQ2OA_9f2ade40-3cb5-419f-ba78-0cab9ba4f236">864</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icd98783dea56424ba1c71b4e834b425a_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfMy03LTEtMS0xNTQ2OA_7545d64f-a457-44cb-ab4d-ade386c4d1ed">39,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfNC0xLTEtMS0xNTQ2OA_d3f1567a-58e7-47cb-a83e-5f98fa22904d">127,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfNC0zLTEtMS0xNTQ2OA_a870be99-bfca-4ce6-a9cf-01172efdb567">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfNC01LTEtMS0xNTQ2OA_58c029ac-c305-47b5-9c72-434754d7a8e1">1,781</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfNC03LTEtMS0xNTQ2OA_52f03255-5b72-4859-a1cd-13330711d49d">125,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, investments were comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.398%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6c17159b04ab4338b714552e7330de6e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOjNlMWE4NzIyMzY0MDQ3N2Q5Y2Y1MDkwZDY0ZmU3NTJlL3RhYmxlcmFuZ2U6M2UxYTg3MjIzNjQwNDc3ZDljZjUwOTBkNjRmZTc1MmVfMi0xLTEtMS0xNTQ2OA_1b9b0528-0207-4183-9160-7fe8ea9ae621">104,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6c17159b04ab4338b714552e7330de6e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOjNlMWE4NzIyMzY0MDQ3N2Q5Y2Y1MDkwZDY0ZmU3NTJlL3RhYmxlcmFuZ2U6M2UxYTg3MjIzNjQwNDc3ZDljZjUwOTBkNjRmZTc1MmVfMi0zLTEtMS0xNTQ2OA_5ffda916-c9f3-4799-8712-f1283abcd51e">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i6c17159b04ab4338b714552e7330de6e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOjNlMWE4NzIyMzY0MDQ3N2Q5Y2Y1MDkwZDY0ZmU3NTJlL3RhYmxlcmFuZ2U6M2UxYTg3MjIzNjQwNDc3ZDljZjUwOTBkNjRmZTc1MmVfMi01LTEtMS0xNTQ2OA_390e0795-e410-4049-a258-de60fc0edd9b">242</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6c17159b04ab4338b714552e7330de6e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOjNlMWE4NzIyMzY0MDQ3N2Q5Y2Y1MDkwZDY0ZmU3NTJlL3RhYmxlcmFuZ2U6M2UxYTg3MjIzNjQwNDc3ZDljZjUwOTBkNjRmZTc1MmVfMi03LTEtMS0xNTQ2OA_a7c1fb47-c5a2-4c64-b441-95f85cef6df7">104,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib197786787854aa08e044a89989c79be_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOjNlMWE4NzIyMzY0MDQ3N2Q5Y2Y1MDkwZDY0ZmU3NTJlL3RhYmxlcmFuZ2U6M2UxYTg3MjIzNjQwNDc3ZDljZjUwOTBkNjRmZTc1MmVfMy0xLTEtMS0xNTQ2OA_778b4bfc-5b61-442b-ab30-33f0e74c38f8">40,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib197786787854aa08e044a89989c79be_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOjNlMWE4NzIyMzY0MDQ3N2Q5Y2Y1MDkwZDY0ZmU3NTJlL3RhYmxlcmFuZ2U6M2UxYTg3MjIzNjQwNDc3ZDljZjUwOTBkNjRmZTc1MmVfMy0zLTEtMS0xNTQ2OA_e9621f6a-3956-42f2-850c-453cd451459e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib197786787854aa08e044a89989c79be_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOjNlMWE4NzIyMzY0MDQ3N2Q5Y2Y1MDkwZDY0ZmU3NTJlL3RhYmxlcmFuZ2U6M2UxYTg3MjIzNjQwNDc3ZDljZjUwOTBkNjRmZTc1MmVfMy01LTEtMS0xNTQ2OA_f7661611-6a4b-4d3b-8b43-a25513b079e4">219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib197786787854aa08e044a89989c79be_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOjNlMWE4NzIyMzY0MDQ3N2Q5Y2Y1MDkwZDY0ZmU3NTJlL3RhYmxlcmFuZ2U6M2UxYTg3MjIzNjQwNDc3ZDljZjUwOTBkNjRmZTc1MmVfMy03LTEtMS0xNTQ2OA_d596c2e9-0f22-404a-8221-65ef074abaed">39,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOjNlMWE4NzIyMzY0MDQ3N2Q5Y2Y1MDkwZDY0ZmU3NTJlL3RhYmxlcmFuZ2U6M2UxYTg3MjIzNjQwNDc3ZDljZjUwOTBkNjRmZTc1MmVfNC0xLTEtMS0xNTQ2OA_1175dcdb-7871-4371-88b2-e1de70a9a919">144,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOjNlMWE4NzIyMzY0MDQ3N2Q5Y2Y1MDkwZDY0ZmU3NTJlL3RhYmxlcmFuZ2U6M2UxYTg3MjIzNjQwNDc3ZDljZjUwOTBkNjRmZTc1MmVfNC0zLTEtMS0xNTQ2OA_2660dd29-178d-47a5-959f-8ee286f4eb59">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOjNlMWE4NzIyMzY0MDQ3N2Q5Y2Y1MDkwZDY0ZmU3NTJlL3RhYmxlcmFuZ2U6M2UxYTg3MjIzNjQwNDc3ZDljZjUwOTBkNjRmZTc1MmVfNC01LTEtMS0xNTQ2OA_8c0eb649-8e32-49fd-9091-3ba190f6074e">461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOjNlMWE4NzIyMzY0MDQ3N2Q5Y2Y1MDkwZDY0ZmU3NTJlL3RhYmxlcmFuZ2U6M2UxYTg3MjIzNjQwNDc3ZDljZjUwOTBkNjRmZTc1MmVfNC03LTEtMS0xNTQ2OA_abdaf1fa-47a4-4aee-9b42-e878f41a1ab9">143,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for U.S. government agencies, corporate bonds and commercial paper with a fair value of $<ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="bdtx:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RleHRyZWdpb246OTBlZGMxZGIyYTc0NDA4MDllNTE1YjRjMjRjZGU2NjlfMTA5OTUxMTYzNjQwNQ_587baee2-e16b-4af0-b569-32156e49355f">65,238</ix:nonFraction> that had maturities of one to three years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for  U.S. government agencies and corporate bonds with a fair value of $<ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="bdtx:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RleHRyZWdpb246OTBlZGMxZGIyYTc0NDA4MDllNTE1YjRjMjRjZGU2NjlfMTA5OTUxMTYzNTY3Mg_08544f15-0a65-4bc1-93be-49096c3cc7bd">86,187</ix:nonFraction> that had maturities of one to three years.</span></div></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><ix:continuation id="i71dc6cd4201445cd95f91e31ed8f8020"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the marketable securities in a loss position had a maturity of less than one year, except for U.S. government agencies, corporate bonds and commercial paper with a fair value of $<ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RleHRyZWdpb246OTBlZGMxZGIyYTc0NDA4MDllNTE1YjRjMjRjZGU2NjlfMTA5OTUxMTY0MDI2Ng_0a0f0aac-36e6-47f4-b9ab-d5beb43050d2">65,238</ix:nonFraction>, that had maturities of one to three years. As of December&#160;31, 2021, the marketable securities in a loss position had a maturity of less than one year, except for U.S. government agencies and corporate bonds, with a fair value of $<ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RleHRyZWdpb246OTBlZGMxZGIyYTc0NDA4MDllNTE1YjRjMjRjZGU2NjlfMTA5OTUxMTYzNjQxNA_36c4ffd5-1910-452d-b635-40b183179582">86,187</ix:nonFraction>, that had maturities of one to three years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company reviewed its investment portfolio to assess whether the unrealized losses on its available-for-sale investments were temporary. In determining whether the decline in fair value of these securities was temporary, the Company evaluated whether it intended to sell the security and whether it was more likely than not that the Company would be required to sell the security before recovering its amortized cost basis. There have been <ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="0" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RleHRyZWdpb246OTBlZGMxZGIyYTc0NDA4MDllNTE1YjRjMjRjZGU2NjlfMzU5_734e1caa-862c-4432-b1fa-38bc567c4785"><ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="0" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RleHRyZWdpb246OTBlZGMxZGIyYTc0NDA4MDllNTE1YjRjMjRjZGU2NjlfMzU5_b25ed3ff-ceb7-4861-bd27-40437ea72aa6">no</ix:nonFraction></ix:nonFraction> impairments of the Company&#8217;s assets measured and carried at fair value during the three months ended March&#160;31, 2022 and the year ended December&#160;31, 2021.</span></div></ix:continuation><div id="i9b58afd7c815450f9ef9acc3673fe027_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RleHRyZWdpb246Y2U1OWE2YTc4Y2U2NDVkMjkyNzg3MmNhMTQ4M2VjMDZfMTcx_8696c602-29a4-4154-b669-fd66d99740bc" continuedAt="i2f44eebf2663438eb742b07c253fc5fd" escape="true">PROPERTY AND EQUIPMENT</ix:nonNumeric></span></div><ix:continuation id="i2f44eebf2663438eb742b07c253fc5fd"><div style="margin-top:12pt"><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RleHRyZWdpb246Y2U1OWE2YTc4Y2U2NDVkMjkyNzg3MmNhMTQ4M2VjMDZfMTcy_860b9377-b354-42e8-8e5e-cc776da28704" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i592581da0c5c4d148c499857a0970854_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfMS0xLTEtMS0xNTQ2OA_bbc5bd40-24e0-4951-8260-571e8771cff4">689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia34f847e770542fbb1c0526bcd0521db_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfMS0zLTEtMS0xNTQ2OA_f2feb1a6-cc0b-4dad-bfd9-278ef2c7d849">682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2cf6dcdd2d6846acbcfd0f4697fbbd29_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfMi0xLTEtMS0xNTQ2OA_35b35b27-c663-4c5a-b30b-285efe178c92">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3c3fc5df5cff491cb5578febfa6291bf_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfMi0zLTEtMS0xNTQ2OA_5ceb72b3-aa66-417a-873b-e3745ad4938d">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Computer and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icee8d91286f54b40b3f46d39ea9f5b62_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfMy0xLTEtMS0xNTQ2OA_d7e59cc4-077b-4553-b309-167801e02bf9">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2a5f439d7d2246559ccab58abf38d308_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfMy0zLTEtMS0xNTQ2OA_2851370c-8360-4f84-b063-0cf6553dc76e">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b03f59264e74ddaa03048707c7f0deb_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfNC0xLTEtMS0xNTQ2OA_149f79e7-c705-4204-9ee2-3ccbe0fca592">2,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8fa0e12ae93a4ef0b5f7c326a00d7970_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfNC0zLTEtMS0xNTQ2OA_fa0b09b2-82e5-4bca-ad65-ee357c905b5c">2,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Construction in process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iae9953ec0cd04a469a57c8508f2c84ef_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfNS0xLTEtMS0xNTQ2OA_eed7a15e-5bf5-4f49-94de-f32670b10f39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i601e1559c5444c6aadd65a73f7aba8dd_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfNS0zLTEtMS0xNTQ2OA_1f1da6e7-6350-4f02-939a-98009088489d">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfNi0xLTEtMS0xNTQ2OA_f752d404-c65d-4a75-bf25-1737eb6c926a">3,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfNi0zLTEtMS0xNTQ2OA_bed15293-da51-403e-9022-feeb923e5808">3,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfNy0xLTEtMS0xNTQ2OA_4c5ead6d-4016-4873-ac5b-11efb4689d52">494</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfNy0zLTEtMS0xNTQ2OA_d089f07c-9365-49d2-9872-a02249752f76">369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total Property and Equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfOC0xLTEtMS0xNTQ2OA_e83caa91-11c9-43f1-88a5-45a8ddbf4a71">2,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfOC0zLTEtMS0xNTQ2OA_456375a6-3026-4de1-8825-c6de73d82b52">3,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Depreciation expense for the three months ended March&#160;31, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RleHRyZWdpb246Y2U1OWE2YTc4Y2U2NDVkMjkyNzg3MmNhMTQ4M2VjMDZfMTQ4_bcf82265-dd9a-450e-82a9-8c723492c6a7">125</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RleHRyZWdpb246Y2U1OWE2YTc4Y2U2NDVkMjkyNzg3MmNhMTQ4M2VjMDZfMTU1_7d5206be-67be-4abc-9312-5f9f7fef9819">19</ix:nonFraction>, respectively.</span></div></ix:continuation><div id="i9b58afd7c815450f9ef9acc3673fe027_46"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RleHRyZWdpb246MzU3YzgwZDY1OGFiNDgxNGI4M2ExNGYwNjdhNWM1OTNfMTMx_ff10910c-0822-4c3d-93a5-689e262c4680" continuedAt="i04d5a00f88304033876ca4057b5b85d5" escape="true">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES </ix:nonNumeric></span></div><div style="margin-top:12pt"><ix:continuation id="i04d5a00f88304033876ca4057b5b85d5"><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RleHRyZWdpb246MzU3YzgwZDY1OGFiNDgxNGI4M2ExNGYwNjdhNWM1OTNfMTMy_e60bafb4-925f-4841-a490-9d9c80d31fe7" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Contracted research services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="bdtx:AccruedContractResearchServiceFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfMS0xLTEtMS0xNTQ2OA_16eebe7b-cf18-4cd6-8617-f0464fd4be2d">12,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="bdtx:AccruedContractResearchServiceFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfMS0zLTEtMS0xNTQ2OA_f2407a26-0d71-4316-923c-29c7248ccd9a">12,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Payroll and related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfMi0xLTEtMS0xNTQ2OA_cecf4c89-5f0c-4c74-a61b-f6cd77621a4f">2,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfMi0zLTEtMS0xNTQ2OA_e94d8cd8-c799-4efb-b3b1-e6c72651ec9e">5,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Professional and consulting fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfMy0xLTEtMS0xNTQ2OA_34c2513c-ab73-4ced-abc3-98dbedf7eb32">1,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfMy0zLTEtMS0xNTQ2OA_a2b1a984-20a0-4b86-a40e-70806b2557ab">1,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfNS0wLTEtMS0xNTQ2OA_c195240d-53ce-44bf-b8a4-8e123e896ff6"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfNS0wLTEtMS0xNTQ2OA_fcf82e1a-149c-4590-8cc4-cc8f47ea4618">Current portion of operating lease liability</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfNS0xLTEtMS0xNTQ2OA_036a3369-4834-45b5-b0f6-abf23e6898e3">793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfNS0zLTEtMS0xNTQ2OA_b0be2c6d-cb59-4f9e-80c3-eb288532daf3">320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfNi0xLTEtMS0xNTQ2OA_5a40d9df-1355-460c-bd4a-57ce9b62a9f9">17,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfNi0zLTEtMS0xNTQ2OA_64aee4a1-2e43-48b7-a617-f52497992737">19,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div><span><br/></span></div><div id="i9b58afd7c815450f9ef9acc3673fe027_52"></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfNDU0Mw_dff2dc75-13b6-40a6-a7a6-7ba0e9429881" continuedAt="i0c59b92c4a2645d68fb5aaafdcde3cc2" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="i0c59b92c4a2645d68fb5aaafdcde3cc2" continuedAt="icac9c4626c4a40189a1530f33b676c25"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">2020 Stock Option and Incentive Plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The 2020 Stock Option and Incentive Plan (the &#8220;2020 Plan&#8221;) was approved by the Company&#8217;s board of directors on December 5, 2019, and the Company&#8217;s stockholders on January 14, 2020 and became effective on the date immediately prior to the date on which the registration statement for the Company&#8217;s initial public offering (&#8220;IPO&#8221;) was declared effective. The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company&#8217;s officers, employees, directors and consultants. The 2020 Plan provides for an annual increase, to be added on the first day of each fiscal year, by up to <ix:nonFraction unitRef="number" contextRef="i5aee93ec0e6140c1967b90030b644693_I20200114" decimals="2" name="bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfODEy_d0e11451-f731-4522-95e3-edb7ac07c3c0">4</ix:nonFraction>% of the Company&#8217;s outstanding shares of common stock as of the last day of the prior year. On January 1, 2022, <ix:nonFraction unitRef="shares" contextRef="i121d14ec620443948bfb2446cf6369a8_D20220101-20220101" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfOTI1_85afc236-1101-457b-b5c0-f5eccba9cb9d">1,449,384</ix:nonFraction> shares of common stock, representing <ix:nonFraction unitRef="number" contextRef="i6c5c649da96f4bf6a852cad3b98671b5_I20220101" decimals="2" name="bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfOTY1_d3f2d331-055b-46a5-b36c-ec83d7b4f987">4</ix:nonFraction>% of the Company&#8217;s outstanding shares of common stock as of December 31, 2021, were added to the 2020 Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The 2020 Employee Stock Purchase Plan (the &#8220;2020 ESPP&#8221;) was approved by the Company&#8217;s board of directors on December 5, 2019, and the Company&#8217;s stockholders on January 14, 2020, and became effective on the date immediately prior to the date on which the registration statement for the Company&#8217;s IPO was declared effective. The 2020 ESPP provides for an annual increase, to be added on the first day of each fiscal year, by up to <ix:nonFraction unitRef="number" contextRef="i73e473532efc4938a233763c7ef748f4_I20200114" decimals="2" name="bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfMTUzNw_15bf28ba-a4f2-4741-be89-d6dd790a86b1">1</ix:nonFraction>% of the number of shares of the Company&#8217;s common stock outstanding on the immediately preceding December 31. The number of authorized shares reserved for issuance under the 2020 ESPP was increased by <ix:nonFraction unitRef="shares" contextRef="ib84b1455b06c44f2b4f0df628ece6347_D20220101-20220101" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfMTY0OTI2NzQ0NjIxOQ_b3009c34-8ec7-4d3c-a741-55a731806ad3">326,364</ix:nonFraction> shares effective as of January 1, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation expense </span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfNDUzOQ_2b34d25d-5d41-43b8-8ba7-afdca9a1e635" continuedAt="ib1a47eed762a413f842a7e0ab7fb5876" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following award type categories included within the condensed consolidated statements of operations and comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.750%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top">Three Months Ended<br/>March 31,</td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ced07d6335641afa9f14288d1f7a2e1_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjY4Yzg2MTljNGM5MzQzMjQ4NjA1Njc2NWU1NzhmZjY5L3RhYmxlcmFuZ2U6NjhjODYxOWM0YzkzNDMyNDg2MDU2NzY1ZTU3OGZmNjlfMi01LTEtMS0xNTQ2OA_816d5997-1501-4f7e-b442-b95f092d3166">3,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9e9380f128ab4b63b1d6e7a850a44abd_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjY4Yzg2MTljNGM5MzQzMjQ4NjA1Njc2NWU1NzhmZjY5L3RhYmxlcmFuZ2U6NjhjODYxOWM0YzkzNDMyNDg2MDU2NzY1ZTU3OGZmNjlfMi03LTEtMS0xNTQ2OA_67f87171-4b1f-4aa3-9d9f-262f5710fcfe">2,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia65875741ae542c78ed7dd0c432423a4_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjY4Yzg2MTljNGM5MzQzMjQ4NjA1Njc2NWU1NzhmZjY5L3RhYmxlcmFuZ2U6NjhjODYxOWM0YzkzNDMyNDg2MDU2NzY1ZTU3OGZmNjlfMy01LTEtMS0xNTQ2OA_5b3175e1-28b7-4450-b108-e902e0d2053c">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id260c31e9c0140f3a78bffba8953b169_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjY4Yzg2MTljNGM5MzQzMjQ4NjA1Njc2NWU1NzhmZjY5L3RhYmxlcmFuZ2U6NjhjODYxOWM0YzkzNDMyNDg2MDU2NzY1ZTU3OGZmNjlfMy03LTEtMS0xNTQ2OA_15ac4cff-0695-4b8a-a2a7-b3fec47265c8">270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Employee Stock Purchase Plan and Other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1f5c3ddf78054fd0ba9932327695ba3c_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjY4Yzg2MTljNGM5MzQzMjQ4NjA1Njc2NWU1NzhmZjY5L3RhYmxlcmFuZ2U6NjhjODYxOWM0YzkzNDMyNDg2MDU2NzY1ZTU3OGZmNjlfNC01LTEtMS0xNTQ2OA_a115a993-6a0e-410b-be62-3b7e0574ce10">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibde6c6664ee5474ea71ce7b63f837206_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjY4Yzg2MTljNGM5MzQzMjQ4NjA1Njc2NWU1NzhmZjY5L3RhYmxlcmFuZ2U6NjhjODYxOWM0YzkzNDMyNDg2MDU2NzY1ZTU3OGZmNjlfNC03LTEtMS0xNTQ2OA_d6c9b531-74ed-46a4-834d-175b1cfbd712">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjY4Yzg2MTljNGM5MzQzMjQ4NjA1Njc2NWU1NzhmZjY5L3RhYmxlcmFuZ2U6NjhjODYxOWM0YzkzNDMyNDg2MDU2NzY1ZTU3OGZmNjlfNS01LTEtMS0xNTQ2OA_c37e6fc9-447f-4494-8632-5d80c5ae46be">3,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjY4Yzg2MTljNGM5MzQzMjQ4NjA1Njc2NWU1NzhmZjY5L3RhYmxlcmFuZ2U6NjhjODYxOWM0YzkzNDMyNDg2MDU2NzY1ZTU3OGZmNjlfNS03LTEtMS0xNTQ2OA_85de25ef-f48f-4b5c-b955-02369893c78d">3,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2022, the Company issued <ix:nonFraction unitRef="shares" contextRef="i83ac7265af3c4a80b9a2081786c15aec_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfMjA0OQ_788e4320-deb0-4ec6-b5b2-597772e27974">13,038</ix:nonFraction> shares of common stock out of our 2020 Plan under our policy where non-employee directors may elect to receive their compensation in the form of common stock in lieu of cash.</span></div><div style="margin-top:12pt"><ix:continuation id="ib1a47eed762a413f842a7e0ab7fb5876"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.750%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>March 31,</td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ife37765db49e41bf81afa44e8728613a_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjJhODBiNTFlMmQ2ZjRiZGY5ZDBlNjgxZDE1Yzg3MjY1L3RhYmxlcmFuZ2U6MmE4MGI1MWUyZDZmNGJkZjlkMGU2ODFkMTVjODcyNjVfMi01LTEtMS0xNTQ2OA_4cc630f0-9957-4bb6-a509-c9cd17bf2206">1,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iab8781eeec934caf84183887064bbbca_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjJhODBiNTFlMmQ2ZjRiZGY5ZDBlNjgxZDE1Yzg3MjY1L3RhYmxlcmFuZ2U6MmE4MGI1MWUyZDZmNGJkZjlkMGU2ODFkMTVjODcyNjVfMi03LTEtMS0xNTQ2OA_21824ab0-9d25-47a4-a3c2-6c98c7a2fe71">1,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifdd9e72b3a7b4336a10b4ac7dea8e88c_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjJhODBiNTFlMmQ2ZjRiZGY5ZDBlNjgxZDE1Yzg3MjY1L3RhYmxlcmFuZ2U6MmE4MGI1MWUyZDZmNGJkZjlkMGU2ODFkMTVjODcyNjVfMy01LTEtMS0xNTQ2OA_900b2db0-cca9-4e06-a93b-788b1a53828f">1,847</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7445afb88fcd42778b16246f068e465b_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjJhODBiNTFlMmQ2ZjRiZGY5ZDBlNjgxZDE1Yzg3MjY1L3RhYmxlcmFuZ2U6MmE4MGI1MWUyZDZmNGJkZjlkMGU2ODFkMTVjODcyNjVfMy03LTEtMS0xNTQ2OA_80eb9a26-066a-437b-8e4e-678d295a333d">1,474</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjJhODBiNTFlMmQ2ZjRiZGY5ZDBlNjgxZDE1Yzg3MjY1L3RhYmxlcmFuZ2U6MmE4MGI1MWUyZDZmNGJkZjlkMGU2ODFkMTVjODcyNjVfNC01LTEtMS0xNTQ2OA_e4e4857a-5e36-405a-a0fc-400f54d9ddf0">3,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjJhODBiNTFlMmQ2ZjRiZGY5ZDBlNjgxZDE1Yzg3MjY1L3RhYmxlcmFuZ2U6MmE4MGI1MWUyZDZmNGJkZjlkMGU2ODFkMTVjODcyNjVfNC03LTEtMS0xNTQ2OA_f30d9b01-fb42-4984-bbcd-1a37a6e97b46">3,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><ix:continuation id="icac9c4626c4a40189a1530f33b676c25" continuedAt="i2d6244b38138483cab837532f5ba2991"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Options </span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfNDU0NQ_194357ae-20a9-478c-a6ba-1465abedd5c2" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity under the Company&#8217;s equity awards plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:46.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.456%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Exercise</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Price</span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Life</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(in Years)</span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Outstanding December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfMS0xLTEtMS0xNTQ2OA_0eea34f5-9be0-4a47-86bd-bc037ad51bf2">4,903,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfMS0zLTEtMS0xNTQ2OA_d72117e2-67c1-4b0c-beaa-e595bf9cd273">17.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id953a840a46b432da2c79d8a575bc2a7_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfMS01LTEtMS0xNTQ2OA_67665312-b761-460e-a057-8b6d485096ce">7.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfMS03LTEtMS0xNTQ2OA_ad80821b-d033-4fc5-bd43-087998f24500">847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfMi0xLTEtMS0xNTQ2OA_f5f8b0c3-7625-4cbc-b78f-9db05305bd60">1,366,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfMi0zLTEtMS0xNTQ2OA_5937e11b-7572-4b74-bce4-2bd6d2a23875">3.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfMy0xLTEtMS0xNTQ2OA_fc96fc6e-b9e6-4929-9bef-11669b172ed2">3,565</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfMy0zLTEtMS0xNTQ2OA_48227c87-7d3e-44ce-8940-411896b15bcf">3.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cancelled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfNC0xLTEtMS0xNTQ2OA_19303e58-3694-4f93-b1c6-1ba85f844d42">347,830</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfNC0zLTEtMS0xNTQ2OA_75a77a05-32de-42a0-a210-6418f522c222">16.59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Outstanding March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfNS0xLTEtMS0xNTQ2OA_8b8a80fb-bad5-4aa1-8384-14c349a023ac">5,918,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfNS0zLTEtMS0xNTQ2OA_e777e26e-419d-4f3e-9d2e-00f7c32d02ec">14.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfNS01LTEtMS0xNTQ2OA_a5150654-205a-4c47-b429-35e4d36483d9">8.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfNS03LTEtMS0xNTQ2OA_89e386a2-caf2-4168-ba00-0a936199eec5">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options vested or expected to vest at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfNi0xLTEtMS0xNTQ2OA_a0a18f6f-a5e6-4145-9d83-4bfbb5d93a94">5,918,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfNi0zLTEtMS0xNTQ2OA_09da6e67-9716-4c02-a2c2-c5299999f965">14.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfNi01LTEtMS0xNTQ2OA_56c4b6dc-ecac-4759-9071-83a9beab3f6b">8.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfNi03LTEtMS0xNTQ2OA_91e7fe15-cc62-4e82-ae83-104416fe62a6">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options exercisable at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfNy0xLTEtMS0xNTQ2OA_c23b3fa6-65e8-40a6-a752-391d8a63cd47">2,082,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfNy0zLTEtMS0xNTQ2OA_323cd41c-e4f4-4b40-b4d9-daf7daee0d90">16.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfNy01LTEtMS0xNTQ2OA_4af6b13f-adae-47b1-abd6-2ed65108bef7">6.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfNy03LTEtMS0xNTQ2OA_1eb8c66a-4ec9-49ff-8119-b9f8cefab876">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2022, total unrecognized compensation cost related to the unvested stock-options was $<ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfMjYxMg_d207098f-e964-4d20-b481-2dba9ee6a9d3">29,471</ix:nonFraction>, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i9ced07d6335641afa9f14288d1f7a2e1_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfMjY4NQ_c7d32ecc-0822-4d24-9aec-b031fca60c1c">2.5</ix:nonNumeric> years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Restricted stock units </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The fair values of restricted stock units are based on the market value of the Company&#8217;s stock on the date of the grant. Under terms of the time-based restricted stock agreements covering the common stock, shares of restricted common stock are subject to a vesting schedule. <ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfNDU0MA_9c3f6c47-6c20-4f89-ae8a-6d7b2954342e" continuedAt="icb74b741c3db47ed8ea658225b4935e7" escape="true">The following table summarizes time-based restricted stock activity since January 1, 2022:</ix:nonNumeric></span><ix:continuation id="icb74b741c3db47ed8ea658225b4935e7"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Number&#160;of</span></div><div style="margin-bottom:0.75pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">shares</span></div></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">average</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">grant&#160;date</span></div><div style="margin-bottom:0.75pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">fair value</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unvested restricted common stock as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id3281f5219574c05b5edcdfcb8708b8f_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjZjYjllMzNjYWE0MTQxODliOWNmMjlhNDI1MWRlOTcwL3RhYmxlcmFuZ2U6NmNiOWUzM2NhYTQxNDE4OWI5Y2YyOWE0MjUxZGU5NzBfNC0xLTEtMS0xNTQ2OA_2d154504-0260-4725-bcce-44b4d075939a">30,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="id3281f5219574c05b5edcdfcb8708b8f_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjZjYjllMzNjYWE0MTQxODliOWNmMjlhNDI1MWRlOTcwL3RhYmxlcmFuZ2U6NmNiOWUzM2NhYTQxNDE4OWI5Y2YyOWE0MjUxZGU5NzBfNC0zLTEtMS0xNTQ2OA_af9c3909-8682-4f80-9133-95d119533217">29.53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0604fd99be6c400cb46383e020232cc3_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjZjYjllMzNjYWE0MTQxODliOWNmMjlhNDI1MWRlOTcwL3RhYmxlcmFuZ2U6NmNiOWUzM2NhYTQxNDE4OWI5Y2YyOWE0MjUxZGU5NzBfNS0xLTEtMS0xNTQ2OA_5ae60243-2ba0-40f8-bd99-78012ee370a8">20,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0604fd99be6c400cb46383e020232cc3_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjZjYjllMzNjYWE0MTQxODliOWNmMjlhNDI1MWRlOTcwL3RhYmxlcmFuZ2U6NmNiOWUzM2NhYTQxNDE4OWI5Y2YyOWE0MjUxZGU5NzBfNS0zLTEtMS0xNTQ2OA_19d72e77-8e4f-427b-8809-4d3024e4d768">3.79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i0604fd99be6c400cb46383e020232cc3_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjZjYjllMzNjYWE0MTQxODliOWNmMjlhNDI1MWRlOTcwL3RhYmxlcmFuZ2U6NmNiOWUzM2NhYTQxNDE4OWI5Y2YyOWE0MjUxZGU5NzBfNi0xLTEtMS0xNTQ2OA_fe989578-6bf2-4fa5-9644-4a5d6f29a5d3">5,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0604fd99be6c400cb46383e020232cc3_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjZjYjllMzNjYWE0MTQxODliOWNmMjlhNDI1MWRlOTcwL3RhYmxlcmFuZ2U6NmNiOWUzM2NhYTQxNDE4OWI5Y2YyOWE0MjUxZGU5NzBfNi0zLTEtMS0xNTQ2OA_feb33bf1-0e08-4a28-91f2-8205851cf080">28.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unvested restricted common stock as of March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="idfb5ec15550c48b5ba40e04db8d95d68_I20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjZjYjllMzNjYWE0MTQxODliOWNmMjlhNDI1MWRlOTcwL3RhYmxlcmFuZ2U6NmNiOWUzM2NhYTQxNDE4OWI5Y2YyOWE0MjUxZGU5NzBfOC0xLTEtMS0xNTQ2OA_98736610-9b00-4e8c-bc22-c754df18cd91">45,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="idfb5ec15550c48b5ba40e04db8d95d68_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjZjYjllMzNjYWE0MTQxODliOWNmMjlhNDI1MWRlOTcwL3RhYmxlcmFuZ2U6NmNiOWUzM2NhYTQxNDE4OWI5Y2YyOWE0MjUxZGU5NzBfOC0zLTEtMS0xNTQ2OA_d6601735-7be6-473c-937d-cb879a6b9b35">18.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The total fair value of time-based restricted stock units vested during the three months ended March&#160;31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="ia65875741ae542c78ed7dd0c432423a4_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfMzE0Ng_819c9477-0586-4988-87b6-55dd9aa49665">143</ix:nonFraction>. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2022, total unrecognized compensation cost related to the time-based unvested restricted stock units was $<ix:nonFraction unitRef="usd" contextRef="i9607feb9fa2e47abb53ba9ad7befeaf9_I20220331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfMzI2Nw_c360244a-f4d5-49bc-b58b-3843bd90e454">591</ix:nonFraction>, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="ia65875741ae542c78ed7dd0c432423a4_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfMzM0MA_11c9cb9f-04cf-4f3f-8d1f-404df8a5f4e6">1.2</ix:nonNumeric> years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2022, the Company granted to its employees <ix:nonFraction unitRef="shares" contextRef="i6bed481b20eb42c4b7b7f8e7b60c3743_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfMTA5OTUxMTYzNTMwMQ_db61a67f-ebc2-422a-87d6-76504c9aab06">193,000</ix:nonFraction> performance restricted stock units related to the achievement of certain clinical development and/or financing milestones. As of March&#160;31, 2022, the Company had <ix:nonFraction unitRef="shares" contextRef="ic3cbdfd3eaf5479f8e2be722e19d3d35_I20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfMTA5OTUxMTYzNTA3NA_a65ddfcd-6f35-4459-8e25-1e90d5cf8698">212,000</ix:nonFraction> performance restricted stock units outstanding.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Recognition of stock-based compensation expense associated with performance restricted stock units commences when the performance conditions are considered probable of achievement, using management&#8217;s best estimates, which consider the inherent risk and uncertainty regarding the future outcomes of the milestones.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><ix:continuation id="i2d6244b38138483cab837532f5ba2991"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, for performance-based restricted stock units that were outstanding, the achievement of the milestones that had not been met was considered not probable, and therefore <ix:nonFraction unitRef="usd" contextRef="i6bed481b20eb42c4b7b7f8e7b60c3743_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfMTA5OTUxMTYzNTE0OA_708a92da-fb17-4980-9e5f-55112f31252a">no</ix:nonFraction> expense has been recognized related to these awards in the three months ended March&#160;31, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Employee stock purchase plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The 2020 ESPP enables eligible employees to purchase shares of the Company's common stock at the end of each <ix:nonNumeric contextRef="i96258d5fc0c3444cbbfc78ce061c9bef_D20220101-20220331" name="bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfNDU0Nw_d744ebf8-03bc-4624-be5b-2d033854a534">six-month</ix:nonNumeric> offering period at a price equal to <ix:nonFraction unitRef="number" contextRef="i96258d5fc0c3444cbbfc78ce061c9bef_D20220101-20220331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfMzgwOA_31134c6c-6c4d-4168-8d74-b2c136b3663a">85</ix:nonFraction>% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Eligible employees generally included all employees. Offering periods begin on the first trading day of January and July of each year and end on the last trading day in June and December of each year, except for the first offering period which began on the first trading day in March and ended on the last trading day in June. Share purchases are funded through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="i1f60a8da3d204a1d84243bb405682e2e_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfNDMzNQ_9cabccda-35f3-4604-bad9-553b6f38c2ca">10</ix:nonFraction>% of an employee&#8217;s eligible compensation for each payroll period, up to $<ix:nonFraction unitRef="usd" contextRef="i96258d5fc0c3444cbbfc78ce061c9bef_D20220101-20220331" decimals="-3" name="bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfNDQwOA_384e448f-8a8f-4a09-967e-6da59b23097e">25</ix:nonFraction> each calendar year.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022 and 2021, there were <ix:nonFraction unitRef="shares" contextRef="i96258d5fc0c3444cbbfc78ce061c9bef_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfNDQ4MA_002e66d2-914e-44f2-82c2-8eb438e7dc5d">31,341</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i9100305f99b146729261bbdc162cb093_D20210101-20210331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfNDQ4Nw_e3d6d55c-6130-4f4d-94ca-4cec9f9debff">no</ix:nonFraction> shares, respectively, issued under the 2020 ESPP.</span></div></ix:continuation><div id="i9b58afd7c815450f9ef9acc3673fe027_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RleHRyZWdpb246ODI0NmZmYjg1Yzc2NGUwMzg4YjQ5NmQ5YTVlMjllYjFfODY1_7775650f-03b4-43d6-bf77-6ae91d9ede27" continuedAt="id1a16d04b0934fb088d8dfb793a214e3" escape="true">NET LOSS PER SHARE</ix:nonNumeric></span></div><ix:continuation id="id1a16d04b0934fb088d8dfb793a214e3"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Net loss per share</span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RleHRyZWdpb246ODI0NmZmYjg1Yzc2NGUwMzg4YjQ5NmQ5YTVlMjllYjFfODY2_562ae4cb-855d-4a5b-a9f4-1bb63cc19029" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes the computation of basic and diluted net loss per share of the Company (in thousands, except share and per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.750%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOmM1NTk4MTQ4ZGIzZDQ3ZjFhNjdmYmIwYWY3N2RjYmE5L3RhYmxlcmFuZ2U6YzU1OTgxNDhkYjNkNDdmMWE2N2ZiYjBhZjc3ZGNiYTlfMi01LTEtMS0xNTQ2OA_61c9c85e-33e2-444c-aa13-f2542a696ca1">25,507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOmM1NTk4MTQ4ZGIzZDQ3ZjFhNjdmYmIwYWY3N2RjYmE5L3RhYmxlcmFuZ2U6YzU1OTgxNDhkYjNkNDdmMWE2N2ZiYjBhZjc3ZGNiYTlfMi03LTEtMS0xNTQ2OA_c1d81fd2-4ff8-4d69-9dd8-00e5967edf85">30,301</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOmM1NTk4MTQ4ZGIzZDQ3ZjFhNjdmYmIwYWY3N2RjYmE5L3RhYmxlcmFuZ2U6YzU1OTgxNDhkYjNkNDdmMWE2N2ZiYjBhZjc3ZGNiYTlfMy01LTEtMS0xNTQ2OA_5ebbba76-d7fb-4c79-a64a-ea2b37cd100f"><ix:nonFraction unitRef="shares" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOmM1NTk4MTQ4ZGIzZDQ3ZjFhNjdmYmIwYWY3N2RjYmE5L3RhYmxlcmFuZ2U6YzU1OTgxNDhkYjNkNDdmMWE2N2ZiYjBhZjc3ZGNiYTlfMy01LTEtMS0xNTQ2OA_c6c04341-468f-4f67-aee8-70279ddde08a">36,271,291</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOmM1NTk4MTQ4ZGIzZDQ3ZjFhNjdmYmIwYWY3N2RjYmE5L3RhYmxlcmFuZ2U6YzU1OTgxNDhkYjNkNDdmMWE2N2ZiYjBhZjc3ZGNiYTlfMy03LTEtMS0xNTQ2OA_52e8d0c4-e1b2-49d9-879c-7f2230c463c2"><ix:nonFraction unitRef="shares" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOmM1NTk4MTQ4ZGIzZDQ3ZjFhNjdmYmIwYWY3N2RjYmE5L3RhYmxlcmFuZ2U6YzU1OTgxNDhkYjNkNDdmMWE2N2ZiYjBhZjc3ZGNiYTlfMy03LTEtMS0xNTQ2OA_a24b0f36-c667-44e3-81e3-11cbf2052b0c">36,123,014</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOmM1NTk4MTQ4ZGIzZDQ3ZjFhNjdmYmIwYWY3N2RjYmE5L3RhYmxlcmFuZ2U6YzU1OTgxNDhkYjNkNDdmMWE2N2ZiYjBhZjc3ZGNiYTlfNC01LTEtMS0xNTQ2OA_0c20e5ee-2483-47fb-a62e-7f75d22c093d"><ix:nonFraction unitRef="usdPerShare" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOmM1NTk4MTQ4ZGIzZDQ3ZjFhNjdmYmIwYWY3N2RjYmE5L3RhYmxlcmFuZ2U6YzU1OTgxNDhkYjNkNDdmMWE2N2ZiYjBhZjc3ZGNiYTlfNC01LTEtMS0xNTQ2OA_39d718c5-a936-41ff-8c4c-c6f81574f1bb">0.70</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOmM1NTk4MTQ4ZGIzZDQ3ZjFhNjdmYmIwYWY3N2RjYmE5L3RhYmxlcmFuZ2U6YzU1OTgxNDhkYjNkNDdmMWE2N2ZiYjBhZjc3ZGNiYTlfNC03LTEtMS0xNTQ2OA_5a8e69bb-0987-4af9-98cb-ad94f9719400"><ix:nonFraction unitRef="usdPerShare" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOmM1NTk4MTQ4ZGIzZDQ3ZjFhNjdmYmIwYWY3N2RjYmE5L3RhYmxlcmFuZ2U6YzU1OTgxNDhkYjNkNDdmMWE2N2ZiYjBhZjc3ZGNiYTlfNC03LTEtMS0xNTQ2OA_6bd9508f-d25e-4267-a9f0-5a3b0694b3a4">0.84</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s potentially dilutive securities, which include options, unvested restricted stock and warrants to purchase common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. <ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RleHRyZWdpb246ODI0NmZmYjg1Yzc2NGUwMzg4YjQ5NmQ5YTVlMjllYjFfODY0_129f9cdc-979b-4ad7-a534-e4c5b2ed5aef" continuedAt="i01918e24759643eca75945922f60b74b" escape="true">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</ix:nonNumeric></span></div><div style="margin-top:12pt"><ix:continuation id="i01918e24759643eca75945922f60b74b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibe1143b3d4d645b7b96eb90d189b5d47_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOjNlZGI2ZWZjZjI0NjQ2NzI4MDIwZmI5Njg2YmVhZmFkL3RhYmxlcmFuZ2U6M2VkYjZlZmNmMjQ2NDY3MjgwMjBmYjk2ODZiZWFmYWRfMi0xLTEtMS0xNTQ2OA_5a2447a4-6ce9-40d9-addf-2e265c174c10">5,918,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iff2984996ead4b0a9658704d11ad854b_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOjNlZGI2ZWZjZjI0NjQ2NzI4MDIwZmI5Njg2YmVhZmFkL3RhYmxlcmFuZ2U6M2VkYjZlZmNmMjQ2NDY3MjgwMjBmYjk2ODZiZWFmYWRfMi0zLTEtMS0xNTQ2OA_2d9c06c4-e898-4121-b0c6-be4853b740b5">4,810,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unvested restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i41ea06ffd4224202a713d2f339bde058_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOjNlZGI2ZWZjZjI0NjQ2NzI4MDIwZmI5Njg2YmVhZmFkL3RhYmxlcmFuZ2U6M2VkYjZlZmNmMjQ2NDY3MjgwMjBmYjk2ODZiZWFmYWRfMy0xLTEtMS0xNTQ2OA_6da18ea2-a92d-4e58-a14f-7a06a51a6369">45,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6dcd8e4f8ad5440c98fd9db5a027ce37_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOjNlZGI2ZWZjZjI0NjQ2NzI4MDIwZmI5Njg2YmVhZmFkL3RhYmxlcmFuZ2U6M2VkYjZlZmNmMjQ2NDY3MjgwMjBmYjk2ODZiZWFmYWRfMy0zLTEtMS0xNTQ2OA_7d65132b-d2fe-48a7-85d8-164dd78d9678">59,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Shares issuable under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9a5f037265fe4d04a7f18d30566bb541_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOjNlZGI2ZWZjZjI0NjQ2NzI4MDIwZmI5Njg2YmVhZmFkL3RhYmxlcmFuZ2U6M2VkYjZlZmNmMjQ2NDY3MjgwMjBmYjk2ODZiZWFmYWRfNC0xLTEtMS0xNTQ2OA_1fc83f55-59a7-4497-ab82-8d2c926ecf24">27,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8b57788e875c480ba8c662e821360cb1_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOjNlZGI2ZWZjZjI0NjQ2NzI4MDIwZmI5Njg2YmVhZmFkL3RhYmxlcmFuZ2U6M2VkYjZlZmNmMjQ2NDY3MjgwMjBmYjk2ODZiZWFmYWRfNC0zLTEtMS0xNTQ2OA_1d98572e-702d-4564-be74-911c19419ed3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="icda07b5a5283444f941929ded278868b_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOjNlZGI2ZWZjZjI0NjQ2NzI4MDIwZmI5Njg2YmVhZmFkL3RhYmxlcmFuZ2U6M2VkYjZlZmNmMjQ2NDY3MjgwMjBmYjk2ODZiZWFmYWRfNS0xLTEtMS0xNTQ2OA_1d5a235c-4a47-4dc7-a4d3-563169eabe17">10,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i11c8ad192542472fae54a22841a0002f_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOjNlZGI2ZWZjZjI0NjQ2NzI4MDIwZmI5Njg2YmVhZmFkL3RhYmxlcmFuZ2U6M2VkYjZlZmNmMjQ2NDY3MjgwMjBmYjk2ODZiZWFmYWRfNS0zLTEtMS0xNTQ2OA_15d238f3-d330-405e-bbdb-6fcc5e2c08fb">10,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOjNlZGI2ZWZjZjI0NjQ2NzI4MDIwZmI5Njg2YmVhZmFkL3RhYmxlcmFuZ2U6M2VkYjZlZmNmMjQ2NDY3MjgwMjBmYjk2ODZiZWFmYWRfNi0xLTEtMS0xNTQ2OA_0e00d041-c4d5-4eeb-b382-5e85dc21af5e">6,002,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOjNlZGI2ZWZjZjI0NjQ2NzI4MDIwZmI5Njg2YmVhZmFkL3RhYmxlcmFuZ2U6M2VkYjZlZmNmMjQ2NDY3MjgwMjBmYjk2ODZiZWFmYWRfNi0zLTEtMS0xNTQ2OA_54f885a5-f481-4b47-b7b5-993bcdb7201d">4,880,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">17</span></div></div></div><div id="i9b58afd7c815450f9ef9acc3673fe027_58"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfMjYyMg_0bb7a267-0d21-4e47-a967-03721ee6bc57" continuedAt="i8963f50fad7442fa9f78bf2d6869681b" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="i8963f50fad7442fa9f78bf2d6869681b" continuedAt="ie20f790167f744f69c63973996d19c57"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has historically entered into lease arrangements for its facilities. As of March&#160;31, 2022, the Company had <ix:nonFraction unitRef="contract" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="INF" name="bdtx:LesseeOperatingLeaseNumberOfContracts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfMTIz_8a97dd46-1be3-4a30-ae04-7d70653bd004">two</ix:nonFraction> operating leases with required future minimum payments. The Company determined the classification of these leases to be operating leases and recorded right-of-use assets and lease liabilities as of the effective dates. The Company&#8217;s leases generally do not include termination or purchase options. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Operating leases </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In July 2020, the Company entered into a <ix:nonNumeric contextRef="i698d38b82399483e9b66aecdbb49ea01_I20200731" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfMjYyMw_66e6c3a9-d4c9-4bbd-a773-77ba78213560">seven-year</ix:nonNumeric> agreement with an option to extend for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfNTgy_c161a703-7086-4d07-92a4-b87f9bfb15b3">five</span> additional years to lease two floors totaling approximately <ix:nonFraction unitRef="sqft" contextRef="i698d38b82399483e9b66aecdbb49ea01_I20200731" decimals="0" name="bdtx:LesseeOperatingLeaseArea" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfNjQ1_f5c9277b-313c-401f-9fae-232da6a90602">25,578</ix:nonFraction> square feet of office space for its principal office, which is located in Cambridge, MA. The lease on the first floor commenced on August 1, 2020 and the lease on the second floor commenced March 9, 2021. The Company recognized the respective lease balances on the condensed consolidated balance sheets when the lease of each floor commenced. Under the terms of the lease, the Company was required to issue a $<ix:nonFraction unitRef="usd" contextRef="i698d38b82399483e9b66aecdbb49ea01_I20200731" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfMTA1Nw_3e73a624-0b01-422d-a5e9-1f59abaf0956">1,168</ix:nonFraction> letter of credit as security for the lease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company previously leased an office space in Cambridge, MA under a lease that commenced in February 2019 for approximately <ix:nonFraction unitRef="sqft" contextRef="i2fb5e46658e2428a9f4d40e61ba2085a_I20190228" decimals="0" name="bdtx:LesseeOperatingLeaseArea" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfMTIzMQ_11fd87a2-4384-4e58-b524-62bdf02a279a">2,357</ix:nonFraction> square feet of office space, which was set to expire on April 30, 2022, subject to an option to extend the lease for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfMTM1MQ_fb0605bf-86e1-4515-94ea-01a6d35b03a5">three</span> additional years. Effective June 15, 2021, the lease was terminated, and the remaining right-of-use asset and lease liability were derecognized. A gain of $<ix:nonFraction unitRef="usd" contextRef="ia1bcd124beab438caab6f8c9006bed30_D20210615-20210615" decimals="-3" name="us-gaap:GainLossOnTerminationOfLease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfMTA5OTUxMTYzMDQxMw_98a6ff6e-8c14-446d-9de9-507be38fb963">5</ix:nonFraction> was recognized for the termination of the lease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In December 2020, the Company entered into an <ix:nonNumeric contextRef="i54692e00a6974fcd89b396554614c7ad_I20201231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfMjYyOQ_85310468-aa27-42c0-9098-cc0c16859a47">eleven-year</ix:nonNumeric> agreement to lease approximately <ix:nonFraction unitRef="sqft" contextRef="i54692e00a6974fcd89b396554614c7ad_I20201231" decimals="0" name="bdtx:LesseeOperatingLeaseArea" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfMTYzNw_34b37162-2c32-4530-87a1-ffc674353511">18,120</ix:nonFraction> square feet of office and laboratory space in New York, NY. The Company has an option to extend the lease for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfMTc1MA_0ef0df9a-0a44-47d0-a64e-d0e4a8dda2cf">five</span> additional years. The lease commenced August 26, 2021 and the related lease balance was recognized on the condensed consolidated balance sheet.</span></div><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfMjYyNA_738d4b24-6219-47c8-8646-e85405353837" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#8217;s operating lease for the three months ended March 31, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.681%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.437%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Lease Cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjYxYmU4MTg3ODYxNTQ1NTA5NDE2ODc3MGUxNWE2OWE1L3RhYmxlcmFuZ2U6NjFiZTgxODc4NjE1NDU1MDk0MTY4NzcwZTE1YTY5YTVfMy01LTEtMS0xNjc4NA_d77f2afc-de7e-4670-b0eb-2ef8a68db99d">1,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjYxYmU4MTg3ODYxNTQ1NTA5NDE2ODc3MGUxNWE2OWE1L3RhYmxlcmFuZ2U6NjFiZTgxODc4NjE1NDU1MDk0MTY4NzcwZTE1YTY5YTVfMy03LTEtMS0xNjc4NA_d6dc84e1-c2b0-47fa-9c83-2a1ff70fb69c">462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjYxYmU4MTg3ODYxNTQ1NTA5NDE2ODc3MGUxNWE2OWE1L3RhYmxlcmFuZ2U6NjFiZTgxODc4NjE1NDU1MDk0MTY4NzcwZTE1YTY5YTVfNC01LTEtMS0xNjc4NA_379b5536-bd12-4198-8685-e55ff02cab9f">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjYxYmU4MTg3ODYxNTQ1NTA5NDE2ODc3MGUxNWE2OWE1L3RhYmxlcmFuZ2U6NjFiZTgxODc4NjE1NDU1MDk0MTY4NzcwZTE1YTY5YTVfNC03LTEtMS0xNjc4NA_b027b74f-81bb-485c-8dab-200ca83492d8">287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjYxYmU4MTg3ODYxNTQ1NTA5NDE2ODc3MGUxNWE2OWE1L3RhYmxlcmFuZ2U6NjFiZTgxODc4NjE1NDU1MDk0MTY4NzcwZTE1YTY5YTVfNS01LTEtMS0xNjc4NA_565674cc-5fe3-4ea0-ae1e-fbefa7182f5d">257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjYxYmU4MTg3ODYxNTQ1NTA5NDE2ODc3MGUxNWE2OWE1L3RhYmxlcmFuZ2U6NjFiZTgxODc4NjE1NDU1MDk0MTY4NzcwZTE1YTY5YTVfNS03LTEtMS0xNjc4NA_7c180f90-80fd-4ea5-9101-3f8b4cf0b8cb">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjYxYmU4MTg3ODYxNTQ1NTA5NDE2ODc3MGUxNWE2OWE1L3RhYmxlcmFuZ2U6NjFiZTgxODc4NjE1NDU1MDk0MTY4NzcwZTE1YTY5YTVfNi01LTEtMS0xNjc4NA_f143447b-128e-45a6-9ba0-4e1710abe27e">1,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjYxYmU4MTg3ODYxNTQ1NTA5NDE2ODc3MGUxNWE2OWE1L3RhYmxlcmFuZ2U6NjFiZTgxODc4NjE1NDU1MDk0MTY4NzcwZTE1YTY5YTVfNi03LTEtMS0xNjc4NA_5da745c1-2006-4fcd-9a58-953fd245c59d">782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.436%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Operating Lease Information</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjkwZDhmYzVmN2IyZTQ5ZTVhNzU1MDkwMzcyZjRhZjNkL3RhYmxlcmFuZ2U6OTBkOGZjNWY3YjJlNDllNWE3NTUwOTAzNzJmNGFmM2RfMi0xLTEtMS0xNTQ2OA_1984fcc0-be7a-414d-8251-a792bdbe1feb">702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjkwZDhmYzVmN2IyZTQ5ZTVhNzU1MDkwMzcyZjRhZjNkL3RhYmxlcmFuZ2U6OTBkOGZjNWY3YjJlNDllNWE3NTUwOTAzNzJmNGFmM2RfMi0zLTEtMS0xNjc2Mw_4c683829-f2dd-4a30-86c6-aa4f3f3ac83c">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjkwZDhmYzVmN2IyZTQ5ZTVhNzU1MDkwMzcyZjRhZjNkL3RhYmxlcmFuZ2U6OTBkOGZjNWY3YjJlNDllNWE3NTUwOTAzNzJmNGFmM2RfMy0xLTEtMS0xNTQ2OA_0ec6254d-9125-4d56-8570-ba6969c4b78e">8.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5c8a085e141b45ee84f490448563d1f1_I20210331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjkwZDhmYzVmN2IyZTQ5ZTVhNzU1MDkwMzcyZjRhZjNkL3RhYmxlcmFuZ2U6OTBkOGZjNWY3YjJlNDllNWE3NTUwOTAzNzJmNGFmM2RfMy0zLTEtMS0xNjc2Mw_f63f7abc-d6c0-4046-8c75-6587c42bb74c">7.3</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjkwZDhmYzVmN2IyZTQ5ZTVhNzU1MDkwMzcyZjRhZjNkL3RhYmxlcmFuZ2U6OTBkOGZjNWY3YjJlNDllNWE3NTUwOTAzNzJmNGFmM2RfNC0xLTEtMS0xNTQ2OA_ec8ebb6c-3734-4035-a998-408fa246e08e">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i5c8a085e141b45ee84f490448563d1f1_I20210331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjkwZDhmYzVmN2IyZTQ5ZTVhNzU1MDkwMzcyZjRhZjNkL3RhYmxlcmFuZ2U6OTBkOGZjNWY3YjJlNDllNWE3NTUwOTAzNzJmNGFmM2RfNC0zLTEtMS0xNjc2Mw_5189c020-4b65-45c7-b07c-1b6fdd532781">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The variable lease costs for the three months ended March&#160;31, 2022 and 2021 include common area maintenance and other operating charges. As the Company&#8217;s leases do not provide an implicit rate, the Company utilized its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><ix:continuation id="ie20f790167f744f69c63973996d19c57"><ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfMjYyNQ_97274787-3071-4e1c-a61f-120724a0edb2" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Future minimum lease payments under the Company&#8217;s operating leases as of March&#160;31, 2022 were as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.480%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.320%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">As of March 31, 2022</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022 (excluding the three months ended March&#160;31, 2022)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjI4ZWVkZWE4YWYwOTQzNjc5MzdlODU0MDMxMWU1ODJhL3RhYmxlcmFuZ2U6MjhlZWRlYThhZjA5NDM2NzkzN2U4NTQwMzExZTU4MmFfMS0xLTEtMS0xNTQ2OA_ce023e34-4c3a-44b0-a3c5-d8b7832c3909">1,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjI4ZWVkZWE4YWYwOTQzNjc5MzdlODU0MDMxMWU1ODJhL3RhYmxlcmFuZ2U6MjhlZWRlYThhZjA5NDM2NzkzN2U4NTQwMzExZTU4MmFfMi0xLTEtMS0xNTQ2OA_5b12ca85-eec8-46a8-aab0-269b2b9a27e7">4,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjI4ZWVkZWE4YWYwOTQzNjc5MzdlODU0MDMxMWU1ODJhL3RhYmxlcmFuZ2U6MjhlZWRlYThhZjA5NDM2NzkzN2U4NTQwMzExZTU4MmFfMy0xLTEtMS0xNTQ2OA_75241fd4-95ab-482e-a1b2-cc3fa55f0631">4,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjI4ZWVkZWE4YWYwOTQzNjc5MzdlODU0MDMxMWU1ODJhL3RhYmxlcmFuZ2U6MjhlZWRlYThhZjA5NDM2NzkzN2U4NTQwMzExZTU4MmFfNC0xLTEtMS0xNTQ2OA_13c8e75a-bdfe-4195-b0ce-2155427e2266">4,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjI4ZWVkZWE4YWYwOTQzNjc5MzdlODU0MDMxMWU1ODJhL3RhYmxlcmFuZ2U6MjhlZWRlYThhZjA5NDM2NzkzN2U4NTQwMzExZTU4MmFfNS0xLTEtMS0xNTQ2OA_37021e35-7ee6-4f7e-b5a3-ba2726df3c6a">4,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="bdtx:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjI4ZWVkZWE4YWYwOTQzNjc5MzdlODU0MDMxMWU1ODJhL3RhYmxlcmFuZ2U6MjhlZWRlYThhZjA5NDM2NzkzN2U4NTQwMzExZTU4MmFfNi0xLTEtMS0xNTQ2OA_c9233ae9-cd5a-4bb3-8528-4c702eb7d60d">16,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjI4ZWVkZWE4YWYwOTQzNjc5MzdlODU0MDMxMWU1ODJhL3RhYmxlcmFuZ2U6MjhlZWRlYThhZjA5NDM2NzkzN2U4NTQwMzExZTU4MmFfNy0xLTEtMS0xNTQ2OA_b72808c3-b370-4b32-9c2e-06e34c96925a">35,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less: interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjI4ZWVkZWE4YWYwOTQzNjc5MzdlODU0MDMxMWU1ODJhL3RhYmxlcmFuZ2U6MjhlZWRlYThhZjA5NDM2NzkzN2U4NTQwMzExZTU4MmFfOC0xLTEtMS0xNTQ2OA_76e6e2ea-0fa3-4ae8-ba02-dcd659ccdace">7,646</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjI4ZWVkZWE4YWYwOTQzNjc5MzdlODU0MDMxMWU1ODJhL3RhYmxlcmFuZ2U6MjhlZWRlYThhZjA5NDM2NzkzN2U4NTQwMzExZTU4MmFfOS0xLTEtMS0xNTQ2OA_3c466d58-50aa-44b7-833e-8879355e2aeb">28,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div><span><br/></span></div><div id="i9b58afd7c815450f9ef9acc3673fe027_61"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN182MS9mcmFnOmU0YjJmZWE4NDlkNzQ3YzNiNzk5YTQ5MmI5ZDU4YzUyL3RleHRyZWdpb246ZTRiMmZlYTg0OWQ3NDdjM2I3OTlhNDkyYjlkNThjNTJfMjU3Ng_cdbe2b72-f37e-4f15-90e8-73385894f754" continuedAt="i9b99c79359394f159269035c0bd715f1" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i9b99c79359394f159269035c0bd715f1"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We enter into contracts in the normal course of business with contract research organizations ("CROs"), contract manufacturing organizations ("CMOs") and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts do not contain minimum purchase commitments and are cancelable upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of service providers, up to the date of cancellation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">License agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is party to license agreements, which include contingent payments. These payments will become payable if and when certain development, regulatory and commercial milestones are achieved. As of March&#160;31, 2022, the satisfaction and timing of the contingent payments is uncertain and not reasonably estimable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Indemnification agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of March&#160;31, 2022 or December&#160;31, 2021. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Legal proceedings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is not currently party to and is not aware of any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">19</span></div></div></div><div id="i9b58afd7c815450f9ef9acc3673fe027_64"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN182NC9mcmFnOjM0NmZmOWRmNmQ0NDQzZjVhOTc5ZGIwMmNjY2JhMTI3L3RleHRyZWdpb246MzQ2ZmY5ZGY2ZDQ0NDNmNWE5NzlkYjAyY2NjYmExMjdfNzMz_ee5c6815-e292-4a3e-93a7-8e92d1ffaeb7" continuedAt="ia83af391541943789be8e3e1d9095d36" escape="true">BENEFIT PLANS</ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:continuation id="ia83af391541943789be8e3e1d9095d36">The Company has a tax-qualified 401(k) and Profit Sharing defined contribution plan (the &#8220;401(k) Plan&#8221;). Under the 401(k) Plan, the Company provides an employer safe harbor matching contribution equal to <ix:nonFraction unitRef="number" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="0" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN182NC9mcmFnOjM0NmZmOWRmNmQ0NDQzZjVhOTc5ZGIwMmNjY2JhMTI3L3RleHRyZWdpb246MzQ2ZmY5ZGY2ZDQ0NDNmNWE5NzlkYjAyY2NjYmExMjdfMzI1_e3d31346-7c5d-40dd-bedf-ba73dc27b088">100</ix:nonFraction>% of a participant&#8217;s eligible contributions of up to <ix:nonFraction unitRef="number" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN182NC9mcmFnOjM0NmZmOWRmNmQ0NDQzZjVhOTc5ZGIwMmNjY2JhMTI3L3RleHRyZWdpb246MzQ2ZmY5ZGY2ZDQ0NDNmNWE5NzlkYjAyY2NjYmExMjdfMzc5_84db80ae-8ba3-427a-ae1b-8d82c8594dd1">6</ix:nonFraction>% of eligible compensation, subject to limits established by the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the &#8220;Code&#8221;). All matching contributions are fully vested when made. During the three months ended March&#160;31, 2022 and 2021 the Company contributed $<ix:nonFraction unitRef="usd" contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331" decimals="-3" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN182NC9mcmFnOjM0NmZmOWRmNmQ0NDQzZjVhOTc5ZGIwMmNjY2JhMTI3L3RleHRyZWdpb246MzQ2ZmY5ZGY2ZDQ0NDNmNWE5NzlkYjAyY2NjYmExMjdfNjY4_0bd7d25b-9760-4813-9caa-d60ed0625e0c">558</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331" decimals="-3" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN182NC9mcmFnOjM0NmZmOWRmNmQ0NDQzZjVhOTc5ZGIwMmNjY2JhMTI3L3RleHRyZWdpb246MzQ2ZmY5ZGY2ZDQ0NDNmNWE5NzlkYjAyY2NjYmExMjdfNzAx_60ad13f6-58ac-4c31-8adc-69732e726417">345</ix:nonFraction> to the 401(k) Plan, respectively.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">20</span></div></div></div><div id="i9b58afd7c815450f9ef9acc3673fe027_70"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis should be read in conjunction with the unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report and our audited consolidated financial statements and related notes thereto for the year ended December 31, 2021 included in our Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the SEC on March 17, 2022. This discussion and analysis and other parts of this Quarterly Report contain forward-looking statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth in our Annual Report on Form 10-K and in other SEC filings.</span></div><div id="i9b58afd7c815450f9ef9acc3673fe027_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are a precision oncology medicine company pioneering the discovery and development of MasterKey therapies. We target undrugged oncogenic driver mutations in patients with genetically defined cancers. The foundation of our company is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. Our proprietary technology platform, which we refer to as our Mutation-Allostery-Pharmacology, or MAP, drug discovery engine, is designed to allow us to analyze population-level genetic sequencing data to discover oncogenic mutations that promote cancer across tumor types. Our goal is to identify families of mutations that can be inhibited with MasterKey therapies thereby providing precision oncology to greater numbers of patients with genetically defined tumors. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We have designed our product candidates, including BDTX-1535 and BDTX-4933, to potently and selectively inhibit families of oncogenic mutations which occur across a range of tumor types. BDTX-1535 was designed to bind to the active site of the ErbB-1 epidermal growth factor receptor, or EGFR, while sparing normal, or wild type EGFR (WT-EGFR) activity which we believe will improve upon the toxicity profiles of current EGFR family inhibitors. The brain penetration properties of BDTX-1535 support the potential treatment of GBM and NSCLC patients with or without brain disease. BDTX-4933 was designed to inhibit families of Class I, II and III canonical and non-canonical mutations. In addition to being a highly selective and potent inhibitor, BDTX-4933 avoids paradoxical activation and is brain penetrant for the treatment of patients with or without brain tumors. We are also leveraging our MAP drug discovery engine to identify other families of non-canonical mutations in validated oncogenes, which has the potential to expand the reach of targeted therapies. In April 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> we announced the discontinuation of the development of BDTX-189 to focus on progressing our pipeline through important upcoming milestones for BDTX-1535 and BDTX-4933 as well as discovery efforts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Since our inception in 2014, we have devoted substantially all of our efforts and financial resources to organizing and staffing our company, business planning, raising capital, discovering product candidates and securing related intellectual property rights while conducting research and development activities for our programs. We do not have any products approved for sale and have not generated any revenue from product sales. We may never be able to develop or commercialize a marketable product. We have not yet successfully completed any pivotal clinical trials, obtained any regulatory approvals, manufactured a commercial-scale drug, or conducted sales and marketing activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To date, we have funded our operations with proceeds from the sale of preferred stock and common stock. Since inception we have incurred significant operating losses. Our net losses were $25.5 million and $30.3 million for the three months ended March&#160;31, 2022 and 2021, respectively. As of March&#160;31, 2022, we had an accumulated deficit of $269.3 million. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates. We expect that our expenses and capital requirements will increase substantially in connection with our ongoing activities, particularly if and as we: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">advance clinical studies for BDTX-1535 and continue preclinical studies for BDTX-4933 and our other product candidates; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">continue to identify additional product candidates from our proprietary MAP drug discovery engine; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">obtain, maintain, expand and protect our intellectual property portfolio; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">hire additional clinical, scientific and commercial personnel; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">seek marketing approvals for our product candidates that successfully complete clinical trials, if any; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">acquire or in-license additional product candidates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, which may include collaborations with other companies or other strategic transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our product candidates or delay our pursuit of potential in-licenses or acquisitions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had cash, cash equivalents and investments of approximately $179.7 million, which we believe will fund our operating expenses and capital expenditure requirements into the third quarter of 2024. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See &#8220;&#8212;Liquidity and capital resources.&#8221; To finance our operations beyond that point, we will need to raise additional capital, which cannot be assured. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">COVID-19 considerations </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The ongoing COVID-19 pandemic is evolving, and to date has led to the implementation of various responses, including government-imposed quarantines, travel restrictions, and other public health safety measures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has been closely monitoring the impact of the ongoing COVID-19 pandemic on all aspects of the Company&#8217;s business, including how it has impacted and may continue to impact the Company&#8217;s operations and the operations of its suppliers, vendors and business partners, and may take further precautionary and preemptive actions as may be required by federal, state or local authorities. In addition, the Company has taken steps to minimize the current environment&#8217;s impact on its business and strategy, including devising contingency plans and securing additional resources from third party service providers. Furthermore, for the safety of the Company&#8217;s employees and families, the Company has introduced enhanced safety measures for scientists to be present in its labs and increased the use of third party service providers for the conduct of certain experiments and studies for research programs. Certain of the Company&#8217;s third party service providers have also experienced shutdowns or other business disruptions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The extent to which COVID-19 ultimately impacts the Company&#8217;s business, results of operations or financial condition will depend on future developments, which, despite progress in vaccination efforts, remain highly uncertain and cannot be predicted with confidence, such as the duration of the COVID-19 pandemic, new strains of the virus, including any future variants that may emerge, which may impact rates of infection and vaccination efforts, developments or perceptions regarding the safety of vaccines, new information that may emerge concerning the severity of COVID-19, and any additional preventative and protective actions taken to contain the pandemic or treat its impact, among others. The Company does not yet know the full extent of potential delays or impacts on the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Company&#8217;s business, clinical trials, research programs, healthcare systems or the global economy and cannot presently predict the scope and severity of any potential business shutdowns or disruptions but if we or any of the third parties with whom we engage were to experience prolonged business shutdowns or other disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on our business, results of operations and financial condition. The estimates of the impact on our business may change based on new information that may emerge concerning COVID-19 and the actions to contain it or treat its impact and the economic impact on local, regional, national and international markets.</span></div><div id="i9b58afd7c815450f9ef9acc3673fe027_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Components of our results of operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from any sources, including from product sales, and we do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, or license agreements with third parties, we may generate revenue in the future from product sales. However, there can be no assurance as to when we will generate such revenue, if at all. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Operating expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for our research activities, including our drug discovery efforts and the development of our product candidates. We expense research and development costs as incurred, which include: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">expenses incurred to conduct the necessary preclinical studies and clinical trials required to obtain regulatory approval; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">expenses incurred under agreements with contract research organizations, or CROs, that are primarily engaged in the oversight and conduct of our drug discovery efforts and preclinical studies, clinical trials and contract manufacturing organizations, or CMOs, that are primarily engaged to provide preclinical and clinical drug substance and product for our research and development programs; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">other costs related to acquiring and manufacturing materials in connection with our drug discovery efforts and preclinical studies and clinical trial materials, including manufacturing validation batches, as well as investigative sites and consultants that conduct our clinical trials, preclinical studies and other scientific development services; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">payments made in cash or equity securities under third-party licensing, acquisition and option agreements; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">employee-related expenses, including salaries and benefits, travel and stock-based compensation expense for employees engaged in research and development functions; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">costs related to compliance with regulatory requirements; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">allocated facilities-related costs, depreciation and other expenses, which include rent and utilities. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. Any nonrefundable advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such amounts are expensed as the related goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered or the services rendered. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our direct external research and development expenses consist primarily of external costs, such as fees paid to outside consultants, CROs, CMOs and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. Our direct research and development expenses also include fees incurred under license, acquisition and option agreements. We do not allocate employee costs, costs associated with our discovery efforts, laboratory supplies, and facilities, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources primarily to conduct our research and discovery as well as for managing our preclinical development, process development, manufacturing and clinical development activities. These employees work across multiple programs and, therefore, we do not track their costs by program. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect that our research and development expenses will increase substantially over the next several years as we continue our clinical trials for BDTX-1535, as well as conduct other preclinical and clinical development, including submitting regulatory filings for other product candidates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We expect our discovery research efforts and our related personnel costs will increase and, as a result, we expect our research and development expenses, including costs associated with stock-based compensation, will increase above historical levels. In addition, we may incur additional expenses related to milestone and royalty payments payable to third parties with whom we may enter into license, acquisition and option agreements to acquire the rights to future product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any of our product candidates or when, if ever, material net cash inflows may commence from any of our product candidates. The successful development and commercialization of our product candidates is highly uncertain. This uncertainty is due to the numerous risks and uncertainties associated with product development and commercialization, including the uncertainty of the following: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the scope, progress, outcome and costs of our preclinical development activities, clinical trials and other research and development activities; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">establishing an appropriate safety and efficacy profile with IND-enabling studies; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">successful patient enrollment in and the initiation and completion of clinical trials; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the timing, receipt and terms of any marketing approvals from applicable regulatory authorities including the FDA and non-U.S. regulators; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the extent of any required post-marketing approval commitments to applicable regulatory authorities; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">establishing clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers in order to ensure that we or our third-party manufacturers are able to make product successfully; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">development and timely delivery of clinical-grade and commercial-grade drug formulations that can be used in our clinical trials and for commercial launch; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">significant and changing government regulation; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">maintaining a continued acceptable safety profile of our product candidates following approval, if any, of our product candidates. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any changes in the outcome of any of these variables with respect to the development of our product candidates in preclinical and clinical development could mean a significant change in the costs and timing associated with the development of these product candidates. For example, if the FDA or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development of that product candidate. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and benefits, travel and stock-based compensation expense for personnel in executive, business development, finance, human resources, legal, information technology, pre-commercial and support personnel functions. General and administrative expenses also include direct and allocated facility-related costs as well as insurance costs and professional fees for legal, patent, consulting, investor and public relations, accounting and audit services. </span></div><div style="margin-top:12pt;padding-left:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research activities and development of our product candidates and prepare for potential commercialization activities. We also anticipate that we will incur significantly increased accounting, audit, legal, regulatory, compliance and director and officer insurance costs as well as investor and public relations expenses associated with operating as a public company. Additionally, if and when we believe a regulatory approval of a product candidate appears likely, we anticipate an increase in payroll and other employee-related expenses as a result of our preparation for commercial operations, especially as it relates to the sales and marketing of that product candidate. </span></div><div style="margin-top:12pt;padding-left:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Other income (expense)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other income (expense) consists primarily of interest income earned on our cash equivalents and investment balances, and realized and unrealized foreign currency transaction gains and losses. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">25</span></div></div></div><div id="i9b58afd7c815450f9ef9acc3673fe027_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Results of operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">three months</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">ended March&#160;31, 2022 and 2021</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended March&#160;31, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17,786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">22,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(5,034)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25,679&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30,713&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(5,034)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(25,679)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(30,713)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,034&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(746)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other (expense) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(740)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(240)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(25,507)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(30,301)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,794&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development expenses were $17.8 million for the three months ended March&#160;31, 2022, compared to $22.8 million for the three months ended March&#160;31, 2021. The following table summarizes our research and development expenses for the three months ended March&#160;31, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">BDTX-189 research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,118&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(5,635)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">BDTX-1535 research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other research programs and platform development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2,362)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Personnel expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Allocated facility expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17,786&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">22,820&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(5,034)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The decrease of $5.0 million was primarily due to a decrease of $5.6 million in spend relating to BDTX-189 associated with reduced trial activities stemming from the gating of the initiation of the Phase 2 portion of the MasterKey-01 study. In April 2022, we announced the discontinuation of the development of BDTX-189 to focus on upcoming milestones for our pipeline programs, BDTX-1535 and BDTX-4933. In addition, we decreased spend relating to other research programs and platform development by $2.4 million for the three months ended March&#160;31, 2022 due to reduced spending on early discovery projects, compared to the three months ended March&#160;31, 2021. Personnel expenses increased $1.3 million as we have increased our headcount and related personnel expenses. Facility costs increased $0.5 million for the three months ended March&#160;31, 2022, compared to the three months ended March&#160;31, 2021 due to the signing of a new lease.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General and administrative</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General and administrative expenses were $7.9 million for the three months ended March&#160;31, 2022 and 2021. This was primarily a result of flat personnel-related costs, legal, and other professional fees.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Other income (expense) </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other income was $0.2 million for the three months ended March&#160;31, 2022, compared to $0.4 million for the three months ended March&#160;31, 2021. The decrease was primarily attributable to amortization of premium on investments decreasing at a higher rate in 2022 compared to 2021 and interest income decreasing due to market conditions.</span></div><div id="i9b58afd7c815450f9ef9acc3673fe027_82"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Liquidity and capital resources</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Sources of liquidity</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Since our inception, we have not generated any revenue from any product sales or any other sources and have incurred significant operating losses and negative cash flows from our operations. We have not yet commercialized any of our product candidates, and we do not expect to generate revenue from sales of any product candidates for several years, if at all. We have funded our operations to date primarily with proceeds from the sale of preferred stock. On February 3, 2020, we completed an IPO of 12,174,263 shares of our common stock, including the exercise in full by the underwriters of their option to purchase up to 1,587,947 additional shares of common stock, for aggregate gross proceeds of $231.3&#160;million. We received $212.1&#160;million in net proceeds after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. Through March&#160;31, 2022, we had received net cash proceeds of $200.6 million from previous sales of our preferred stock and as of March&#160;31, 2022, we had cash, cash equivalents and investments of $179.7&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Cash flows</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes our sources and uses of cash for each of the periods presented (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.839%"><tr><td style="width:1.0%"></td><td style="width:71.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.808%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(28,600)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(24,455)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash provided by investing activities</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16,729&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,474&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash provided by financing activities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net decrease in cash and cash equivalents</span></div></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(11,718)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(20,500)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Operating activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, we used cash in operating activities of $28.6&#160;million, primarily resulting from our net loss of $25.5&#160;million, partially offset by the non-cash charge related to stock compensation expense of $3.4&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, we used cash in operating activities of $24.5&#160;million, primarily resulting from our net loss of $30.3&#160;million, partially offset by the non-cash charge related to stock compensation expense of $3.1&#160;million and an increase in prepaid expenses and other current assets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Changes in accounts payable and accrued expenses in all periods were generally due to growth in our business, the advancement of our product candidates, and the timing of vendor invoicing and payments. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Investing activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, we had cash provided by investing activities of $16.7&#160;million primarily from the sales and maturities of investments. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, we had cash provided by investing activities of $3.5&#160;million primarily from the sales and maturities of investments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Financing activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, we had cash provided by financing activities of $0.2&#160;million, consisting of proceeds from exercise of stock options and participation in the employee stock purchase plan. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, we had cash provided by financing activities of $0.5&#160;million consisting of proceeds from exercise of stock options.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Funding requirements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials of our product candidates. In addition, we expect to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses. The timing and amount of our operating expenditures will depend largely on our ability to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">advance BDTX-1535 through clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">advance preclinical development of our early stage programs, including BDTX-4933, currently in IND-enabling studies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">manufacture, or have manufactured on our behalf, our preclinical and clinical drug material and develop processes for late state and commercial manufacturing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">seek regulatory approvals for any product candidates that successfully complete clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval and intend to commercialize on our own;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">hire additional clinical, quality control and scientific personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">expand our operational, financial and management systems and increase personnel, including personnel to support our clinical development, manufacturing and commercialization efforts and our operations as a public company; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">obtain, maintain, expand and protect our intellectual property portfolio.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had cash, cash equivalents and investments of $179.7 million, which we believe will fund our operating expenses and capital expenditure requirements into the third quarter of 2024. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. We anticipate that we will require additional capital as we seek regulatory approval of our product candidates and if we choose to pursue in-licenses or acquisitions of other product candidates. If we receive regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with research, development and commercialization of product candidates, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could increase significantly as a result of many factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the scope, progress, results and costs of researching and developing our product candidates, and conducting preclinical and clinical trials;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the costs, timing and outcome of regulatory review of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the costs, timing and ability to manufacture our product candidates to supply our clinical and preclinical development efforts and our clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the costs of manufacturing commercial-grade product and necessary inventory to support commercial launch;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the ability to receive additional non-dilutive funding;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the revenue, if any, received from commercial sale of our products, should any of our product candidates receive marketing approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining, expanding and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our ability to establish and maintain collaborations on favorable terms, if at all; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the extent to which we acquire or in-license other product candidates and technologies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of public or private equity offerings, debt financings, collaborations, strategic partnerships and alliances or marketing, distribution or licensing arrangements with third parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. In addition, debt financing would result in fixed payment obligations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If we raise additional funds through collaborations, strategic partnerships and alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div id="i9b58afd7c815450f9ef9acc3673fe027_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contractual obligations and commitments</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following summarizes our contractual obligations as of March&#160;31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Payments Due by Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less than 1 Year</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1 to 3 Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3 to 5 Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">More than 5 Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property leases - commenced</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9,137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15,801&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">35,892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,293&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,661&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9,137&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15,801&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">35,892&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Property leases &#8211; commenced</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The amounts reported for property leases represent future minimum lease payments under non-cancelable operating leases in effect as of March&#160;31, 2022. The minimum lease payments do not include common area maintenance charges or real estate taxes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Other contractual obligations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The contractual obligations table does not include any potential future milestone payments or royalty payments we may be required to make under our existing license agreements due to the uncertainty of the occurrence of the events requiring payment under those agreements.</span></div><div id="i9b58afd7c815450f9ef9acc3673fe027_91"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Critical accounting policies and significant judgments and use of estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of our condensed consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our critical accounting policies are described under the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212; Critical Accounting Policies and Use of Estimates&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the SEC on March 17, 2022. During the three months ended March&#160;31, 2022, there were no material changes to our critical accounting policies from those previously disclosed.</span></div><div id="i9b58afd7c815450f9ef9acc3673fe027_94"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note&#160;2 to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report.</span></div><div id="i9b58afd7c815450f9ef9acc3673fe027_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Emerging growth company and smaller reporting company status </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Jumpstart Our Business Startups Act of 2012 permits an &#8220;emerging growth company&#8221; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected to not &#8220;opt out&#8221; of this provision and, as a result, we will adopt new or revised accounting standards at the time private companies adopt the new or revised accounting standard and will do so until such time that we either (i) irrevocably elect to &#8220;opt out&#8221; of such extended transition period or (ii) no longer qualify as an emerging growth company. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are also a &#8220;smaller reporting company&#8221; meaning that the market value of our stock held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</span></div><div id="i9b58afd7c815450f9ef9acc3673fe027_100"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosure About Market Risk</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">30</span></div></div></div><div id="i9b58afd7c815450f9ef9acc3673fe027_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Interim Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) as of the end of the period covered by this Quarterly Report. Based on that evaluation, our Chief Executive Officer and Interim Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March&#160;31, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the period covered by this Quarterly Report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">31</span></div></div></div><div id="i9b58afd7c815450f9ef9acc3673fe027_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PART II - OTHER INFORMATION</span></div><div id="i9b58afd7c815450f9ef9acc3673fe027_109"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The information required with respect to this item can be found under &#8220;Legal Proceedings&#8221; in Note 10 to our condensed financial statements included elsewhere in this Quarterly Report on Form 10-Q and is incorporated by reference into this Item 1. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business, the resolution of which we do not anticipate would have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.</span></div><div id="i9b58afd7c815450f9ef9acc3673fe027_112"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Our business faces significant risks and uncertainties. Certain important factors may have a material adverse effect on our business prospects, financial condition and results of operations, and you should carefully consider them. Accordingly, in evaluating our business, we encourage you to carefully consider the discussion of risk factors in Part I, &#8220;Item 1A. Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2021, which could materially affect our business, financial condition or future results, in addition to other information contained in or incorporated by reference into this Quarterly Report on Form 10-Q and our other public filings with the Securities and Exchange Commission, or the SEC. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business, prospects, financial condition and results of operations. Certain statements in this Quarterly Report are forward-looking statements. Please also see the section entitled &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</span></div><div id="i9b58afd7c815450f9ef9acc3673fe027_115"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Recent Sales of Unregistered Equity Securities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Use of Proceeds from IPO of Common Stock</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On February 3, 2020, we completed the IPO of our common stock pursuant to which we issued and sold 12,174,263 shares of our common stock, including the exercise in full by the underwriters of their option to purchase up to 1,587,947 additional shares of common stock, at a public offering price of $19.00 per share.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The offer and sale of all of the shares of our common stock in our IPO were registered under the Securities Act pursuant to a registration statement on Form S-1, as amended (File No. 333-235789), which was declared effective by the SEC on January 29, 2020. J.P. Morgan Securities LLC, Jefferies LLC, Cowen and Company, LLC and Canaccord Genuity LLC acted as joint book-running managers of the offering and as representatives of the underwriters.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We received aggregate gross proceeds from our IPO of $231.3 million, or aggregate net proceeds of $212.1 million after deducting underwriting discounts and commissions and other offering costs. None of the underwriting discounts and commissions or offering expenses were incurred or paid, directly or indirectly, to any of our directors or officers or their associates or to persons owning 10% or more of our common stock or to any of our affiliates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There has been no material change in our planned use of the net proceeds from the IPO as described in our final prospectus, filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act on January 30, 2020.</span></div><div id="i9b58afd7c815450f9ef9acc3673fe027_118"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">None.</span></div><div id="i9b58afd7c815450f9ef9acc3673fe027_121"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">32</span></div></div></div><div id="i9b58afd7c815450f9ef9acc3673fe027_124"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span><br/></span></div><div id="i9b58afd7c815450f9ef9acc3673fe027_127"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The exhibits listed on the Exhibit Index immediately preceding such exhibits, which is incorporated herein by reference, are filed or furnished as part of this Quarterly Report.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.131%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit</span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">No.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1#*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline" href="bdtx-nonxemployeedirectorc.htm">Amended and Restated Non-Employee Director Compensation Plan.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit311_q12022.htm">Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit312_q12022.htm">Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1*+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit321_q12022.htm">Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Labels Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.)</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.945%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.137%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed herewith.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indicates a management contract or any compensatory plan, contract or arrangement. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This certification will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.</span></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">34</span></div></div></div><div id="i9b58afd7c815450f9ef9acc3673fe027_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i9b58afd7c815450f9ef9acc3673fe027_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.033%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Black Diamond Therapeutics, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Date: May 11, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">/s/ David M. Epstein</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">David M. Epstein</span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">President and Chief Executive Officer</span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(Principal Executive Officer)</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.033%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Black Diamond Therapeutics, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Date: May 11, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">/s/ Fang Ni</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Fang Ni</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Chief Business and Interim Chief Financial Officer</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(Principal Financial Officer)</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">35</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>bdtx-nonxemployeedirectorc.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i97bde1e029cd45c7be4f338803bfbe89_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BLACK DIAMOND THERAPEUTICS, INC.</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:77.65pt;padding-right:77.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THIRD AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY</font></div><div style="margin-top:0.75pt"><font><br></font></div><div style="padding-right:2.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The purpose of this Non-Employee Director Compensation Policy (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of Black Diamond Therapeutics, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries. In furtherance of the purpose stated above, all non-employee directors shall be paid compensation for services provided to the Company as set forth below&#58;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-right:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:113%;text-decoration:underline">Cash Retainers</font></div><div style="margin-top:0.55pt;padding-right:22.5pt"><font><br></font></div><div style="margin-top:1.45pt;padding-right:3.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Annual Retainer for Board Membership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;   $35,000 for general availability and participation in meetings and conference calls of our Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), to be paid quarterly in arrears, pro-rated based on the number of actual days served by the director during such calendar quarter.</font></div><div style="margin-top:1.45pt;padding-right:3.05pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.45pt;padding-left:2.75pt;padding-right:5.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Additional Annual Retainer for Non-Executive Chair of the Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline"> </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.45pt;padding-left:2.75pt;padding-right:5.8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">$30,000 </font></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:1.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Additional Retainers for Committee Membership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#58;</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-top:1.45pt;padding-left:2.75pt;padding-right:5.8pt;text-align:right"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-top:1.45pt;padding-left:2.75pt;padding-right:5.8pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.45pt;padding-left:2.75pt;padding-right:5.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Audit Committee Chair&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.45pt;padding-left:2.75pt;padding-right:5.8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">$15,000</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-top:1.45pt;padding-left:2.75pt;padding-right:5.8pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.45pt;padding-left:2.75pt;padding-right:5.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Audit Committee member&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.45pt;padding-left:2.75pt;padding-right:5.8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">$7,500</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-top:1.45pt;padding-left:2.75pt;padding-right:5.8pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.45pt;padding-left:2.75pt;padding-right:5.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Compensation Committee Chair&#58; </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.45pt;padding-left:2.75pt;padding-right:5.8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">$10,000</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-top:1.45pt;padding-left:2.75pt;padding-right:5.8pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.45pt;padding-left:2.75pt;padding-right:5.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Compensation Committee member&#58; </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.45pt;padding-left:2.75pt;padding-right:5.8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">$5,000</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-top:1.45pt;padding-left:2.75pt;padding-right:5.8pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.45pt;padding-left:2.75pt;padding-right:5.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Nominating and Corporate Governance Committee Chair&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.45pt;padding-left:2.75pt;padding-right:5.8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">$8,000</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-top:1.45pt;padding-left:2.75pt;padding-right:5.8pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.45pt;padding-left:2.75pt;padding-right:5.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Nominating and Corporate Governance Committee member&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.45pt;padding-left:2.75pt;padding-right:5.8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">$4,000</font></div></td></tr></table></div><div><font><br></font></div><div style="padding-right:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Note&#58; Chair and committee member retainers are in addition to retainers for members of the Board. </font></div><div style="padding-right:3pt"><font><br></font></div><div style="padding-right:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each non-employee director may elect to receive all or a portion of his or her cash compensation in the form of unrestricted shares having a grant date fair value equal to the amount (or portion thereof) of such compensation.  Any such election (i) shall be made (x) for any continuing non-employee director, before the start of the calendar year with respect to any cash compensation for such calendar year and (y) for any new non-employee director, within 30 days of her or his election to the Board, (ii) shall be irrevocable with respect to such calendar year and (iii) shall automatically apply to the cash compensation for each subsequent calendar year unless otherwise revoked prior to the start of such calendar year. </font></div><div style="padding-right:3pt"><font><br></font></div><div style="padding-right:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:113%;text-decoration:underline">Equity Retainers</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; An initial, one-time equity award (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of an option to purchase 30,000 shares of our common stock to each new non-employee director upon his or her election to the Board, which shall vest in 36 equal monthly installment from the date of vesting commencement, provided, however, that all vesting shall cease if the director resigns from the Board or otherwise ceases to serve as a director of the Company.  This Initial Award applies only to non-employee directors who are first elected to the Board subsequent to the Company&#8217;s initial public offering.  If the Initial Award is in the form of a stock option, such stock option shall have </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a per share exercise price equal to the Fair Market Value (as defined in the Company&#8217;s 2020 Stock Option and Incentive Plan) of the Company&#8217;s common stock on the date of grant.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Annual Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  On each date of the Company&#8217;s Annual Meeting of Stockholders following the completion of the Company&#8217;s initial public offering (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Annual Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), each continuing non-employee member of the Board, other than a director receiving an Initial Award, will receive an annual equity award (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Annual Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of an option to purchase 15,000 shares of our common stock, which shall vest in full on the earlier of the date that is one year from the date of grant or the date of the first annual meeting of the Company&#8217;s stockholders held after the date of grant&#59; provided, however, that all vesting shall cease if the director resigns from the Board or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting.  If the Annual Award is in the form of a stock option, such stock option shall have a per share exercise price equal to the Fair Market Value (as defined in the Company&#8217;s 2020 Stock Option and Incentive Plan) of the Company&#8217;s common stock on the date of grant.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:113%;text-decoration:underline">Expenses</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:1.45pt;padding-right:2.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company will reimburse all reasonable out-of-pocket expenses incurred by non-employee directors in attending meetings of the Board or any Committee.</font></div><div style="margin-top:0.3pt;padding-left:9pt"><font><br></font></div><div style="padding-left:9pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Originally adopted by the Board on December 5, 2019.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Amended and Restated by the Board on September 25, 2020, February 17, 2021 and April 27, 2022.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exhibit311_q12022.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2631c00b550d4da0a82eccd017ed3412_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 31.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-14(a) OR 15d-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I, David M. Epstein, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.75pt">I have reviewed this Quarterly Report on Form 10-Q for the period ended March 31, 2022 of Black Diamond Therapeutics, Inc.&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.68pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.68pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.68pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:43.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.795%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.597%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; May&#160;11, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; David M. Epstein</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">David M. Epstein</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">President, Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and Director</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>exhibit312_q12022.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i818dcadbc6ab4302a75c29a7bf2c4ac9_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 31.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-14(a) OR 15d-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I, Fang Ni, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.75pt">I have reviewed this Quarterly Report on Form 10-Q for the period ended March 31, 2022 of Black Diamond Therapeutics, Inc.&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.68pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.68pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.68pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:52.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.616%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; May&#160;11, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Fang Ni</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Fang Ni</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Business and Interim Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Principal Financial Officer)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>exhibit321_q12022.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i781f100f3db142cd8ee668cd16c021ca_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 32.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, David M. Epstein, the Principal Executive Officer, and Fang Ni, the Principal Financial Officer, of Black Diamond Therapeutics, Inc. (the &#8220;Company&#8221;), hereby certify, that, to their knowledge&#58; </font></div><div style="text-indent:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:4.02pt">the Quarterly Report on Form 10-Q for the period ended March 31, 2022 (the &#8220;Report&#8221;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="text-indent:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.02pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:47.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.292%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; May&#160;11, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; David M. Epstein</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">David M. Epstein</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">President, Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and Director</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:47.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.292%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; May&#160;11, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Fang Ni</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Fang Ni</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Business and Interim Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Principal Financial Officer)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>bdtx-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:674e53d2-18f0-47df-b195-3621df688bf3,g:abed15df-df65-4b1b-8a1f-1c79fbf06613-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bdtx="http://www.blackdiamondtherapeutics.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.blackdiamondtherapeutics.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bdtx-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bdtx-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bdtx-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bdtx-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.blackdiamondtherapeutics.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityUnaudited" roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFBUSINESSANDBASISOFPRESENTATION" roleURI="http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION">
        <link:definition>2101101 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails">
        <link:definition>2402401 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2103102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2204201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>2105103 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>2306301 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails">
        <link:definition>2407402 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTS" roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTS">
        <link:definition>2108104 - Disclosure - INVESTMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTSTables" roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables">
        <link:definition>2309302 - Disclosure - INVESTMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTSScheduleofMarketableSecuritiesDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails">
        <link:definition>2410403 - Disclosure - INVESTMENTS - Schedule of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTSAdditionalInformationDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSAdditionalInformationDetails">
        <link:definition>2411404 - Disclosure - INVESTMENTS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENT" roleURI="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT">
        <link:definition>2112105 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTTables" roleURI="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables">
        <link:definition>2313303 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails">
        <link:definition>2414405 - Disclosure - PROPERTY AND EQUIPMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" roleURI="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES">
        <link:definition>2115106 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" roleURI="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables">
        <link:definition>2316304 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails">
        <link:definition>2417406 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>2118107 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>2319305 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>2420407 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails">
        <link:definition>2421408 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails">
        <link:definition>2422409 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails">
        <link:definition>2423410 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHARE" roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE">
        <link:definition>2124108 - Disclosure - NET LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHARETables" roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables">
        <link:definition>2325306 - Disclosure - NET LOSS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHAREComputationofNetLossperShareDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails">
        <link:definition>2426411 - Disclosure - NET LOSS PER SHARE - Computation of Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails">
        <link:definition>2427412 - Disclosure - NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://www.blackdiamondtherapeutics.com/role/LEASES">
        <link:definition>2128109 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESTables">
        <link:definition>2329307 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESNarrativeDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails">
        <link:definition>2430413 - Disclosure - LEASES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails">
        <link:definition>2431414 - Disclosure - LEASES - Summary of Lease Cost and Other Operating Lease Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofFutureMinimumLeasePaymentsDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails">
        <link:definition>2432415 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofFutureMinimumLeasePaymentsDetails_1" roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1">
        <link:definition>2432415 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2133110 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BENEFITPLANS" roleURI="http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS">
        <link:definition>2134111 - Disclosure - BENEFIT PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BENEFITPLANSDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails">
        <link:definition>2435416 - Disclosure - BENEFIT PLANS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="bdtx_OperatingLeasePrincipalOfficeTwoMember" abstract="true" name="OperatingLeasePrincipalOfficeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bdtx_OperatingLeasePrincipalOfficeOneMember" abstract="true" name="OperatingLeasePrincipalOfficeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bdtx_A2020StockOptionPlanMember" abstract="true" name="A2020StockOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember" abstract="true" name="OperatingLeaseOfficeAndLaboratorySpaceNYMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bdtx_PerformanceRestrictedStockUnitsMember" abstract="true" name="PerformanceRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" abstract="false" name="DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bdtx_AccruedContractResearchServiceFeesCurrent" abstract="false" name="AccruedContractResearchServiceFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bdtx_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bdtx_RentExpense" abstract="false" name="RentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bdtx_OpenMarketSaleMember" abstract="true" name="OpenMarketSaleMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bdtx_LeaseOtherInformationAbstract" abstract="true" name="LeaseOtherInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bdtx_LesseeOperatingLeaseNumberOfContracts" abstract="false" name="LesseeOperatingLeaseNumberOfContracts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bdtx_OtherAwardTypeMember" abstract="true" name="OtherAwardTypeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bdtx_LesseeOperatingLeaseArea" abstract="false" name="LesseeOperatingLeaseArea" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="bdtx_A2020EmployeeStockPurchasePlanMember" abstract="true" name="A2020EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>bdtx-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:674e53d2-18f0-47df-b195-3621df688bf3,g:abed15df-df65-4b1b-8a1f-1c79fbf06613-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="bdtx-20220331.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_204ccc92-d369-413d-b515-79aafca6140e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e46dba48-6dd5-4604-a14f-7d4105e3792f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_204ccc92-d369-413d-b515-79aafca6140e" xlink:to="loc_us-gaap_StockholdersEquity_e46dba48-6dd5-4604-a14f-7d4105e3792f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_967d4283-e1ec-4682-ba20-df2241913966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_204ccc92-d369-413d-b515-79aafca6140e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_967d4283-e1ec-4682-ba20-df2241913966" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3b81de1e-5302-4cd4-8489-48a858482d97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_204ccc92-d369-413d-b515-79aafca6140e" xlink:to="loc_us-gaap_Liabilities_3b81de1e-5302-4cd4-8489-48a858482d97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4062c356-412e-46f6-97f8-a9aeee7cb03e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1cfaca9b-341a-48e0-89f6-d64dbcdcde73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4062c356-412e-46f6-97f8-a9aeee7cb03e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1cfaca9b-341a-48e0-89f6-d64dbcdcde73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6cb1e322-bca1-4b7c-9f70-edd994673655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4062c356-412e-46f6-97f8-a9aeee7cb03e" xlink:to="loc_us-gaap_AccountsPayableCurrent_6cb1e322-bca1-4b7c-9f70-edd994673655" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9c249758-7bbb-4436-ad89-95fbf37208b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8607c754-6055-4fa0-ba95-a00a6a6021c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9c249758-7bbb-4436-ad89-95fbf37208b0" xlink:to="loc_us-gaap_AssetsCurrent_8607c754-6055-4fa0-ba95-a00a6a6021c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2eb817b5-c00b-420f-9e5d-5af88110352f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9c249758-7bbb-4436-ad89-95fbf37208b0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2eb817b5-c00b-420f-9e5d-5af88110352f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_9712c9ae-4ad2-4c0b-bb73-de63283373f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9c249758-7bbb-4436-ad89-95fbf37208b0" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_9712c9ae-4ad2-4c0b-bb73-de63283373f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9aa618ea-5fc4-40c2-ad3d-f947a887f4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9c249758-7bbb-4436-ad89-95fbf37208b0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9aa618ea-5fc4-40c2-ad3d-f947a887f4ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0500b25d-2f79-4e61-9b87-334fe0b670cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9c249758-7bbb-4436-ad89-95fbf37208b0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0500b25d-2f79-4e61-9b87-334fe0b670cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_fe3c2cf4-ba92-4a77-bc53-80f7f7be9608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_33decbf3-9e14-484a-82f5-1e471f1461e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fe3c2cf4-ba92-4a77-bc53-80f7f7be9608" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_33decbf3-9e14-484a-82f5-1e471f1461e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a3ebb61f-88e1-4016-8317-e141da4061e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fe3c2cf4-ba92-4a77-bc53-80f7f7be9608" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a3ebb61f-88e1-4016-8317-e141da4061e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f3e2ad60-b03e-4387-a41a-623e5341ba6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fe3c2cf4-ba92-4a77-bc53-80f7f7be9608" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f3e2ad60-b03e-4387-a41a-623e5341ba6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_bce73cb9-693f-418f-a170-173a69e6d163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_cbe6d63b-b5ed-4e1c-8293-4b9e620dc60c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_bce73cb9-693f-418f-a170-173a69e6d163" xlink:to="loc_us-gaap_LiabilitiesCurrent_cbe6d63b-b5ed-4e1c-8293-4b9e620dc60c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b5409600-7a1f-43c8-bdfa-9daab4bde951" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_bce73cb9-693f-418f-a170-173a69e6d163" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b5409600-7a1f-43c8-bdfa-9daab4bde951" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fba0b340-15f2-4721-a865-4df423d56bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6f27963c-260f-425c-abdd-1aaca0a4d20b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fba0b340-15f2-4721-a865-4df423d56bc1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6f27963c-260f-425c-abdd-1aaca0a4d20b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_74763d58-42bd-45c3-951e-9c1536c2b66b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fba0b340-15f2-4721-a865-4df423d56bc1" xlink:to="loc_us-gaap_CommonStockValue_74763d58-42bd-45c3-951e-9c1536c2b66b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_dc8f7116-0c20-4a29-90e9-5327c2e26996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fba0b340-15f2-4721-a865-4df423d56bc1" xlink:to="loc_us-gaap_AdditionalPaidInCapital_dc8f7116-0c20-4a29-90e9-5327c2e26996" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0d96dc75-5ddf-4e3b-8327-cbe3ca541c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fba0b340-15f2-4721-a865-4df423d56bc1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0d96dc75-5ddf-4e3b-8327-cbe3ca541c1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_839273c7-cd4a-4f54-86e1-219744b7cde9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fba0b340-15f2-4721-a865-4df423d56bc1" xlink:to="loc_us-gaap_PreferredStockValue_839273c7-cd4a-4f54-86e1-219744b7cde9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="simple" xlink:href="bdtx-20220331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_cec61eaf-9275-4b13-91c4-aab0f6db69a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f5d2ef83-3576-433d-8fd7-a537b0bfba88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_cec61eaf-9275-4b13-91c4-aab0f6db69a1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f5d2ef83-3576-433d-8fd7-a537b0bfba88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_e9f3dece-d0a4-49cb-87e6-d874a2ee522f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_cec61eaf-9275-4b13-91c4-aab0f6db69a1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_e9f3dece-d0a4-49cb-87e6-d874a2ee522f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_fa11beb6-8fe9-4744-8ceb-cdc4587d4e23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_44c3efdb-9465-478a-9670-d56ba182b18e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_fa11beb6-8fe9-4744-8ceb-cdc4587d4e23" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_44c3efdb-9465-478a-9670-d56ba182b18e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_217d9397-c566-4d4c-9dc4-73b148a6ac5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_fa11beb6-8fe9-4744-8ceb-cdc4587d4e23" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_217d9397-c566-4d4c-9dc4-73b148a6ac5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_488f5e26-73e5-4173-88d1-4732bc5584f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_72fbefda-e364-4df2-9457-3f3a13236e07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_488f5e26-73e5-4173-88d1-4732bc5584f4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_72fbefda-e364-4df2-9457-3f3a13236e07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_da34ff27-2c78-4392-9e9c-e22f8dfe6927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_488f5e26-73e5-4173-88d1-4732bc5584f4" xlink:to="loc_us-gaap_NetIncomeLoss_da34ff27-2c78-4392-9e9c-e22f8dfe6927" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_950c105a-64b4-4ded-a401-5867d1beff99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_26eb0c8e-6ff5-40ad-9658-46661fca66be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_950c105a-64b4-4ded-a401-5867d1beff99" xlink:to="loc_us-gaap_OperatingExpenses_26eb0c8e-6ff5-40ad-9658-46661fca66be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_72aff7c6-99d7-4103-899e-87346f14ef8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_b9b3fb35-b0dc-420a-863f-91c604fd2905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_72aff7c6-99d7-4103-899e-87346f14ef8e" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_b9b3fb35-b0dc-420a-863f-91c604fd2905" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d20da3ad-8cad-4d60-ad62-5ee0140e88bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_72aff7c6-99d7-4103-899e-87346f14ef8e" xlink:to="loc_us-gaap_OperatingIncomeLoss_d20da3ad-8cad-4d60-ad62-5ee0140e88bd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="bdtx-20220331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_78f195c3-0ef8-4211-9c03-f4c183cf44e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0514fc5b-27b8-42bf-aa6e-71975ef2230a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_78f195c3-0ef8-4211-9c03-f4c183cf44e9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0514fc5b-27b8-42bf-aa6e-71975ef2230a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_45bd473d-33fc-4e23-b354-c22331c4ea81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_78f195c3-0ef8-4211-9c03-f4c183cf44e9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_45bd473d-33fc-4e23-b354-c22331c4ea81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_83553059-3fe1-4048-ad31-e3d9d9e4bace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_78f195c3-0ef8-4211-9c03-f4c183cf44e9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_83553059-3fe1-4048-ad31-e3d9d9e4bace" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_31922b75-25a2-44f6-abef-6b109ef73a20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_0dd2071c-4187-477e-ae4c-5fa41cb8a4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_31922b75-25a2-44f6-abef-6b109ef73a20" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_0dd2071c-4187-477e-ae4c-5fa41cb8a4ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d3c10d00-a297-414b-9569-bd855f5f7230" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_57a25537-d225-4347-9c9c-84e4d5db3bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d3c10d00-a297-414b-9569-bd855f5f7230" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_57a25537-d225-4347-9c9c-84e4d5db3bfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e71b0079-0872-4414-8a9b-4da127be3287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d3c10d00-a297-414b-9569-bd855f5f7230" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e71b0079-0872-4414-8a9b-4da127be3287" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_315dd852-d208-41d4-b4cc-fc11ee3f0a58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d3c10d00-a297-414b-9569-bd855f5f7230" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_315dd852-d208-41d4-b4cc-fc11ee3f0a58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5847ea93-0c66-4cd8-bac2-712e619a6ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_e991f673-8e16-4fd4-a3cc-8da1177c6f96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5847ea93-0c66-4cd8-bac2-712e619a6ddd" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_e991f673-8e16-4fd4-a3cc-8da1177c6f96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1b6d665a-9203-4d0c-8965-3752901de57b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5847ea93-0c66-4cd8-bac2-712e619a6ddd" xlink:to="loc_us-gaap_NetIncomeLoss_1b6d665a-9203-4d0c-8965-3752901de57b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_85c6280d-21ee-4ab0-8dfd-9261a0c96175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5847ea93-0c66-4cd8-bac2-712e619a6ddd" xlink:to="loc_us-gaap_ShareBasedCompensation_85c6280d-21ee-4ab0-8dfd-9261a0c96175" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_99185877-b601-4458-9b60-6d79a9699a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5847ea93-0c66-4cd8-bac2-712e619a6ddd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_99185877-b601-4458-9b60-6d79a9699a0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_6f5fd226-2d4d-41fb-bfa5-a836bbfbc0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5847ea93-0c66-4cd8-bac2-712e619a6ddd" xlink:to="loc_us-gaap_Depreciation_6f5fd226-2d4d-41fb-bfa5-a836bbfbc0b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_44fe5dff-e4cf-416e-9a1e-a1e037b28fff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5847ea93-0c66-4cd8-bac2-712e619a6ddd" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_44fe5dff-e4cf-416e-9a1e-a1e037b28fff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_b05d0da5-2657-48e2-96dd-2d848a07a2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5847ea93-0c66-4cd8-bac2-712e619a6ddd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_b05d0da5-2657-48e2-96dd-2d848a07a2cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities_b54839e7-68a2-447a-be91-d8ba7443459d" xlink:href="bdtx-20220331.xsd#bdtx_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5847ea93-0c66-4cd8-bac2-712e619a6ddd" xlink:to="loc_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities_b54839e7-68a2-447a-be91-d8ba7443459d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_RentExpense_50fa16ea-70a3-40ef-875d-4dac7539b6a5" xlink:href="bdtx-20220331.xsd#bdtx_RentExpense"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5847ea93-0c66-4cd8-bac2-712e619a6ddd" xlink:to="loc_bdtx_RentExpense_50fa16ea-70a3-40ef-875d-4dac7539b6a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_5f0156df-8e5c-417a-a10b-a20a79275226" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5847ea93-0c66-4cd8-bac2-712e619a6ddd" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_5f0156df-8e5c-417a-a10b-a20a79275226" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_3d4085c9-9f69-4c16-b2ff-6b9bb2af92b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5847ea93-0c66-4cd8-bac2-712e619a6ddd" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_3d4085c9-9f69-4c16-b2ff-6b9bb2af92b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8e466688-7b9d-4558-bd22-69738b547a27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6539101a-7c86-4589-8977-e5b6b91ab148" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8e466688-7b9d-4558-bd22-69738b547a27" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6539101a-7c86-4589-8977-e5b6b91ab148" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_87e961be-31a4-44c7-8261-d2bfeb06cb65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8e466688-7b9d-4558-bd22-69738b547a27" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_87e961be-31a4-44c7-8261-d2bfeb06cb65" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="bdtx-20220331.xsd#FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_6532ee67-1456-4c4a-bc72-19e15b8809b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_6791f829-a6aa-4790-aabb-3c7b796c8109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_6532ee67-1456-4c4a-bc72-19e15b8809b7" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_6791f829-a6aa-4790-aabb-3c7b796c8109" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_071f959a-dad8-4ed2-bb51-a5bfbca24326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_6532ee67-1456-4c4a-bc72-19e15b8809b7" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_071f959a-dad8-4ed2-bb51-a5bfbca24326" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="bdtx-20220331.xsd#INVESTMENTSScheduleofMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9e3584c8-76f9-4c04-bcc0-88c59756ece7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6f6ed0c6-6183-4c5a-baba-9486884d8c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9e3584c8-76f9-4c04-bcc0-88c59756ece7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6f6ed0c6-6183-4c5a-baba-9486884d8c4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6eb89382-41a0-4d23-84e2-2de720d97daf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9e3584c8-76f9-4c04-bcc0-88c59756ece7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6eb89382-41a0-4d23-84e2-2de720d97daf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_02795129-b78e-4098-9d60-c1287ff36246" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9e3584c8-76f9-4c04-bcc0-88c59756ece7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_02795129-b78e-4098-9d60-c1287ff36246" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="simple" xlink:href="bdtx-20220331.xsd#PROPERTYANDEQUIPMENTDetails"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d02e0795-59a2-4fda-9585-00748008994d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f985788c-d902-477a-a57b-eb62116aef7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_d02e0795-59a2-4fda-9585-00748008994d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f985788c-d902-477a-a57b-eb62116aef7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_81d0fb55-48ba-4d11-80e3-fcfd9baabed6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_d02e0795-59a2-4fda-9585-00748008994d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_81d0fb55-48ba-4d11-80e3-fcfd9baabed6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="simple" xlink:href="bdtx-20220331.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9991cfeb-0ebc-4cda-a0b5-a3f1b7b95a91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_99830edd-e95c-4bcc-a472-83293e36061f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_9991cfeb-0ebc-4cda-a0b5-a3f1b7b95a91" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_99830edd-e95c-4bcc-a472-83293e36061f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_55c1065c-bc46-481b-bf9e-b2c144cfe1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_9991cfeb-0ebc-4cda-a0b5-a3f1b7b95a91" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_55c1065c-bc46-481b-bf9e-b2c144cfe1fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_AccruedContractResearchServiceFeesCurrent_339b0baf-0291-437e-a4fd-fb09e78f03c5" xlink:href="bdtx-20220331.xsd#bdtx_AccruedContractResearchServiceFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_9991cfeb-0ebc-4cda-a0b5-a3f1b7b95a91" xlink:to="loc_bdtx_AccruedContractResearchServiceFeesCurrent_339b0baf-0291-437e-a4fd-fb09e78f03c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c354c01b-04a4-45f2-b70d-05128c2ebde3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_9991cfeb-0ebc-4cda-a0b5-a3f1b7b95a91" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c354c01b-04a4-45f2-b70d-05128c2ebde3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" xlink:type="simple" xlink:href="bdtx-20220331.xsd#LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_d31d4e4a-cf35-4301-8433-df3b0b5e345f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_c4e3f084-d6d3-4f2f-8ca6-d6b2128d5cab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_d31d4e4a-cf35-4301-8433-df3b0b5e345f" xlink:to="loc_us-gaap_OperatingLeaseCost_c4e3f084-d6d3-4f2f-8ca6-d6b2128d5cab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_18aee3d4-4441-4088-a040-5b1e7db733f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_d31d4e4a-cf35-4301-8433-df3b0b5e345f" xlink:to="loc_us-gaap_ShortTermLeaseCost_18aee3d4-4441-4088-a040-5b1e7db733f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_f9824f56-c3da-4959-b6d2-e31ee704cae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_d31d4e4a-cf35-4301-8433-df3b0b5e345f" xlink:to="loc_us-gaap_VariableLeaseCost_f9824f56-c3da-4959-b6d2-e31ee704cae5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="bdtx-20220331.xsd#LEASESScheduleofFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b7cedde4-911b-49cd-8b89-65aabb8400e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4cdb9132-a480-413d-8776-5954610870ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b7cedde4-911b-49cd-8b89-65aabb8400e6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4cdb9132-a480-413d-8776-5954610870ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_63ecc8a2-4415-4169-952e-c814494bf312" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b7cedde4-911b-49cd-8b89-65aabb8400e6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_63ecc8a2-4415-4169-952e-c814494bf312" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7dc7e381-b745-4caf-b157-510d2415ed1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b7cedde4-911b-49cd-8b89-65aabb8400e6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7dc7e381-b745-4caf-b157-510d2415ed1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_1e5b8565-cbe9-4431-87ba-1ea055f20639" xlink:href="bdtx-20220331.xsd#bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b7cedde4-911b-49cd-8b89-65aabb8400e6" xlink:to="loc_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_1e5b8565-cbe9-4431-87ba-1ea055f20639" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2110fd22-ad60-4b59-805c-7c5fb781cc06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b7cedde4-911b-49cd-8b89-65aabb8400e6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2110fd22-ad60-4b59-805c-7c5fb781cc06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bb13995f-026f-4244-b314-9c09c63d022f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b7cedde4-911b-49cd-8b89-65aabb8400e6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bb13995f-026f-4244-b314-9c09c63d022f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="bdtx-20220331.xsd#LEASESScheduleofFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_03a8c26e-5e9f-4536-ab40-e3b1d2a3e0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c69c5d24-1865-4668-83e0-747f5ada4b35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_03a8c26e-5e9f-4536-ab40-e3b1d2a3e0d8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c69c5d24-1865-4668-83e0-747f5ada4b35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_747914f7-ba91-4d33-bf16-1243d525e4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_03a8c26e-5e9f-4536-ab40-e3b1d2a3e0d8" xlink:to="loc_us-gaap_OperatingLeaseLiability_747914f7-ba91-4d33-bf16-1243d525e4c0" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>bdtx-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:674e53d2-18f0-47df-b195-3621df688bf3,g:abed15df-df65-4b1b-8a1f-1c79fbf06613-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CoverPage" xlink:type="simple" xlink:href="bdtx-20220331.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CoverPage" xlink:type="extended" id="i9e76c9bf8d684c98aa5719670a78764b_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d5365583-47cb-421e-8f37-266e080e9684" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_DocumentType_d5365583-47cb-421e-8f37-266e080e9684" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_9929ac1b-287f-4a0b-841b-80cab9c4f053" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_DocumentQuarterlyReport_9929ac1b-287f-4a0b-841b-80cab9c4f053" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_39d65f13-eb3d-47f0-83c5-ec0ab8bffeea" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_DocumentPeriodEndDate_39d65f13-eb3d-47f0-83c5-ec0ab8bffeea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_868cc243-1ea9-4df7-afca-29e37f9631f2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_DocumentTransitionReport_868cc243-1ea9-4df7-afca-29e37f9631f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ad516d65-389d-4f39-ad96-64b77a7f3abb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityFileNumber_ad516d65-389d-4f39-ad96-64b77a7f3abb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9d4985d3-2815-452f-86aa-28151815c2a4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityRegistrantName_9d4985d3-2815-452f-86aa-28151815c2a4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_43ed4f22-419e-4f03-a0e4-54757fd64ef5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityIncorporationStateCountryCode_43ed4f22-419e-4f03-a0e4-54757fd64ef5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_353830cf-3d05-4e0b-b3e5-d657cefbd464" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityTaxIdentificationNumber_353830cf-3d05-4e0b-b3e5-d657cefbd464" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_3db2dfa0-ebae-49aa-aa96-026b60e5ceeb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityAddressAddressLine1_3db2dfa0-ebae-49aa-aa96-026b60e5ceeb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_bec09ce6-4599-461c-83f6-9b38e54475a3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityAddressCityOrTown_bec09ce6-4599-461c-83f6-9b38e54475a3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_8174deef-7f48-456c-a70f-c9dc06f2da20" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityAddressStateOrProvince_8174deef-7f48-456c-a70f-c9dc06f2da20" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_84f7dbbc-bfa4-4fce-8759-34d0c8e3678f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityAddressPostalZipCode_84f7dbbc-bfa4-4fce-8759-34d0c8e3678f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d2b4378f-35de-4593-a25e-60bc463d61c6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_CityAreaCode_d2b4378f-35de-4593-a25e-60bc463d61c6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a9b25de4-595e-44fe-b49b-912e140946a6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_LocalPhoneNumber_a9b25de4-595e-44fe-b49b-912e140946a6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6a5bd8f0-0ec5-4310-a062-4babeb1a03e6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_Security12bTitle_6a5bd8f0-0ec5-4310-a062-4babeb1a03e6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d7a5b641-30ed-4cbe-a03f-961814c802cc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_TradingSymbol_d7a5b641-30ed-4cbe-a03f-961814c802cc" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_740b2a1a-db55-4656-a6d7-4dcc955dde03" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_SecurityExchangeName_740b2a1a-db55-4656-a6d7-4dcc955dde03" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_405b885a-60bf-431e-acd6-d0452eae4ec5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityCurrentReportingStatus_405b885a-60bf-431e-acd6-d0452eae4ec5" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_adb64013-0f5b-4511-b53c-33ca51e36d4c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityInteractiveDataCurrent_adb64013-0f5b-4511-b53c-33ca51e36d4c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_1187bc8a-0fdb-4285-89ac-318c055f376c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityFilerCategory_1187bc8a-0fdb-4285-89ac-318c055f376c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_28bc2c29-2fb2-43a3-b437-d3e253dbecfb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntitySmallBusiness_28bc2c29-2fb2-43a3-b437-d3e253dbecfb" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_73a45631-fdcb-4490-b2ed-7182b47d6193" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityEmergingGrowthCompany_73a45631-fdcb-4490-b2ed-7182b47d6193" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_5740edb7-16a5-4c72-85b7-22201a28c1cd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityExTransitionPeriod_5740edb7-16a5-4c72-85b7-22201a28c1cd" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b77c2504-136a-4bf2-8a13-6756cf650c39" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityShellCompany_b77c2504-136a-4bf2-8a13-6756cf650c39" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_e55a499e-7917-442e-b704-0f4e5fb37a20" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_e55a499e-7917-442e-b704-0f4e5fb37a20" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b2286bf1-85c6-45af-b391-2f94612cfb6c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_AmendmentFlag_b2286bf1-85c6-45af-b391-2f94612cfb6c" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_3fe65ba7-5749-4060-878f-66e39dbc4e03" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_DocumentFiscalPeriodFocus_3fe65ba7-5749-4060-878f-66e39dbc4e03" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_12167c73-1087-4be6-85a8-3bbe37488a9c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_DocumentFiscalYearFocus_12167c73-1087-4be6-85a8-3bbe37488a9c" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_83f1b021-2119-4b22-b7dc-abe484632280" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityCentralIndexKey_83f1b021-2119-4b22-b7dc-abe484632280" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_fc77fcb1-8cd8-496e-a24b-defd30293a31" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_CurrentFiscalYearEndDate_fc77fcb1-8cd8-496e-a24b-defd30293a31" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesTable_9dc907f6-1242-4282-9ca4-d0d79788f5f9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityAddressesTable_9dc907f6-1242-4282-9ca4-d0d79788f5f9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_bb70df7f-fcd9-4a5a-ae73-b705a5985e2f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntityAddressesTable_9dc907f6-1242-4282-9ca4-d0d79788f5f9" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_bb70df7f-fcd9-4a5a-ae73-b705a5985e2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_bb70df7f-fcd9-4a5a-ae73-b705a5985e2f_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_bb70df7f-fcd9-4a5a-ae73-b705a5985e2f" xlink:to="loc_dei_AddressTypeDomain_bb70df7f-fcd9-4a5a-ae73-b705a5985e2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_444f2d5e-a2ac-4954-9c78-e26da96d8da2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_bb70df7f-fcd9-4a5a-ae73-b705a5985e2f" xlink:to="loc_dei_AddressTypeDomain_444f2d5e-a2ac-4954-9c78-e26da96d8da2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_FormerAddressMember_39e8497d-e41a-4024-b6d3-3296f498c400" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_FormerAddressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_444f2d5e-a2ac-4954-9c78-e26da96d8da2" xlink:to="loc_dei_FormerAddressMember_39e8497d-e41a-4024-b6d3-3296f498c400" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="simple" xlink:href="bdtx-20220331.xsd#CondensedConsolidatedStatementsofStockholdersEquityUnaudited"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="extended" id="i444c8eddbf034e8ea71d9328158eed87_CondensedConsolidatedStatementsofStockholdersEquityUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_520cc4a2-0842-4e0d-9393-909bc9669ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21d20e6b-e539-4bb2-8de9-e2d64ad5e0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_520cc4a2-0842-4e0d-9393-909bc9669ac8" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21d20e6b-e539-4bb2-8de9-e2d64ad5e0f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b52a92d4-1c31-4ea8-b989-a8c28d274acc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21d20e6b-e539-4bb2-8de9-e2d64ad5e0f5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b52a92d4-1c31-4ea8-b989-a8c28d274acc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5b476cc4-5716-4644-b544-e6a5d111c7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21d20e6b-e539-4bb2-8de9-e2d64ad5e0f5" xlink:to="loc_us-gaap_StockholdersEquity_5b476cc4-5716-4644-b544-e6a5d111c7a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_060504df-17c0-48fb-9767-8a3bb00b1d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21d20e6b-e539-4bb2-8de9-e2d64ad5e0f5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_060504df-17c0-48fb-9767-8a3bb00b1d8f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5cb2f725-e5fa-494b-a002-5bebc7253a88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21d20e6b-e539-4bb2-8de9-e2d64ad5e0f5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5cb2f725-e5fa-494b-a002-5bebc7253a88" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_45f375f5-acc5-40cc-b5e8-333f3ed9c426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21d20e6b-e539-4bb2-8de9-e2d64ad5e0f5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_45f375f5-acc5-40cc-b5e8-333f3ed9c426" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7e4d8102-d19d-4e6e-8c27-0b39fc481c74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21d20e6b-e539-4bb2-8de9-e2d64ad5e0f5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7e4d8102-d19d-4e6e-8c27-0b39fc481c74" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_da4f56e4-5322-4ff3-a810-402266372ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21d20e6b-e539-4bb2-8de9-e2d64ad5e0f5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_da4f56e4-5322-4ff3-a810-402266372ff7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_fdfd1dae-b00e-40c4-812d-888b31f2476a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21d20e6b-e539-4bb2-8de9-e2d64ad5e0f5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_fdfd1dae-b00e-40c4-812d-888b31f2476a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4cf63ec5-715e-4a8b-afa1-227c3e6b6f93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21d20e6b-e539-4bb2-8de9-e2d64ad5e0f5" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4cf63ec5-715e-4a8b-afa1-227c3e6b6f93" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_23643caf-35e7-448a-ae21-cd28b7ce5701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21d20e6b-e539-4bb2-8de9-e2d64ad5e0f5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_23643caf-35e7-448a-ae21-cd28b7ce5701" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_947a0531-7ae5-4356-9b41-cae2200c6509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21d20e6b-e539-4bb2-8de9-e2d64ad5e0f5" xlink:to="loc_us-gaap_NetIncomeLoss_947a0531-7ae5-4356-9b41-cae2200c6509" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d1513efa-4dda-45a0-bc78-715be8d5172a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_42fb42f3-790c-453c-a347-e7ff79396a17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_02029dc2-7db6-4773-b3a3-1df5ec05bbfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_520cc4a2-0842-4e0d-9393-909bc9669ac8" xlink:to="loc_us-gaap_StatementTable_02029dc2-7db6-4773-b3a3-1df5ec05bbfd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9ffc78c9-2c44-4acb-9742-d39da0d40429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_02029dc2-7db6-4773-b3a3-1df5ec05bbfd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9ffc78c9-2c44-4acb-9742-d39da0d40429" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9ffc78c9-2c44-4acb-9742-d39da0d40429_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9ffc78c9-2c44-4acb-9742-d39da0d40429" xlink:to="loc_us-gaap_EquityComponentDomain_9ffc78c9-2c44-4acb-9742-d39da0d40429_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fb30cce1-4059-46eb-94a2-a3e47fc8e18e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9ffc78c9-2c44-4acb-9742-d39da0d40429" xlink:to="loc_us-gaap_EquityComponentDomain_fb30cce1-4059-46eb-94a2-a3e47fc8e18e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e89c25fa-044b-4f50-bc86-36d1e08c2c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fb30cce1-4059-46eb-94a2-a3e47fc8e18e" xlink:to="loc_us-gaap_CommonStockMember_e89c25fa-044b-4f50-bc86-36d1e08c2c4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_96dd9ce7-d79b-4c4e-af38-87633e71f8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fb30cce1-4059-46eb-94a2-a3e47fc8e18e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_96dd9ce7-d79b-4c4e-af38-87633e71f8aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fb60aa23-bf26-4a12-8795-cef002acdec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fb30cce1-4059-46eb-94a2-a3e47fc8e18e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fb60aa23-bf26-4a12-8795-cef002acdec3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c6ef99f4-377c-485f-8184-9d6c2f0bfb42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fb30cce1-4059-46eb-94a2-a3e47fc8e18e" xlink:to="loc_us-gaap_RetainedEarningsMember_c6ef99f4-377c-485f-8184-9d6c2f0bfb42" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" xlink:type="simple" xlink:href="bdtx-20220331.xsd#NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" xlink:type="extended" id="i91d048b474f74e79b9527972b449f41b_NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_c7177622-6840-47e2-aebe-2cee14546636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_06299d0a-96e5-4464-af23-e5a523923ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c7177622-6840-47e2-aebe-2cee14546636" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_06299d0a-96e5-4464-af23-e5a523923ee9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_0d7afd1f-7dac-4028-a285-5b90ab419a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c7177622-6840-47e2-aebe-2cee14546636" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_0d7afd1f-7dac-4028-a285-5b90ab419a09" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5f9471ca-0c81-4f5e-a8a1-12451715a890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_0d7afd1f-7dac-4028-a285-5b90ab419a09" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5f9471ca-0c81-4f5e-a8a1-12451715a890" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5f9471ca-0c81-4f5e-a8a1-12451715a890_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5f9471ca-0c81-4f5e-a8a1-12451715a890" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5f9471ca-0c81-4f5e-a8a1-12451715a890_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_efd10481-5360-43e2-95ab-f4bc19e7b6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5f9471ca-0c81-4f5e-a8a1-12451715a890" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_efd10481-5360-43e2-95ab-f4bc19e7b6ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OpenMarketSaleMember_164e67db-432f-41aa-911a-ebc5cb257afa" xlink:href="bdtx-20220331.xsd#bdtx_OpenMarketSaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_efd10481-5360-43e2-95ab-f4bc19e7b6ed" xlink:to="loc_bdtx_OpenMarketSaleMember_164e67db-432f-41aa-911a-ebc5cb257afa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_26bc45f9-16e7-4b27-bfc4-9970e6814f20" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_0d7afd1f-7dac-4028-a285-5b90ab419a09" xlink:to="loc_srt_RangeAxis_26bc45f9-16e7-4b27-bfc4-9970e6814f20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_26bc45f9-16e7-4b27-bfc4-9970e6814f20_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_26bc45f9-16e7-4b27-bfc4-9970e6814f20" xlink:to="loc_srt_RangeMember_26bc45f9-16e7-4b27-bfc4-9970e6814f20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f72c3799-48fa-4624-b02c-244f4b07a3da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_26bc45f9-16e7-4b27-bfc4-9970e6814f20" xlink:to="loc_srt_RangeMember_f72c3799-48fa-4624-b02c-244f4b07a3da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_66e182aa-b4d2-4057-85ee-2c5302c3cf00" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f72c3799-48fa-4624-b02c-244f4b07a3da" xlink:to="loc_srt_MaximumMember_66e182aa-b4d2-4057-85ee-2c5302c3cf00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_4be6f016-2843-45ed-b230-8772083167d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_0d7afd1f-7dac-4028-a285-5b90ab419a09" xlink:to="loc_srt_StatementScenarioAxis_4be6f016-2843-45ed-b230-8772083167d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_4be6f016-2843-45ed-b230-8772083167d7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_4be6f016-2843-45ed-b230-8772083167d7" xlink:to="loc_srt_ScenarioUnspecifiedDomain_4be6f016-2843-45ed-b230-8772083167d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_4cc892da-7830-4541-a2c8-2fa4f1a428d5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_4be6f016-2843-45ed-b230-8772083167d7" xlink:to="loc_srt_ScenarioUnspecifiedDomain_4cc892da-7830-4541-a2c8-2fa4f1a428d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_855fd6d8-0293-4b4a-8a3e-f511eff78a37" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_4cc892da-7830-4541-a2c8-2fa4f1a428d5" xlink:to="loc_srt_ScenarioForecastMember_855fd6d8-0293-4b4a-8a3e-f511eff78a37" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="bdtx-20220331.xsd#FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended" id="i4218a78befd14689b3ebbef6da05e1fe_FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21d3cca-4d15-4d5a-8e7b-379ada144c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_3c100701-39ee-4e55-b50f-f3bcc9f97b13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21d3cca-4d15-4d5a-8e7b-379ada144c3c" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_3c100701-39ee-4e55-b50f-f3bcc9f97b13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fc682cba-9086-48c6-8c5a-71357bcddc05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3c100701-39ee-4e55-b50f-f3bcc9f97b13" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fc682cba-9086-48c6-8c5a-71357bcddc05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_5427df30-16b7-4c59-a61c-2403fc609d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3c100701-39ee-4e55-b50f-f3bcc9f97b13" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_5427df30-16b7-4c59-a61c-2403fc609d5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_43acbd4d-81c4-47ed-a74d-29b12004fcba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3c100701-39ee-4e55-b50f-f3bcc9f97b13" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_43acbd4d-81c4-47ed-a74d-29b12004fcba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7c8006ed-ab54-4f7e-b524-8db53202adb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21d3cca-4d15-4d5a-8e7b-379ada144c3c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7c8006ed-ab54-4f7e-b524-8db53202adb2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9882d0e7-8806-4a4e-8a0e-658292ae2dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7c8006ed-ab54-4f7e-b524-8db53202adb2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9882d0e7-8806-4a4e-8a0e-658292ae2dc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9882d0e7-8806-4a4e-8a0e-658292ae2dc1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9882d0e7-8806-4a4e-8a0e-658292ae2dc1" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9882d0e7-8806-4a4e-8a0e-658292ae2dc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4ddfe57d-e05a-4d9d-8e5c-b3f033b1ad85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9882d0e7-8806-4a4e-8a0e-658292ae2dc1" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4ddfe57d-e05a-4d9d-8e5c-b3f033b1ad85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1f8e9be9-b220-443d-a499-614dc23157ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_4ddfe57d-e05a-4d9d-8e5c-b3f033b1ad85" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1f8e9be9-b220-443d-a499-614dc23157ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b8739947-931c-45b3-acf8-92f9429aaf77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7c8006ed-ab54-4f7e-b524-8db53202adb2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b8739947-931c-45b3-acf8-92f9429aaf77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8739947-931c-45b3-acf8-92f9429aaf77_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b8739947-931c-45b3-acf8-92f9429aaf77" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8739947-931c-45b3-acf8-92f9429aaf77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d0ac1219-d1df-4090-a15c-242e39bc9d77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b8739947-931c-45b3-acf8-92f9429aaf77" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d0ac1219-d1df-4090-a15c-242e39bc9d77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_41e720ef-9145-4c19-9c29-c172f3d0d1b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d0ac1219-d1df-4090-a15c-242e39bc9d77" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_41e720ef-9145-4c19-9c29-c172f3d0d1b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7eac1e9b-fd86-454f-a835-b5d4edd29ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d0ac1219-d1df-4090-a15c-242e39bc9d77" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7eac1e9b-fd86-454f-a835-b5d4edd29ebf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_23aeb358-6539-4aca-9b64-9ba6350e7738" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d0ac1219-d1df-4090-a15c-242e39bc9d77" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_23aeb358-6539-4aca-9b64-9ba6350e7738" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a491dccd-00cb-4e59-bb8b-b332a1f5f2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7c8006ed-ab54-4f7e-b524-8db53202adb2" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a491dccd-00cb-4e59-bb8b-b332a1f5f2cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a491dccd-00cb-4e59-bb8b-b332a1f5f2cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a491dccd-00cb-4e59-bb8b-b332a1f5f2cf" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a491dccd-00cb-4e59-bb8b-b332a1f5f2cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_507c6a36-675f-4595-b751-339ec7fd3c21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a491dccd-00cb-4e59-bb8b-b332a1f5f2cf" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_507c6a36-675f-4595-b751-339ec7fd3c21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_76b120c1-13aa-42de-98a9-55d78b4f5c62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_507c6a36-675f-4595-b751-339ec7fd3c21" xlink:to="loc_us-gaap_MoneyMarketFundsMember_76b120c1-13aa-42de-98a9-55d78b4f5c62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_3fe5abb8-194f-4162-aaa5-a36fc1f96a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_507c6a36-675f-4595-b751-339ec7fd3c21" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_3fe5abb8-194f-4162-aaa5-a36fc1f96a7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_ace8f949-04d7-4ab3-9d4c-2da85f515865" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_507c6a36-675f-4595-b751-339ec7fd3c21" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_ace8f949-04d7-4ab3-9d4c-2da85f515865" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_0e7440b1-a23f-480c-b77b-4c7693010bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_507c6a36-675f-4595-b751-339ec7fd3c21" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_0e7440b1-a23f-480c-b77b-4c7693010bf6" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="bdtx-20220331.xsd#INVESTMENTSScheduleofMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" xlink:type="extended" id="i4b422712c0654c38b51c5f259d5d01e9_INVESTMENTSScheduleofMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_287c4b7a-2ab2-4b8d-bb27-4f1ffbc490fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ca798968-a3ad-4b99-a304-78173fb1436d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_287c4b7a-2ab2-4b8d-bb27-4f1ffbc490fc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ca798968-a3ad-4b99-a304-78173fb1436d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_35e0ad00-ec9c-4ac4-8653-1f72b364290a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_287c4b7a-2ab2-4b8d-bb27-4f1ffbc490fc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_35e0ad00-ec9c-4ac4-8653-1f72b364290a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6b08d16b-6a1f-41ce-9d7a-01dc883ece42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_287c4b7a-2ab2-4b8d-bb27-4f1ffbc490fc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6b08d16b-6a1f-41ce-9d7a-01dc883ece42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e573a7ea-5512-49a4-924d-f15cc5cc57bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_287c4b7a-2ab2-4b8d-bb27-4f1ffbc490fc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e573a7ea-5512-49a4-924d-f15cc5cc57bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1cbc9f69-2b58-438e-80c5-ea054b492e80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_287c4b7a-2ab2-4b8d-bb27-4f1ffbc490fc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1cbc9f69-2b58-438e-80c5-ea054b492e80" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_87815e91-c3f3-4c3b-87f7-b35308d0f600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1cbc9f69-2b58-438e-80c5-ea054b492e80" xlink:to="loc_us-gaap_FinancialInstrumentAxis_87815e91-c3f3-4c3b-87f7-b35308d0f600" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_87815e91-c3f3-4c3b-87f7-b35308d0f600_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_87815e91-c3f3-4c3b-87f7-b35308d0f600" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_87815e91-c3f3-4c3b-87f7-b35308d0f600_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a9e8d76-66f7-4c68-8622-65d77185aaed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_87815e91-c3f3-4c3b-87f7-b35308d0f600" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a9e8d76-66f7-4c68-8622-65d77185aaed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_11f08a32-9a80-4a87-9f2e-eadd9e6633ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a9e8d76-66f7-4c68-8622-65d77185aaed" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_11f08a32-9a80-4a87-9f2e-eadd9e6633ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_c54a55c0-7e2a-4eef-9a68-46ebed577d20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a9e8d76-66f7-4c68-8622-65d77185aaed" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_c54a55c0-7e2a-4eef-9a68-46ebed577d20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_29cefc2a-f3f2-42c1-b868-4da443280b16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a9e8d76-66f7-4c68-8622-65d77185aaed" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_29cefc2a-f3f2-42c1-b868-4da443280b16" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="simple" xlink:href="bdtx-20220331.xsd#PROPERTYANDEQUIPMENTDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="extended" id="i7d0944a39d09429192748c1ab2dfb5ff_PROPERTYANDEQUIPMENTDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ad0c8293-2ffb-4e2c-bf42-60b0f97c00b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_132617f9-109a-49cb-a353-fe015d72cbda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ad0c8293-2ffb-4e2c-bf42-60b0f97c00b9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_132617f9-109a-49cb-a353-fe015d72cbda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a9dfddb0-e79e-4fe5-b76c-e84c200ac5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ad0c8293-2ffb-4e2c-bf42-60b0f97c00b9" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a9dfddb0-e79e-4fe5-b76c-e84c200ac5b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_594f583e-68e7-4e6e-8352-b6df74bd6dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ad0c8293-2ffb-4e2c-bf42-60b0f97c00b9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_594f583e-68e7-4e6e-8352-b6df74bd6dfc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_4620e572-70b1-41a6-a816-066712806e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ad0c8293-2ffb-4e2c-bf42-60b0f97c00b9" xlink:to="loc_us-gaap_Depreciation_4620e572-70b1-41a6-a816-066712806e8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aac4d391-c7e1-452f-916e-b8e6fe0d2fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ad0c8293-2ffb-4e2c-bf42-60b0f97c00b9" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aac4d391-c7e1-452f-916e-b8e6fe0d2fd6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8c9bdeb7-9de9-4b8f-95cc-abf038e15dee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aac4d391-c7e1-452f-916e-b8e6fe0d2fd6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8c9bdeb7-9de9-4b8f-95cc-abf038e15dee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8c9bdeb7-9de9-4b8f-95cc-abf038e15dee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8c9bdeb7-9de9-4b8f-95cc-abf038e15dee" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8c9bdeb7-9de9-4b8f-95cc-abf038e15dee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52609ac3-bf71-46c3-8cae-8d7c35648d32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8c9bdeb7-9de9-4b8f-95cc-abf038e15dee" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52609ac3-bf71-46c3-8cae-8d7c35648d32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_9c5bf2e7-a318-450f-94fe-47698d6dc6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52609ac3-bf71-46c3-8cae-8d7c35648d32" xlink:to="loc_us-gaap_EquipmentMember_9c5bf2e7-a318-450f-94fe-47698d6dc6f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_daea2b0a-685f-4817-af9d-cf22b649b0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52609ac3-bf71-46c3-8cae-8d7c35648d32" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_daea2b0a-685f-4817-af9d-cf22b649b0d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_8930c8a0-67f5-440b-bf1c-9973eb83442c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52609ac3-bf71-46c3-8cae-8d7c35648d32" xlink:to="loc_us-gaap_OfficeEquipmentMember_8930c8a0-67f5-440b-bf1c-9973eb83442c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_dc0a73fc-6967-484c-a943-3b0cf9677e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52609ac3-bf71-46c3-8cae-8d7c35648d32" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_dc0a73fc-6967-484c-a943-3b0cf9677e6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_de27a83f-227d-4247-8f4b-278147108a82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52609ac3-bf71-46c3-8cae-8d7c35648d32" xlink:to="loc_us-gaap_ConstructionInProgressMember_de27a83f-227d-4247-8f4b-278147108a82" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="bdtx-20220331.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended" id="i5c743e74c97c472aa72307702f91f8c2_STOCKBASEDCOMPENSATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding_688ecb3b-1f08-40ad-b86d-ff07b115e493" xlink:href="bdtx-20220331.xsd#bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:to="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding_688ecb3b-1f08-40ad-b86d-ff07b115e493" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_2abbcd68-db9a-48a4-b417-bac2b442c2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_2abbcd68-db9a-48a4-b417-bac2b442c2e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_78f204ed-7fc0-49e0-a1ac-6babe9017b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_78f204ed-7fc0-49e0-a1ac-6babe9017b5c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c4e9af94-f671-43a5-85b5-298eb721dd6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c4e9af94-f671-43a5-85b5-298eb721dd6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9dcc5740-be25-4b02-b975-b711c948290d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9dcc5740-be25-4b02-b975-b711c948290d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_8bafb8e7-a01c-4f0e-9ed2-a0ffb6cbd8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_8bafb8e7-a01c-4f0e-9ed2-a0ffb6cbd8f2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_9960ff1b-f689-454b-bc5d-ff766a94f548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_9960ff1b-f689-454b-bc5d-ff766a94f548" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_58d7b258-78e5-46fc-ac93-e498226a8d67" xlink:href="bdtx-20220331.xsd#bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:to="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_58d7b258-78e5-46fc-ac93-e498226a8d67" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_634158ae-2e7d-473d-86df-d3622fdc22f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_634158ae-2e7d-473d-86df-d3622fdc22f1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_2cf44845-03c4-449b-a843-148a5965ee53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_2cf44845-03c4-449b-a843-148a5965ee53" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_16c4f1d8-a047-4109-bcbb-96ee814f0f32" xlink:href="bdtx-20220331.xsd#bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:to="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_16c4f1d8-a047-4109-bcbb-96ee814f0f32" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_33008482-ce94-4ff5-bc07-bf1cee033c31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_33008482-ce94-4ff5-bc07-bf1cee033c31" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_97f67182-2607-4ab9-b675-1794ee1b489d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_97f67182-2607-4ab9-b675-1794ee1b489d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_23ee3403-9ef0-4c3f-bc32-548a2535519e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_23ee3403-9ef0-4c3f-bc32-548a2535519e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e393334-645f-4b2c-aa1e-d5357a025369" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e393334-645f-4b2c-aa1e-d5357a025369" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fc108f85-36cc-4872-96a0-94146ee1219a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e393334-645f-4b2c-aa1e-d5357a025369" xlink:to="loc_us-gaap_AwardTypeAxis_fc108f85-36cc-4872-96a0-94146ee1219a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc108f85-36cc-4872-96a0-94146ee1219a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_fc108f85-36cc-4872-96a0-94146ee1219a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc108f85-36cc-4872-96a0-94146ee1219a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f469c705-89a4-48c5-8611-21916c472dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_fc108f85-36cc-4872-96a0-94146ee1219a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f469c705-89a4-48c5-8611-21916c472dc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_96d19226-9db5-4c88-a7ef-895d7a0a45f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f469c705-89a4-48c5-8611-21916c472dc8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_96d19226-9db5-4c88-a7ef-895d7a0a45f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d1c3130b-fbc9-4fc8-8670-22478051da61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f469c705-89a4-48c5-8611-21916c472dc8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d1c3130b-fbc9-4fc8-8670-22478051da61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_944105c6-795e-4010-9022-d77399977b94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f469c705-89a4-48c5-8611-21916c472dc8" xlink:to="loc_us-gaap_EmployeeStockMember_944105c6-795e-4010-9022-d77399977b94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_PerformanceRestrictedStockUnitsMember_8378d825-94f6-44c5-a8f1-7fbfa4fd5172" xlink:href="bdtx-20220331.xsd#bdtx_PerformanceRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f469c705-89a4-48c5-8611-21916c472dc8" xlink:to="loc_bdtx_PerformanceRestrictedStockUnitsMember_8378d825-94f6-44c5-a8f1-7fbfa4fd5172" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_aec5900b-5821-4c97-bead-7962924c61b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e393334-645f-4b2c-aa1e-d5357a025369" xlink:to="loc_us-gaap_PlanNameAxis_aec5900b-5821-4c97-bead-7962924c61b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_aec5900b-5821-4c97-bead-7962924c61b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_aec5900b-5821-4c97-bead-7962924c61b1" xlink:to="loc_us-gaap_PlanNameDomain_aec5900b-5821-4c97-bead-7962924c61b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fc9e564e-dec6-49ff-97ac-8ba89b07e6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_aec5900b-5821-4c97-bead-7962924c61b1" xlink:to="loc_us-gaap_PlanNameDomain_fc9e564e-dec6-49ff-97ac-8ba89b07e6bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_A2020StockOptionPlanMember_b038346a-b759-4ec7-92af-1ef61b50294d" xlink:href="bdtx-20220331.xsd#bdtx_A2020StockOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_fc9e564e-dec6-49ff-97ac-8ba89b07e6bd" xlink:to="loc_bdtx_A2020StockOptionPlanMember_b038346a-b759-4ec7-92af-1ef61b50294d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_A2020EmployeeStockPurchasePlanMember_93dbf008-8adc-484e-b58d-1a1955637def" xlink:href="bdtx-20220331.xsd#bdtx_A2020EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_fc9e564e-dec6-49ff-97ac-8ba89b07e6bd" xlink:to="loc_bdtx_A2020EmployeeStockPurchasePlanMember_93dbf008-8adc-484e-b58d-1a1955637def" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" xlink:type="simple" xlink:href="bdtx-20220331.xsd#STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" xlink:type="extended" id="i3dab02791b7f443380e46e6f6ac9341d_STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3f2b07b-ab76-41ea-917d-b4148fe13289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_bb122bf1-f7b5-4d5d-8b5e-5499b109977f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3f2b07b-ab76-41ea-917d-b4148fe13289" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_bb122bf1-f7b5-4d5d-8b5e-5499b109977f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_aeeb620f-cc45-43b5-a1e5-43e3c4a7c23f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3f2b07b-ab76-41ea-917d-b4148fe13289" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_aeeb620f-cc45-43b5-a1e5-43e3c4a7c23f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_44fcf67e-b457-4271-abe9-6d6a196b0fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_aeeb620f-cc45-43b5-a1e5-43e3c4a7c23f" xlink:to="loc_us-gaap_AwardTypeAxis_44fcf67e-b457-4271-abe9-6d6a196b0fd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44fcf67e-b457-4271-abe9-6d6a196b0fd1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_44fcf67e-b457-4271-abe9-6d6a196b0fd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44fcf67e-b457-4271-abe9-6d6a196b0fd1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d808b09-82af-4560-b1ef-0a6099c11fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_44fcf67e-b457-4271-abe9-6d6a196b0fd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d808b09-82af-4560-b1ef-0a6099c11fe4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_383d460c-5560-4c55-b4a0-70a40cdfad79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d808b09-82af-4560-b1ef-0a6099c11fe4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_383d460c-5560-4c55-b4a0-70a40cdfad79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e542a6aa-7b34-4bee-9176-a43c25a127ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d808b09-82af-4560-b1ef-0a6099c11fe4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e542a6aa-7b34-4bee-9176-a43c25a127ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OtherAwardTypeMember_c1e55c80-bd7f-4601-b96e-13f7b4af1d53" xlink:href="bdtx-20220331.xsd#bdtx_OtherAwardTypeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d808b09-82af-4560-b1ef-0a6099c11fe4" xlink:to="loc_bdtx_OtherAwardTypeMember_c1e55c80-bd7f-4601-b96e-13f7b4af1d53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_32b848cb-26e8-43bc-b3fa-216044fe8a15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_aeeb620f-cc45-43b5-a1e5-43e3c4a7c23f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_32b848cb-26e8-43bc-b3fa-216044fe8a15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_32b848cb-26e8-43bc-b3fa-216044fe8a15_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_32b848cb-26e8-43bc-b3fa-216044fe8a15" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_32b848cb-26e8-43bc-b3fa-216044fe8a15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_78757aba-2406-40e6-851a-1307bd7799ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_32b848cb-26e8-43bc-b3fa-216044fe8a15" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_78757aba-2406-40e6-851a-1307bd7799ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_03ebffb2-3254-4bf6-8812-df5e7eafb796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_78757aba-2406-40e6-851a-1307bd7799ff" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_03ebffb2-3254-4bf6-8812-df5e7eafb796" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_30834b21-3cdc-4083-828e-a6065647d2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_78757aba-2406-40e6-851a-1307bd7799ff" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_30834b21-3cdc-4083-828e-a6065647d2fe" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="bdtx-20220331.xsd#STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" xlink:type="extended" id="i7f6b8860a7f24970a2b8f5deb71ede03_STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_505ff420-9d12-485b-8823-68e8f26b64c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8a670a79-e747-40bb-83e0-a56ab5ce59cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_505ff420-9d12-485b-8823-68e8f26b64c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8a670a79-e747-40bb-83e0-a56ab5ce59cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6b9d8014-2617-4b22-8d18-23b6560a052f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8a670a79-e747-40bb-83e0-a56ab5ce59cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6b9d8014-2617-4b22-8d18-23b6560a052f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_af846391-5049-4a70-bc27-0e4e6cdf5235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8a670a79-e747-40bb-83e0-a56ab5ce59cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_af846391-5049-4a70-bc27-0e4e6cdf5235" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_161f386f-5a4d-4c92-a765-030ed015beb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8a670a79-e747-40bb-83e0-a56ab5ce59cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_161f386f-5a4d-4c92-a765-030ed015beb9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3039bb37-80c5-4194-b691-ef6255c6831d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_07015711-7074-438d-bf75-e2a7640276bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_505ff420-9d12-485b-8823-68e8f26b64c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_07015711-7074-438d-bf75-e2a7640276bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f2a73055-5ab2-418e-8870-6a6c418ab35c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_07015711-7074-438d-bf75-e2a7640276bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f2a73055-5ab2-418e-8870-6a6c418ab35c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_407a3d31-9f46-496f-9ac1-f1ddfacda7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_07015711-7074-438d-bf75-e2a7640276bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_407a3d31-9f46-496f-9ac1-f1ddfacda7f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e2caa304-7811-4099-9ba7-99627338b6de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_07015711-7074-438d-bf75-e2a7640276bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e2caa304-7811-4099-9ba7-99627338b6de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3f49d57c-6256-4957-b85e-c7c00c6edd03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6a5e8ae-6de5-4072-a7f0-650520864551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_505ff420-9d12-485b-8823-68e8f26b64c6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6a5e8ae-6de5-4072-a7f0-650520864551" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_878a0d18-6cba-4955-b95c-66b84c7ece51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6a5e8ae-6de5-4072-a7f0-650520864551" xlink:to="loc_us-gaap_AwardTypeAxis_878a0d18-6cba-4955-b95c-66b84c7ece51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_878a0d18-6cba-4955-b95c-66b84c7ece51_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_878a0d18-6cba-4955-b95c-66b84c7ece51" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_878a0d18-6cba-4955-b95c-66b84c7ece51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db81c107-e616-4313-94a1-0854bd8a129f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_878a0d18-6cba-4955-b95c-66b84c7ece51" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db81c107-e616-4313-94a1-0854bd8a129f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b226852a-d801-4c51-80e3-3f0aa6b78c14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db81c107-e616-4313-94a1-0854bd8a129f" xlink:to="loc_us-gaap_RestrictedStockMember_b226852a-d801-4c51-80e3-3f0aa6b78c14" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" xlink:type="simple" xlink:href="bdtx-20220331.xsd#NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" xlink:type="extended" id="ibe6ef9a923a042e19272626df01af175_NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f5adce7e-20bf-42d8-9587-7d7c3d859e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d6b75dfe-e8fd-4276-b783-33ee6c1b02c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f5adce7e-20bf-42d8-9587-7d7c3d859e0c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d6b75dfe-e8fd-4276-b783-33ee6c1b02c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_035533b5-a56c-4aed-819a-319709170fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f5adce7e-20bf-42d8-9587-7d7c3d859e0c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_035533b5-a56c-4aed-819a-319709170fa7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8ea0793c-3aa9-4a34-8719-009b31bb3e58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_035533b5-a56c-4aed-819a-319709170fa7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8ea0793c-3aa9-4a34-8719-009b31bb3e58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8ea0793c-3aa9-4a34-8719-009b31bb3e58_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8ea0793c-3aa9-4a34-8719-009b31bb3e58" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8ea0793c-3aa9-4a34-8719-009b31bb3e58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cce5c81b-6322-4d41-9433-8c93ac7ce4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8ea0793c-3aa9-4a34-8719-009b31bb3e58" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cce5c81b-6322-4d41-9433-8c93ac7ce4d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ab5e5d67-06da-49f9-88a7-1b90c2896c48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cce5c81b-6322-4d41-9433-8c93ac7ce4d9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ab5e5d67-06da-49f9-88a7-1b90c2896c48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c72f056a-5a8a-4757-a37c-29d966d1d381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cce5c81b-6322-4d41-9433-8c93ac7ce4d9" xlink:to="loc_us-gaap_RestrictedStockMember_c72f056a-5a8a-4757-a37c-29d966d1d381" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_6d0a93b4-993f-4be4-973e-e75ed79b9c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cce5c81b-6322-4d41-9433-8c93ac7ce4d9" xlink:to="loc_us-gaap_EmployeeStockMember_6d0a93b4-993f-4be4-973e-e75ed79b9c1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_a4ff57b4-d61e-40ab-a07c-38128f0863c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cce5c81b-6322-4d41-9433-8c93ac7ce4d9" xlink:to="loc_us-gaap_WarrantMember_a4ff57b4-d61e-40ab-a07c-38128f0863c7" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="bdtx-20220331.xsd#LEASESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" xlink:type="extended" id="if9e623a6409e488b9848cd10b06794b9_LEASESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_4c8f32db-aae5-4d25-b063-3785c52601f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LesseeOperatingLeaseNumberOfContracts_e70f0de8-7d18-455f-85a3-2c09b3d85525" xlink:href="bdtx-20220331.xsd#bdtx_LesseeOperatingLeaseNumberOfContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4c8f32db-aae5-4d25-b063-3785c52601f6" xlink:to="loc_bdtx_LesseeOperatingLeaseNumberOfContracts_e70f0de8-7d18-455f-85a3-2c09b3d85525" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e772a7bb-8dd5-4f52-90a1-292c03c153e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4c8f32db-aae5-4d25-b063-3785c52601f6" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e772a7bb-8dd5-4f52-90a1-292c03c153e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_737f81fa-1683-4d45-83a5-0fa2176af2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4c8f32db-aae5-4d25-b063-3785c52601f6" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_737f81fa-1683-4d45-83a5-0fa2176af2a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LesseeOperatingLeaseArea_f4cbc498-af81-4716-8429-3deb7e3f6007" xlink:href="bdtx-20220331.xsd#bdtx_LesseeOperatingLeaseArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4c8f32db-aae5-4d25-b063-3785c52601f6" xlink:to="loc_bdtx_LesseeOperatingLeaseArea_f4cbc498-af81-4716-8429-3deb7e3f6007" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_da59feef-54d7-4fbc-8d54-3d3ec215cce4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4c8f32db-aae5-4d25-b063-3785c52601f6" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_da59feef-54d7-4fbc-8d54-3d3ec215cce4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_6fc2e1e2-10ac-446a-be6e-748ed2313933" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4c8f32db-aae5-4d25-b063-3785c52601f6" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_6fc2e1e2-10ac-446a-be6e-748ed2313933" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_946fb47f-4ea8-4de3-9808-1106df9ac230" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4c8f32db-aae5-4d25-b063-3785c52601f6" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_946fb47f-4ea8-4de3-9808-1106df9ac230" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_ae1a8fa9-d6c0-46f1-924e-8e2fbfdaf645" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_946fb47f-4ea8-4de3-9808-1106df9ac230" xlink:to="loc_us-gaap_LeaseContractualTermAxis_ae1a8fa9-d6c0-46f1-924e-8e2fbfdaf645" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_ae1a8fa9-d6c0-46f1-924e-8e2fbfdaf645_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_ae1a8fa9-d6c0-46f1-924e-8e2fbfdaf645" xlink:to="loc_us-gaap_LeaseContractualTermDomain_ae1a8fa9-d6c0-46f1-924e-8e2fbfdaf645_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_f90ff334-d981-4afc-8e3b-63a755357b22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_ae1a8fa9-d6c0-46f1-924e-8e2fbfdaf645" xlink:to="loc_us-gaap_LeaseContractualTermDomain_f90ff334-d981-4afc-8e3b-63a755357b22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OperatingLeasePrincipalOfficeTwoMember_029a046b-6cae-437c-9d76-5c847bd4df51" xlink:href="bdtx-20220331.xsd#bdtx_OperatingLeasePrincipalOfficeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_f90ff334-d981-4afc-8e3b-63a755357b22" xlink:to="loc_bdtx_OperatingLeasePrincipalOfficeTwoMember_029a046b-6cae-437c-9d76-5c847bd4df51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OperatingLeasePrincipalOfficeOneMember_dc6fd02e-0469-44d0-8a2f-0e2fba7f5e5c" xlink:href="bdtx-20220331.xsd#bdtx_OperatingLeasePrincipalOfficeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_f90ff334-d981-4afc-8e3b-63a755357b22" xlink:to="loc_bdtx_OperatingLeasePrincipalOfficeOneMember_dc6fd02e-0469-44d0-8a2f-0e2fba7f5e5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember_c59f1d86-2ccd-4282-8b20-fb53cb9206bc" xlink:href="bdtx-20220331.xsd#bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_f90ff334-d981-4afc-8e3b-63a755357b22" xlink:to="loc_bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember_c59f1d86-2ccd-4282-8b20-fb53cb9206bc" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>bdtx-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:674e53d2-18f0-47df-b195-3621df688bf3,g:abed15df-df65-4b1b-8a1f-1c79fbf06613-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_e89256aa-a4c5-4bfc-a46c-2b24094fde85_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_fbba198e-1376-4510-8a4e-fac59d2584a9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2b6cd55c-bb14-4b75-be01-567e93e29bdb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_9c45a380-ef37-470e-a825-8ea0cd01cafc_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fb33f091-f12a-45ea-931a-5ea13a3d59fb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_d4578653-bdf6-4305-bc21-4983ef5701dd_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_6a90eaf2-e633-4880-a3da-73939be38361_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_66d4f6db-1f77-47c4-b6d7-d051418f41cd_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_66b50eae-3404-4fcb-ae35-5fffcd7abf38_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d6fdfec8-c828-4712-bea0-73fdec67eba4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_OpenMarketSaleMember_a4142fab-69f7-4a14-a022-859b8b0f6796_terseLabel_en-US" xlink:label="lab_bdtx_OpenMarketSaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sale</link:label>
    <link:label id="lab_bdtx_OpenMarketSaleMember_label_en-US" xlink:label="lab_bdtx_OpenMarketSaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sale [Member]</link:label>
    <link:label id="lab_bdtx_OpenMarketSaleMember_documentation_en-US" xlink:label="lab_bdtx_OpenMarketSaleMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OpenMarketSaleMember" xlink:href="bdtx-20220331.xsd#bdtx_OpenMarketSaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_OpenMarketSaleMember" xlink:to="lab_bdtx_OpenMarketSaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_a7d09af4-3639-426a-a9ce-acb26d09c513_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_8c56009b-42ec-4f62-9184-5df1c93127de_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll and related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_df2af49d-e231-4ba0-ad7b-a33ca971325a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_43d6960e-9689-4ff6-87f4-a7ba16d040ab_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_7a9fd872-7bed-445b-8833-dd415c1d4783_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_FormerAddressMember_40a641b6-fc27-4eb9-9845-4c30e8af02fa_terseLabel_en-US" xlink:label="lab_dei_FormerAddressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Address</link:label>
    <link:label id="lab_dei_FormerAddressMember_label_en-US" xlink:label="lab_dei_FormerAddressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Address [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_FormerAddressMember" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_FormerAddressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_FormerAddressMember" xlink:to="lab_dei_FormerAddressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_9b2c6c1f-ba70-4765-a8e5-f0fb23e9dbce_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_d8be1190-7b70-4515-87f0-c0ead50aaf76_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_label_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_ec1c0742-24a9-4053-ac28-717725d2a397_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e90398f2-7003-4c4a-a09e-e3442fff72e3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock related to ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_353e9f17-217c-4f75-abc2-7932ac25ae0c_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_c1abc77b-b8f5-4140-8183-7e8825928145_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contribution, matching contribution percentage</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_57bf85a6-ff96-40c3-8a01-9b85b8479a9a_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_3534030b-25fe-4d64-b233-eaec39fa79c2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of fair value assets</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_73df0a92-f7d7-4735-aae8-c931f5215b27_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_de5d9f45-f32b-426b-8630-8280cec856bf_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_d77abc08-42ab-4c13-8075-7c9b2ddefffa_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f3838641-58c2-42b5-a6c8-a5c380de2938_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_895d7379-ed17-4be3-95f6-0237da836510_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0e046f8-3bb4-4055-bf84-adb633830f23_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_2428754b-bf75-46ed-9b0f-59b6ca68db36_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_00766bc4-1c4f-4dd0-9a08-95a7c9b715d5_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_285f0288-5d78-454a-ae61-2ad900694001_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_LesseeOperatingLeaseArea_4f47916e-f779-4fe2-8a2b-0b4be308198d_terseLabel_en-US" xlink:label="lab_bdtx_LesseeOperatingLeaseArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area leased (square feet)</link:label>
    <link:label id="lab_bdtx_LesseeOperatingLeaseArea_label_en-US" xlink:label="lab_bdtx_LesseeOperatingLeaseArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area</link:label>
    <link:label id="lab_bdtx_LesseeOperatingLeaseArea_documentation_en-US" xlink:label="lab_bdtx_LesseeOperatingLeaseArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LesseeOperatingLeaseArea" xlink:href="bdtx-20220331.xsd#bdtx_LesseeOperatingLeaseArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_LesseeOperatingLeaseArea" xlink:to="lab_bdtx_LesseeOperatingLeaseArea" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_46d5cbcb-46e7-4a42-9d26-2e4feb750f4e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_447941b0-fd11-4365-933c-2aa41997155c_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_5a19da06-263b-4853-b2c3-a469034f8435_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_9c22ff10-9b11-4ffc-b3f7-f349ef9e3b86_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_d6c93084-144c-4e33-b567-8a664f43c273_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled or forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_24b354f0-803c-498a-a99c-b9dc696f351f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_86d276e0-72b0-457c-a8f9-6622fe6bbe4b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_0c8f3a72-6d81-4983-aaf9-b30a50a360ab_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_b851b800-96cb-437e-a23d-ecd1df4ed241_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f86bd3db-be8b-47bd-96cc-85ef806ee324_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_8f0c612d-29b2-4658-bd11-4efbc44cee59_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_3d981d4a-1d37-4a70-b581-a34aaf83a393_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b8753207-ecf3-4515-9a10-2e9ff4a7ca95_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_eb9ec105-eb7e-48b8-a319-056ea1085477_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_eadb1e2d-829e-41f0-8088-3612edaec778_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_OperatingLeasePrincipalOfficeOneMember_465ae04c-c642-4ec0-9f7b-96654b548b96_terseLabel_en-US" xlink:label="lab_bdtx_OperatingLeasePrincipalOfficeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal office, lease one</link:label>
    <link:label id="lab_bdtx_OperatingLeasePrincipalOfficeOneMember_label_en-US" xlink:label="lab_bdtx_OperatingLeasePrincipalOfficeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Principal Office, One [Member]</link:label>
    <link:label id="lab_bdtx_OperatingLeasePrincipalOfficeOneMember_documentation_en-US" xlink:label="lab_bdtx_OperatingLeasePrincipalOfficeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Principal Office, One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OperatingLeasePrincipalOfficeOneMember" xlink:href="bdtx-20220331.xsd#bdtx_OperatingLeasePrincipalOfficeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_OperatingLeasePrincipalOfficeOneMember" xlink:to="lab_bdtx_OperatingLeasePrincipalOfficeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ceb983fc-32a7-4231-b403-48d8058bed16_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_133c6080-c260-4a8c-92bc-c3362ff7bdd7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_768bdf18-8935-460f-9006-6734d0de8c6c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost, options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_86a19ef5-248f-4395-9747-4485e3025adf_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_35de870a-de63-4cb5-b299-0f947e7db3c4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_41550cb8-3598-498b-b680-20c67c44cedb_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_e4d41f6c-b739-434d-9348-bd74c0ed03df_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_333d4288-d0a2-4fc6-bc18-54bf75457b64_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_34d584e6-32a4-4e69-8cb3-bb3efd94644d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_d2bac22d-0d96-4bb4-8c3e-da34c1edf73a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of units vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_2b58b1b3-016e-4fe0-b140-365bafa390c2_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_25ecd67b-ca9f-4c12-9207-bf22d06c25f0_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_bcd47ebc-d0da-47a5-8d13-cda3e4b67dac_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_293971c3-9816-4ec3-a308-58f89f484b06_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_c2aa1735-72d5-491c-afd1-fc01ff1fa39a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under share-based compensation plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0d4dac6-abdb-4b15-a615-d02b7830dcaa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e27cdcf1-9ae9-4ae8-825c-ef4fa71fa790_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_432996fb-bdea-4050-bbcb-d53618fbe5a3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e67d81dd-4edd-4c5d-bd94-94449b148351_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Life and Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_38b0c015-7b8f-4491-b1d3-4adc2f1dfffd_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_990cd196-5c62-4836-ad21-4e0b45330a67_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_81680968-b8e3-421a-bcbe-a72311925e34_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2e86d9e0-cfba-4252-beb4-4272f48a8574_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested or expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_RentExpense_04bd942a-3d07-4d56-9606-15ad895c4ee9_terseLabel_en-US" xlink:label="lab_bdtx_RentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash rent expense</link:label>
    <link:label id="lab_bdtx_RentExpense_label_en-US" xlink:label="lab_bdtx_RentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent Expense</link:label>
    <link:label id="lab_bdtx_RentExpense_documentation_en-US" xlink:label="lab_bdtx_RentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_RentExpense" xlink:href="bdtx-20220331.xsd#bdtx_RentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_RentExpense" xlink:to="lab_bdtx_RentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_983276a0-b50e-4ecb-871a-c919f187edec_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_51b40905-003c-4c12-a048-b339103b9dc6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_A2020StockOptionPlanMember_7f21b894-7ca9-476e-8cb2-34dc796f516a_terseLabel_en-US" xlink:label="lab_bdtx_A2020StockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Option Plan</link:label>
    <link:label id="lab_bdtx_A2020StockOptionPlanMember_label_en-US" xlink:label="lab_bdtx_A2020StockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Option Plan [Member]</link:label>
    <link:label id="lab_bdtx_A2020StockOptionPlanMember_documentation_en-US" xlink:label="lab_bdtx_A2020StockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Option Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_A2020StockOptionPlanMember" xlink:href="bdtx-20220331.xsd#bdtx_A2020StockOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_A2020StockOptionPlanMember" xlink:to="lab_bdtx_A2020StockOptionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8214c0ea-8265-48fe-b927-249f40c10681_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_42763f57-747b-4e72-b6a3-270ab83479ac_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000,000 shares and 10,000,000 shares authorized at March&#160;31, 2022 and December&#160;31, 2021, respectively; no shares issued or outstanding at March&#160;31, 2022 and December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_3114630d-454c-4b44-bef8-a0350963ff8f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of common stock options and ESPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_ae8e0c31-7b03-45dc-8768-ab20726a4ebe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesLineItems_ab22c723-d55b-4d57-99aa-73c529b58a45_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses [Line Items]</link:label>
    <link:label id="lab_dei_EntityAddressesLineItems_label_en-US" xlink:label="lab_dei_EntityAddressesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesLineItems" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesLineItems" xlink:to="lab_dei_EntityAddressesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c8c30185-84dd-4098-b9f5-d29d1cad5481_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_659620b3-a890-457a-adf7-f758d1eb6144_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f1ee14a0-dec2-4903-8bbe-2b31c63d5ca6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_5f5ce7e5-61e4-4a9b-997b-c035f8dfbcf5_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b6febfd0-ff39-4ab5-9ba3-42ffd0c77f26_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_dd6c3ad7-b1d7-4c26-a06f-4c25971a9b13_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_715e716f-8dd6-4362-bf5b-ef652fe8e26c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1660fb30-c9c8-449e-95be-b4f7130fd8ef_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percent of fair market value of common stock</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_5ba34beb-9a6a-4ee4-8290-a1cefe9d1f13_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_02ca54b0-eab6-4af2-9af7-a82f7f674d3a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_23391518-6fb2-4405-b6b2-329c117c255b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_638f4244-cc1b-473f-92ca-d9909dfee1c3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_aa768196-bb8b-4a67-906f-f986a988e7ae_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_dbe7f9f0-c00a-46f4-8fd6-229aa70a04f2_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equipment included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e03e7072-4551-4c3e-96c6-e4990bfc5439_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease obligation</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_9af04cfb-cb05-4176-8be6-e785782ac57f_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_f63af87a-9baf-499b-815b-62ded3031d56_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4111ef06-2b78-4833-a56d-9fc27ade01cd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Computation of Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f5d44f22-0171-48c0-ac0c-6b738232c9f9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_ce26f6d3-b9ab-4b2d-808e-9bedbc46b1a1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum employee subscription rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0f7d0b74-05e5-44df-8a93-077dbe5b3a2b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNonoperating_eaa51850-b50a-41c5-83af-532137c12c84_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNonoperating_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNonoperating" xlink:to="lab_us-gaap_InvestmentIncomeNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c19f79c5-d2d3-457d-8edb-05a6b4588966_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_0041b131-ebf6-4d29-bc30-8cf0a74b212d_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_dc007b8d-4301-4c1b-a608-dc6cc29d620f_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_937e5d43-0c75-4da4-a17a-6f74c21e3756_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_cce307f2-18da-466e-87e3-a51ff55bb6f9_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_3aa2042e-51af-41da-8334-3f97459b84ba_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_8952e272-a345-4e9c-953b-6f5fb323d414_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4fba5a8b-96a8-47b3-a72c-751a236e2bd4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding_08633361-0758-4d89-b60a-f9012caac3e5_terseLabel_en-US" xlink:label="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase of authorized shares, percent of common stock outstanding</link:label>
    <link:label id="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding_label_en-US" xlink:label="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Authorized Shares, Percent of Common Stock Outstanding</link:label>
    <link:label id="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding_documentation_en-US" xlink:label="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Authorized Shares, Percent of Common Stock Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" xlink:href="bdtx-20220331.xsd#bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" xlink:to="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_e72f4006-cde5-4aac-8741-a92158e54dbe_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_aa188f73-38c5-477f-9f9e-49b35fcde092_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_30faaf5b-a2fd-4462-8524-725ae01d1319_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_7700e012-f407-4b5d-969c-a0decf1330f4_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_31773baf-6165-4f79-8b16-5903ccb8ed22_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_adab61a1-9806-4b7d-8360-dec30a4edeff_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_97c6a383-75ed-44eb-a8bf-a3414f62f5ad_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_c8c73fa1-bf29-4d4e-9cdf-6d5b04f4b2bd_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d96d18a7-eb0f-40b6-a231-54921be947e6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b6e16a3e-ccde-4a74-96f7-696f2f1eb632_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted common stock, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dac15f9b-3a37-4453-b1c4-fd09539fe4a3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted common stock, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnTerminationOfLease_53aa5a0a-7c12-4b95-b36c-711837f6e2c1_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnTerminationOfLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on lease termination</link:label>
    <link:label id="lab_us-gaap_GainLossOnTerminationOfLease_label_en-US" xlink:label="lab_us-gaap_GainLossOnTerminationOfLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Termination of Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnTerminationOfLease" xlink:to="lab_us-gaap_GainLossOnTerminationOfLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_688606bd-05ae-4d8c-b041-4f01db17e4ee_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term, optional extension (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2923f708-c8ee-45f9-9c08-ac17b8d7499b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_ad06877e-6b72-458e-8cbc-1eec0653ac93_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premium on investments</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5d429cfe-b7ac-4bbc-95d5-b28d02938032_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_f12aa6e3-5ac3-455f-b921-838bc58454d8_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_01f3ffb4-5685-41c8-825e-2287ec83120a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_25b4e0ce-8887-4516-ae4e-7423ea428b3d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_6aa27d22-c5ef-496a-8a03-a965fb6db8b0_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_273d9653-c3f4-4c04-b9c0-99cb511c063a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_aa7dcf23-5b95-43a5-bb09-95d23be25cb2_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Lease Cost and Other Operating Lease Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_ad03f1e4-e3d2-460e-be59-6822e91304f8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_727133b8-7ec7-407f-a4dc-fed13c28fa09_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_15aa2b89-2ab1-424e-83b4-667630f81f3c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash items</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_6a7b3e9a-e761-41c4-896d-dc252fbae877_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_d3a417ca-c23a-4223-9d41-11fd6db82b0c_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e9583670-07e7-4cb7-9bc3-c2af32ab10e4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_7293da54-da37-4f9b-b30c-8645bcbf73d1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_685a0796-3e1c-4571-ba1f-344edeb6a572_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_8ebdef9d-c161-4d9f-bb80-498207d67761_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_638c4cd8-7865-4b70-ab32-9755456db143_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_e1a6b1c5-5b6e-4116-9a74-fcdef3b6cc7e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_a3296b70-838f-4608-8acd-456861c18392_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_397c2396-2aa5-458d-9def-c99b90f00eaf_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_3fce7b04-2d84-4aa5-a1ac-9006a29cfbe6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_ceb042ce-2d68-463e-9813-10e1612dab02_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_035f4ea7-d129-47f0-9a7c-4f839c7b7bce_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_369e353a-f44a-4be7-b90e-0cf0808ef296_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC 842</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesTable_91dadab7-5d84-4f63-82e6-13adea08cfde_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses [Table]</link:label>
    <link:label id="lab_dei_EntityAddressesTable_label_en-US" xlink:label="lab_dei_EntityAddressesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesTable" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesTable" xlink:to="lab_dei_EntityAddressesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_395cfc4d-dc93-4bc5-a2dd-e3e675a2c3ca_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_a8e1c032-5d99-433b-b041-a58a8e901cfb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_cc87aa9c-682b-46d6-b37f-b9599ae50cab_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_5f4020d4-185a-4ef4-8161-28c7177a57e7_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_19847d0e-729c-452e-bcdd-5e07fbdd7e09_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_18182a0c-2969-4410-91e9-7e9aa356d62f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_bc71fcd8-a0d5-4405-ae65-306072cdcf99_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_cc6a45b6-f2a8-4c91-8f26-f24c12bbd455_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_9b5a3493-216f-4055-810d-c3d9a82c0554_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Government agencies</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_e1792ce0-53cb-4b02-a2d7-48a865520b16_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_23d4304e-6e77-4529-a407-e6749c0f6520_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62b6c8bb-5c51-48c8-9362-e45a9ee79339_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_def021b7-d133-4610-bf2a-75b9015a1986_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_22499e5f-32b3-488a-b417-9cd15ca5985b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NATURE OF BUSINESS AND BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_45e8ccc8-14de-4d74-be2f-be6fde70790a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d300dc9f-e8aa-43e2-85c1-4f92262f85a5_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c9b28cde-f106-4eb1-ab61-76ff14b45276_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_6da5c78e-f2e4-4d7a-9bc0-d283c9d401e7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET LOSS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9671b981-a49d-4208-94f2-6c07ad2a8285_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_e488bd68-816c-4f10-a15d-6038c3c768bb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_4c065a75-eaad-4f8c-bc5b-65af4fc438d4_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_81d44c08-dfa8-4b7a-8caa-0d12fa451bd1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_bbd117b5-8bbc-4c4e-a990-a6b38a6d7679_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_cf2ce066-7745-4b6f-ab00-90d07bb9b3cc_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_695c3ff5-6e18-48c4-b28c-488257b44d4f_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_f4c2ba7e-f86b-4249-a543-8d988d35d63c_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0b8e17f0-3d3b-4f73-a6d8-40e9a375e58d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ec1625b4-542d-4439-8aa9-a887031875e4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5783e555-ddd4-4373-bac3-5de621ed5a18_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_3f718a8a-f570-488f-9547-51da573aa457_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled or forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_507f662b-48f6-4ad8-a57f-43f7a74418d4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5c391128-8890-40e6-9a39-5e87b2923d0c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_7121e8dc-aee3-4fc4-b66a-4231bcc9ed26_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_b3c407b5-c290-4e67-a899-35754e087fd2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_b1328133-7308-450b-935c-980eb34f64bf_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_b33c0ed6-d101-4ae8-bf10-bc14e86eda12_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_6c5809a5-c40a-4ce6-af62-7a04e9be9f2e_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0304c3ac-e1b3-4d3c-b440-f08c4b5ec6c9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_7856d722-0d49-472e-bb26-ecc442bb0389_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_c5c334f9-2074-4b38-be3f-5fa8815dbd88_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments:</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_67f76455-3a55-470b-bf9d-898b9d22ae7b_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_cb2e691c-ae20-4659-9212-51e991698567_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_0ad11cc3-642e-4cf3-b80e-8cd80527ecd9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_ea9465e4-a727-495b-bf4f-cda9ec88bc5b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss position fair value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c2934218-529b-44e4-8a12-75eda2d745d4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1f1de531-7bc2-4ff6-8462-e08cc4b7cc60_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_75957c8b-2090-4dd6-a4e6-b94fcfddca85_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_d3cfe8eb-49c2-4c59-877b-b388e2e1a8fb_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_LesseeOperatingLeaseNumberOfContracts_a416e3f1-62c9-4568-8783-5c3e39d279f4_terseLabel_en-US" xlink:label="lab_bdtx_LesseeOperatingLeaseNumberOfContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of leases</link:label>
    <link:label id="lab_bdtx_LesseeOperatingLeaseNumberOfContracts_label_en-US" xlink:label="lab_bdtx_LesseeOperatingLeaseNumberOfContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Contracts</link:label>
    <link:label id="lab_bdtx_LesseeOperatingLeaseNumberOfContracts_documentation_en-US" xlink:label="lab_bdtx_LesseeOperatingLeaseNumberOfContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LesseeOperatingLeaseNumberOfContracts" xlink:href="bdtx-20220331.xsd#bdtx_LesseeOperatingLeaseNumberOfContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_LesseeOperatingLeaseNumberOfContracts" xlink:to="lab_bdtx_LesseeOperatingLeaseNumberOfContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_4ecfb683-77de-4d04-b1c9-82c2c6b1d9ce_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_d5403240-f18a-40ec-836a-01d2748cd158_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_34dca47e-0c4d-42e7-a2e1-d710add797f2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d641af04-a1c4-483c-89f7-c8b4bee965b3_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_8bbc03e5-b770-4168-a6c3-6a47f167ea2b_terseLabel_en-US" xlink:label="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award purchase period (in months)</link:label>
    <link:label id="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_label_en-US" xlink:label="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</link:label>
    <link:label id="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_documentation_en-US" xlink:label="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:href="bdtx-20220331.xsd#bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:to="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9b9bd110-8401-402d-9340-d088a4f51159_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_11d2703f-231c-497b-a00a-ac670ced3c4f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_0cce57be-41dd-4829-8175-8713a64b4c9f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_a3ffb4c1-d50d-4d9f-beb9-33db1e1300ab_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2ba90e67-754f-4503-9513-ac4337cce974_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, remaining life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_25fba47c-ca08-45be-895c-376cc31a0914_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_6f07ce25-7c78-42cf-a94b-d83716123b45_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested or expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_64c2a895-5a06-48b7-8872-1fc9fb41e93e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional and consulting fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_f0291c83-f4fa-4705-9ab1-6ecd3c0471d3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_9b67fc37-c85b-4351-9af2-22aa4c2e18ae_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit outstanding</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_054965bf-05db-4cf6-809b-e0a14a9db9c4_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_62a257c6-473a-4616-8095-9e1c3991fc1f_terseLabel_en-US" xlink:label="lab_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_label_en-US" xlink:label="lab_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Four</link:label>
    <link:label id="lab_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_documentation_en-US" xlink:label="lab_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:href="bdtx-20220331.xsd#bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="lab_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_15270b9b-de51-4ddc-b183-48ce0f536cd5_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4884bc01-1a09-441b-8c05-ac4a2cfa7f54_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_762f5bc1-c967-49c7-a322-56d4ddecdb8e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_9916b4fd-7292-473d-91fc-f8b51c1914f1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock; $0.0001 par value; 500,000,000 shares authorized at March&#160;31, 2022 and 500,000,000 shares authorized at December&#160;31, 2021; 36,287,568 shares issued and outstanding at March&#160;31, 2022 and 36,234,624 shares issued and outstanding at December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_a0b865ed-2384-4b94-801a-c593456f6a94_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_057bf81e-43e2-4778-82df-ff33a2a48ffc_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost, recognition period (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8d21d207-dc61-4c67-933e-8c50eff0f4b4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted common stock, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8c04dd47-4c2e-4100-9cc4-f26e04df87be_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted common stock, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_af39eedd-b73e-4235-b291-2bf366d674b1_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of consolidation and unaudited interim financial information</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_099b9262-37dd-4471-96e3-ffc007fbfe9d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note&#160;10)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_73d1c1df-d990-4036-b3c3-27e1281b137f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_5121456a-4423-4567-b311-c0cbe203ef09_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9ac303a0-5a26-4d4a-a170-94dc92cb64e5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_AccruedContractResearchServiceFeesCurrent_ca375775-5fd1-4894-a5ea-32fafbed9c5d_terseLabel_en-US" xlink:label="lab_bdtx_AccruedContractResearchServiceFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contracted research services</link:label>
    <link:label id="lab_bdtx_AccruedContractResearchServiceFeesCurrent_label_en-US" xlink:label="lab_bdtx_AccruedContractResearchServiceFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Contract Research Service Fees, Current</link:label>
    <link:label id="lab_bdtx_AccruedContractResearchServiceFeesCurrent_documentation_en-US" xlink:label="lab_bdtx_AccruedContractResearchServiceFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Contract Research Service Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_AccruedContractResearchServiceFeesCurrent" xlink:href="bdtx-20220331.xsd#bdtx_AccruedContractResearchServiceFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_AccruedContractResearchServiceFeesCurrent" xlink:to="lab_bdtx_AccruedContractResearchServiceFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2c479b25-7a9a-4a52-a217-9f1083d7f866_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6bf71c88-ba08-4360-8237-e2752b0b00a9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, remaining life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_624e1ca7-a903-444c-8fe7-de16b7b27365_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a769f302-c007-4833-a06f-bc95087aa10e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 (excluding the three months ended March&#160;31, 2022)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_46aa7d2e-2617-4412-9baa-d4a3eafce638_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant&#160;date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_f1ce9b53-0108-4de2-9682-2ae6e903829d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_3b81bd9c-eae2-4219-9d97-956986ed2c0f_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BENEFIT PLANS</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_A2020EmployeeStockPurchasePlanMember_df3541a4-1f5e-4428-b369-0bff4ee71d21_terseLabel_en-US" xlink:label="lab_bdtx_A2020EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 ESPP</link:label>
    <link:label id="lab_bdtx_A2020EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_bdtx_A2020EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_bdtx_A2020EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_bdtx_A2020EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_A2020EmployeeStockPurchasePlanMember" xlink:href="bdtx-20220331.xsd#bdtx_A2020EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_A2020EmployeeStockPurchasePlanMember" xlink:to="lab_bdtx_A2020EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_4535ec04-68fe-41f7-820d-eeb5320bd5be_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_07e70fb1-e33e-4b7b-92f6-3b2e20ea4fb2_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVESTMENTS</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_164bd59b-3b22-4fed-9ed7-94227121abf7_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in process</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2744272c-0210-4ca3-8e82-b8527a705806_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_25950bd8-34f2-49d5-9209-ce51bfff6229_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_18048899-45bd-4443-bfdf-ac81e1abc791_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_3f111593-a84e-4378-bfee-e56c7d33ee7b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_LeaseOtherInformationAbstract_fa7a695a-a655-4c61-83b5-f81be2c6dc63_terseLabel_en-US" xlink:label="lab_bdtx_LeaseOtherInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Lease Information</link:label>
    <link:label id="lab_bdtx_LeaseOtherInformationAbstract_label_en-US" xlink:label="lab_bdtx_LeaseOtherInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Other Information [Abstract]</link:label>
    <link:label id="lab_bdtx_LeaseOtherInformationAbstract_documentation_en-US" xlink:label="lab_bdtx_LeaseOtherInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Other Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LeaseOtherInformationAbstract" xlink:href="bdtx-20220331.xsd#bdtx_LeaseOtherInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_LeaseOtherInformationAbstract" xlink:to="lab_bdtx_LeaseOtherInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_28fe5587-4714-493b-b3c2-7fa178ac55fa_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_afc591b3-8f49-4119-b74c-c74f0dd4cbea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_PerformanceRestrictedStockUnitsMember_b04aa879-e620-4751-ba26-11bc92e26475_terseLabel_en-US" xlink:label="lab_bdtx_PerformanceRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Restricted Stock Units</link:label>
    <link:label id="lab_bdtx_PerformanceRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bdtx_PerformanceRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bdtx_PerformanceRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bdtx_PerformanceRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_PerformanceRestrictedStockUnitsMember" xlink:href="bdtx-20220331.xsd#bdtx_PerformanceRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_PerformanceRestrictedStockUnitsMember" xlink:to="lab_bdtx_PerformanceRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_11700a40-db42-4635-baff-3741a349d292_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_OtherAwardTypeMember_06ae2abc-b893-42a5-9772-9e7653a0027b_terseLabel_en-US" xlink:label="lab_bdtx_OtherAwardTypeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan and Other</link:label>
    <link:label id="lab_bdtx_OtherAwardTypeMember_label_en-US" xlink:label="lab_bdtx_OtherAwardTypeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Award Type [Member]</link:label>
    <link:label id="lab_bdtx_OtherAwardTypeMember_documentation_en-US" xlink:label="lab_bdtx_OtherAwardTypeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Award Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OtherAwardTypeMember" xlink:href="bdtx-20220331.xsd#bdtx_OtherAwardTypeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_OtherAwardTypeMember" xlink:to="lab_bdtx_OtherAwardTypeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_81314464-3bd2-4338-b365-598758e6eb26_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock issuance, net</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_47d70790-54bb-4980-873c-c82a9a1f2019_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_bb0707e1-d3fd-4a08-9b76-f1962dba7d8a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_f3536db7-5064-490f-aee8-c3848caa2488_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d09c1cfa-31c0-4af1-a004-d13f049c4589_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_10ef136e-51be-4c95-a703-d0d9d5de42ab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f208d28f-2825-41a3-aaaa-ebac2eeca633_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_165ae06c-b3a7-4713-8b49-04da85ce4c00_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c34e737a-ae0d-4b59-8603-19b84c832086_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_8e6d1066-e541-40a0-8e77-f73f40603a91_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_96642261-2dea-4280-bed1-2008d04037ab_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_bc06416b-3bac-4e86-9a8d-2a4b6f21cdd6_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_b0a7a76c-9962-46a8-9ff4-bce87918a1f8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_fb2f93b7-87a7-4f76-ac55-55866235e86a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_cdb10f9d-d1b1-4b1b-95d6-e88aa9d18693_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer and office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_6bac8b70-d41b-4e57-83d0-1dba0ebd5b03_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_1aca0991-ee7f-48fa-aff6-9344ee6acc51_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3e614d83-57a5-48e7-9126-ba5f66217fab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_decd1dea-1f36-4836-b2cd-5ccd3e7d88fe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_91146d93-806b-4b6f-a530-fca73b048fba_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_55efabbe-51f6-4aef-90bd-23c8d1637781_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a10bd638-10f6-43a2-bd76-a18810ec4952_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_cefaa873-27fe-48e5-8f49-88e60957c044_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b02645d9-6e39-4e40-9c40-f79b9fe9f722_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in current assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1e1660d7-671e-424b-b821-08954ad29b5e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_f5727b2b-20fe-4465-8cf6-092145191b0f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock related to ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_a316b533-a270-43aa-9b53-ccfb94964a83_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_6ac4e340-cad8-43ec-b656-178e2aa701b0_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contribution amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9b9b2e47-9367-48a4-a033-bdef40bad3fc_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_eb7ceb0b-484d-4fc5-9df7-fa04fd000eb7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f441de6e-0d8a-4750-a6e0-f8798528bf32_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_e4062b82-b151-44ab-a6bc-02cf1540e3ae_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_a75423a9-0a40-4f03-83ee-793391c384ae_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_e169b795-a0ce-43cc-a0cf-540a01cfbd66_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_2453a9f6-19b9-48fe-a091-ad0bb8b0b0d6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a43c2a58-0173-4763-aadb-c1efda8efca0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5fe72e86-9459-47ab-a87a-9f3c2cc63c62_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree_f82c286a-a0bb-4b9d-8236-2e44e796eb67_terseLabel_en-US" xlink:label="lab_bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree_label_en-US" xlink:label="lab_bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Three</link:label>
    <link:label id="lab_bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree_documentation_en-US" xlink:label="lab_bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:href="bdtx-20220331.xsd#bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:to="lab_bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_265b7d45-faf3-4a3e-a463-eca749e96941_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_1d92eb53-9325-47a3-bac0-7b86ec1bbfce_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issuable under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2becda0e-b43c-4481-9a5c-e3d71d1fb0d3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_ff4f51a6-2818-4f1b-b027-ec1b64d03fab_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_1b0d24b4-525d-4e79-9e22-8421eac59894_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_f85d692d-5db7-41f8-bf6d-1230fcd3eb1b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities_aee182b3-dabb-4f60-8689-faec5ad55984_terseLabel_en-US" xlink:label="lab_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current operating lease liabilities</link:label>
    <link:label id="lab_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liabilities</link:label>
    <link:label id="lab_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="bdtx-20220331.xsd#bdtx_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_18c57aae-52e5-4645-bc95-e47e6f7aa22b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_0176522b-da6d-4bea-9773-48f8a307b8a7_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_8ba0ebfd-013e-40e8-817e-ce03e84112d0_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_b0a44067-e8eb-47c1-9d57-de6114e51957_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contribution, percent of each participant's salary</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5c9d2a9f-e5ae-4575-bee6-2bd4aead4796_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested or expected to vest, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_33b4ae86-43ee-4bf1-86db-8edf1e97ebd0_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_60313709-035b-4a53-8924-fc81080f3600_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_37ea3e63-8a49-4986-b49c-f8a25cb5997c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_7b688d9e-c0f8-4d61-a1e7-2a792cf73e98_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f9641f08-0767-492f-aff1-71f88da12b80_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently issued accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_98dee8b8-6f6e-4994-a18a-5936edcde082_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_ee37c62b-b91a-4294-82e4-a6c20d49f8aa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_5810e791-c430-4342-a8b6-7fafa3bab7e6_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_08c9cc18-a914-4bef-98d8-91a4a0d7302b_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AddressTypeDomain_eb329f2d-270a-41a8-9fe4-49db0acd8841_terseLabel_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:label id="lab_dei_AddressTypeDomain_label_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_031522f5-191b-4945-b545-e5658b715da4_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_fa967859-ae9e-4291-9e81-83cd73c7ae9f_terseLabel_en-US" xlink:label="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum employee subscription amount</link:label>
    <link:label id="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_label_en-US" xlink:label="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount</link:label>
    <link:label id="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_documentation_en-US" xlink:label="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:href="bdtx-20220331.xsd#bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:to="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_bd43b1a4-6fd2-44d3-b543-974412ef7a0d_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_87756681-7745-436f-a616-b139d9d35b62_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0b373f32-36f4-4af0-a331-e170497fa566_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_59d5ca1b-3c70-46df-a94a-db93c68fac67_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_e2e4bd2e-5451-44bb-8454-456a84b39abb_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_85a5ce06-fd4d-402f-8744-3c24df9c4156_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_b785f463-4403-4863-9709-3cdba6e44163_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_3a1b5c29-0d2d-44d0-916d-873033315f62_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_23601977-9121-46b1-90c8-8d72a2f5e215_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a4d9b0b0-3f71-431d-9ac7-10a4cc9c2561_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_OperatingLeasePrincipalOfficeTwoMember_e8e20573-1a25-406d-8204-8595cca3239a_terseLabel_en-US" xlink:label="lab_bdtx_OperatingLeasePrincipalOfficeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal office, lease two</link:label>
    <link:label id="lab_bdtx_OperatingLeasePrincipalOfficeTwoMember_label_en-US" xlink:label="lab_bdtx_OperatingLeasePrincipalOfficeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Principal Office, Two [Member]</link:label>
    <link:label id="lab_bdtx_OperatingLeasePrincipalOfficeTwoMember_documentation_en-US" xlink:label="lab_bdtx_OperatingLeasePrincipalOfficeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Principal Office, Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OperatingLeasePrincipalOfficeTwoMember" xlink:href="bdtx-20220331.xsd#bdtx_OperatingLeasePrincipalOfficeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_OperatingLeasePrincipalOfficeTwoMember" xlink:to="lab_bdtx_OperatingLeasePrincipalOfficeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_16b5bb6f-09e7-4248-b4c4-5ceeebd3f931_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_f613dc96-df26-4334-b31d-8474dc465948_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c0aab2b3-628b-4f17-bc3e-004d32e0007b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_97ca6edb-122b-4898-b79c-9e0654165546_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember_63371882-883b-4f91-943c-b6eceb6ba887_terseLabel_en-US" xlink:label="lab_bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Office and Laboratory Space, NY</link:label>
    <link:label id="lab_bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember_label_en-US" xlink:label="lab_bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Office and Laboratory Space, NY [Member]</link:label>
    <link:label id="lab_bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember_documentation_en-US" xlink:label="lab_bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Office and Laboratory Space, NY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember" xlink:href="bdtx-20220331.xsd#bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember" xlink:to="lab_bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e9d1e1cf-9620-4ec1-b4ee-87f65d8db775_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_b64f5089-fba2-4ec1-8540-b9d39e4440b8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_a9c74b9b-ad62-47ca-9f6d-4b4438abb07c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested or expected to vest, remaining life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>bdtx-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:674e53d2-18f0-47df-b195-3621df688bf3,g:abed15df-df65-4b1b-8a1f-1c79fbf06613-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CoverPage" xlink:type="simple" xlink:href="bdtx-20220331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_726faa36-9209-4a5b-9a09-4f252a5ffe0a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesTable_9dc907f6-1242-4282-9ca4-d0d79788f5f9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_726faa36-9209-4a5b-9a09-4f252a5ffe0a" xlink:to="loc_dei_EntityAddressesTable_9dc907f6-1242-4282-9ca4-d0d79788f5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_bb70df7f-fcd9-4a5a-ae73-b705a5985e2f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesTable_9dc907f6-1242-4282-9ca4-d0d79788f5f9" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_bb70df7f-fcd9-4a5a-ae73-b705a5985e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_444f2d5e-a2ac-4954-9c78-e26da96d8da2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_bb70df7f-fcd9-4a5a-ae73-b705a5985e2f" xlink:to="loc_dei_AddressTypeDomain_444f2d5e-a2ac-4954-9c78-e26da96d8da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_FormerAddressMember_39e8497d-e41a-4024-b6d3-3296f498c400" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_FormerAddressMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_444f2d5e-a2ac-4954-9c78-e26da96d8da2" xlink:to="loc_dei_FormerAddressMember_39e8497d-e41a-4024-b6d3-3296f498c400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesTable_9dc907f6-1242-4282-9ca4-d0d79788f5f9" xlink:to="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d5365583-47cb-421e-8f37-266e080e9684" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_DocumentType_d5365583-47cb-421e-8f37-266e080e9684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_9929ac1b-287f-4a0b-841b-80cab9c4f053" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_DocumentQuarterlyReport_9929ac1b-287f-4a0b-841b-80cab9c4f053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_39d65f13-eb3d-47f0-83c5-ec0ab8bffeea" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_DocumentPeriodEndDate_39d65f13-eb3d-47f0-83c5-ec0ab8bffeea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_868cc243-1ea9-4df7-afca-29e37f9631f2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_DocumentTransitionReport_868cc243-1ea9-4df7-afca-29e37f9631f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ad516d65-389d-4f39-ad96-64b77a7f3abb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityFileNumber_ad516d65-389d-4f39-ad96-64b77a7f3abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9d4985d3-2815-452f-86aa-28151815c2a4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityRegistrantName_9d4985d3-2815-452f-86aa-28151815c2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_43ed4f22-419e-4f03-a0e4-54757fd64ef5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityIncorporationStateCountryCode_43ed4f22-419e-4f03-a0e4-54757fd64ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_353830cf-3d05-4e0b-b3e5-d657cefbd464" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityTaxIdentificationNumber_353830cf-3d05-4e0b-b3e5-d657cefbd464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_3db2dfa0-ebae-49aa-aa96-026b60e5ceeb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityAddressAddressLine1_3db2dfa0-ebae-49aa-aa96-026b60e5ceeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_bec09ce6-4599-461c-83f6-9b38e54475a3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityAddressCityOrTown_bec09ce6-4599-461c-83f6-9b38e54475a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_8174deef-7f48-456c-a70f-c9dc06f2da20" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityAddressStateOrProvince_8174deef-7f48-456c-a70f-c9dc06f2da20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_84f7dbbc-bfa4-4fce-8759-34d0c8e3678f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityAddressPostalZipCode_84f7dbbc-bfa4-4fce-8759-34d0c8e3678f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d2b4378f-35de-4593-a25e-60bc463d61c6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_CityAreaCode_d2b4378f-35de-4593-a25e-60bc463d61c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a9b25de4-595e-44fe-b49b-912e140946a6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_LocalPhoneNumber_a9b25de4-595e-44fe-b49b-912e140946a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6a5bd8f0-0ec5-4310-a062-4babeb1a03e6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_Security12bTitle_6a5bd8f0-0ec5-4310-a062-4babeb1a03e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d7a5b641-30ed-4cbe-a03f-961814c802cc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_TradingSymbol_d7a5b641-30ed-4cbe-a03f-961814c802cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_740b2a1a-db55-4656-a6d7-4dcc955dde03" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_SecurityExchangeName_740b2a1a-db55-4656-a6d7-4dcc955dde03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_405b885a-60bf-431e-acd6-d0452eae4ec5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityCurrentReportingStatus_405b885a-60bf-431e-acd6-d0452eae4ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_adb64013-0f5b-4511-b53c-33ca51e36d4c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityInteractiveDataCurrent_adb64013-0f5b-4511-b53c-33ca51e36d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_1187bc8a-0fdb-4285-89ac-318c055f376c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityFilerCategory_1187bc8a-0fdb-4285-89ac-318c055f376c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_28bc2c29-2fb2-43a3-b437-d3e253dbecfb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntitySmallBusiness_28bc2c29-2fb2-43a3-b437-d3e253dbecfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_73a45631-fdcb-4490-b2ed-7182b47d6193" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityEmergingGrowthCompany_73a45631-fdcb-4490-b2ed-7182b47d6193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_5740edb7-16a5-4c72-85b7-22201a28c1cd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityExTransitionPeriod_5740edb7-16a5-4c72-85b7-22201a28c1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b77c2504-136a-4bf2-8a13-6756cf650c39" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityShellCompany_b77c2504-136a-4bf2-8a13-6756cf650c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_e55a499e-7917-442e-b704-0f4e5fb37a20" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_e55a499e-7917-442e-b704-0f4e5fb37a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b2286bf1-85c6-45af-b391-2f94612cfb6c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_AmendmentFlag_b2286bf1-85c6-45af-b391-2f94612cfb6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_3fe65ba7-5749-4060-878f-66e39dbc4e03" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_DocumentFiscalPeriodFocus_3fe65ba7-5749-4060-878f-66e39dbc4e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_12167c73-1087-4be6-85a8-3bbe37488a9c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_DocumentFiscalYearFocus_12167c73-1087-4be6-85a8-3bbe37488a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_83f1b021-2119-4b22-b7dc-abe484632280" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_EntityCentralIndexKey_83f1b021-2119-4b22-b7dc-abe484632280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_fc77fcb1-8cd8-496e-a24b-defd30293a31" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_0862d1ca-bcd9-46e8-9770-af9a3c089667" xlink:to="loc_dei_CurrentFiscalYearEndDate_fc77fcb1-8cd8-496e-a24b-defd30293a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="bdtx-20220331.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e1a55fd9-e5ae-4577-bfb5-06d0082270ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_cc8c6214-c295-4607-a40d-b9702fecb5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e1a55fd9-e5ae-4577-bfb5-06d0082270ef" xlink:to="loc_us-gaap_AssetsAbstract_cc8c6214-c295-4607-a40d-b9702fecb5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_619e3c18-5ce1-4057-a2b2-67fd9506c36c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cc8c6214-c295-4607-a40d-b9702fecb5a5" xlink:to="loc_us-gaap_AssetsCurrentAbstract_619e3c18-5ce1-4057-a2b2-67fd9506c36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_16364923-75c9-4bb4-b616-65655e442c67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_619e3c18-5ce1-4057-a2b2-67fd9506c36c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_16364923-75c9-4bb4-b616-65655e442c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_271f7f19-5057-484c-9f53-d5b3101db197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_619e3c18-5ce1-4057-a2b2-67fd9506c36c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_271f7f19-5057-484c-9f53-d5b3101db197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e2b5d774-cb6d-435a-8eab-4597a76540a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_619e3c18-5ce1-4057-a2b2-67fd9506c36c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e2b5d774-cb6d-435a-8eab-4597a76540a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a3be4071-fefb-4096-b7da-dec8cc6d55ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_619e3c18-5ce1-4057-a2b2-67fd9506c36c" xlink:to="loc_us-gaap_AssetsCurrent_a3be4071-fefb-4096-b7da-dec8cc6d55ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4e9044af-23ce-445a-be02-01797ea9621d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cc8c6214-c295-4607-a40d-b9702fecb5a5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4e9044af-23ce-445a-be02-01797ea9621d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_dc36d2e0-9fa6-44f9-95ef-101127579a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cc8c6214-c295-4607-a40d-b9702fecb5a5" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_dc36d2e0-9fa6-44f9-95ef-101127579a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1d6e738e-a668-4b60-8c93-dcadf40216ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cc8c6214-c295-4607-a40d-b9702fecb5a5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1d6e738e-a668-4b60-8c93-dcadf40216ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b9ce17bf-258e-49fe-bfd6-149f695b0e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cc8c6214-c295-4607-a40d-b9702fecb5a5" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b9ce17bf-258e-49fe-bfd6-149f695b0e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_55603a8d-1eee-4834-8202-ee890701bb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cc8c6214-c295-4607-a40d-b9702fecb5a5" xlink:to="loc_us-gaap_Assets_55603a8d-1eee-4834-8202-ee890701bb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_41811e63-b121-44dc-9145-59b5ea608a27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e1a55fd9-e5ae-4577-bfb5-06d0082270ef" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_41811e63-b121-44dc-9145-59b5ea608a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_961f1040-8328-4f3f-9fbd-8ff5fed3278a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_41811e63-b121-44dc-9145-59b5ea608a27" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_961f1040-8328-4f3f-9fbd-8ff5fed3278a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2bc03c4f-95d4-408e-93ed-8b2a6f55510c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_961f1040-8328-4f3f-9fbd-8ff5fed3278a" xlink:to="loc_us-gaap_AccountsPayableCurrent_2bc03c4f-95d4-408e-93ed-8b2a6f55510c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_cb0e91de-8dbb-43bb-b337-c287fe40e552" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_961f1040-8328-4f3f-9fbd-8ff5fed3278a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_cb0e91de-8dbb-43bb-b337-c287fe40e552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_20dfe0c6-60f0-4edf-a168-cedecf25de4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_961f1040-8328-4f3f-9fbd-8ff5fed3278a" xlink:to="loc_us-gaap_LiabilitiesCurrent_20dfe0c6-60f0-4edf-a168-cedecf25de4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c0da2195-97ab-4a02-aba5-f00e469a19a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_41811e63-b121-44dc-9145-59b5ea608a27" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c0da2195-97ab-4a02-aba5-f00e469a19a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5abc8449-49fc-49b2-8c37-593fce9e1364" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_41811e63-b121-44dc-9145-59b5ea608a27" xlink:to="loc_us-gaap_Liabilities_5abc8449-49fc-49b2-8c37-593fce9e1364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b8b94ee1-afa0-445a-887d-51b490e830fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_41811e63-b121-44dc-9145-59b5ea608a27" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b8b94ee1-afa0-445a-887d-51b490e830fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_00747c77-bc68-4ccc-99c6-6defab962300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_41811e63-b121-44dc-9145-59b5ea608a27" xlink:to="loc_us-gaap_StockholdersEquityAbstract_00747c77-bc68-4ccc-99c6-6defab962300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_79cf38c2-182a-426a-a3e9-09295166d46d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_00747c77-bc68-4ccc-99c6-6defab962300" xlink:to="loc_us-gaap_PreferredStockValue_79cf38c2-182a-426a-a3e9-09295166d46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ddf756f9-0304-492d-ac91-93adb8bddb7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_00747c77-bc68-4ccc-99c6-6defab962300" xlink:to="loc_us-gaap_CommonStockValue_ddf756f9-0304-492d-ac91-93adb8bddb7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_36548945-b561-404c-a00b-d3e3da13b727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_00747c77-bc68-4ccc-99c6-6defab962300" xlink:to="loc_us-gaap_AdditionalPaidInCapital_36548945-b561-404c-a00b-d3e3da13b727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b5c13a3c-ce5c-464e-8e4e-110ff5d48872" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_00747c77-bc68-4ccc-99c6-6defab962300" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b5c13a3c-ce5c-464e-8e4e-110ff5d48872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c9d711f3-2e9d-400c-b4fe-1c836ac16add" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_00747c77-bc68-4ccc-99c6-6defab962300" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c9d711f3-2e9d-400c-b4fe-1c836ac16add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_74ac004c-3e63-46f2-91bf-0deaf24ba52e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_00747c77-bc68-4ccc-99c6-6defab962300" xlink:to="loc_us-gaap_StockholdersEquity_74ac004c-3e63-46f2-91bf-0deaf24ba52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7993e2ce-7aca-40fd-acd3-4f46e0205a21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_41811e63-b121-44dc-9145-59b5ea608a27" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_7993e2ce-7aca-40fd-acd3-4f46e0205a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="bdtx-20220331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d260e5c0-6cc8-41b2-bdd6-a3e2ccd5eb72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a26348f5-df18-4b32-adc1-16d5ea2034b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d260e5c0-6cc8-41b2-bdd6-a3e2ccd5eb72" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a26348f5-df18-4b32-adc1-16d5ea2034b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_30fbc1a4-75ff-4b53-9bd0-8a54b3265008" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d260e5c0-6cc8-41b2-bdd6-a3e2ccd5eb72" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_30fbc1a4-75ff-4b53-9bd0-8a54b3265008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_f96964f3-257c-4d0e-aa8e-b592e90c32b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d260e5c0-6cc8-41b2-bdd6-a3e2ccd5eb72" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_f96964f3-257c-4d0e-aa8e-b592e90c32b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_e0020881-d185-49ac-8e78-646ac554e638" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d260e5c0-6cc8-41b2-bdd6-a3e2ccd5eb72" xlink:to="loc_us-gaap_PreferredStockSharesIssued_e0020881-d185-49ac-8e78-646ac554e638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_988ea79c-3c5e-4372-9d75-3affb02a89db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d260e5c0-6cc8-41b2-bdd6-a3e2ccd5eb72" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_988ea79c-3c5e-4372-9d75-3affb02a89db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_9248366c-b3f1-439c-bbad-1a22214e4253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d260e5c0-6cc8-41b2-bdd6-a3e2ccd5eb72" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_9248366c-b3f1-439c-bbad-1a22214e4253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_53d616e8-59c0-4086-9de4-b0ebb0ecd809" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d260e5c0-6cc8-41b2-bdd6-a3e2ccd5eb72" xlink:to="loc_us-gaap_CommonStockSharesIssued_53d616e8-59c0-4086-9de4-b0ebb0ecd809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7de27957-65f2-439e-bf84-5e0f91e8c789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d260e5c0-6cc8-41b2-bdd6-a3e2ccd5eb72" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7de27957-65f2-439e-bf84-5e0f91e8c789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="simple" xlink:href="bdtx-20220331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5f4734a7-cf59-4a49-ab69-118beb311eca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_efbee7ff-29bc-4d4b-bee4-14560f1ed4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5f4734a7-cf59-4a49-ab69-118beb311eca" xlink:to="loc_us-gaap_OperatingExpensesAbstract_efbee7ff-29bc-4d4b-bee4-14560f1ed4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c2d4cdd6-0ed2-4dc0-97da-bc8cd8c2c87e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_efbee7ff-29bc-4d4b-bee4-14560f1ed4e2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c2d4cdd6-0ed2-4dc0-97da-bc8cd8c2c87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_092d90a3-6bc3-44b2-8512-b76b3b1861ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_efbee7ff-29bc-4d4b-bee4-14560f1ed4e2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_092d90a3-6bc3-44b2-8512-b76b3b1861ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_2f7cbf7d-1cac-4dd8-84c2-18ed033baa36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_efbee7ff-29bc-4d4b-bee4-14560f1ed4e2" xlink:to="loc_us-gaap_OperatingExpenses_2f7cbf7d-1cac-4dd8-84c2-18ed033baa36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b0ea3a79-193b-485e-8459-c6bf35449dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5f4734a7-cf59-4a49-ab69-118beb311eca" xlink:to="loc_us-gaap_OperatingIncomeLoss_b0ea3a79-193b-485e-8459-c6bf35449dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_635a33a4-7cee-492d-b026-bd13c08b80c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5f4734a7-cf59-4a49-ab69-118beb311eca" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_635a33a4-7cee-492d-b026-bd13c08b80c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_fe620afb-e22b-439e-9c88-e9434ddb3c65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_635a33a4-7cee-492d-b026-bd13c08b80c3" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_fe620afb-e22b-439e-9c88-e9434ddb3c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7e922d6b-239d-4780-812d-1a13488e62a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_635a33a4-7cee-492d-b026-bd13c08b80c3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7e922d6b-239d-4780-812d-1a13488e62a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_123bfb83-43e1-45b7-8c9b-784958d4e4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_635a33a4-7cee-492d-b026-bd13c08b80c3" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_123bfb83-43e1-45b7-8c9b-784958d4e4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cff4add2-d326-4e6b-9fd3-db4881265d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5f4734a7-cf59-4a49-ab69-118beb311eca" xlink:to="loc_us-gaap_NetIncomeLoss_cff4add2-d326-4e6b-9fd3-db4881265d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c1532826-51e0-4c74-91d4-b240d42d9079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5f4734a7-cf59-4a49-ab69-118beb311eca" xlink:to="loc_us-gaap_EarningsPerShareBasic_c1532826-51e0-4c74-91d4-b240d42d9079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2b5285d9-3237-4085-af5e-348d4e7391cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5f4734a7-cf59-4a49-ab69-118beb311eca" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2b5285d9-3237-4085-af5e-348d4e7391cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c0c56dff-2b23-4b9b-a7d1-2417825ab772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5f4734a7-cf59-4a49-ab69-118beb311eca" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c0c56dff-2b23-4b9b-a7d1-2417825ab772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ba845302-b7ca-4ea9-9b64-7632f5dbc0a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5f4734a7-cf59-4a49-ab69-118beb311eca" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ba845302-b7ca-4ea9-9b64-7632f5dbc0a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_1a11be02-188b-4bfd-96d3-e6bacc84dd72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5f4734a7-cf59-4a49-ab69-118beb311eca" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_1a11be02-188b-4bfd-96d3-e6bacc84dd72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8f3f8e40-c504-4e9e-8ddc-59bf56cf3f60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_1a11be02-188b-4bfd-96d3-e6bacc84dd72" xlink:to="loc_us-gaap_NetIncomeLoss_8f3f8e40-c504-4e9e-8ddc-59bf56cf3f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8e343508-d8a1-455a-963e-c8dd9f0e7624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_1a11be02-188b-4bfd-96d3-e6bacc84dd72" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8e343508-d8a1-455a-963e-c8dd9f0e7624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_5f56d935-dc7c-48cf-bc25-415ecb73f8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8e343508-d8a1-455a-963e-c8dd9f0e7624" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_5f56d935-dc7c-48cf-bc25-415ecb73f8aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9f55bcc9-c94d-4f98-b909-6790976605ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_1a11be02-188b-4bfd-96d3-e6bacc84dd72" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_9f55bcc9-c94d-4f98-b909-6790976605ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="bdtx-20220331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_e4134a05-edd7-442a-8465-b441dfa3ae7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f816cc4a-24fd-41ea-bb50-2e55b43e4a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e4134a05-edd7-442a-8465-b441dfa3ae7e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f816cc4a-24fd-41ea-bb50-2e55b43e4a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_42f6caca-6ac2-4832-a4bf-2ff12523ca05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f816cc4a-24fd-41ea-bb50-2e55b43e4a3c" xlink:to="loc_us-gaap_NetIncomeLoss_42f6caca-6ac2-4832-a4bf-2ff12523ca05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_131d342f-56e5-4aa1-8433-75d1a3e5541f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f816cc4a-24fd-41ea-bb50-2e55b43e4a3c" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_131d342f-56e5-4aa1-8433-75d1a3e5541f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2174b3f6-6bdb-4cb8-b1c5-f4e00be95507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_131d342f-56e5-4aa1-8433-75d1a3e5541f" xlink:to="loc_us-gaap_ShareBasedCompensation_2174b3f6-6bdb-4cb8-b1c5-f4e00be95507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_c1ab3b48-9bbc-41cb-8c1d-6a9f45430a65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_131d342f-56e5-4aa1-8433-75d1a3e5541f" xlink:to="loc_us-gaap_Depreciation_c1ab3b48-9bbc-41cb-8c1d-6a9f45430a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_2fe2b54e-fea8-4dcc-9b75-9d4c0be64b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_131d342f-56e5-4aa1-8433-75d1a3e5541f" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_2fe2b54e-fea8-4dcc-9b75-9d4c0be64b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_RentExpense_84f04f08-9010-4ada-a7a6-c23855a8afdd" xlink:href="bdtx-20220331.xsd#bdtx_RentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_131d342f-56e5-4aa1-8433-75d1a3e5541f" xlink:to="loc_bdtx_RentExpense_84f04f08-9010-4ada-a7a6-c23855a8afdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_c244f1dd-6caf-4079-bcf0-264541c9cb77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_131d342f-56e5-4aa1-8433-75d1a3e5541f" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_c244f1dd-6caf-4079-bcf0-264541c9cb77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f743e6ef-3aba-4d06-8a40-d95307ff4492" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_131d342f-56e5-4aa1-8433-75d1a3e5541f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f743e6ef-3aba-4d06-8a40-d95307ff4492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7c305a5a-1d56-44dc-a8c5-a97675f4be1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f743e6ef-3aba-4d06-8a40-d95307ff4492" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7c305a5a-1d56-44dc-a8c5-a97675f4be1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_f3daa58c-110a-45c2-a139-dcebbe5e06fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f743e6ef-3aba-4d06-8a40-d95307ff4492" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_f3daa58c-110a-45c2-a139-dcebbe5e06fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_ae9a7d83-d5c1-4f84-9524-03d2a658548e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f743e6ef-3aba-4d06-8a40-d95307ff4492" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_ae9a7d83-d5c1-4f84-9524-03d2a658548e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_6e0d2183-2b1d-4173-a903-26fc3e12c807" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f743e6ef-3aba-4d06-8a40-d95307ff4492" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_6e0d2183-2b1d-4173-a903-26fc3e12c807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities_a90968df-460d-4551-8d2f-60bfcfecb63a" xlink:href="bdtx-20220331.xsd#bdtx_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f743e6ef-3aba-4d06-8a40-d95307ff4492" xlink:to="loc_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities_a90968df-460d-4551-8d2f-60bfcfecb63a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_44d7bc74-06d2-4f4d-b8d2-d48652033e63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f816cc4a-24fd-41ea-bb50-2e55b43e4a3c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_44d7bc74-06d2-4f4d-b8d2-d48652033e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_d17ac4f1-cf10-4c47-b101-a0f15261f5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e4134a05-edd7-442a-8465-b441dfa3ae7e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_d17ac4f1-cf10-4c47-b101-a0f15261f5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_478a4678-f9ab-4aba-a940-e42693680e34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_d17ac4f1-cf10-4c47-b101-a0f15261f5f8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_478a4678-f9ab-4aba-a940-e42693680e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9cbb2828-2df3-4d7d-bf98-377ef41a2226" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_d17ac4f1-cf10-4c47-b101-a0f15261f5f8" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9cbb2828-2df3-4d7d-bf98-377ef41a2226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_1814c68f-5448-45b8-be91-46d2f285ccb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_d17ac4f1-cf10-4c47-b101-a0f15261f5f8" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_1814c68f-5448-45b8-be91-46d2f285ccb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_271a50d9-06e7-4b68-b934-c9f92d232f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_d17ac4f1-cf10-4c47-b101-a0f15261f5f8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_271a50d9-06e7-4b68-b934-c9f92d232f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_99dda080-1c94-4143-86e0-4cdf16bea9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e4134a05-edd7-442a-8465-b441dfa3ae7e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_99dda080-1c94-4143-86e0-4cdf16bea9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_db1a7b47-05c4-4937-ac82-63cdefd2b009" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_99dda080-1c94-4143-86e0-4cdf16bea9fa" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_db1a7b47-05c4-4937-ac82-63cdefd2b009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_51f5c902-035b-4032-8fcc-59e507ebae3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_99dda080-1c94-4143-86e0-4cdf16bea9fa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_51f5c902-035b-4032-8fcc-59e507ebae3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b8d32141-e8d9-4288-99f0-3e1436ddb69d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e4134a05-edd7-442a-8465-b441dfa3ae7e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b8d32141-e8d9-4288-99f0-3e1436ddb69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_06271445-7000-4385-8499-855cef6c839f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e4134a05-edd7-442a-8465-b441dfa3ae7e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_06271445-7000-4385-8499-855cef6c839f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7eab8faa-c9f1-44b1-aae1-ed71ff2f2ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e4134a05-edd7-442a-8465-b441dfa3ae7e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7eab8faa-c9f1-44b1-aae1-ed71ff2f2ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_d8b82a7b-6961-4589-8982-6c0dcd8b5218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e4134a05-edd7-442a-8465-b441dfa3ae7e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_d8b82a7b-6961-4589-8982-6c0dcd8b5218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b8eaa9f9-4d9d-4da2-8419-c99b1e862b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_d8b82a7b-6961-4589-8982-6c0dcd8b5218" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b8eaa9f9-4d9d-4da2-8419-c99b1e862b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_c5f0e415-8efa-41d4-8032-dc12c6962fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_d8b82a7b-6961-4589-8982-6c0dcd8b5218" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_c5f0e415-8efa-41d4-8032-dc12c6962fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f21b4de0-9f00-4a40-ab64-0193f1863a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_d8b82a7b-6961-4589-8982-6c0dcd8b5218" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f21b4de0-9f00-4a40-ab64-0193f1863a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f596c23b-841b-41b3-a309-bf477e2566a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e4134a05-edd7-442a-8465-b441dfa3ae7e" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f596c23b-841b-41b3-a309-bf477e2566a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_3c03f7f4-0fd8-46a8-beea-718cd3213072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f596c23b-841b-41b3-a309-bf477e2566a2" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_3c03f7f4-0fd8-46a8-beea-718cd3213072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_38ee4a50-6d15-4410-87ac-eadac5352690" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f596c23b-841b-41b3-a309-bf477e2566a2" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_38ee4a50-6d15-4410-87ac-eadac5352690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="simple" xlink:href="bdtx-20220331.xsd#CondensedConsolidatedStatementsofStockholdersEquityUnaudited"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_c486da87-5793-42d8-83ae-c704b5a1bfea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_02029dc2-7db6-4773-b3a3-1df5ec05bbfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_c486da87-5793-42d8-83ae-c704b5a1bfea" xlink:to="loc_us-gaap_StatementTable_02029dc2-7db6-4773-b3a3-1df5ec05bbfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9ffc78c9-2c44-4acb-9742-d39da0d40429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_02029dc2-7db6-4773-b3a3-1df5ec05bbfd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9ffc78c9-2c44-4acb-9742-d39da0d40429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fb30cce1-4059-46eb-94a2-a3e47fc8e18e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9ffc78c9-2c44-4acb-9742-d39da0d40429" xlink:to="loc_us-gaap_EquityComponentDomain_fb30cce1-4059-46eb-94a2-a3e47fc8e18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e89c25fa-044b-4f50-bc86-36d1e08c2c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fb30cce1-4059-46eb-94a2-a3e47fc8e18e" xlink:to="loc_us-gaap_CommonStockMember_e89c25fa-044b-4f50-bc86-36d1e08c2c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_96dd9ce7-d79b-4c4e-af38-87633e71f8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fb30cce1-4059-46eb-94a2-a3e47fc8e18e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_96dd9ce7-d79b-4c4e-af38-87633e71f8aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fb60aa23-bf26-4a12-8795-cef002acdec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fb30cce1-4059-46eb-94a2-a3e47fc8e18e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fb60aa23-bf26-4a12-8795-cef002acdec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c6ef99f4-377c-485f-8184-9d6c2f0bfb42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fb30cce1-4059-46eb-94a2-a3e47fc8e18e" xlink:to="loc_us-gaap_RetainedEarningsMember_c6ef99f4-377c-485f-8184-9d6c2f0bfb42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_520cc4a2-0842-4e0d-9393-909bc9669ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_02029dc2-7db6-4773-b3a3-1df5ec05bbfd" xlink:to="loc_us-gaap_StatementLineItems_520cc4a2-0842-4e0d-9393-909bc9669ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21d20e6b-e539-4bb2-8de9-e2d64ad5e0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_520cc4a2-0842-4e0d-9393-909bc9669ac8" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21d20e6b-e539-4bb2-8de9-e2d64ad5e0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b52a92d4-1c31-4ea8-b989-a8c28d274acc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21d20e6b-e539-4bb2-8de9-e2d64ad5e0f5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b52a92d4-1c31-4ea8-b989-a8c28d274acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5b476cc4-5716-4644-b544-e6a5d111c7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21d20e6b-e539-4bb2-8de9-e2d64ad5e0f5" xlink:to="loc_us-gaap_StockholdersEquity_5b476cc4-5716-4644-b544-e6a5d111c7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_060504df-17c0-48fb-9767-8a3bb00b1d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21d20e6b-e539-4bb2-8de9-e2d64ad5e0f5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_060504df-17c0-48fb-9767-8a3bb00b1d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5cb2f725-e5fa-494b-a002-5bebc7253a88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21d20e6b-e539-4bb2-8de9-e2d64ad5e0f5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5cb2f725-e5fa-494b-a002-5bebc7253a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_45f375f5-acc5-40cc-b5e8-333f3ed9c426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21d20e6b-e539-4bb2-8de9-e2d64ad5e0f5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_45f375f5-acc5-40cc-b5e8-333f3ed9c426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7e4d8102-d19d-4e6e-8c27-0b39fc481c74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21d20e6b-e539-4bb2-8de9-e2d64ad5e0f5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7e4d8102-d19d-4e6e-8c27-0b39fc481c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_da4f56e4-5322-4ff3-a810-402266372ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21d20e6b-e539-4bb2-8de9-e2d64ad5e0f5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_da4f56e4-5322-4ff3-a810-402266372ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_fdfd1dae-b00e-40c4-812d-888b31f2476a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21d20e6b-e539-4bb2-8de9-e2d64ad5e0f5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_fdfd1dae-b00e-40c4-812d-888b31f2476a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4cf63ec5-715e-4a8b-afa1-227c3e6b6f93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21d20e6b-e539-4bb2-8de9-e2d64ad5e0f5" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4cf63ec5-715e-4a8b-afa1-227c3e6b6f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_23643caf-35e7-448a-ae21-cd28b7ce5701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21d20e6b-e539-4bb2-8de9-e2d64ad5e0f5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_23643caf-35e7-448a-ae21-cd28b7ce5701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_947a0531-7ae5-4356-9b41-cae2200c6509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21d20e6b-e539-4bb2-8de9-e2d64ad5e0f5" xlink:to="loc_us-gaap_NetIncomeLoss_947a0531-7ae5-4356-9b41-cae2200c6509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d1513efa-4dda-45a0-bc78-715be8d5172a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21d20e6b-e539-4bb2-8de9-e2d64ad5e0f5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d1513efa-4dda-45a0-bc78-715be8d5172a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_42fb42f3-790c-453c-a347-e7ff79396a17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21d20e6b-e539-4bb2-8de9-e2d64ad5e0f5" xlink:to="loc_us-gaap_StockholdersEquity_42fb42f3-790c-453c-a347-e7ff79396a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION" xlink:type="simple" xlink:href="bdtx-20220331.xsd#NATUREOFBUSINESSANDBASISOFPRESENTATION"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f8d14970-2d64-4815-8bbf-cf0df2a8366f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_d111484f-be74-44c9-8421-95b751109409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f8d14970-2d64-4815-8bbf-cf0df2a8366f" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_d111484f-be74-44c9-8421-95b751109409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" xlink:type="simple" xlink:href="bdtx-20220331.xsd#NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_673000db-ac81-4268-aa76-e2c128ee1e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_0d7afd1f-7dac-4028-a285-5b90ab419a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_673000db-ac81-4268-aa76-e2c128ee1e3f" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_0d7afd1f-7dac-4028-a285-5b90ab419a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5f9471ca-0c81-4f5e-a8a1-12451715a890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_0d7afd1f-7dac-4028-a285-5b90ab419a09" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5f9471ca-0c81-4f5e-a8a1-12451715a890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_efd10481-5360-43e2-95ab-f4bc19e7b6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5f9471ca-0c81-4f5e-a8a1-12451715a890" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_efd10481-5360-43e2-95ab-f4bc19e7b6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OpenMarketSaleMember_164e67db-432f-41aa-911a-ebc5cb257afa" xlink:href="bdtx-20220331.xsd#bdtx_OpenMarketSaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_efd10481-5360-43e2-95ab-f4bc19e7b6ed" xlink:to="loc_bdtx_OpenMarketSaleMember_164e67db-432f-41aa-911a-ebc5cb257afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_26bc45f9-16e7-4b27-bfc4-9970e6814f20" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_0d7afd1f-7dac-4028-a285-5b90ab419a09" xlink:to="loc_srt_RangeAxis_26bc45f9-16e7-4b27-bfc4-9970e6814f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f72c3799-48fa-4624-b02c-244f4b07a3da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_26bc45f9-16e7-4b27-bfc4-9970e6814f20" xlink:to="loc_srt_RangeMember_f72c3799-48fa-4624-b02c-244f4b07a3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_66e182aa-b4d2-4057-85ee-2c5302c3cf00" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f72c3799-48fa-4624-b02c-244f4b07a3da" xlink:to="loc_srt_MaximumMember_66e182aa-b4d2-4057-85ee-2c5302c3cf00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_4be6f016-2843-45ed-b230-8772083167d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_0d7afd1f-7dac-4028-a285-5b90ab419a09" xlink:to="loc_srt_StatementScenarioAxis_4be6f016-2843-45ed-b230-8772083167d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_4cc892da-7830-4541-a2c8-2fa4f1a428d5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_4be6f016-2843-45ed-b230-8772083167d7" xlink:to="loc_srt_ScenarioUnspecifiedDomain_4cc892da-7830-4541-a2c8-2fa4f1a428d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_855fd6d8-0293-4b4a-8a3e-f511eff78a37" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_4cc892da-7830-4541-a2c8-2fa4f1a428d5" xlink:to="loc_srt_ScenarioForecastMember_855fd6d8-0293-4b4a-8a3e-f511eff78a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_c7177622-6840-47e2-aebe-2cee14546636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_0d7afd1f-7dac-4028-a285-5b90ab419a09" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_c7177622-6840-47e2-aebe-2cee14546636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_06299d0a-96e5-4464-af23-e5a523923ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c7177622-6840-47e2-aebe-2cee14546636" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_06299d0a-96e5-4464-af23-e5a523923ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="bdtx-20220331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_943f215d-76ea-4f4d-a519-26cfac8049f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_0944f3a8-e025-4aa7-bab4-60d583e027c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_943f215d-76ea-4f4d-a519-26cfac8049f8" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_0944f3a8-e025-4aa7-bab4-60d583e027c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="bdtx-20220331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9bc7cdab-c136-4a71-b9e5-638ad1a5909c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4f31966c-e736-4e8c-b7b2-d85d2a5d9bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9bc7cdab-c136-4a71-b9e5-638ad1a5909c" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4f31966c-e736-4e8c-b7b2-d85d2a5d9bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_ecd63d63-62a0-4180-a49c-8033d9854bec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9bc7cdab-c136-4a71-b9e5-638ad1a5909c" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_ecd63d63-62a0-4180-a49c-8033d9854bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_c5f60a63-ffac-46f1-860c-3d9af8abb249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9bc7cdab-c136-4a71-b9e5-638ad1a5909c" xlink:to="loc_us-gaap_UseOfEstimates_c5f60a63-ffac-46f1-860c-3d9af8abb249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9844999f-f6b9-4519-91ec-66dc0421b9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9bc7cdab-c136-4a71-b9e5-638ad1a5909c" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9844999f-f6b9-4519-91ec-66dc0421b9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="bdtx-20220331.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_af54edda-c514-4add-a668-654bd143f1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_96feee0a-0049-4175-b944-ade7495bdc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_af54edda-c514-4add-a668-654bd143f1dd" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_96feee0a-0049-4175-b944-ade7495bdc8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="bdtx-20220331.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b3eccf6d-c822-4510-9c45-6f4faf4221ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_19463fe9-eacf-4214-872e-e5a8805cca10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b3eccf6d-c822-4510-9c45-6f4faf4221ee" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_19463fe9-eacf-4214-872e-e5a8805cca10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="bdtx-20220331.xsd#FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_66b9b70a-fa89-45f6-9a34-a4bdcdb5a656" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7c8006ed-ab54-4f7e-b524-8db53202adb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_66b9b70a-fa89-45f6-9a34-a4bdcdb5a656" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7c8006ed-ab54-4f7e-b524-8db53202adb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9882d0e7-8806-4a4e-8a0e-658292ae2dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7c8006ed-ab54-4f7e-b524-8db53202adb2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9882d0e7-8806-4a4e-8a0e-658292ae2dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4ddfe57d-e05a-4d9d-8e5c-b3f033b1ad85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9882d0e7-8806-4a4e-8a0e-658292ae2dc1" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4ddfe57d-e05a-4d9d-8e5c-b3f033b1ad85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1f8e9be9-b220-443d-a499-614dc23157ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_4ddfe57d-e05a-4d9d-8e5c-b3f033b1ad85" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1f8e9be9-b220-443d-a499-614dc23157ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b8739947-931c-45b3-acf8-92f9429aaf77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7c8006ed-ab54-4f7e-b524-8db53202adb2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b8739947-931c-45b3-acf8-92f9429aaf77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d0ac1219-d1df-4090-a15c-242e39bc9d77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b8739947-931c-45b3-acf8-92f9429aaf77" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d0ac1219-d1df-4090-a15c-242e39bc9d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_41e720ef-9145-4c19-9c29-c172f3d0d1b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d0ac1219-d1df-4090-a15c-242e39bc9d77" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_41e720ef-9145-4c19-9c29-c172f3d0d1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7eac1e9b-fd86-454f-a835-b5d4edd29ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d0ac1219-d1df-4090-a15c-242e39bc9d77" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7eac1e9b-fd86-454f-a835-b5d4edd29ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_23aeb358-6539-4aca-9b64-9ba6350e7738" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d0ac1219-d1df-4090-a15c-242e39bc9d77" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_23aeb358-6539-4aca-9b64-9ba6350e7738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a491dccd-00cb-4e59-bb8b-b332a1f5f2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7c8006ed-ab54-4f7e-b524-8db53202adb2" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a491dccd-00cb-4e59-bb8b-b332a1f5f2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_507c6a36-675f-4595-b751-339ec7fd3c21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a491dccd-00cb-4e59-bb8b-b332a1f5f2cf" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_507c6a36-675f-4595-b751-339ec7fd3c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_76b120c1-13aa-42de-98a9-55d78b4f5c62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_507c6a36-675f-4595-b751-339ec7fd3c21" xlink:to="loc_us-gaap_MoneyMarketFundsMember_76b120c1-13aa-42de-98a9-55d78b4f5c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_3fe5abb8-194f-4162-aaa5-a36fc1f96a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_507c6a36-675f-4595-b751-339ec7fd3c21" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_3fe5abb8-194f-4162-aaa5-a36fc1f96a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_ace8f949-04d7-4ab3-9d4c-2da85f515865" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_507c6a36-675f-4595-b751-339ec7fd3c21" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_ace8f949-04d7-4ab3-9d4c-2da85f515865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_0e7440b1-a23f-480c-b77b-4c7693010bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_507c6a36-675f-4595-b751-339ec7fd3c21" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_0e7440b1-a23f-480c-b77b-4c7693010bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21d3cca-4d15-4d5a-8e7b-379ada144c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7c8006ed-ab54-4f7e-b524-8db53202adb2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21d3cca-4d15-4d5a-8e7b-379ada144c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_3c100701-39ee-4e55-b50f-f3bcc9f97b13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21d3cca-4d15-4d5a-8e7b-379ada144c3c" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_3c100701-39ee-4e55-b50f-f3bcc9f97b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fc682cba-9086-48c6-8c5a-71357bcddc05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3c100701-39ee-4e55-b50f-f3bcc9f97b13" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fc682cba-9086-48c6-8c5a-71357bcddc05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_5427df30-16b7-4c59-a61c-2403fc609d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3c100701-39ee-4e55-b50f-f3bcc9f97b13" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_5427df30-16b7-4c59-a61c-2403fc609d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_43acbd4d-81c4-47ed-a74d-29b12004fcba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3c100701-39ee-4e55-b50f-f3bcc9f97b13" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_43acbd4d-81c4-47ed-a74d-29b12004fcba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTS" xlink:type="simple" xlink:href="bdtx-20220331.xsd#INVESTMENTS"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/INVESTMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_efaff0f0-175c-4aaf-bb7a-a46e08078791" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_bffe8709-e26f-490c-9942-4f5912d91d94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_efaff0f0-175c-4aaf-bb7a-a46e08078791" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_bffe8709-e26f-490c-9942-4f5912d91d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables" xlink:type="simple" xlink:href="bdtx-20220331.xsd#INVESTMENTSTables"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c7974e9c-7fb5-41c2-a901-e8b8eb972313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_22453b4a-55e0-4c67-ba74-3e4317732960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c7974e9c-7fb5-41c2-a901-e8b8eb972313" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_22453b4a-55e0-4c67-ba74-3e4317732960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="bdtx-20220331.xsd#INVESTMENTSScheduleofMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bb216572-00e6-448d-b0c9-5413fd949ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1cbc9f69-2b58-438e-80c5-ea054b492e80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bb216572-00e6-448d-b0c9-5413fd949ca9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1cbc9f69-2b58-438e-80c5-ea054b492e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_87815e91-c3f3-4c3b-87f7-b35308d0f600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1cbc9f69-2b58-438e-80c5-ea054b492e80" xlink:to="loc_us-gaap_FinancialInstrumentAxis_87815e91-c3f3-4c3b-87f7-b35308d0f600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a9e8d76-66f7-4c68-8622-65d77185aaed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_87815e91-c3f3-4c3b-87f7-b35308d0f600" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a9e8d76-66f7-4c68-8622-65d77185aaed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_11f08a32-9a80-4a87-9f2e-eadd9e6633ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a9e8d76-66f7-4c68-8622-65d77185aaed" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_11f08a32-9a80-4a87-9f2e-eadd9e6633ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_c54a55c0-7e2a-4eef-9a68-46ebed577d20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a9e8d76-66f7-4c68-8622-65d77185aaed" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_c54a55c0-7e2a-4eef-9a68-46ebed577d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_29cefc2a-f3f2-42c1-b868-4da443280b16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a9e8d76-66f7-4c68-8622-65d77185aaed" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_29cefc2a-f3f2-42c1-b868-4da443280b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_287c4b7a-2ab2-4b8d-bb27-4f1ffbc490fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1cbc9f69-2b58-438e-80c5-ea054b492e80" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_287c4b7a-2ab2-4b8d-bb27-4f1ffbc490fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ca798968-a3ad-4b99-a304-78173fb1436d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_287c4b7a-2ab2-4b8d-bb27-4f1ffbc490fc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ca798968-a3ad-4b99-a304-78173fb1436d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_35e0ad00-ec9c-4ac4-8653-1f72b364290a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_287c4b7a-2ab2-4b8d-bb27-4f1ffbc490fc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_35e0ad00-ec9c-4ac4-8653-1f72b364290a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6b08d16b-6a1f-41ce-9d7a-01dc883ece42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_287c4b7a-2ab2-4b8d-bb27-4f1ffbc490fc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6b08d16b-6a1f-41ce-9d7a-01dc883ece42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e573a7ea-5512-49a4-924d-f15cc5cc57bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_287c4b7a-2ab2-4b8d-bb27-4f1ffbc490fc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e573a7ea-5512-49a4-924d-f15cc5cc57bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSAdditionalInformationDetails" xlink:type="simple" xlink:href="bdtx-20220331.xsd#INVESTMENTSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_79a89c0a-ae0e-4a14-b7b7-1b7a490c8924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree_486b68ea-86a6-4b5e-8657-db711c9286f5" xlink:href="bdtx-20220331.xsd#bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_79a89c0a-ae0e-4a14-b7b7-1b7a490c8924" xlink:to="loc_bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree_486b68ea-86a6-4b5e-8657-db711c9286f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_53dd811c-e6d1-4b8b-acc6-3da7ec146e95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_79a89c0a-ae0e-4a14-b7b7-1b7a490c8924" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_53dd811c-e6d1-4b8b-acc6-3da7ec146e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_e9aa4b9d-5d0f-4664-ba73-13293e300380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_79a89c0a-ae0e-4a14-b7b7-1b7a490c8924" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_e9aa4b9d-5d0f-4664-ba73-13293e300380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="bdtx-20220331.xsd#PROPERTYANDEQUIPMENT"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3044da74-8839-4382-8a2a-4469e9d9db19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_32a5e9bf-1819-4688-a0e6-661188107875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3044da74-8839-4382-8a2a-4469e9d9db19" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_32a5e9bf-1819-4688-a0e6-661188107875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="simple" xlink:href="bdtx-20220331.xsd#PROPERTYANDEQUIPMENTTables"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ecd86dc4-4664-4892-bd82-0060884720b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_21106652-1d8b-4dd4-a069-831864e1bdbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ecd86dc4-4664-4892-bd82-0060884720b2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_21106652-1d8b-4dd4-a069-831864e1bdbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="simple" xlink:href="bdtx-20220331.xsd#PROPERTYANDEQUIPMENTDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5d68817c-c90c-41a4-bdc4-daad83305ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aac4d391-c7e1-452f-916e-b8e6fe0d2fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5d68817c-c90c-41a4-bdc4-daad83305ac5" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aac4d391-c7e1-452f-916e-b8e6fe0d2fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8c9bdeb7-9de9-4b8f-95cc-abf038e15dee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aac4d391-c7e1-452f-916e-b8e6fe0d2fd6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8c9bdeb7-9de9-4b8f-95cc-abf038e15dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52609ac3-bf71-46c3-8cae-8d7c35648d32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8c9bdeb7-9de9-4b8f-95cc-abf038e15dee" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52609ac3-bf71-46c3-8cae-8d7c35648d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_9c5bf2e7-a318-450f-94fe-47698d6dc6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52609ac3-bf71-46c3-8cae-8d7c35648d32" xlink:to="loc_us-gaap_EquipmentMember_9c5bf2e7-a318-450f-94fe-47698d6dc6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_daea2b0a-685f-4817-af9d-cf22b649b0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52609ac3-bf71-46c3-8cae-8d7c35648d32" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_daea2b0a-685f-4817-af9d-cf22b649b0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_8930c8a0-67f5-440b-bf1c-9973eb83442c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52609ac3-bf71-46c3-8cae-8d7c35648d32" xlink:to="loc_us-gaap_OfficeEquipmentMember_8930c8a0-67f5-440b-bf1c-9973eb83442c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_dc0a73fc-6967-484c-a943-3b0cf9677e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52609ac3-bf71-46c3-8cae-8d7c35648d32" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_dc0a73fc-6967-484c-a943-3b0cf9677e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_de27a83f-227d-4247-8f4b-278147108a82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52609ac3-bf71-46c3-8cae-8d7c35648d32" xlink:to="loc_us-gaap_ConstructionInProgressMember_de27a83f-227d-4247-8f4b-278147108a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ad0c8293-2ffb-4e2c-bf42-60b0f97c00b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aac4d391-c7e1-452f-916e-b8e6fe0d2fd6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ad0c8293-2ffb-4e2c-bf42-60b0f97c00b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_132617f9-109a-49cb-a353-fe015d72cbda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ad0c8293-2ffb-4e2c-bf42-60b0f97c00b9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_132617f9-109a-49cb-a353-fe015d72cbda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a9dfddb0-e79e-4fe5-b76c-e84c200ac5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ad0c8293-2ffb-4e2c-bf42-60b0f97c00b9" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a9dfddb0-e79e-4fe5-b76c-e84c200ac5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_594f583e-68e7-4e6e-8352-b6df74bd6dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ad0c8293-2ffb-4e2c-bf42-60b0f97c00b9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_594f583e-68e7-4e6e-8352-b6df74bd6dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_4620e572-70b1-41a6-a816-066712806e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ad0c8293-2ffb-4e2c-bf42-60b0f97c00b9" xlink:to="loc_us-gaap_Depreciation_4620e572-70b1-41a6-a816-066712806e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="simple" xlink:href="bdtx-20220331.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_359b5349-f5fc-4deb-8197-42fa65deb630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0ad598ef-6087-4b9b-b7d4-b203ab3d6139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_359b5349-f5fc-4deb-8197-42fa65deb630" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0ad598ef-6087-4b9b-b7d4-b203ab3d6139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="simple" xlink:href="bdtx-20220331.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_09bbc39c-25e9-4fdd-ba0c-f93590a99645" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_22fda9e8-f693-4726-88b4-c2e5e245e835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_09bbc39c-25e9-4fdd-ba0c-f93590a99645" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_22fda9e8-f693-4726-88b4-c2e5e245e835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="simple" xlink:href="bdtx-20220331.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_b618e204-ad3c-4a21-a074-d48a934ed276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_AccruedContractResearchServiceFeesCurrent_f3066f4e-7305-418e-a402-70261122dbf2" xlink:href="bdtx-20220331.xsd#bdtx_AccruedContractResearchServiceFeesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b618e204-ad3c-4a21-a074-d48a934ed276" xlink:to="loc_bdtx_AccruedContractResearchServiceFeesCurrent_f3066f4e-7305-418e-a402-70261122dbf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8db973d7-00b1-4b6c-8f58-46e5afc041f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b618e204-ad3c-4a21-a074-d48a934ed276" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8db973d7-00b1-4b6c-8f58-46e5afc041f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_0d2f0345-2782-4bd3-b672-e964c5403a11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b618e204-ad3c-4a21-a074-d48a934ed276" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_0d2f0345-2782-4bd3-b672-e964c5403a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_1f3f7d15-8dfa-41e8-9490-b0bd49b95cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b618e204-ad3c-4a21-a074-d48a934ed276" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_1f3f7d15-8dfa-41e8-9490-b0bd49b95cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9ec19c6c-ee01-4f46-8070-4d1eb27504b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b618e204-ad3c-4a21-a074-d48a934ed276" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9ec19c6c-ee01-4f46-8070-4d1eb27504b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_19c32eee-ec5f-437e-acba-d31f01f2392f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b618e204-ad3c-4a21-a074-d48a934ed276" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_19c32eee-ec5f-437e-acba-d31f01f2392f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="bdtx-20220331.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f808bf99-40f3-4474-88a4-b3837ea567aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_bfea30f9-f64b-4221-a001-4409c6ec6fda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f808bf99-40f3-4474-88a4-b3837ea567aa" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_bfea30f9-f64b-4221-a001-4409c6ec6fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="bdtx-20220331.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3ce974b2-9370-4fb0-a6ac-e2b4f8be8849" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a3d89161-3857-4ad5-9cd0-05681aac2b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3ce974b2-9370-4fb0-a6ac-e2b4f8be8849" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a3d89161-3857-4ad5-9cd0-05681aac2b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_237abcd7-fe0d-40b9-bd37-9791ae66bcbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3ce974b2-9370-4fb0-a6ac-e2b4f8be8849" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_237abcd7-fe0d-40b9-bd37-9791ae66bcbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_0e57b0fb-a27b-44c1-a8cc-f34ba640ae3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3ce974b2-9370-4fb0-a6ac-e2b4f8be8849" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_0e57b0fb-a27b-44c1-a8cc-f34ba640ae3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="bdtx-20220331.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_881a12a8-8e7b-4583-a7dc-cd9263225b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e393334-645f-4b2c-aa1e-d5357a025369" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_881a12a8-8e7b-4583-a7dc-cd9263225b7d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e393334-645f-4b2c-aa1e-d5357a025369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fc108f85-36cc-4872-96a0-94146ee1219a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e393334-645f-4b2c-aa1e-d5357a025369" xlink:to="loc_us-gaap_AwardTypeAxis_fc108f85-36cc-4872-96a0-94146ee1219a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f469c705-89a4-48c5-8611-21916c472dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_fc108f85-36cc-4872-96a0-94146ee1219a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f469c705-89a4-48c5-8611-21916c472dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_96d19226-9db5-4c88-a7ef-895d7a0a45f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f469c705-89a4-48c5-8611-21916c472dc8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_96d19226-9db5-4c88-a7ef-895d7a0a45f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d1c3130b-fbc9-4fc8-8670-22478051da61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f469c705-89a4-48c5-8611-21916c472dc8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d1c3130b-fbc9-4fc8-8670-22478051da61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_944105c6-795e-4010-9022-d77399977b94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f469c705-89a4-48c5-8611-21916c472dc8" xlink:to="loc_us-gaap_EmployeeStockMember_944105c6-795e-4010-9022-d77399977b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_PerformanceRestrictedStockUnitsMember_8378d825-94f6-44c5-a8f1-7fbfa4fd5172" xlink:href="bdtx-20220331.xsd#bdtx_PerformanceRestrictedStockUnitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f469c705-89a4-48c5-8611-21916c472dc8" xlink:to="loc_bdtx_PerformanceRestrictedStockUnitsMember_8378d825-94f6-44c5-a8f1-7fbfa4fd5172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_aec5900b-5821-4c97-bead-7962924c61b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e393334-645f-4b2c-aa1e-d5357a025369" xlink:to="loc_us-gaap_PlanNameAxis_aec5900b-5821-4c97-bead-7962924c61b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fc9e564e-dec6-49ff-97ac-8ba89b07e6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_aec5900b-5821-4c97-bead-7962924c61b1" xlink:to="loc_us-gaap_PlanNameDomain_fc9e564e-dec6-49ff-97ac-8ba89b07e6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_A2020StockOptionPlanMember_b038346a-b759-4ec7-92af-1ef61b50294d" xlink:href="bdtx-20220331.xsd#bdtx_A2020StockOptionPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_fc9e564e-dec6-49ff-97ac-8ba89b07e6bd" xlink:to="loc_bdtx_A2020StockOptionPlanMember_b038346a-b759-4ec7-92af-1ef61b50294d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_A2020EmployeeStockPurchasePlanMember_93dbf008-8adc-484e-b58d-1a1955637def" xlink:href="bdtx-20220331.xsd#bdtx_A2020EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_fc9e564e-dec6-49ff-97ac-8ba89b07e6bd" xlink:to="loc_bdtx_A2020EmployeeStockPurchasePlanMember_93dbf008-8adc-484e-b58d-1a1955637def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e393334-645f-4b2c-aa1e-d5357a025369" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding_688ecb3b-1f08-40ad-b86d-ff07b115e493" xlink:href="bdtx-20220331.xsd#bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:to="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding_688ecb3b-1f08-40ad-b86d-ff07b115e493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_2abbcd68-db9a-48a4-b417-bac2b442c2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_2abbcd68-db9a-48a4-b417-bac2b442c2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_78f204ed-7fc0-49e0-a1ac-6babe9017b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_78f204ed-7fc0-49e0-a1ac-6babe9017b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c4e9af94-f671-43a5-85b5-298eb721dd6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c4e9af94-f671-43a5-85b5-298eb721dd6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9dcc5740-be25-4b02-b975-b711c948290d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9dcc5740-be25-4b02-b975-b711c948290d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_8bafb8e7-a01c-4f0e-9ed2-a0ffb6cbd8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_8bafb8e7-a01c-4f0e-9ed2-a0ffb6cbd8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_9960ff1b-f689-454b-bc5d-ff766a94f548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_9960ff1b-f689-454b-bc5d-ff766a94f548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_58d7b258-78e5-46fc-ac93-e498226a8d67" xlink:href="bdtx-20220331.xsd#bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:to="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_58d7b258-78e5-46fc-ac93-e498226a8d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_634158ae-2e7d-473d-86df-d3622fdc22f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_634158ae-2e7d-473d-86df-d3622fdc22f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_2cf44845-03c4-449b-a843-148a5965ee53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_2cf44845-03c4-449b-a843-148a5965ee53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_16c4f1d8-a047-4109-bcbb-96ee814f0f32" xlink:href="bdtx-20220331.xsd#bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:to="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_16c4f1d8-a047-4109-bcbb-96ee814f0f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_33008482-ce94-4ff5-bc07-bf1cee033c31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_33008482-ce94-4ff5-bc07-bf1cee033c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_97f67182-2607-4ab9-b675-1794ee1b489d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_97f67182-2607-4ab9-b675-1794ee1b489d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_23ee3403-9ef0-4c3f-bc32-548a2535519e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4380409c-1530-4e56-9690-388621cca479" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_23ee3403-9ef0-4c3f-bc32-548a2535519e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" xlink:type="simple" xlink:href="bdtx-20220331.xsd#STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6e375226-c1c8-47e8-9f32-eea026d72cda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_aeeb620f-cc45-43b5-a1e5-43e3c4a7c23f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6e375226-c1c8-47e8-9f32-eea026d72cda" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_aeeb620f-cc45-43b5-a1e5-43e3c4a7c23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_44fcf67e-b457-4271-abe9-6d6a196b0fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_aeeb620f-cc45-43b5-a1e5-43e3c4a7c23f" xlink:to="loc_us-gaap_AwardTypeAxis_44fcf67e-b457-4271-abe9-6d6a196b0fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d808b09-82af-4560-b1ef-0a6099c11fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_44fcf67e-b457-4271-abe9-6d6a196b0fd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d808b09-82af-4560-b1ef-0a6099c11fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_383d460c-5560-4c55-b4a0-70a40cdfad79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d808b09-82af-4560-b1ef-0a6099c11fe4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_383d460c-5560-4c55-b4a0-70a40cdfad79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e542a6aa-7b34-4bee-9176-a43c25a127ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d808b09-82af-4560-b1ef-0a6099c11fe4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e542a6aa-7b34-4bee-9176-a43c25a127ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OtherAwardTypeMember_c1e55c80-bd7f-4601-b96e-13f7b4af1d53" xlink:href="bdtx-20220331.xsd#bdtx_OtherAwardTypeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d808b09-82af-4560-b1ef-0a6099c11fe4" xlink:to="loc_bdtx_OtherAwardTypeMember_c1e55c80-bd7f-4601-b96e-13f7b4af1d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_32b848cb-26e8-43bc-b3fa-216044fe8a15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_aeeb620f-cc45-43b5-a1e5-43e3c4a7c23f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_32b848cb-26e8-43bc-b3fa-216044fe8a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_78757aba-2406-40e6-851a-1307bd7799ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_32b848cb-26e8-43bc-b3fa-216044fe8a15" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_78757aba-2406-40e6-851a-1307bd7799ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_03ebffb2-3254-4bf6-8812-df5e7eafb796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_78757aba-2406-40e6-851a-1307bd7799ff" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_03ebffb2-3254-4bf6-8812-df5e7eafb796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_30834b21-3cdc-4083-828e-a6065647d2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_78757aba-2406-40e6-851a-1307bd7799ff" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_30834b21-3cdc-4083-828e-a6065647d2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3f2b07b-ab76-41ea-917d-b4148fe13289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_aeeb620f-cc45-43b5-a1e5-43e3c4a7c23f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3f2b07b-ab76-41ea-917d-b4148fe13289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_bb122bf1-f7b5-4d5d-8b5e-5499b109977f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3f2b07b-ab76-41ea-917d-b4148fe13289" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_bb122bf1-f7b5-4d5d-8b5e-5499b109977f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="bdtx-20220331.xsd#STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a965991-af00-40dd-909f-d0d62acae972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4eef4128-d663-4853-a624-cda784986294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a965991-af00-40dd-909f-d0d62acae972" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4eef4128-d663-4853-a624-cda784986294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_627cdec2-7d0f-450c-b784-7fff31e08e73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4eef4128-d663-4853-a624-cda784986294" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_627cdec2-7d0f-450c-b784-7fff31e08e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4dd837a9-b88a-4c9b-9c00-32687223318e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4eef4128-d663-4853-a624-cda784986294" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4dd837a9-b88a-4c9b-9c00-32687223318e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5dede145-5c45-47bf-8115-284b328584db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4eef4128-d663-4853-a624-cda784986294" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5dede145-5c45-47bf-8115-284b328584db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_5015061b-78ab-445d-ab10-61bcef6b7642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4eef4128-d663-4853-a624-cda784986294" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_5015061b-78ab-445d-ab10-61bcef6b7642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0f694ebf-514e-4fab-9b84-c28c67ed116d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4eef4128-d663-4853-a624-cda784986294" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0f694ebf-514e-4fab-9b84-c28c67ed116d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_da7b2a92-b3b7-4ba0-a5b4-f2942a5d84c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a965991-af00-40dd-909f-d0d62acae972" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_da7b2a92-b3b7-4ba0-a5b4-f2942a5d84c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_eb627ab4-c56a-442e-9954-64770a7d742b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a965991-af00-40dd-909f-d0d62acae972" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_eb627ab4-c56a-442e-9954-64770a7d742b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3d820995-d55b-40c9-86c6-e7b0153b26a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a965991-af00-40dd-909f-d0d62acae972" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3d820995-d55b-40c9-86c6-e7b0153b26a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6b9bdb67-c428-4b27-8ba6-5d9dcab29869" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3d820995-d55b-40c9-86c6-e7b0153b26a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6b9bdb67-c428-4b27-8ba6-5d9dcab29869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a472a1b0-3f24-48a9-86c0-ca8dc4441181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3d820995-d55b-40c9-86c6-e7b0153b26a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a472a1b0-3f24-48a9-86c0-ca8dc4441181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_590b85ba-e914-454c-8071-f07991ea5b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3d820995-d55b-40c9-86c6-e7b0153b26a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_590b85ba-e914-454c-8071-f07991ea5b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_0604ad47-0de8-48e2-aa27-e869393c8c79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3d820995-d55b-40c9-86c6-e7b0153b26a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_0604ad47-0de8-48e2-aa27-e869393c8c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a5d683da-c40d-4490-b59c-42f0cea4952b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3d820995-d55b-40c9-86c6-e7b0153b26a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a5d683da-c40d-4490-b59c-42f0cea4952b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_d5e31d93-d132-4bd1-b220-0c071c283a81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a965991-af00-40dd-909f-d0d62acae972" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_d5e31d93-d132-4bd1-b220-0c071c283a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3855d598-addb-4568-a56d-4fa6e06975d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a965991-af00-40dd-909f-d0d62acae972" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3855d598-addb-4568-a56d-4fa6e06975d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8c97bb91-e66a-466f-b19e-1c46c0ed94bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a965991-af00-40dd-909f-d0d62acae972" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8c97bb91-e66a-466f-b19e-1c46c0ed94bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_80e9923f-7301-4737-927b-caa4605edb3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8c97bb91-e66a-466f-b19e-1c46c0ed94bd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_80e9923f-7301-4737-927b-caa4605edb3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dff6fee5-9dc0-4290-abf7-2eeab4d88e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8c97bb91-e66a-466f-b19e-1c46c0ed94bd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dff6fee5-9dc0-4290-abf7-2eeab4d88e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5fd6fcaf-3bcf-4fa9-a999-e9b97052d4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8c97bb91-e66a-466f-b19e-1c46c0ed94bd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5fd6fcaf-3bcf-4fa9-a999-e9b97052d4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4c6f65ae-a454-46c6-a0b9-2c10f9ba4058" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8c97bb91-e66a-466f-b19e-1c46c0ed94bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4c6f65ae-a454-46c6-a0b9-2c10f9ba4058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_98e6757e-ee54-46a1-858a-5170af75de35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8c97bb91-e66a-466f-b19e-1c46c0ed94bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_98e6757e-ee54-46a1-858a-5170af75de35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_82fc347a-85f4-4662-974e-8d6e975b0b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8c97bb91-e66a-466f-b19e-1c46c0ed94bd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_82fc347a-85f4-4662-974e-8d6e975b0b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="bdtx-20220331.xsd#STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c93f8798-48ef-4c0b-8126-7a5b8f7a880d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6a5e8ae-6de5-4072-a7f0-650520864551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c93f8798-48ef-4c0b-8126-7a5b8f7a880d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6a5e8ae-6de5-4072-a7f0-650520864551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_878a0d18-6cba-4955-b95c-66b84c7ece51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6a5e8ae-6de5-4072-a7f0-650520864551" xlink:to="loc_us-gaap_AwardTypeAxis_878a0d18-6cba-4955-b95c-66b84c7ece51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db81c107-e616-4313-94a1-0854bd8a129f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_878a0d18-6cba-4955-b95c-66b84c7ece51" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db81c107-e616-4313-94a1-0854bd8a129f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b226852a-d801-4c51-80e3-3f0aa6b78c14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db81c107-e616-4313-94a1-0854bd8a129f" xlink:to="loc_us-gaap_RestrictedStockMember_b226852a-d801-4c51-80e3-3f0aa6b78c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_505ff420-9d12-485b-8823-68e8f26b64c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6a5e8ae-6de5-4072-a7f0-650520864551" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_505ff420-9d12-485b-8823-68e8f26b64c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8a670a79-e747-40bb-83e0-a56ab5ce59cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_505ff420-9d12-485b-8823-68e8f26b64c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8a670a79-e747-40bb-83e0-a56ab5ce59cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6b9d8014-2617-4b22-8d18-23b6560a052f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8a670a79-e747-40bb-83e0-a56ab5ce59cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6b9d8014-2617-4b22-8d18-23b6560a052f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_af846391-5049-4a70-bc27-0e4e6cdf5235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8a670a79-e747-40bb-83e0-a56ab5ce59cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_af846391-5049-4a70-bc27-0e4e6cdf5235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_161f386f-5a4d-4c92-a765-030ed015beb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8a670a79-e747-40bb-83e0-a56ab5ce59cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_161f386f-5a4d-4c92-a765-030ed015beb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3039bb37-80c5-4194-b691-ef6255c6831d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8a670a79-e747-40bb-83e0-a56ab5ce59cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3039bb37-80c5-4194-b691-ef6255c6831d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_07015711-7074-438d-bf75-e2a7640276bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_505ff420-9d12-485b-8823-68e8f26b64c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_07015711-7074-438d-bf75-e2a7640276bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f2a73055-5ab2-418e-8870-6a6c418ab35c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_07015711-7074-438d-bf75-e2a7640276bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f2a73055-5ab2-418e-8870-6a6c418ab35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_407a3d31-9f46-496f-9ac1-f1ddfacda7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_07015711-7074-438d-bf75-e2a7640276bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_407a3d31-9f46-496f-9ac1-f1ddfacda7f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e2caa304-7811-4099-9ba7-99627338b6de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_07015711-7074-438d-bf75-e2a7640276bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e2caa304-7811-4099-9ba7-99627338b6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3f49d57c-6256-4957-b85e-c7c00c6edd03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_07015711-7074-438d-bf75-e2a7640276bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3f49d57c-6256-4957-b85e-c7c00c6edd03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE" xlink:type="simple" xlink:href="bdtx-20220331.xsd#NETLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_496cc8cf-8bcb-4c0c-a273-f1bd25653575" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_5f251d42-9063-4d9b-9c23-807df5aa9510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_496cc8cf-8bcb-4c0c-a273-f1bd25653575" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_5f251d42-9063-4d9b-9c23-807df5aa9510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables" xlink:type="simple" xlink:href="bdtx-20220331.xsd#NETLOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_347587ab-7ab9-4807-98ff-e3b35dad6bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_99ffd24e-a2b7-4e00-b694-420c77e5da39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_347587ab-7ab9-4807-98ff-e3b35dad6bbf" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_99ffd24e-a2b7-4e00-b694-420c77e5da39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c5849a2b-6584-48d2-a439-684d786679ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_347587ab-7ab9-4807-98ff-e3b35dad6bbf" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c5849a2b-6584-48d2-a439-684d786679ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails" xlink:type="simple" xlink:href="bdtx-20220331.xsd#NETLOSSPERSHAREComputationofNetLossperShareDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a2f90a62-2c4f-424b-9c58-5b9e7c4e31a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bee3056c-1852-463f-a8ff-cfadcca59312" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a2f90a62-2c4f-424b-9c58-5b9e7c4e31a1" xlink:to="loc_us-gaap_NetIncomeLoss_bee3056c-1852-463f-a8ff-cfadcca59312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fe4d199d-1ce1-4e43-9fd5-2ba0a550450a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a2f90a62-2c4f-424b-9c58-5b9e7c4e31a1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fe4d199d-1ce1-4e43-9fd5-2ba0a550450a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_584a55c6-f14e-4ef9-b43e-b43e84cf16f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a2f90a62-2c4f-424b-9c58-5b9e7c4e31a1" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_584a55c6-f14e-4ef9-b43e-b43e84cf16f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_356bf458-3430-4423-8bbd-d8aeb9e0b7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a2f90a62-2c4f-424b-9c58-5b9e7c4e31a1" xlink:to="loc_us-gaap_EarningsPerShareBasic_356bf458-3430-4423-8bbd-d8aeb9e0b7d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d744bdbb-b008-4345-b341-595c033bd360" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a2f90a62-2c4f-424b-9c58-5b9e7c4e31a1" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d744bdbb-b008-4345-b341-595c033bd360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" xlink:type="simple" xlink:href="bdtx-20220331.xsd#NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_62551f73-118e-4db0-9c77-b7936e63e30b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_035533b5-a56c-4aed-819a-319709170fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_62551f73-118e-4db0-9c77-b7936e63e30b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_035533b5-a56c-4aed-819a-319709170fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8ea0793c-3aa9-4a34-8719-009b31bb3e58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_035533b5-a56c-4aed-819a-319709170fa7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8ea0793c-3aa9-4a34-8719-009b31bb3e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cce5c81b-6322-4d41-9433-8c93ac7ce4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8ea0793c-3aa9-4a34-8719-009b31bb3e58" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cce5c81b-6322-4d41-9433-8c93ac7ce4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ab5e5d67-06da-49f9-88a7-1b90c2896c48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cce5c81b-6322-4d41-9433-8c93ac7ce4d9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ab5e5d67-06da-49f9-88a7-1b90c2896c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c72f056a-5a8a-4757-a37c-29d966d1d381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cce5c81b-6322-4d41-9433-8c93ac7ce4d9" xlink:to="loc_us-gaap_RestrictedStockMember_c72f056a-5a8a-4757-a37c-29d966d1d381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_6d0a93b4-993f-4be4-973e-e75ed79b9c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cce5c81b-6322-4d41-9433-8c93ac7ce4d9" xlink:to="loc_us-gaap_EmployeeStockMember_6d0a93b4-993f-4be4-973e-e75ed79b9c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_a4ff57b4-d61e-40ab-a07c-38128f0863c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cce5c81b-6322-4d41-9433-8c93ac7ce4d9" xlink:to="loc_us-gaap_WarrantMember_a4ff57b4-d61e-40ab-a07c-38128f0863c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f5adce7e-20bf-42d8-9587-7d7c3d859e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_035533b5-a56c-4aed-819a-319709170fa7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f5adce7e-20bf-42d8-9587-7d7c3d859e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d6b75dfe-e8fd-4276-b783-33ee6c1b02c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f5adce7e-20bf-42d8-9587-7d7c3d859e0c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d6b75dfe-e8fd-4276-b783-33ee6c1b02c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASES" xlink:type="simple" xlink:href="bdtx-20220331.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_cb93b2b1-9889-4592-b22f-bb127b03e941" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_b061883e-525e-4cdf-a3fd-43bd70493081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cb93b2b1-9889-4592-b22f-bb127b03e941" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_b061883e-525e-4cdf-a3fd-43bd70493081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESTables" xlink:type="simple" xlink:href="bdtx-20220331.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_057f39ab-8f36-4084-8578-d905e0a0c79b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_4d148902-fd1b-4d1f-8d49-0807ce77f64f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_057f39ab-8f36-4084-8578-d905e0a0c79b" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_4d148902-fd1b-4d1f-8d49-0807ce77f64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_602fbf9c-f3fe-4289-a640-264fbed6a50d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_057f39ab-8f36-4084-8578-d905e0a0c79b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_602fbf9c-f3fe-4289-a640-264fbed6a50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="bdtx-20220331.xsd#LEASESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_91b5bbab-b307-4528-b55a-0e68750a80c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_946fb47f-4ea8-4de3-9808-1106df9ac230" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_91b5bbab-b307-4528-b55a-0e68750a80c5" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_946fb47f-4ea8-4de3-9808-1106df9ac230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_ae1a8fa9-d6c0-46f1-924e-8e2fbfdaf645" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_946fb47f-4ea8-4de3-9808-1106df9ac230" xlink:to="loc_us-gaap_LeaseContractualTermAxis_ae1a8fa9-d6c0-46f1-924e-8e2fbfdaf645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_f90ff334-d981-4afc-8e3b-63a755357b22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_ae1a8fa9-d6c0-46f1-924e-8e2fbfdaf645" xlink:to="loc_us-gaap_LeaseContractualTermDomain_f90ff334-d981-4afc-8e3b-63a755357b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OperatingLeasePrincipalOfficeTwoMember_029a046b-6cae-437c-9d76-5c847bd4df51" xlink:href="bdtx-20220331.xsd#bdtx_OperatingLeasePrincipalOfficeTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_f90ff334-d981-4afc-8e3b-63a755357b22" xlink:to="loc_bdtx_OperatingLeasePrincipalOfficeTwoMember_029a046b-6cae-437c-9d76-5c847bd4df51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OperatingLeasePrincipalOfficeOneMember_dc6fd02e-0469-44d0-8a2f-0e2fba7f5e5c" xlink:href="bdtx-20220331.xsd#bdtx_OperatingLeasePrincipalOfficeOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_f90ff334-d981-4afc-8e3b-63a755357b22" xlink:to="loc_bdtx_OperatingLeasePrincipalOfficeOneMember_dc6fd02e-0469-44d0-8a2f-0e2fba7f5e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember_c59f1d86-2ccd-4282-8b20-fb53cb9206bc" xlink:href="bdtx-20220331.xsd#bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_f90ff334-d981-4afc-8e3b-63a755357b22" xlink:to="loc_bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember_c59f1d86-2ccd-4282-8b20-fb53cb9206bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_4c8f32db-aae5-4d25-b063-3785c52601f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_946fb47f-4ea8-4de3-9808-1106df9ac230" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_4c8f32db-aae5-4d25-b063-3785c52601f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LesseeOperatingLeaseNumberOfContracts_e70f0de8-7d18-455f-85a3-2c09b3d85525" xlink:href="bdtx-20220331.xsd#bdtx_LesseeOperatingLeaseNumberOfContracts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4c8f32db-aae5-4d25-b063-3785c52601f6" xlink:to="loc_bdtx_LesseeOperatingLeaseNumberOfContracts_e70f0de8-7d18-455f-85a3-2c09b3d85525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e772a7bb-8dd5-4f52-90a1-292c03c153e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4c8f32db-aae5-4d25-b063-3785c52601f6" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e772a7bb-8dd5-4f52-90a1-292c03c153e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_737f81fa-1683-4d45-83a5-0fa2176af2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4c8f32db-aae5-4d25-b063-3785c52601f6" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_737f81fa-1683-4d45-83a5-0fa2176af2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LesseeOperatingLeaseArea_f4cbc498-af81-4716-8429-3deb7e3f6007" xlink:href="bdtx-20220331.xsd#bdtx_LesseeOperatingLeaseArea"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4c8f32db-aae5-4d25-b063-3785c52601f6" xlink:to="loc_bdtx_LesseeOperatingLeaseArea_f4cbc498-af81-4716-8429-3deb7e3f6007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_da59feef-54d7-4fbc-8d54-3d3ec215cce4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4c8f32db-aae5-4d25-b063-3785c52601f6" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_da59feef-54d7-4fbc-8d54-3d3ec215cce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_6fc2e1e2-10ac-446a-be6e-748ed2313933" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4c8f32db-aae5-4d25-b063-3785c52601f6" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_6fc2e1e2-10ac-446a-be6e-748ed2313933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" xlink:type="simple" xlink:href="bdtx-20220331.xsd#LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b93dd546-b700-4f4f-a18e-1746b39b7214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_7cf972ac-3c41-4169-a590-e115ac0dac14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b93dd546-b700-4f4f-a18e-1746b39b7214" xlink:to="loc_us-gaap_LeaseCostAbstract_7cf972ac-3c41-4169-a590-e115ac0dac14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_1f1d127b-f01a-4bcb-85cf-45f21c6b5455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_7cf972ac-3c41-4169-a590-e115ac0dac14" xlink:to="loc_us-gaap_OperatingLeaseCost_1f1d127b-f01a-4bcb-85cf-45f21c6b5455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_d90a011c-c683-4d0f-af0b-1211556d8969" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_7cf972ac-3c41-4169-a590-e115ac0dac14" xlink:to="loc_us-gaap_ShortTermLeaseCost_d90a011c-c683-4d0f-af0b-1211556d8969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_45e54418-8357-424d-b13e-31ec149f5522" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_7cf972ac-3c41-4169-a590-e115ac0dac14" xlink:to="loc_us-gaap_VariableLeaseCost_45e54418-8357-424d-b13e-31ec149f5522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_5b606b50-cca7-41b4-ab4e-a49ad4a96b27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_7cf972ac-3c41-4169-a590-e115ac0dac14" xlink:to="loc_us-gaap_LeaseCost_5b606b50-cca7-41b4-ab4e-a49ad4a96b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LeaseOtherInformationAbstract_9f4d2933-49e4-4b6e-83ba-34fcef287577" xlink:href="bdtx-20220331.xsd#bdtx_LeaseOtherInformationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b93dd546-b700-4f4f-a18e-1746b39b7214" xlink:to="loc_bdtx_LeaseOtherInformationAbstract_9f4d2933-49e4-4b6e-83ba-34fcef287577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_7017aa2b-8711-485e-b182-641d96cc7553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bdtx_LeaseOtherInformationAbstract_9f4d2933-49e4-4b6e-83ba-34fcef287577" xlink:to="loc_us-gaap_OperatingLeasePayments_7017aa2b-8711-485e-b182-641d96cc7553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2130b3ab-fdde-40f8-b830-cac49fd889d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bdtx_LeaseOtherInformationAbstract_9f4d2933-49e4-4b6e-83ba-34fcef287577" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2130b3ab-fdde-40f8-b830-cac49fd889d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6a8e13ec-856b-4881-a464-0b7ae7220750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bdtx_LeaseOtherInformationAbstract_9f4d2933-49e4-4b6e-83ba-34fcef287577" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6a8e13ec-856b-4881-a464-0b7ae7220750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="bdtx-20220331.xsd#LEASESScheduleofFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c20ea6fc-8fda-4776-865c-fe06b19e6d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c769e332-5b7e-435b-8684-f0e4317107b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c20ea6fc-8fda-4776-865c-fe06b19e6d7b" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c769e332-5b7e-435b-8684-f0e4317107b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_75424984-4492-4c25-9082-96361085e34b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c769e332-5b7e-435b-8684-f0e4317107b4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_75424984-4492-4c25-9082-96361085e34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2ff0eac7-9b8d-4bec-92ee-037bb55b8a22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c769e332-5b7e-435b-8684-f0e4317107b4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2ff0eac7-9b8d-4bec-92ee-037bb55b8a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_53fe00cb-246b-4e7d-9079-bd4df76763a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c769e332-5b7e-435b-8684-f0e4317107b4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_53fe00cb-246b-4e7d-9079-bd4df76763a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_09c4a47b-30de-4df0-a741-37736c0a335e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c769e332-5b7e-435b-8684-f0e4317107b4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_09c4a47b-30de-4df0-a741-37736c0a335e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2b085877-d7a5-42eb-a044-50c78bb899bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c769e332-5b7e-435b-8684-f0e4317107b4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2b085877-d7a5-42eb-a044-50c78bb899bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_08c43a8e-75c6-4f06-807c-12e8ac3798c0" xlink:href="bdtx-20220331.xsd#bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c769e332-5b7e-435b-8684-f0e4317107b4" xlink:to="loc_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_08c43a8e-75c6-4f06-807c-12e8ac3798c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_012c42eb-671b-4f46-9a78-600560ae92a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c769e332-5b7e-435b-8684-f0e4317107b4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_012c42eb-671b-4f46-9a78-600560ae92a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0157a2ee-ce92-483b-9185-0b431415cfdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c769e332-5b7e-435b-8684-f0e4317107b4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0157a2ee-ce92-483b-9185-0b431415cfdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a819084e-d8c5-499e-96ab-7ef665dab9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c769e332-5b7e-435b-8684-f0e4317107b4" xlink:to="loc_us-gaap_OperatingLeaseLiability_a819084e-d8c5-499e-96ab-7ef665dab9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="bdtx-20220331.xsd#LEASESScheduleofFutureMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="bdtx-20220331.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6cda8cc8-a3c4-474b-862b-809513821859" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b7e9963f-9866-4695-9ac0-a54fa4eb8901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6cda8cc8-a3c4-474b-862b-809513821859" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b7e9963f-9866-4695-9ac0-a54fa4eb8901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS" xlink:type="simple" xlink:href="bdtx-20220331.xsd#BENEFITPLANS"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_846729c2-6e36-4795-ba36-9f807bc1b429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_66699935-9a33-49a8-a15a-0431680fd285" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_846729c2-6e36-4795-ba36-9f807bc1b429" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_66699935-9a33-49a8-a15a-0431680fd285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails" xlink:type="simple" xlink:href="bdtx-20220331.xsd#BENEFITPLANSDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_89d4d5ca-dbdc-4e6f-8717-2e14a22ad1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_80628b11-4a31-41a8-add2-0f1596199828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_89d4d5ca-dbdc-4e6f-8717-2e14a22ad1a0" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_80628b11-4a31-41a8-add2-0f1596199828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_6aae0449-2199-4097-a3cd-67814a78d198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_89d4d5ca-dbdc-4e6f-8717-2e14a22ad1a0" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_6aae0449-2199-4097-a3cd-67814a78d198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_b5d2511e-2fc0-4fba-b29b-41684c5bead9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_89d4d5ca-dbdc-4e6f-8717-2e14a22ad1a0" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_b5d2511e-2fc0-4fba-b29b-41684c5bead9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658427415880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BLACK DIAMOND THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-4254660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Main Street, 14th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">252-0848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BDTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,290,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001701541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember', window );">Former Address</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Main Street, 10th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658427441064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 54,081<span></span>
</td>
<td class="nump">$ 65,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">125,658<span></span>
</td>
<td class="nump">143,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">8,565<span></span>
</td>
<td class="nump">5,917<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">188,304<span></span>
</td>
<td class="nump">215,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,811<span></span>
</td>
<td class="nump">3,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,223<span></span>
</td>
<td class="nump">1,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">27,134<span></span>
</td>
<td class="nump">27,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">219,482<span></span>
</td>
<td class="nump">247,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,883<span></span>
</td>
<td class="nump">4,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">17,586<span></span>
</td>
<td class="nump">19,535<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">19,469<span></span>
</td>
<td class="nump">23,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">27,453<span></span>
</td>
<td class="nump">28,140<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">46,922<span></span>
</td>
<td class="nump">51,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note&#160;10)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 shares and 10,000,000 shares authorized at March&#160;31, 2022 and December&#160;31, 2021, respectively; no shares issued or outstanding at March&#160;31, 2022 and December&#160;31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock; $0.0001 par value; 500,000,000 shares authorized at March&#160;31, 2022 and 500,000,000 shares authorized at December&#160;31, 2021; 36,287,568 shares issued and outstanding at March&#160;31, 2022 and 36,234,624 shares issued and outstanding at December&#160;31, 2021</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">443,657<span></span>
</td>
<td class="nump">440,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,775)<span></span>
</td>
<td class="num">(414)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(269,327)<span></span>
</td>
<td class="num">(243,820)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">172,560<span></span>
</td>
<td class="nump">195,900<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 219,482<span></span>
</td>
<td class="nump">$ 247,682<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658427399112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">36,287,568<span></span>
</td>
<td class="nump">36,234,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">36,287,568<span></span>
</td>
<td class="nump">36,234,624<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658427361368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 17,786<span></span>
</td>
<td class="nump">$ 22,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">7,893<span></span>
</td>
<td class="nump">7,893<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">25,679<span></span>
</td>
<td class="nump">30,713<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(25,679)<span></span>
</td>
<td class="num">(30,713)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Interest income</a></td>
<td class="nump">406<span></span>
</td>
<td class="nump">1,152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income</a></td>
<td class="num">(234)<span></span>
</td>
<td class="num">(740)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">412<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (25,507)<span></span>
</td>
<td class="num">$ (30,301)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.70)<span></span>
</td>
<td class="num">$ (0.84)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.70)<span></span>
</td>
<td class="num">$ (0.84)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">36,271,291<span></span>
</td>
<td class="nump">36,123,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">36,271,291<span></span>
</td>
<td class="nump">36,123,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (25,507)<span></span>
</td>
<td class="num">$ (30,301)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Unrealized loss on investments</a></td>
<td class="num">(1,361)<span></span>
</td>
<td class="num">(279)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (26,868)<span></span>
</td>
<td class="num">$ (30,580)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658427426136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (25,507)<span></span>
</td>
<td class="num">$ (30,301)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustment to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">3,375<span></span>
</td>
<td class="nump">3,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization of premium on investments</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_RentExpense', window );">Noncash rent expense</a></td>
<td class="nump">686<span></span>
</td>
<td class="nump">321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in current assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(2,648)<span></span>
</td>
<td class="num">(2,805)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="num">(2,224)<span></span>
</td>
<td class="nump">1,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(1,958)<span></span>
</td>
<td class="nump">2,836<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Non-current operating lease liabilities</a></td>
<td class="num">(687)<span></span>
</td>
<td class="num">(335)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(28,600)<span></span>
</td>
<td class="num">(24,455)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of equipment</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of investments</a></td>
<td class="nump">37,240<span></span>
</td>
<td class="nump">45,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(20,504)<span></span>
</td>
<td class="num">(41,526)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">16,729<span></span>
</td>
<td class="nump">3,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercise of common stock options and ESPP</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">481<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">481<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(11,718)<span></span>
</td>
<td class="num">(20,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">67,022<span></span>
</td>
<td class="nump">35,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">55,304<span></span>
</td>
<td class="nump">15,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">54,081<span></span>
</td>
<td class="nump">14,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,223<span></span>
</td>
<td class="nump">1,223<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">55,304<span></span>
</td>
<td class="nump">15,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of equipment included in accounts payable and accrued expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease obligation</a></td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">$ 5,717<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_RentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rent Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_RentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658424885752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Accumulated deficit</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,078,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 307,758<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 425,363<span></span>
</td>
<td class="nump">$ 614<span></span>
</td>
<td class="num">$ (118,224)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(279)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(279)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(30,301)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,301)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,147,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">$ 280,753<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">428,938<span></span>
</td>
<td class="nump">335<span></span>
</td>
<td class="num">(148,525)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">36,234,624<span></span>
</td>
<td class="nump">36,234,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 195,900<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">440,129<span></span>
</td>
<td class="num">(414)<span></span>
</td>
<td class="num">(243,820)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
<td class="nump">3,565<span></span>
</td>
<td class="nump">3,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock related to ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock related to ESPP</a></td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(1,361)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,361)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (25,507)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,507)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="nump">36,287,568<span></span>
</td>
<td class="nump">36,287,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 172,560<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 443,657<span></span>
</td>
<td class="num">$ (1,775)<span></span>
</td>
<td class="num">$ (269,327)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658429519896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF BUSINESS AND BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">NATURE OF BUSINESS AND BASIS OF PRESENTATION</a></td>
<td class="text">NATURE OF BUSINESS AND BASIS OF PRESENTATION<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Black Diamond Therapeutics, Inc. (the &#8220;Company&#8221;) is a precision oncology medicine company pioneering the discovery and development of MasterKey therapies. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing, and incurring research and development costs related to the development of its mutation, allostery, and pharmacology computational and drug discovery engine. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On February 1, 2021, the Company filed a shelf registration statement on Form S-3 ASR (the &#8220;Shelf&#8221;), with the Securities and Exchange Commission (the &#8220;SEC&#8221;), which covers the offering, issuance and sale of the Company&#8217;s common stock, preferred stock, debt securities, warrants and/or units of any combination thereof. The Company simultaneously entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with Jefferies LLC, as sales agent, to provide for the issuance and sale by the Company of up to $150 million of its common stock from time to time through Jefferies as its sales agent (the &#8220;ATM Program&#8221;). The Shelf became automatically effective upon filing on February 1, 2021. As of March&#160;31, 2022, no sales have been made pursuant to the ATM Program.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. Historically, the Company has funded its operations primarily with proceeds from the sale of preferred and common stock. The Company expects to continue to generate operating losses for the foreseeable future. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of May&#160;11, 2022, the issuance date of the condensed consolidated financial statements, the Company expects that its cash, cash equivalents and investments will be sufficient to fund its currently planned operations for at least the next 12 months from the filing date of these unaudited interim condensed consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company may seek additional funding through private or public equity financings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The ongoing COVID-19 pandemic is evolving, and to date has led to the implementation of various responses, including government-imposed quarantines, travel restrictions, and other public health safety measures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has been closely monitoring the impact of the ongoing COVID-19 pandemic on all aspects of the Company&#8217;s business, including how it has impacted and may continue to impact the Company&#8217;s operations and the operations of its suppliers, vendors and business partners, and may take further precautionary and preemptive actions as may be required by federal, state or local authorities. In addition, the Company has taken steps to minimize the current environment&#8217;s impact on its business and strategy, including devising contingency plans and securing additional resources from third party service providers. Furthermore, for the safety of the Company&#8217;s employees and families, the Company has introduced enhanced safety measures for scientists to be present in its labs and increased the use of third party service providers for the conduct of certain experiments and studies for research programs. Certain of the Company&#8217;s third party service providers have also experienced shutdowns or other business disruptions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The extent to which COVID-19 ultimately impacts the Company&#8217;s business, results of operations or financial condition will depend on future developments, which, despite progress in vaccination efforts, remain highly uncertain and cannot be predicted with confidence, such as the duration of the COVID-19 pandemic, new strains of the virus, including any future variants that may emerge, which may impact rates of infection and vaccination efforts, developments or perceptions regarding the safety of vaccines, new information that may emerge concerning the severity of COVID-19, and any additional preventative and protective actions taken to contain the pandemic or treat its impact, among others. The Company does not yet know the full extent of potential delays or impacts on the Company&#8217;s business, clinical trials, research programs, healthcare systems or the global economy and cannot presently predict the scope and severity of any potential business shutdowns or disruptions but if we or any of the third parties with whom we engage were to experience prolonged business shutdowns or other disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on our business, results of operations and financial condition. The estimates of the impact on our business may change based on new information that may emerge concerning COVID-19 and the actions to contain it or treat its impact and the economic impact on local, regional, national and international markets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658425712904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following is a summary of significant accounting policies followed in the preparation of these condensed consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Principles of consolidation </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Unaudited interim financial information</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company&#8217;s Annual Report. In the opinion of the Company&#8217;s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The full extent to which the ongoing COVID-19 pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including expenses, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered the impact of COVID-19 on estimates within its financial statements and there may be changes to those estimates in future periods. As of the date of issuance of these consolidated financial statements, the Company has not experienced material business disruptions or incurred impairment losses in the carrying value of its assets as a result of the pandemic and is not aware of any specific related event or circumstance that would require it to update its estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company believes that no recently issued accounting standards will have a material impact on its consolidated financial statements, or apply to its operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658425864152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value measurements at March 31, 2022 using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">52,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">52,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">65,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">65,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">52,003&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">125,658&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">177,661&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value measurements at December 31, 2021 using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">63,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">63,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">104,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">104,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">63,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">143,987&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">207,717&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">When developing fair value estimates, the Company maximizes the use of observable inputs and minimizes the use of unobservable inputs. When available, the Company uses quoted market prices to measure fair value. The valuation technique used to measure fair value for the Company's Level 1 and Level 2 assets is a market approach, using prices and other relevant information generated by market transactions involving identical or comparable assets. If market prices are not available, the fair value measurement is based on models that use primarily market-based parameters including yield curves, volatilities, credit ratings and currency rates. In certain cases where market rate assumptions are not available, the Company is required to make judgments about assumptions market participants would use to estimate the fair value of a financial instrument. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There were no transfers in or out of Level 3 categories in the periods presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658425715992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">INVESTMENTS</a></td>
<td class="text">INVESTMENTS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, investments were comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.398%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,515&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(14)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">66,782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(903)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">65,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">40,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(864)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">127,433&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,781)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">125,658&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, investments were comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.398%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">104,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(242)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">104,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">40,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">144,401&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">47&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(461)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">143,987&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for U.S. government agencies, corporate bonds and commercial paper with a fair value of $65,238 that had maturities of one to three years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for  U.S. government agencies and corporate bonds with a fair value of $86,187 that had maturities of one to three years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the marketable securities in a loss position had a maturity of less than one year, except for U.S. government agencies, corporate bonds and commercial paper with a fair value of $65,238, that had maturities of one to three years. As of December&#160;31, 2021, the marketable securities in a loss position had a maturity of less than one year, except for U.S. government agencies and corporate bonds, with a fair value of $86,187, that had maturities of one to three years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company reviewed its investment portfolio to assess whether the unrealized losses on its available-for-sale investments were temporary. In determining whether the decline in fair value of these securities was temporary, the Company evaluated whether it intended to sell the security and whether it was more likely than not that the Company would be required to sell the security before recovering its amortized cost basis. There have been no impairments of the Company&#8217;s assets measured and carried at fair value during the three months ended March&#160;31, 2022 and the year ended December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658425864152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text">PROPERTY AND EQUIPMENT<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Computer and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Construction in process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,305&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,404&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(494)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(369)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total Property and Equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,811&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,035&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Depreciation expense for the three months ended March&#160;31, 2022 and 2021 was $125 and $19, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658429792856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Contracted research services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12,571&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12,192&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Payroll and related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Professional and consulting fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfNS0wLTEtMS0xNTQ2OA_c195240d-53ce-44bf-b8a4-8e123e896ff6"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfNS0wLTEtMS0xNTQ2OA_fcf82e1a-149c-4590-8cc4-cc8f47ea4618">Current portion of operating lease liability</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17,586&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19,535&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658425880104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">2020 Stock Option and Incentive Plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The 2020 Stock Option and Incentive Plan (the &#8220;2020 Plan&#8221;) was approved by the Company&#8217;s board of directors on December 5, 2019, and the Company&#8217;s stockholders on January 14, 2020 and became effective on the date immediately prior to the date on which the registration statement for the Company&#8217;s initial public offering (&#8220;IPO&#8221;) was declared effective. The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company&#8217;s officers, employees, directors and consultants. The 2020 Plan provides for an annual increase, to be added on the first day of each fiscal year, by up to 4% of the Company&#8217;s outstanding shares of common stock as of the last day of the prior year. On January 1, 2022, 1,449,384 shares of common stock, representing 4% of the Company&#8217;s outstanding shares of common stock as of December 31, 2021, were added to the 2020 Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The 2020 Employee Stock Purchase Plan (the &#8220;2020 ESPP&#8221;) was approved by the Company&#8217;s board of directors on December 5, 2019, and the Company&#8217;s stockholders on January 14, 2020, and became effective on the date immediately prior to the date on which the registration statement for the Company&#8217;s IPO was declared effective. The 2020 ESPP provides for an annual increase, to be added on the first day of each fiscal year, by up to 1% of the number of shares of the Company&#8217;s common stock outstanding on the immediately preceding December 31. The number of authorized shares reserved for issuance under the 2020 ESPP was increased by 326,364 shares effective as of January 1, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation expense </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following award type categories included within the condensed consolidated statements of operations and comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.750%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top">Three Months Ended<br/>March 31,</td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,193&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Employee Stock Purchase Plan and Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,375&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,094&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2022, the Company issued 13,038 shares of common stock out of our 2020 Plan under our policy where non-employee directors may elect to receive their compensation in the form of common stock in lieu of cash.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.750%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>March 31,</td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,528&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,620&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,847&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,474&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,375&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,094&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Options </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity under the Company&#8217;s equity awards plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:46.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.456%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Exercise</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Price</span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Life</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(in Years)</span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Outstanding December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,903,839&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17.38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">847&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,366,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(3,565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cancelled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(347,830)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Outstanding March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,918,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options vested or expected to vest at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,918,794&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options exercisable at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,082,574&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2022, total unrecognized compensation cost related to the unvested stock-options was $29,471, which is expected to be recognized over a weighted average period of 2.5 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Restricted stock units </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The fair values of restricted stock units are based on the market value of the Company&#8217;s stock on the date of the grant. Under terms of the time-based restricted stock agreements covering the common stock, shares of restricted common stock are subject to a vesting schedule. The following table summarizes time-based restricted stock activity since January 1, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.457%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.269%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Number&#160;of</span></div><div style="margin-bottom:0.75pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">shares</span></div></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">average</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">grant&#160;date</span></div><div style="margin-bottom:0.75pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">fair value</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unvested restricted common stock as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">29.53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(5,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unvested restricted common stock as of March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45,742&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">18.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The total fair value of time-based restricted stock units vested during the three months ended March&#160;31, 2022 was $143. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2022, total unrecognized compensation cost related to the time-based unvested restricted stock units was $591, which is expected to be recognized over a weighted average period of 1.2 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2022, the Company granted to its employees 193,000 performance restricted stock units related to the achievement of certain clinical development and/or financing milestones. As of March&#160;31, 2022, the Company had 212,000 performance restricted stock units outstanding.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Recognition of stock-based compensation expense associated with performance restricted stock units commences when the performance conditions are considered probable of achievement, using management&#8217;s best estimates, which consider the inherent risk and uncertainty regarding the future outcomes of the milestones.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, for performance-based restricted stock units that were outstanding, the achievement of the milestones that had not been met was considered not probable, and therefore no expense has been recognized related to these awards in the three months ended March&#160;31, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Employee stock purchase plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The 2020 ESPP enables eligible employees to purchase shares of the Company's common stock at the end of each six-month offering period at a price equal to 85% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Eligible employees generally included all employees. Offering periods begin on the first trading day of January and July of each year and end on the last trading day in June and December of each year, except for the first offering period which began on the first trading day in March and ended on the last trading day in June. Share purchases are funded through payroll deductions of up to 10% of an employee&#8217;s eligible compensation for each payroll period, up to $25 each calendar year.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022 and 2021, there were 31,341 and no shares, respectively, issued under the 2020 ESPP.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658429823000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text">NET LOSS PER SHARE<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Net loss per share</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes the computation of basic and diluted net loss per share of the Company (in thousands, except share and per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.750%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(25,507)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(30,301)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,271,291&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,123,014&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(0.70)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(0.84)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s potentially dilutive securities, which include options, unvested restricted stock and warrants to purchase common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,918,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,810,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unvested restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">59,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Shares issuable under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">27,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,002,865&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,880,357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658429513848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has historically entered into lease arrangements for its facilities. As of March&#160;31, 2022, the Company had two operating leases with required future minimum payments. The Company determined the classification of these leases to be operating leases and recorded right-of-use assets and lease liabilities as of the effective dates. The Company&#8217;s leases generally do not include termination or purchase options. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Operating leases </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In July 2020, the Company entered into a seven-year agreement with an option to extend for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfNTgy_c161a703-7086-4d07-92a4-b87f9bfb15b3">five</span> additional years to lease two floors totaling approximately 25,578 square feet of office space for its principal office, which is located in Cambridge, MA. The lease on the first floor commenced on August 1, 2020 and the lease on the second floor commenced March 9, 2021. The Company recognized the respective lease balances on the condensed consolidated balance sheets when the lease of each floor commenced. Under the terms of the lease, the Company was required to issue a $1,168 letter of credit as security for the lease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company previously leased an office space in Cambridge, MA under a lease that commenced in February 2019 for approximately 2,357 square feet of office space, which was set to expire on April 30, 2022, subject to an option to extend the lease for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfMTM1MQ_fb0605bf-86e1-4515-94ea-01a6d35b03a5">three</span> additional years. Effective June 15, 2021, the lease was terminated, and the remaining right-of-use asset and lease liability were derecognized. A gain of $5 was recognized for the termination of the lease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In December 2020, the Company entered into an eleven-year agreement to lease approximately 18,120 square feet of office and laboratory space in New York, NY. The Company has an option to extend the lease for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfMTc1MA_0ef0df9a-0a44-47d0-a64e-d0e4a8dda2cf">five</span> additional years. The lease commenced August 26, 2021 and the related lease balance was recognized on the condensed consolidated balance sheet.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#8217;s operating lease for the three months ended March 31, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.681%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.434%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.437%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Lease Cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,335&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">782&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.434%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.436%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Operating Lease Information</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">702&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">370&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The variable lease costs for the three months ended March&#160;31, 2022 and 2021 include common area maintenance and other operating charges. As the Company&#8217;s leases do not provide an implicit rate, the Company utilized its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Future minimum lease payments under the Company&#8217;s operating leases as of March&#160;31, 2022 were as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.480%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.320%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">As of March 31, 2022</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022 (excluding the three months ended March&#160;31, 2022)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">35,892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less: interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(7,646)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28,246&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658425732888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We enter into contracts in the normal course of business with contract research organizations ("CROs"), contract manufacturing organizations ("CMOs") and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts do not contain minimum purchase commitments and are cancelable upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of service providers, up to the date of cancellation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">License agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is party to license agreements, which include contingent payments. These payments will become payable if and when certain development, regulatory and commercial milestones are achieved. As of March&#160;31, 2022, the satisfaction and timing of the contingent payments is uncertain and not reasonably estimable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Indemnification agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of March&#160;31, 2022 or December&#160;31, 2021. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Legal proceedings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is not currently party to and is not aware of any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658425853336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BENEFIT PLANS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">BENEFIT PLANS</a></td>
<td class="text">BENEFIT PLANSThe Company has a tax-qualified 401(k) and Profit Sharing defined contribution plan (the &#8220;401(k) Plan&#8221;). Under the 401(k) Plan, the Company provides an employer safe harbor matching contribution equal to 100% of a participant&#8217;s eligible contributions of up to 6% of eligible compensation, subject to limits established by the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the &#8220;Code&#8221;). All matching contributions are fully vested when made. During the three months ended March&#160;31, 2022 and 2021 the Company contributed $558 and $345 to the 401(k) Plan, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658428836376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Principles of consolidation and unaudited interim financial information</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Black Diamond Therapeutics, Inc. (the &#8220;Company&#8221;) is a precision oncology medicine company pioneering the discovery and development of MasterKey therapies. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing, and incurring research and development costs related to the development of its mutation, allostery, and pharmacology computational and drug discovery engine. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Principles of consolidation </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Unaudited interim financial information</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company&#8217;s Annual Report. In the opinion of the Company&#8217;s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text">Principles of consolidation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text">Use of estimates The preparation of the Company&#8217;s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting pronouncements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company believes that no recently issued accounting standards will have a material impact on its consolidated financial statements, or apply to its operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658425759704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value measurements at March 31, 2022 using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">52,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">52,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">65,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">65,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">52,003&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">125,658&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">177,661&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value measurements at December 31, 2021 using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">63,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">63,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">104,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">104,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">63,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">143,987&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">207,717&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658429801176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, investments were comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.398%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,515&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(14)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">66,782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(903)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">65,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">40,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(864)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">127,433&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,781)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">125,658&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, investments were comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.398%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">104,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(242)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">104,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">40,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">144,401&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">47&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(461)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">143,987&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658429538376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Computer and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Construction in process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,305&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,404&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(494)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(369)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total Property and Equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,811&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,035&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658429829432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Contracted research services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12,571&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12,192&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Payroll and related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Professional and consulting fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfNS0wLTEtMS0xNTQ2OA_c195240d-53ce-44bf-b8a4-8e123e896ff6"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfNS0wLTEtMS0xNTQ2OA_fcf82e1a-149c-4590-8cc4-cc8f47ea4618">Current portion of operating lease liability</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17,586&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19,535&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658430926136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following award type categories included within the condensed consolidated statements of operations and comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.750%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top">Three Months Ended<br/>March 31,</td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,193&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Employee Stock Purchase Plan and Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,375&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,094&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.750%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>March 31,</td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,528&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,620&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,847&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,474&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,375&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,094&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity under the Company&#8217;s equity awards plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:46.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.456%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Exercise</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Price</span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Life</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(in Years)</span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Outstanding December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,903,839&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17.38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">847&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,366,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(3,565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cancelled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(347,830)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Outstanding March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,918,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options vested or expected to vest at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,918,794&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options exercisable at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,082,574&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of Restricted Stock Activity</a></td>
<td class="text">The following table summarizes time-based restricted stock activity since January 1, 2022:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.457%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.269%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Number&#160;of</span></div><div style="margin-bottom:0.75pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">shares</span></div></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">average</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">grant&#160;date</span></div><div style="margin-bottom:0.75pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">fair value</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unvested restricted common stock as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">29.53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(5,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unvested restricted common stock as of March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45,742&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">18.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658427286008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Net Loss per Share</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes the computation of basic and diluted net loss per share of the Company (in thousands, except share and per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.750%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(25,507)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(30,301)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,271,291&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,123,014&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(0.70)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(0.84)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share</a></td>
<td class="text">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,918,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,810,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unvested restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">59,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Shares issuable under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">27,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,002,865&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,880,357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658430176616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Lease Cost and Other Operating Lease Information</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#8217;s operating lease for the three months ended March 31, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.681%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.434%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.437%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Lease Cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,335&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">782&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.434%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.436%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Operating Lease Information</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">702&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">370&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Future minimum lease payments under the Company&#8217;s operating leases as of March&#160;31, 2022 were as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.480%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.320%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">As of March 31, 2022</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022 (excluding the three months ended March&#160;31, 2022)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">35,892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less: interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(7,646)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28,246&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658426573272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bdtx_OpenMarketSaleMember', window );">Open Market Sale | Maximum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from stock issuance, net</a></td>
<td class="nump">$ 150<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bdtx_OpenMarketSaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bdtx_OpenMarketSaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658425949704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 177,661<span></span>
</td>
<td class="nump">$ 207,717<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">52,003<span></span>
</td>
<td class="nump">63,730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">20,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">65,885<span></span>
</td>
<td class="nump">104,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">39,272<span></span>
</td>
<td class="nump">39,921<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">52,003<span></span>
</td>
<td class="nump">63,730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">52,003<span></span>
</td>
<td class="nump">63,730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. Government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">125,658<span></span>
</td>
<td class="nump">143,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">20,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">65,885<span></span>
</td>
<td class="nump">104,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. Government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">39,272<span></span>
</td>
<td class="nump">39,921<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3 | U.S. Government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658426526856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVESTMENTS - Schedule of Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 127,433<span></span>
</td>
<td class="nump">$ 144,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(1,781)<span></span>
</td>
<td class="num">(461)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">125,658<span></span>
</td>
<td class="nump">143,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">20,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">20,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">66,782<span></span>
</td>
<td class="nump">104,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(903)<span></span>
</td>
<td class="num">(242)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">65,885<span></span>
</td>
<td class="nump">104,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">40,136<span></span>
</td>
<td class="nump">40,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(864)<span></span>
</td>
<td class="num">(219)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 39,272<span></span>
</td>
<td class="nump">$ 39,921<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658429593736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENTS - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree', window );">Fair value</a></td>
<td class="nump">$ 65,238,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,187,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Loss position fair value</a></td>
<td class="nump">65,238,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,187,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Impairment of fair value assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Three</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658427373240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 3,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(494)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(369)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total Property and Equipment, net</a></td>
<td class="nump">2,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">682<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Computer and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">2,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,437<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658424809560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_AccruedContractResearchServiceFeesCurrent', window );">Contracted research services</a></td>
<td class="nump">$ 12,571<span></span>
</td>
<td class="nump">$ 12,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related expenses</a></td>
<td class="nump">2,821<span></span>
</td>
<td class="nump">5,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional and consulting fees</a></td>
<td class="nump">$ 1,401<span></span>
</td>
<td class="nump">$ 1,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Total accrued expenses and other current liabilities<span></span>
</td>
<td class="text">Total accrued expenses and other current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">$ 793<span></span>
</td>
<td class="nump">$ 320<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 17,586<span></span>
</td>
<td class="nump">$ 19,535<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_AccruedContractResearchServiceFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Contract Research Service Fees, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_AccruedContractResearchServiceFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658426079816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jan. 14, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost, options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,375<span></span>
</td>
<td class="nump">$ 3,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdtx_A2020StockOptionPlanMember', window );">2020 Stock Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding', window );">Increase of authorized shares, percent of common stock outstanding</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="nump">1,449,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdtx_A2020EmployeeStockPurchasePlanMember', window );">2020 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding', window );">Increase of authorized shares, percent of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="nump">326,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, recognition period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,193<span></span>
</td>
<td class="nump">2,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2020 Stock Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued under share-based compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, recognition period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of units vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121<span></span>
</td>
<td class="nump">$ 270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Shares issuable under employee stock purchase plan | 2020 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued under share-based compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,341<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod', window );">Award purchase period (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Maximum percent of fair market value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum employee subscription rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount', window );">Maximum employee subscription amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bdtx_PerformanceRestrictedStockUnitsMember', window );">Performance Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Units outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Authorized Shares, Percent of Common Stock Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bdtx_A2020StockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bdtx_A2020StockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bdtx_A2020EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bdtx_A2020EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bdtx_PerformanceRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bdtx_PerformanceRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658425900568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,375<span></span>
</td>
<td class="nump">$ 3,094<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,528<span></span>
</td>
<td class="nump">1,620<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,847<span></span>
</td>
<td class="nump">1,474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">3,193<span></span>
</td>
<td class="nump">2,794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bdtx_OtherAwardTypeMember', window );">Employee Stock Purchase Plan and Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bdtx_OtherAwardTypeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bdtx_OtherAwardTypeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658425957592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">4,903,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,366,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(3,565)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Canceled or forfeited (in shares)</a></td>
<td class="num">(347,830)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">5,918,794<span></span>
</td>
<td class="nump">4,903,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested or expected to vest (in shares)</a></td>
<td class="nump">5,918,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares)</a></td>
<td class="nump">2,082,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 17.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">3.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">3.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled or forfeited (in dollars per share)</a></td>
<td class="nump">16.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">14.29<span></span>
</td>
<td class="nump">$ 17.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested or expected to vest (in dollars per share)</a></td>
<td class="nump">14.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable (in dollars per share)</a></td>
<td class="nump">$ 16.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Life and Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, remaining life (in years)</a></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options vested or expected to vest, remaining life (in years)</a></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, remaining life (in years)</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, intrinsic value</a></td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">$ 847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options vested or expected to vest, intrinsic value</a></td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, intrinsic value</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658424270520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Schedule of Restricted Stock Activity (Details) - Unvested restricted stock<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number&#160;of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted common stock, beginning balance (in shares) | shares</a></td>
<td class="nump">30,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">20,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted common stock, ending balance (in shares) | shares</a></td>
<td class="nump">45,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average grant&#160;date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested restricted common stock, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 29.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">3.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">28.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested restricted common stock, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 18.32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658424825288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Computation of Net Loss per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (25,507)<span></span>
</td>
<td class="num">$ (30,301)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">36,271,291<span></span>
</td>
<td class="nump">36,123,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">36,271,291<span></span>
</td>
<td class="nump">36,123,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.70)<span></span>
</td>
<td class="num">$ (0.84)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.70)<span></span>
</td>
<td class="num">$ (0.84)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658429740856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">6,002,865<span></span>
</td>
<td class="nump">4,880,357<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">5,918,794<span></span>
</td>
<td class="nump">4,810,262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">45,742<span></span>
</td>
<td class="nump">59,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Shares issuable under employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">27,572<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">10,757<span></span>
</td>
<td class="nump">10,757<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658424892552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 15, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>contract</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_LesseeOperatingLeaseNumberOfContracts', window );">Number of leases | contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain on lease termination | $</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=bdtx_OperatingLeasePrincipalOfficeTwoMember', window );">Principal office, lease two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease term, optional extension (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_LesseeOperatingLeaseArea', window );">Area leased (square feet)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=bdtx_OperatingLeasePrincipalOfficeOneMember', window );">Principal office, lease one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease term, optional extension (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_LesseeOperatingLeaseArea', window );">Area leased (square feet)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,357<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember', window );">Operating Lease, Office and Laboratory Space, NY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease term, optional extension (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_LesseeOperatingLeaseArea', window );">Area leased (square feet)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_LesseeOperatingLeaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_LesseeOperatingLeaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_LesseeOperatingLeaseNumberOfContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Contracts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_LesseeOperatingLeaseNumberOfContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 40<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123386189&amp;loc=SL77918607-209975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=bdtx_OperatingLeasePrincipalOfficeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=bdtx_OperatingLeasePrincipalOfficeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=bdtx_OperatingLeasePrincipalOfficeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=bdtx_OperatingLeasePrincipalOfficeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658424269080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Summary of Lease Cost and Other Operating Lease Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,059<span></span>
</td>
<td class="nump">$ 462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">1,335<span></span>
</td>
<td class="nump">782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_LeaseOtherInformationAbstract', window );"><strong>Other Operating Lease Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liability</a></td>
<td class="nump">$ 702<span></span>
</td>
<td class="nump">$ 370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="nump">5.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_LeaseOtherInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Other Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_LeaseOtherInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658425889464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Schedule of Future Minimum Lease Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>ASC 842</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022 (excluding the three months ended March&#160;31, 2022)</a></td>
<td class="nump">$ 1,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">4,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">4,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">4,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">4,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">16,972<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">35,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest</a></td>
<td class="num">(7,646)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 28,246<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Due after Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140658429705656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BENEFIT PLANS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer contribution, matching contribution percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer contribution, percent of each participant's salary</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer contribution amount</a></td>
<td class="nump">$ 558<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>bdtx-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bdtx="http://www.blackdiamondtherapeutics.com/20220331"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bdtx-20220331.xsd" xlink:type="simple"/>
    <context id="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3f9b46b909e84ad2acd8f6c5f14d4eee_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:FormerAddressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8f21bf96360a419d92cafe6f85c6447b_I20220502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <instant>2022-05-02</instant>
        </period>
    </context>
    <context id="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib4b87c0a8eda41d88bf0d13971431e26_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3f7c42ccd5d04f12b8291c60dcbafea1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5c8a085e141b45ee84f490448563d1f1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9079e499652941b491fb8e9ed7ce1958_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i12c39deff1194b6c92a7c1abee14df8a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0888b6dac5434cacbd33596c1adace82_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibffb8b6ab6ec42548e3a66555c649c15_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ida279286734543b991ef4eed0ef6046e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5c596ceb5049485884e7b2a68aa5916c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3a11083af40b47cfa476274d297e6503_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iaede1a9af65846df94f23afe6ee659b3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i24cb741f3e52499f82800136848ddbcf_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i67ed168c54f645c2b002a94645f0df0a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idaf43c36cb8d458fa8fcfb47211264db_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if6d7e79d27124e3bb23e6b0101055ce0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic3c688356e134568b5de6825391deaf1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0fdd5c7e07db40b08c5a1dcde0c1ffd2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ca47029fd60490abe151e708b67878e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i691561fefea149049b9e700257b2dd11_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i534d154d73254bb5a34550cf1b283ddb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idc707991eeb0410f91d59567f375b8b4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib55e7da72d944e7b8a9e91f5cb12ecdf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibcc979a9141648ffb26ccb55a5e51ebc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iddf6f9051d0a4be3a16017e93ce7ab16_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1326edc9009d45a49158855eb54f6574_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i19221d9ccdb34fd994d9ee776e4585b5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id201833d4a114834a06d053bfa018915_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i377d263c6d38493ca25e90aa73fd3701_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdtx:OpenMarketSaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic7586d8f4b304a96a89edaf4e92faa9f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i962aa1bfb86e483894de2bb2442985bc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8d10b8beeaca440785de2cdb3d8eaf14_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i42a51dbd5f584d6aa6a0cb3330f1fe5c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icadf51cb52294253943e014823f06afb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i62ae75982324469693df81b6e1fc8c23_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i460915c867d24b099b0bf69feb2da59a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibc6ba9d6b5064ee7aec84d28bbd1751d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i34580173a0a9454eb268a5b3ec8b34eb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i64edc7a1a2174b968d823d315842481f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i900b221b23fd4104a7f93150e16b1981_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3ba3f44f3b104a51b92654a9c905ece2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i83fb07b4cc0046609fb9c5c6324001ef_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1cde33f4aa9549d797693a4f207e3ba3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2cb17e460b95429b88a840c5224dd92a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i29ce9fe315284e5abf314fcd5ed28b78_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8fa4d5d4ec21402bb7f85adb8fb71d6a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id0e121bb40fd49258c14401a29e70859_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie054d218517947ee8d0e864d31140ce8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i76fdf0838e4546cd851611fb3634158c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i62c67ae3c8ed44d39ed202dc3a02814d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic6469b9255c64b428aceb5e576c835e6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i21a15014f6814669b4a982787c14c8ed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id6ef99d5dd434984929935c0f6dd1e3e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib6472a833e63467aa7a16b853fed7648_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i421912da66f44fe09b19b8944d07a70d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9bf4c7e984404a6f86e23661b62cf071_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifd344bc37522487781fced407afc94fd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6c3b0ba2c8154adaaceee5c961ea1e9e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7e34a2b0b44e4081b6b378a6828ca51b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i15df054aa48340d4a776ceb4901608d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i68881d5b14084f3c8c973338e687dea2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i131b634efed14bc78fcdf71e68e8a71e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9d2f217ac6a64e4788118680cfa194b3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i21ff474829e8485d8a14024ec03a39f1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4941a960ea32475eb80b88d7de07c5ba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib85e10885b3a4e9b8fb2f090569d6271_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic8310139017c4117a15d446bef048a12_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icd98783dea56424ba1c71b4e834b425a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6c17159b04ab4338b714552e7330de6e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib197786787854aa08e044a89989c79be_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i592581da0c5c4d148c499857a0970854_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia34f847e770542fbb1c0526bcd0521db_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2cf6dcdd2d6846acbcfd0f4697fbbd29_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3c3fc5df5cff491cb5578febfa6291bf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icee8d91286f54b40b3f46d39ea9f5b62_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2a5f439d7d2246559ccab58abf38d308_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2b03f59264e74ddaa03048707c7f0deb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8fa0e12ae93a4ef0b5f7c326a00d7970_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iae9953ec0cd04a469a57c8508f2c84ef_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i601e1559c5444c6aadd65a73f7aba8dd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5aee93ec0e6140c1967b90030b644693_I20200114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-14</instant>
        </period>
    </context>
    <context id="i121d14ec620443948bfb2446cf6369a8_D20220101-20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="i6c5c649da96f4bf6a852cad3b98671b5_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i73e473532efc4938a233763c7ef748f4_I20200114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-14</instant>
        </period>
    </context>
    <context id="ib84b1455b06c44f2b4f0df628ece6347_D20220101-20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="i9ced07d6335641afa9f14288d1f7a2e1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9e9380f128ab4b63b1d6e7a850a44abd_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia65875741ae542c78ed7dd0c432423a4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id260c31e9c0140f3a78bffba8953b169_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1f5c3ddf78054fd0ba9932327695ba3c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdtx:OtherAwardTypeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibde6c6664ee5474ea71ce7b63f837206_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdtx:OtherAwardTypeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i83ac7265af3c4a80b9a2081786c15aec_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ife37765db49e41bf81afa44e8728613a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iab8781eeec934caf84183887064bbbca_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifdd9e72b3a7b4336a10b4ac7dea8e88c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7445afb88fcd42778b16246f068e465b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id953a840a46b432da2c79d8a575bc2a7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id3281f5219574c05b5edcdfcb8708b8f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0604fd99be6c400cb46383e020232cc3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idfb5ec15550c48b5ba40e04db8d95d68_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9607feb9fa2e47abb53ba9ad7befeaf9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6bed481b20eb42c4b7b7f8e7b60c3743_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdtx:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic3cbdfd3eaf5479f8e2be722e19d3d35_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdtx:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i96258d5fc0c3444cbbfc78ce061c9bef_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1f60a8da3d204a1d84243bb405682e2e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9100305f99b146729261bbdc162cb093_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibe1143b3d4d645b7b96eb90d189b5d47_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iff2984996ead4b0a9658704d11ad854b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i41ea06ffd4224202a713d2f339bde058_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6dcd8e4f8ad5440c98fd9db5a027ce37_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9a5f037265fe4d04a7f18d30566bb541_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8b57788e875c480ba8c662e821360cb1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icda07b5a5283444f941929ded278868b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i11c8ad192542472fae54a22841a0002f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i698d38b82399483e9b66aecdbb49ea01_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">bdtx:OperatingLeasePrincipalOfficeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i2fb5e46658e2428a9f4d40e61ba2085a_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">bdtx:OperatingLeasePrincipalOfficeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="ia1bcd124beab438caab6f8c9006bed30_D20210615-20210615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <startDate>2021-06-15</startDate>
            <endDate>2021-06-15</endDate>
        </period>
    </context>
    <context id="i54692e00a6974fcd89b396554614c7ad_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">bdtx:OperatingLeaseOfficeAndLaboratorySpaceNYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="contract">
        <measure>bdtx:contract</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180L2ZyYWc6MGNkOTlhNjRlZWU2NDI5MTgzOWY1NDUzMWVhMjYxODUvdGFibGU6ZmZhZjQ3NWQ3NzlkNDA1ZmEzNmJmMzNiMDhhNzgwN2EvdGFibGVyYW5nZTpmZmFmNDc1ZDc3OWQ0MDVmYTM2YmYzM2IwOGE3ODA3YV8yLTEtMS0xLTE1NDY4_8476db90-5f90-4638-9c53-10863ce31522">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180L2ZyYWc6MGNkOTlhNjRlZWU2NDI5MTgzOWY1NDUzMWVhMjYxODUvdGFibGU6ZmZhZjQ3NWQ3NzlkNDA1ZmEzNmJmMzNiMDhhNzgwN2EvdGFibGVyYW5nZTpmZmFmNDc1ZDc3OWQ0MDVmYTM2YmYzM2IwOGE3ODA3YV8zLTEtMS0xLTE1NDY4_157228a1-d6c9-41d6-bf6a-6c08fd8723a4">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180L2ZyYWc6MGNkOTlhNjRlZWU2NDI5MTgzOWY1NDUzMWVhMjYxODUvdGFibGU6ZmZhZjQ3NWQ3NzlkNDA1ZmEzNmJmMzNiMDhhNzgwN2EvdGFibGVyYW5nZTpmZmFmNDc1ZDc3OWQ0MDVmYTM2YmYzM2IwOGE3ODA3YV80LTEtMS0xLTE1NDY4_baf795ae-d18b-4957-83c3-6805f7dc1d84">2022</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180L2ZyYWc6MGNkOTlhNjRlZWU2NDI5MTgzOWY1NDUzMWVhMjYxODUvdGFibGU6ZmZhZjQ3NWQ3NzlkNDA1ZmEzNmJmMzNiMDhhNzgwN2EvdGFibGVyYW5nZTpmZmFmNDc1ZDc3OWQ0MDVmYTM2YmYzM2IwOGE3ODA3YV81LTEtMS0xLTE1NDY4_72e1512a-216f-424c-8058-b7d007a42398">0001701541</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180L2ZyYWc6MGNkOTlhNjRlZWU2NDI5MTgzOWY1NDUzMWVhMjYxODUvdGFibGU6ZmZhZjQ3NWQ3NzlkNDA1ZmEzNmJmMzNiMDhhNzgwN2EvdGFibGVyYW5nZTpmZmFmNDc1ZDc3OWQ0MDVmYTM2YmYzM2IwOGE3ODA3YV82LTEtMS0xLTE1NDY4_1c26091b-30a1-4de6-b0fc-cc837d12b144">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfNS0wLTEtMS0xNTQ2OA_c195240d-53ce-44bf-b8a4-8e123e896ff6">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfNS0wLTEtMS0xNTQ2OA_fcf82e1a-149c-4590-8cc4-cc8f47ea4618">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i698d38b82399483e9b66aecdbb49ea01_I20200731"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfNTgy_c161a703-7086-4d07-92a4-b87f9bfb15b3">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i2fb5e46658e2428a9f4d40e61ba2085a_I20190228"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfMTM1MQ_fb0605bf-86e1-4515-94ea-01a6d35b03a5">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i54692e00a6974fcd89b396554614c7ad_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfMTc1MA_0ef0df9a-0a44-47d0-a64e-d0e4a8dda2cf">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <dei:DocumentType
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGV4dHJlZ2lvbjoyMzhjZThkNzE5NTg0ZTY2YWE4ZmMwNjBmNTFmMDFiOF8xMjY_d4c99af4-a693-41af-bf8e-b2e466c273dd">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6ZTIxNmM3YjEyOGJhNGQxM2JlMjRmZjRjODQ5ZmU5NTEvdGFibGVyYW5nZTplMjE2YzdiMTI4YmE0ZDEzYmUyNGZmNGM4NDlmZTk1MV8wLTAtMS0xLTE1NDY4_f748eacd-eebc-4c7a-8e3c-c7d6719f0ee9">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGV4dHJlZ2lvbjoyMzhjZThkNzE5NTg0ZTY2YWE4ZmMwNjBmNTFmMDFiOF8yMDU_b29fc52c-8d0e-4623-bb34-747d26124597">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6MmQ5OWY2YTNmNmJmNGE0M2I1ZjZkNWIzYjkyYTk4NjMvdGFibGVyYW5nZToyZDk5ZjZhM2Y2YmY0YTQzYjVmNmQ1YjNiOTJhOTg2M18wLTAtMS0xLTE1NDY4_5a712f15-687e-48bf-ac3e-5ff2d14a845b">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGV4dHJlZ2lvbjoyMzhjZThkNzE5NTg0ZTY2YWE4ZmMwNjBmNTFmMDFiOF8yNzM_9262d1a0-0729-45ee-95c7-e5d4d85cfe16">001-38501</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGV4dHJlZ2lvbjoyMzhjZThkNzE5NTg0ZTY2YWE4ZmMwNjBmNTFmMDFiOF8zMjA_24911250-648d-4080-9a7f-72fa0ebef7a8">BLACK DIAMOND THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6YjRjNGFjM2IxZGUyNDc0NTkyYjBiM2E3OWM5YTY2ODgvdGFibGVyYW5nZTpiNGM0YWMzYjFkZTI0NzQ1OTJiMGIzYTc5YzlhNjY4OF8wLTAtMS0xLTE1NDY4_50414233-60ed-4a40-b8bc-dd9aa6df0f4a">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6YjRjNGFjM2IxZGUyNDc0NTkyYjBiM2E3OWM5YTY2ODgvdGFibGVyYW5nZTpiNGM0YWMzYjFkZTI0NzQ1OTJiMGIzYTc5YzlhNjY4OF8wLTEtMS0xLTE1NDY4_d7ff35fb-bd70-4189-babc-44754eafaaf2">81-4254660</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6YjRjNGFjM2IxZGUyNDc0NTkyYjBiM2E3OWM5YTY2ODgvdGFibGVyYW5nZTpiNGM0YWMzYjFkZTI0NzQ1OTJiMGIzYTc5YzlhNjY4OF8yLTAtMS0xLTE1NDY4L3RleHRyZWdpb246MjkxNDJiMDAyZjA3NDAwM2E2ZTJiNmY1YjIxNzk3MjJfNQ_54048cad-940a-4cc1-9858-3786399277a7">One Main Street, 14th Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6YjRjNGFjM2IxZGUyNDc0NTkyYjBiM2E3OWM5YTY2ODgvdGFibGVyYW5nZTpiNGM0YWMzYjFkZTI0NzQ1OTJiMGIzYTc5YzlhNjY4OF8yLTAtMS0xLTE1NDY4L3RleHRyZWdpb246MjkxNDJiMDAyZjA3NDAwM2E2ZTJiNmY1YjIxNzk3MjJfOQ_57c7b87d-ee2b-4769-ae7a-56f99994cc6e">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6YjRjNGFjM2IxZGUyNDc0NTkyYjBiM2E3OWM5YTY2ODgvdGFibGVyYW5nZTpiNGM0YWMzYjFkZTI0NzQ1OTJiMGIzYTc5YzlhNjY4OF8yLTAtMS0xLTE1NDY4L3RleHRyZWdpb246MjkxNDJiMDAyZjA3NDAwM2E2ZTJiNmY1YjIxNzk3MjJfMTM_f7d85824-3b02-4ccb-8338-c6d3f5559a3e">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6YjRjNGFjM2IxZGUyNDc0NTkyYjBiM2E3OWM5YTY2ODgvdGFibGVyYW5nZTpiNGM0YWMzYjFkZTI0NzQ1OTJiMGIzYTc5YzlhNjY4OF8yLTEtMS0xLTE1NDY4L3RleHRyZWdpb246NzYwOGVjMDMwYWUyNGE3OTg5YmIyOGIyMmNhZTE5MjVfNQ_386fde0d-955c-4475-add5-b952c374dbda">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6YjRjNGFjM2IxZGUyNDc0NTkyYjBiM2E3OWM5YTY2ODgvdGFibGVyYW5nZTpiNGM0YWMzYjFkZTI0NzQ1OTJiMGIzYTc5YzlhNjY4OF8zLTAtMS0xLTE1NDY4L3RleHRyZWdpb246Y2Y0NGIwYzk1OGE1NDM4NTk0YTMyNjkwMzc3NTM3MGFfNQ_642c91a9-bb81-4e70-a179-6124d0e4c07b">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6YjRjNGFjM2IxZGUyNDc0NTkyYjBiM2E3OWM5YTY2ODgvdGFibGVyYW5nZTpiNGM0YWMzYjFkZTI0NzQ1OTJiMGIzYTc5YzlhNjY4OF8zLTAtMS0xLTE1NDY4L3RleHRyZWdpb246Y2Y0NGIwYzk1OGE1NDM4NTk0YTMyNjkwMzc3NTM3MGFfOA_35375a0f-6343-4491-b56e-647708c48c7a">252-0848</dei:LocalPhoneNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i3f9b46b909e84ad2acd8f6c5f14d4eee_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6YjRjNGFjM2IxZGUyNDc0NTkyYjBiM2E3OWM5YTY2ODgvdGFibGVyYW5nZTpiNGM0YWMzYjFkZTI0NzQ1OTJiMGIzYTc5YzlhNjY4OF80LTAtMS0xLTE4MzUzL3RleHRyZWdpb246NmM5YzIyMDQ2OTI1NDM5ZGFhNjQzOTQ1MmNjMWQ1YmVfMTA5OTUxMTYyODkxNw_a14cb85b-3235-446f-b302-683b0012f46f">One Main Street, 10th Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i3f9b46b909e84ad2acd8f6c5f14d4eee_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6YjRjNGFjM2IxZGUyNDc0NTkyYjBiM2E3OWM5YTY2ODgvdGFibGVyYW5nZTpiNGM0YWMzYjFkZTI0NzQ1OTJiMGIzYTc5YzlhNjY4OF80LTAtMS0xLTE4MzUzL3RleHRyZWdpb246NmM5YzIyMDQ2OTI1NDM5ZGFhNjQzOTQ1MmNjMWQ1YmVfMTA5OTUxMTYyODkyNA_babc4996-5599-4bce-9e21-e4a71f291182">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i3f9b46b909e84ad2acd8f6c5f14d4eee_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6YjRjNGFjM2IxZGUyNDc0NTkyYjBiM2E3OWM5YTY2ODgvdGFibGVyYW5nZTpiNGM0YWMzYjFkZTI0NzQ1OTJiMGIzYTc5YzlhNjY4OF80LTAtMS0xLTE4MzUzL3RleHRyZWdpb246NmM5YzIyMDQ2OTI1NDM5ZGFhNjQzOTQ1MmNjMWQ1YmVfMTA5OTUxMTYyODkyOQ_b3efb528-478d-4697-86f3-4d85a9485286">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i3f9b46b909e84ad2acd8f6c5f14d4eee_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6YjRjNGFjM2IxZGUyNDc0NTkyYjBiM2E3OWM5YTY2ODgvdGFibGVyYW5nZTpiNGM0YWMzYjFkZTI0NzQ1OTJiMGIzYTc5YzlhNjY4OF80LTAtMS0xLTE4MzUzL3RleHRyZWdpb246NmM5YzIyMDQ2OTI1NDM5ZGFhNjQzOTQ1MmNjMWQ1YmVfMTA5OTUxMTYyODkzMw_89b9a44f-0fc3-4ec2-a0d1-8c7d62cfaebb">02142</dei:EntityAddressPostalZipCode>
    <dei:Security12bTitle
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6NzJjYThkNTU4ZWI4NGEyMGJjMzY4ZTVjZTU5MGNmMDUvdGFibGVyYW5nZTo3MmNhOGQ1NThlYjg0YTIwYmMzNjhlNWNlNTkwY2YwNV8xLTAtMS0xLTE1NDY4_23a9d3c1-54e3-471f-943f-266b5c5ce479">Common stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6NzJjYThkNTU4ZWI4NGEyMGJjMzY4ZTVjZTU5MGNmMDUvdGFibGVyYW5nZTo3MmNhOGQ1NThlYjg0YTIwYmMzNjhlNWNlNTkwY2YwNV8xLTEtMS0xLTE1NDY4_a8e485f4-d120-49f2-92be-1872d8260122">BDTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6NzJjYThkNTU4ZWI4NGEyMGJjMzY4ZTVjZTU5MGNmMDUvdGFibGVyYW5nZTo3MmNhOGQ1NThlYjg0YTIwYmMzNjhlNWNlNTkwY2YwNV8xLTItMS0xLTE1NDY4_7eef223c-db03-493e-ad1c-fcb5d2bfb190">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGV4dHJlZ2lvbjoyMzhjZThkNzE5NTg0ZTY2YWE4ZmMwNjBmNTFmMDFiOF84NzE_e16fe7cb-fd29-42a1-8c32-bd9b1623c2f8">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGV4dHJlZ2lvbjoyMzhjZThkNzE5NTg0ZTY2YWE4ZmMwNjBmNTFmMDFiOF8xMTk4_fd4e8f14-d706-4130-99e6-9eafe94c89f6">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6ODRlZjczNGU5ODE0NDBmOGIwZjM3ZmUzNjU5YzIxOTkvdGFibGVyYW5nZTo4NGVmNzM0ZTk4MTQ0MGY4YjBmMzdmZTM2NTljMjE5OV8yLTAtMS0xLTE1NDY4_ea8761d6-32e1-4e59-91af-41d8999e067c">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6ODRlZjczNGU5ODE0NDBmOGIwZjM3ZmUzNjU5YzIxOTkvdGFibGVyYW5nZTo4NGVmNzM0ZTk4MTQ0MGY4YjBmMzdmZTM2NTljMjE5OV8yLTMtMS0xLTE1NDY4_4ac1e271-4d43-4507-b77c-9e823dec6726">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGFibGU6ODRlZjczNGU5ODE0NDBmOGIwZjM3ZmUzNjU5YzIxOTkvdGFibGVyYW5nZTo4NGVmNzM0ZTk4MTQ0MGY4YjBmMzdmZTM2NTljMjE5OV80LTMtMS0xLTE1NDY4_070ae3b1-fba6-4283-a29f-f6fe886e8234">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGV4dHJlZ2lvbjoyMzhjZThkNzE5NTg0ZTY2YWE4ZmMwNjBmNTFmMDFiOF8xODEz_37e36721-7ade-42b4-9db3-d9676be0fe19">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGV4dHJlZ2lvbjoyMzhjZThkNzE5NTg0ZTY2YWE4ZmMwNjBmNTFmMDFiOF8xOTM3_cdd2efd4-371f-4d9d-b3b3-daee643d7385">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i8f21bf96360a419d92cafe6f85c6447b_I20220502"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xL2ZyYWc6MjM4Y2U4ZDcxOTU4NGU2NmFhOGZjMDYwZjUxZjAxYjgvdGV4dHJlZ2lvbjoyMzhjZThkNzE5NTg0ZTY2YWE4ZmMwNjBmNTFmMDFiOF8xOTc4_9ae60953-c10b-4fae-a3cd-07d06b11f172"
      unitRef="shares">36290901</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfNC0xLTEtMS0xNTQ2OA_3be49587-ebc2-486e-bfeb-fbb15efa6f1b"
      unitRef="usd">54081000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfNC0zLTEtMS0xNTQ2OA_b526dc33-be1d-486e-82bf-446f4366b04e"
      unitRef="usd">65799000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfNS0xLTEtMS0xNTQ2OA_b444b08a-bc52-4bf7-b022-5b01cd990a5f"
      unitRef="usd">125658000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfNS0zLTEtMS0xNTQ2OA_d1695ad7-f54c-44aa-ba06-a5965a98bf02"
      unitRef="usd">143987000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfNi0xLTEtMS0xNTQ2OA_bbccbc55-6f3a-44a2-ab3a-7964f649d488"
      unitRef="usd">8565000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfNi0zLTEtMS0xNTQ2OA_f4531ccb-efa9-43f2-9acf-4e3104be8a24"
      unitRef="usd">5917000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfNy0xLTEtMS0xNTQ2OA_11269885-a7b3-4ab3-81ec-721200a19e2c"
      unitRef="usd">188304000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfNy0zLTEtMS0xNTQ2OA_8a98641b-17e7-4128-82ea-17c00c5e4ef8"
      unitRef="usd">215703000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfOC0xLTEtMS0xNTQ2OA_3839aa0f-1b2f-4d34-906a-6e68ce152dd4"
      unitRef="usd">2811000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfOC0zLTEtMS0xNTQ2OA_389d4083-d989-4ac7-90de-66e8836da08f"
      unitRef="usd">3035000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfOS0xLTEtMS0xNTQ2OA_8ae732fd-075f-4a02-ac7d-f001eb3de680"
      unitRef="usd">1223000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfOS0zLTEtMS0xNTQ2OA_08527ad1-f824-42ee-a8f7-9281cfb74533"
      unitRef="usd">1223000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMTAtMS0xLTEtMTU0Njg_83f306ad-650e-4b60-afe2-68df32000c94"
      unitRef="usd">27134000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMTAtMy0xLTEtMTU0Njg_f4b50986-5395-47e7-92ca-aeab9527ed5c"
      unitRef="usd">27705000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMTEtMS0xLTEtMTU0Njg_301a9b23-facb-4271-bf99-6d8c28f1a010"
      unitRef="usd">10000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMTEtMy0xLTEtMTU0Njg_ff0152e2-6d98-43d3-8c84-bd167c5afc3c"
      unitRef="usd">16000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMTItMS0xLTEtMTU0Njg_09bc6d8e-a901-49cc-a5bb-cda30771e5b2"
      unitRef="usd">219482000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMTItMy0xLTEtMTU0Njg_68a1cea1-b142-491d-bf85-923ba321eed7"
      unitRef="usd">247682000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMTUtMS0xLTEtMTU0Njg_ef86b178-a2e5-4296-a97c-89abeb079571"
      unitRef="usd">1883000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMTUtMy0xLTEtMTU0Njg_c3a3eebe-3bf3-4d52-9db2-1605d2c2c746"
      unitRef="usd">4107000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMTctMS0xLTEtMTU0Njg_af20ce20-cd8a-4f15-818c-be8ae291dd88"
      unitRef="usd">17586000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMTctMy0xLTEtMTU0Njg_67b481b6-d885-498a-9fe5-4012519ac7f5"
      unitRef="usd">19535000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMTgtMS0xLTEtMTU0Njg_71e0f653-df90-49ae-929c-53e42c75c176"
      unitRef="usd">19469000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMTgtMy0xLTEtMTU0Njg_432f68ef-b7fb-4e8a-80c1-9ec6ce8b8d39"
      unitRef="usd">23642000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMTktMS0xLTEtMTU0Njg_e37c4459-cffd-4fa2-8ff7-88a8809d7a6f"
      unitRef="usd">27453000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMTktMy0xLTEtMTU0Njg_f1ef2400-326a-46d3-ac7d-744505aa4683"
      unitRef="usd">28140000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjAtMS0xLTEtMTU0Njg_a24f3512-c36a-4bd0-8996-bdd0676b6753"
      unitRef="usd">46922000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjAtMy0xLTEtMTU0Njg_3dc3f270-16bb-4f95-b2b6-22b7abda0866"
      unitRef="usd">51782000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjEtMS0xLTEtMTU0Njg_585c151c-ba23-4d3b-9743-cd8105a968c6"
      unitRef="usd">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjEtMy0xLTEtMTU0Njg_18db38e1-7c46-46cc-857b-ef814e6afded"
      unitRef="usd">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjQtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjpjNjg0ZmQyZDNmYjQ0NzVjOWZkNzMyZGRlOTk0Zjc5YV8yMQ_442287c1-4448-4042-9acf-2ad84b719dd2"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjQtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjpjNjg0ZmQyZDNmYjQ0NzVjOWZkNzMyZGRlOTk0Zjc5YV8yMQ_83baa4f7-827e-4cd0-a64b-86a81ea9fb99"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjQtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjpjNjg0ZmQyZDNmYjQ0NzVjOWZkNzMyZGRlOTk0Zjc5YV8zNQ_25c22e2c-2420-46f1-a9d0-ff154d4c24b9"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjQtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjpjNjg0ZmQyZDNmYjQ0NzVjOWZkNzMyZGRlOTk0Zjc5YV80OQ_238bfc70-24e1-4580-a1ba-045566940e32"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjQtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjpjNjg0ZmQyZDNmYjQ0NzVjOWZkNzMyZGRlOTk0Zjc5YV85OA_3e991182-1761-46bd-b651-81f034748360"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjQtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjpjNjg0ZmQyZDNmYjQ0NzVjOWZkNzMyZGRlOTk0Zjc5YV85OA_6968b0d4-942b-4c23-b89b-529338ac4e82"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjQtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjpjNjg0ZmQyZDNmYjQ0NzVjOWZkNzMyZGRlOTk0Zjc5YV85OA_d81b90ca-ebcb-45ad-b533-981a531748b2"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjQtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjpjNjg0ZmQyZDNmYjQ0NzVjOWZkNzMyZGRlOTk0Zjc5YV85OA_ee5dcb40-f147-4f03-adfb-a7a75998e70d"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjQtMS0xLTEtMTU0Njg_e18b64eb-048a-46e3-a11c-16da2d5ea1a4"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjQtMy0xLTEtMTU0Njg_0bfd10ec-6205-4efb-8291-1b14164c2b7f"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjUtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjoxM2M1NWQyYTk1MmM0ZTYyYWE1YmVhMTRhODYwMDBjN18xOQ_5ce29aa3-0752-4a5c-88ce-4fad21518d0a"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjUtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjoxM2M1NWQyYTk1MmM0ZTYyYWE1YmVhMTRhODYwMDBjN18xOQ_9d0953bf-b77c-4d5f-ab25-2f6db1eeb786"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjUtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjoxM2M1NWQyYTk1MmM0ZTYyYWE1YmVhMTRhODYwMDBjN18zMw_b2f9e1ea-417f-4e21-b155-620c3ad684a5"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjUtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjoxM2M1NWQyYTk1MmM0ZTYyYWE1YmVhMTRhODYwMDBjN182NA_696e1bca-4838-4b81-badf-cdc24e1621de"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjUtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjoxM2M1NWQyYTk1MmM0ZTYyYWE1YmVhMTRhODYwMDBjN185Mg_353ab3ea-308b-4264-b7b2-84742e555e78"
      unitRef="shares">36287568</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjUtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjoxM2M1NWQyYTk1MmM0ZTYyYWE1YmVhMTRhODYwMDBjN185Mg_8bb420e0-baa1-4b21-800d-451144485157"
      unitRef="shares">36287568</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjUtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjoxM2M1NWQyYTk1MmM0ZTYyYWE1YmVhMTRhODYwMDBjN18xMzU_64b67a46-e501-4cf6-809d-bf8a023e6a56"
      unitRef="shares">36234624</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjUtMC0xLTEtMTU0NjgvdGV4dHJlZ2lvbjoxM2M1NWQyYTk1MmM0ZTYyYWE1YmVhMTRhODYwMDBjN18xMzU_c976414f-3754-4433-9d00-365aa9e0f384"
      unitRef="shares">36234624</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjUtMS0xLTEtMTU0Njg_5834ca4f-3e17-44ae-94c8-0253ce4cdfb3"
      unitRef="usd">5000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjUtMy0xLTEtMTU0Njg_9c3c8048-6b41-4a66-831f-88fa6611b150"
      unitRef="usd">5000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjYtMS0xLTEtMTU0Njg_57de1235-8bee-4315-a62e-c8b204c9157f"
      unitRef="usd">443657000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjYtMy0xLTEtMTU0Njg_f5008bed-88dc-4e09-94ef-320950b25c7c"
      unitRef="usd">440129000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjctMS0xLTEtMTU0Njg_567dd7ca-d123-40fc-b581-a6d3a5813f6e"
      unitRef="usd">-1775000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjctMy0xLTEtMTU0Njg_28af77f2-cabb-45c3-b5ee-e2a17d53cd12"
      unitRef="usd">-414000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjgtMS0xLTEtMTU0Njg_ba89f107-675a-4f64-a9a0-b98607009bab"
      unitRef="usd">-269327000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjgtMy0xLTEtMTU0Njg_fbe74ff3-3fee-4da6-a7af-47baaf2d8115"
      unitRef="usd">-243820000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjktMS0xLTEtMTU0Njg_35757498-4732-4ffe-8f59-5ba025b521b6"
      unitRef="usd">172560000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMjktMy0xLTEtMTU0Njg_7dbc694f-e0fa-44a1-996c-b04eb1af81f5"
      unitRef="usd">195900000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMzAtMS0xLTEtMTU0Njg_a82ce5eb-8f15-4a51-93ac-56e7a4383155"
      unitRef="usd">219482000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xNi9mcmFnOjhiMGI2ZjI3N2IwYzRmOGNhZWNhODZjYjhhY2MzYjNiL3RhYmxlOjVjZjc4M2NkZGU3ODRiOGI4MTdlNGI3YmJmODQxZjk1L3RhYmxlcmFuZ2U6NWNmNzgzY2RkZTc4NGI4YjgxN2U0YjdiYmY4NDFmOTVfMzAtMy0xLTEtMTU0Njg_9f6db4dc-c9a6-46d3-97fb-57fb259a411a"
      unitRef="usd">247682000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMy01LTEtMS0xNTQ2OA_87a210dc-cf25-4721-88d6-25318895f8fb"
      unitRef="usd">17786000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMy03LTEtMS0xNTQ2OA_c3cc7a38-62a7-4518-b511-73d7e81f10f3"
      unitRef="usd">22820000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfNC01LTEtMS0xNTQ2OA_151b41f9-7c06-4a7e-9bfa-eff1758aa33a"
      unitRef="usd">7893000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfNC03LTEtMS0xNTQ2OA_2f5f79c3-38c1-4ba8-b3dd-183f9c3d545a"
      unitRef="usd">7893000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfNS01LTEtMS0xNTQ2OA_5e8aab2c-a463-48ad-8f81-db257a8ee17b"
      unitRef="usd">25679000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfNS03LTEtMS0xNTQ2OA_13a0ba46-8f41-481f-94c4-0a27d247bc3d"
      unitRef="usd">30713000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfNi01LTEtMS0xNTQ2OA_620de64c-4525-4aad-bb48-2568995ce7a7"
      unitRef="usd">-25679000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfNi03LTEtMS0xNTQ2OA_fed8f9be-4342-4907-b3ae-05ea99e3b0b5"
      unitRef="usd">-30713000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfOS01LTEtMS0xNTQ2OA_40859f53-9529-4d3d-840b-e6ce4d3adcd0"
      unitRef="usd">406000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfOS03LTEtMS0xNTQ2OA_22e08ded-b96c-46be-bebb-6fa421cd94ed"
      unitRef="usd">1152000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTEtNS0xLTEtMTU0Njg_64ba0c23-5e91-4f69-ba2c-7d1136e5d9d1"
      unitRef="usd">-234000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTEtNy0xLTEtMTU0Njg_213aaaf9-c89c-44ed-b526-eba66a67b89c"
      unitRef="usd">-740000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTItNS0xLTEtMTU0Njg_2c4e390d-e73f-4b4c-8a8f-5a976a240782"
      unitRef="usd">172000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTItNy0xLTEtMTU0Njg_adecc92b-adb8-400c-a21b-1f453926c82d"
      unitRef="usd">412000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTMtNS0xLTEtMTU0Njg_35b81f3a-c78d-4dfb-80bb-3e319d83fd51"
      unitRef="usd">-25507000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTMtNy0xLTEtMTU0Njg_96d5c7b1-0a0d-47df-8572-723d2392430e"
      unitRef="usd">-30301000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTQtNS0xLTEtMTU0Njg_41a1cb10-27ea-48ae-b424-65ab7ab2637f"
      unitRef="usdPerShare">-0.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTQtNS0xLTEtMTU0Njg_8494290c-1bca-4650-baec-2d7bb1f50df7"
      unitRef="usdPerShare">-0.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTQtNy0xLTEtMTU0Njg_ac42aac7-437e-4a85-8aad-f7e3e8eb57bd"
      unitRef="usdPerShare">-0.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTQtNy0xLTEtMTU0Njg_c74e8559-2670-4eae-a50a-1c496cd78f90"
      unitRef="usdPerShare">-0.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTUtNS0xLTEtMTU0Njg_6436e7e3-8d8e-4273-bae4-5c8b1150ab11"
      unitRef="shares">36271291</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTUtNS0xLTEtMTU0Njg_84d4b623-0ee0-40c0-84b5-2b7a9b16317a"
      unitRef="shares">36271291</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTUtNy0xLTEtMTU0Njg_42f90b35-0caa-4969-b8d5-4a99982d9b4b"
      unitRef="shares">36123014</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTUtNy0xLTEtMTU0Njg_74068b27-7934-44fd-b073-c579b4156379"
      unitRef="shares">36123014</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTgtNS0xLTEtMTU0Njg_3e8ea98c-a892-4cb0-bfa9-be79ed5e65c4"
      unitRef="usd">-25507000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMTgtNy0xLTEtMTU0Njg_d5e163f4-cb27-4f71-973d-eeb6a67aa6d0"
      unitRef="usd">-30301000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMjAtNS0xLTEtMTU0Njg_b217c118-b19c-47ec-8e16-86bbeb7119e0"
      unitRef="usd">-1361000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMjAtNy0xLTEtMTU0Njg_fdde9f6f-387a-40d9-ba32-08ce3163f084"
      unitRef="usd">-279000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMjEtNS0xLTEtMTU0Njg_eb22104d-3f46-4ea9-8577-a02944ade041"
      unitRef="usd">-26868000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18xOS9mcmFnOjQyNzIxNWY5YjgxMTRkZTg4ZmE3ZjkwNmJmODEwMzU0L3RhYmxlOjZkODc3NTI2Y2RkNjQ4MTVhZWNlMzU4ZmNjYjI5ODIxL3RhYmxlcmFuZ2U6NmQ4Nzc1MjZjZGQ2NDgxNWFlY2UzNThmY2NiMjk4MjFfMjEtNy0xLTEtMTU0Njg_e7026c3a-7898-430b-b9e2-83b5539d634e"
      unitRef="usd">-30580000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMy0xLTEtMS0xNTQ2OA_c2563c73-177a-4b3b-8ef0-c0d6cc66e8ff"
      unitRef="usd">-25507000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMy0zLTEtMS0xNTQ2OA_1c7a8241-1230-44dd-96ba-95e66b668e99"
      unitRef="usd">-30301000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfNS0xLTEtMS0xNTQ2OA_11a03bcc-c007-4a3a-8be0-338bcc1c2e25"
      unitRef="usd">3375000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfNS0zLTEtMS0xNTQ2OA_af4eedf6-db4b-47e1-b1f8-0b0a92f70c62"
      unitRef="usd">3094000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfNi0xLTEtMS0xNTQ2OA_e040cdbd-faba-447e-8cdd-57f0a43e890d"
      unitRef="usd">125000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfNi0zLTEtMS0xNTQ2OA_cf1d74fc-7f88-4ae3-bfd7-e92769966813"
      unitRef="usd">19000</us-gaap:Depreciation>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfOC0xLTEtMS0xNTQ2OA_fe0fd9fd-74e6-434b-84df-c9dc8ba42d54"
      unitRef="usd">-232000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfOC0zLTEtMS0xNTQ2OA_8754726b-d692-4653-ab40-8ef5c05989f1"
      unitRef="usd">-720000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <bdtx:RentExpense
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfOS0xLTEtMS0xNTQ2OA_256c35c1-29a9-4ea0-9951-170e18a90d0d"
      unitRef="usd">686000</bdtx:RentExpense>
    <bdtx:RentExpense
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfOS0zLTEtMS0xNTQ2OA_8364c217-d607-4eac-b4f0-562352e6ff4c"
      unitRef="usd">321000</bdtx:RentExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMTAtMS0xLTEtMTU0Njg_d6a59ef3-f142-47a8-9a23-434ca60fd22b"
      unitRef="usd">0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMTAtMy0xLTEtMTU0Njg_a1e579b0-c0ff-4d5d-851f-4030dc07d859"
      unitRef="usd">1000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMTItMS0xLTEtMTU0Njg_01fe4408-4d8e-45e7-9929-c8acb970c037"
      unitRef="usd">2648000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMTItMy0xLTEtMTU0Njg_d404cffb-d46a-4b18-86b2-637ff670bfcb"
      unitRef="usd">2805000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMTMtMS0xLTEtMTU0Njg_05b96fe9-58e0-477b-97f8-519dfe162fa0"
      unitRef="usd">-6000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMTMtMy0xLTEtMTU0Njg_d4bfc969-56a6-43f6-9e9f-b85b47913f66"
      unitRef="usd">-6000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMTQtMS0xLTEtMTU0Njg_1b2e8be7-0ec9-46fa-ba78-a20ca6527e47"
      unitRef="usd">-2224000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMTQtMy0xLTEtMTU0Njg_9fb93ce4-f352-4994-adec-c92ba671c313"
      unitRef="usd">1991000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMTYtMS0xLTEtMTU0Njg_33973fb6-dfed-4459-a6e2-6c669f9ff14f"
      unitRef="usd">-1958000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMTYtMy0xLTEtMTU0Njg_e67e4041-667a-44f2-bea3-94e63b064e7b"
      unitRef="usd">2836000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <bdtx:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMTctMS0xLTEtMTU0Njg_0e918450-04c6-4646-aced-3fc188dec1f9"
      unitRef="usd">-687000</bdtx:IncreaseDecreaseInOperatingLeaseLiabilities>
    <bdtx:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMTctMy0xLTEtMTU0Njg_64a1a759-c72c-4065-9425-a3dddc0c0833"
      unitRef="usd">-335000</bdtx:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMTgtMS0xLTEtMTU0Njg_1fbb6ecd-0ea6-4d89-944c-0c418ed9252b"
      unitRef="usd">-28600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMTgtMy0xLTEtMTU0Njg_544cea47-c521-44c3-b5a9-9329a8ff8c67"
      unitRef="usd">-24455000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMjEtMS0xLTEtMTU0Njg_94c40f5f-f792-4c38-b1b5-533365a79fc7"
      unitRef="usd">7000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMjEtMy0xLTEtMTU0Njg_17b5ce72-3e6b-40ca-8995-93e9264e5381"
      unitRef="usd">40000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMjItMS0xLTEtMTU0Njg_8bd7d903-e5e2-4d38-a65c-010e0fdec318"
      unitRef="usd">37240000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMjItMy0xLTEtMTU0Njg_b0e8b203-4bfb-4e3e-8689-6fc59c51e442"
      unitRef="usd">45040000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMjMtMS0xLTEtMTU0Njg_24e29372-9cdb-4d5f-bf1a-549e452d6817"
      unitRef="usd">20504000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMjMtMy0xLTEtMTU0Njg_2ac2d27a-9468-4c8d-9aef-c0ccb1a300bb"
      unitRef="usd">41526000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMjQtMS0xLTEtMTU0Njg_24b6ee73-185e-49c5-bd06-74a552ffe600"
      unitRef="usd">16729000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMjQtMy0xLTEtMTU0Njg_0e3e3e7f-6a97-43ad-b364-2b41d8736036"
      unitRef="usd">3474000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMjctMS0xLTEtMTU0Njg_15194a39-1f69-45b7-afd2-4194f3fdc0bf"
      unitRef="usd">153000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMjctMy0xLTEtMTU0Njg_5053af92-10be-424c-a610-6e70ff94d1c7"
      unitRef="usd">481000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMzAtMS0xLTEtMTU0Njg_b1606443-d4cf-4e55-bde5-f47db40da08f"
      unitRef="usd">153000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMzAtMy0xLTEtMTU0Njg_4e282c84-2393-4133-88ac-250a47df317b"
      unitRef="usd">481000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMzEtMS0xLTEtMTU0Njg_3f255857-9c13-4a0f-89b7-3d15debd7e2b"
      unitRef="usd">-11718000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMzEtMy0xLTEtMTU0Njg_bd847532-ae66-4861-954b-81eba83580d5"
      unitRef="usd">-20500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMzItMS0xLTEtMTU0Njg_6c841ae7-1f02-4cf2-b9f0-8bb8a9a2e269"
      unitRef="usd">67022000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3f7c42ccd5d04f12b8291c60dcbafea1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMzItMy0xLTEtMTU0Njg_9a10b7d6-4c69-4470-8344-7f4650c2a17c"
      unitRef="usd">35828000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMzMtMS0xLTEtMTU0Njg_6a1a0323-d031-4a91-a93e-8da841e72c6e"
      unitRef="usd">55304000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5c8a085e141b45ee84f490448563d1f1_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMzMtMy0xLTEtMTU0Njg_bd889f6c-c706-4154-a8e0-78d0f9100d6e"
      unitRef="usd">15328000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMzUtMS0xLTEtMTU0Njg_ddb27de9-da45-4b84-b3ac-5b04e8761d22"
      unitRef="usd">54081000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5c8a085e141b45ee84f490448563d1f1_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMzUtMy0xLTEtMTU0Njg_dce863b1-b408-4291-8508-72c323c4b0c8"
      unitRef="usd">14105000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMzYtMS0xLTEtMTU0Njg_dabca7f1-e557-42da-9134-a1f0f879b926"
      unitRef="usd">1223000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i5c8a085e141b45ee84f490448563d1f1_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMzYtMy0xLTEtMTU0Njg_ebe6aa41-ebff-4c55-a258-a1771ab1ab40"
      unitRef="usd">1223000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMzctMS0xLTEtMTU0Njg_a1df4f6b-56bc-42fe-a604-45b7ab43c210"
      unitRef="usd">55304000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5c8a085e141b45ee84f490448563d1f1_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfMzctMy0xLTEtMTU0Njg_3ebe5009-9c91-43f2-b658-989eedcee927"
      unitRef="usd">15328000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfNDAtMS0xLTEtMTU0Njg_cf1625e8-a34d-4a9c-81da-c43db2fa9a9d"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfNDAtMy0xLTEtMTU0Njg_ddb36799-18f9-4b53-9dc0-b05c2f61e62e"
      unitRef="usd">385000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfNDMtMS0xLTEtMTU0Njg_7ef48664-9f8f-4b16-80cd-41b5ee630ab0"
      unitRef="usd">115000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yMi9mcmFnOmQyYmZkMWNhMDE3NjQxNmI5ZGI2ZGRlNDkzMmJmZjFkL3RhYmxlOjQ5N2MwODEzMTY0NzQ3MTNhNGJiNzRlMTMwYjBiOGNmL3RhYmxlcmFuZ2U6NDk3YzA4MTMxNjQ3NDcxM2E0YmI3NGUxMzBiMGI4Y2ZfNDMtMy0xLTEtMTU0Njg_f128dca7-f394-455e-a1b5-2841b52a4569"
      unitRef="usd">5717000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9079e499652941b491fb8e9ed7ce1958_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMy0xLTEtMS0xNTQ2OA_627e2682-4061-47a6-bbf1-8e4b3e6b5ae4"
      unitRef="shares">36078383</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9079e499652941b491fb8e9ed7ce1958_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMy0zLTEtMS0xNTQ2OA_b4d84063-5d62-43be-810b-bcec3865106b"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i12c39deff1194b6c92a7c1abee14df8a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMy01LTEtMS0xNTQ2OA_18f6a568-a6d4-4c5f-95cb-2aba10f81666"
      unitRef="usd">425363000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0888b6dac5434cacbd33596c1adace82_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMy03LTEtMS0xNTQ2OA_022c4abc-ca31-455c-98d3-3ed1ce882a62"
      unitRef="usd">614000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibffb8b6ab6ec42548e3a66555c649c15_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMy05LTEtMS0xNTQ2OA_f1b36998-aa8b-4b31-9632-0f81a97a6b30"
      unitRef="usd">-118224000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3f7c42ccd5d04f12b8291c60dcbafea1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMy0xMS0xLTEtMTU0Njg_07fe9177-de32-4ce3-b8d3-519277b0debf"
      unitRef="usd">307758000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ida279286734543b991ef4eed0ef6046e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfNC0xLTEtMS0xNTQ2OA_e6e5a227-91ed-40e7-8b0f-dbd8c3eb25c3"
      unitRef="shares">62607</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5c596ceb5049485884e7b2a68aa5916c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfNC01LTEtMS0xNTQ2OA_39c8848d-c280-4006-a123-bb78d94c35c2"
      unitRef="usd">481000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfNC0xMS0xLTEtMTU0Njg_aa030c79-41d6-4a21-b643-a41c68d94b83"
      unitRef="usd">481000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ida279286734543b991ef4eed0ef6046e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfNS0xLTEtMS0xNTQ2OA_25dde64f-e53d-4e31-9808-6ac30b693d2b"
      unitRef="shares">4998</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ida279286734543b991ef4eed0ef6046e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfNi0xLTEtMS0xNTQ2OA_cfd4018a-1a34-4532-b4aa-4f107a602879"
      unitRef="shares">1224</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5c596ceb5049485884e7b2a68aa5916c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfNi01LTEtMS0xNTQ2OA_8aa58560-20c4-450d-bb24-66c399ff98c6"
      unitRef="usd">3094000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfNi0xMS0xLTEtMTU0Njg_e24ae0e2-a668-41ef-a28e-754ff8df43f8"
      unitRef="usd">3094000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i3a11083af40b47cfa476274d297e6503_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfNy03LTEtMS0xNTQ2OA_a662122f-d4f7-41b6-915b-c4ecdd2d6af6"
      unitRef="usd">-279000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfNy0xMS0xLTEtMTU0Njg_db921bd2-05cb-48f3-af44-7cb0ef0ae10b"
      unitRef="usd">-279000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="iaede1a9af65846df94f23afe6ee659b3_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfOC05LTEtMS0xNTQ2OA_236ac9c2-df78-4e55-a4d5-a3e58e171818"
      unitRef="usd">-30301000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfOC0xMS0xLTEtMTU0Njg_ac7cf7cb-c1b0-4d36-bfb9-1e6b8928299c"
      unitRef="usd">-30301000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i24cb741f3e52499f82800136848ddbcf_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfOS0xLTEtMS0xNTQ2OA_920986d4-911b-48d1-a13f-c8e430f66707"
      unitRef="shares">36147212</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i24cb741f3e52499f82800136848ddbcf_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfOS0zLTEtMS0xNTQ2OA_a40d031a-6b00-4dfa-9618-0de3f40ff6d2"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i67ed168c54f645c2b002a94645f0df0a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfOS01LTEtMS0xNTQ2OA_07b85f0c-7d24-4095-ac84-a8783fa1ffec"
      unitRef="usd">428938000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idaf43c36cb8d458fa8fcfb47211264db_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfOS03LTEtMS0xNTQ2OA_79aeeacc-39b1-4435-8ba6-d0732c8c22f1"
      unitRef="usd">335000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if6d7e79d27124e3bb23e6b0101055ce0_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfOS05LTEtMS0xNTQ2OA_6fb86528-7f37-4cb4-bc95-f713dd15e53c"
      unitRef="usd">-148525000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5c8a085e141b45ee84f490448563d1f1_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfOS0xMS0xLTEtMTU0Njg_8ddd068a-44c8-4bce-a004-a4a847a1f67c"
      unitRef="usd">280753000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic3c688356e134568b5de6825391deaf1_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjMtMS0xLTEtMTU0Njg_d0bbe45a-dfdd-4d64-8a4f-987da72f7e83"
      unitRef="shares">36234624</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic3c688356e134568b5de6825391deaf1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjMtMy0xLTEtMTU0Njg_b29e58c1-acda-44c4-a1c5-f11bfbb6a50b"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0fdd5c7e07db40b08c5a1dcde0c1ffd2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjMtNS0xLTEtMTU0Njg_7ef86c73-fd78-49a8-af48-8123bffc4232"
      unitRef="usd">440129000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1ca47029fd60490abe151e708b67878e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjMtNy0xLTEtMTU0Njg_afbdfe93-f371-43c7-a012-6d07a559df99"
      unitRef="usd">-414000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i691561fefea149049b9e700257b2dd11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjMtOS0xLTEtMTU0Njg_5058c661-a157-488b-bdc6-26c467a56f1b"
      unitRef="usd">-243820000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjMtMTEtMS0xLTE1NDY4_ddc8fea3-5141-465e-a799-5860455dc17b"
      unitRef="usd">195900000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i534d154d73254bb5a34550cf1b283ddb_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjQtMS0xLTEtMTU0Njg_f74b3c58-0058-4094-91ea-29a9c7968ad2"
      unitRef="shares">3565</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="idc707991eeb0410f91d59567f375b8b4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjQtNS0xLTEtMTU0Njg_410702f1-7c43-4eca-b357-ce3e9a5f3b3e"
      unitRef="usd">11000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjQtMTEtMS0xLTE1NDY4_5a85fcc6-d52e-4c57-838e-7b2f06f63438"
      unitRef="usd">11000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i534d154d73254bb5a34550cf1b283ddb_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjUtMS0xLTEtMTU0Njg_6f54787f-8c83-47e2-ab1c-b1c3fd3a1f91"
      unitRef="shares">5000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i534d154d73254bb5a34550cf1b283ddb_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjktMS0xLTEtMTU3ODU_486a314c-3bef-42e0-99d0-72ed3c3af97a"
      unitRef="shares">31341</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="idc707991eeb0410f91d59567f375b8b4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjktNS0xLTEtMTU3ODU_70e22599-bc99-47d0-861e-a0bf372c8608"
      unitRef="usd">142000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjktMTEtMS0xLTE1Nzg1_25466986-55dc-4217-8ee2-bad5f4516b86"
      unitRef="usd">142000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i534d154d73254bb5a34550cf1b283ddb_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjYtMS0xLTEtMTU0Njg_04a07df4-e2d1-49c8-8187-9bc38927f606"
      unitRef="shares">13038</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idc707991eeb0410f91d59567f375b8b4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjYtNS0xLTEtMTU0Njg_7aa8a198-dacf-4427-a460-819591872a39"
      unitRef="usd">3375000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjYtMTEtMS0xLTE1NDY4_1ff188bf-2797-4314-a264-505d1ce4d22c"
      unitRef="usd">3375000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="ib55e7da72d944e7b8a9e91f5cb12ecdf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjctNy0xLTEtMTU0Njg_96d9cb57-a7be-4e5c-8e71-47520b539b3b"
      unitRef="usd">-1361000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjctMTEtMS0xLTE1NDY4_d3366e12-f252-41ba-8be3-620bfe9e8eee"
      unitRef="usd">-1361000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ibcc979a9141648ffb26ccb55a5e51ebc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjgtOS0xLTEtMTU0Njg_6c21aeb4-3098-4aee-a748-26a25da4f113"
      unitRef="usd">-25507000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjgtMTEtMS0xLTE1NDY4_9e1c6177-2126-4756-bd9c-8a53ba056ac3"
      unitRef="usd">-25507000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iddf6f9051d0a4be3a16017e93ce7ab16_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjktMS0xLTEtMTU0Njg_4cff16f4-dc84-46d3-b8f2-223c79f8bcfc"
      unitRef="shares">36287568</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iddf6f9051d0a4be3a16017e93ce7ab16_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjktMy0xLTEtMTU0Njg_7f20a540-93b8-40d1-a664-68f10d6faca9"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1326edc9009d45a49158855eb54f6574_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjktNS0xLTEtMTU0Njg_283cba56-96fb-465d-b41b-5fdf1e88378b"
      unitRef="usd">443657000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i19221d9ccdb34fd994d9ee776e4585b5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjktNy0xLTEtMTU0Njg_42f2fabe-27ea-48ef-9108-96728205a35a"
      unitRef="usd">-1775000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id201833d4a114834a06d053bfa018915_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjktOS0xLTEtMTU0Njg_71088426-0f19-415b-b9b8-94ecd7cf483b"
      unitRef="usd">-269327000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18yNS9mcmFnOjQ1MzIxYTk0YjI2ZTQ0NDJhZDkzOTNhOWQxNTY2YmUwL3RhYmxlOjAyMGViMTNmNzRjNzRhMWRiYThmZGUzYmQ0NGI2MGE4L3RhYmxlcmFuZ2U6MDIwZWIxM2Y3NGM3NGExZGJhOGZkZTNiZDQ0YjYwYThfMjktMTEtMS0xLTE1NDY4_d00c15ca-0364-44a3-a7be-5ee41e3acd11"
      unitRef="usd">172560000</us-gaap:StockholdersEquity>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zMS9mcmFnOmM1MWM0NWFhMDNmYzRiMjJiMDMxYzgxMzFlMDEzOGE0L3RleHRyZWdpb246YzUxYzQ1YWEwM2ZjNGIyMmIwMzFjODEzMWUwMTM4YTRfODkxMw_4aec33d3-9d4c-4fa3-b1d6-41ad7b45f2c5">NATURE OF BUSINESS AND BASIS OF PRESENTATION&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Black Diamond Therapeutics, Inc. (the &#x201c;Company&#x201d;) is a precision oncology medicine company pioneering the discovery and development of MasterKey therapies. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing, and incurring research and development costs related to the development of its mutation, allostery, and pharmacology computational and drug discovery engine. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry. There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;On February 1, 2021, the Company filed a shelf registration statement on Form S-3 ASR (the &#x201c;Shelf&#x201d;), with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;), which covers the offering, issuance and sale of the Company&#x2019;s common stock, preferred stock, debt securities, warrants and/or units of any combination thereof. The Company simultaneously entered into an Open Market Sale Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; with Jefferies LLC, as sales agent, to provide for the issuance and sale by the Company of up to $150 million of its common stock from time to time through Jefferies as its sales agent (the &#x201c;ATM Program&#x201d;). The Shelf became automatically effective upon filing on February 1, 2021. As of March&#160;31, 2022, no sales have been made pursuant to the ATM Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. Historically, the Company has funded its operations primarily with proceeds from the sale of preferred and common stock. The Company expects to continue to generate operating losses for the foreseeable future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;As of May&#160;11, 2022, the issuance date of the condensed consolidated financial statements, the Company expects that its cash, cash equivalents and investments will be sufficient to fund its currently planned operations for at least the next 12 months from the filing date of these unaudited interim condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company may seek additional funding through private or public equity financings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The ongoing COVID-19 pandemic is evolving, and to date has led to the implementation of various responses, including government-imposed quarantines, travel restrictions, and other public health safety measures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company has been closely monitoring the impact of the ongoing COVID-19 pandemic on all aspects of the Company&#x2019;s business, including how it has impacted and may continue to impact the Company&#x2019;s operations and the operations of its suppliers, vendors and business partners, and may take further precautionary and preemptive actions as may be required by federal, state or local authorities. In addition, the Company has taken steps to minimize the current environment&#x2019;s impact on its business and strategy, including devising contingency plans and securing additional resources from third party service providers. Furthermore, for the safety of the Company&#x2019;s employees and families, the Company has introduced enhanced safety measures for scientists to be present in its labs and increased the use of third party service providers for the conduct of certain experiments and studies for research programs. Certain of the Company&#x2019;s third party service providers have also experienced shutdowns or other business disruptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The extent to which COVID-19 ultimately impacts the Company&#x2019;s business, results of operations or financial condition will depend on future developments, which, despite progress in vaccination efforts, remain highly uncertain and cannot be predicted with confidence, such as the duration of the COVID-19 pandemic, new strains of the virus, including any future variants that may emerge, which may impact rates of infection and vaccination efforts, developments or perceptions regarding the safety of vaccines, new information that may emerge concerning the severity of COVID-19, and any additional preventative and protective actions taken to contain the pandemic or treat its impact, among others. The Company does not yet know the full extent of potential delays or impacts on the Company&#x2019;s business, clinical trials, research programs, healthcare systems or the global economy and cannot presently predict the scope and severity of any potential business shutdowns or disruptions but if we or any of the third parties with whom we engage were to experience prolonged business shutdowns or other disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on our business, results of operations and financial condition. The estimates of the impact on our business may change based on new information that may emerge concerning COVID-19 and the actions to contain it or treat its impact and the economic impact on local, regional, national and international markets.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zMS9mcmFnOmM1MWM0NWFhMDNmYzRiMjJiMDMxYzgxMzFlMDEzOGE0L3RleHRyZWdpb246YzUxYzQ1YWEwM2ZjNGIyMmIwMzFjODEzMWUwMTM4YTRfODkxNA_2818e8e4-0905-46c3-b69d-cc8df870a80a">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Black Diamond Therapeutics, Inc. (the &#x201c;Company&#x201d;) is a precision oncology medicine company pioneering the discovery and development of MasterKey therapies. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing, and incurring research and development costs related to the development of its mutation, allostery, and pharmacology computational and drug discovery engine. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry. There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of consolidation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited interim financial information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company&#x2019;s Annual Report. In the opinion of the Company&#x2019;s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i377d263c6d38493ca25e90aa73fd3701_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zMS9mcmFnOmM1MWM0NWFhMDNmYzRiMjJiMDMxYzgxMzFlMDEzOGE0L3RleHRyZWdpb246YzUxYzQ1YWEwM2ZjNGIyMmIwMzFjODEzMWUwMTM4YTRfMzQwNg_d1127bec-bdf1-4b7d-b22b-141c4ae8a010"
      unitRef="usd">150000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNC9mcmFnOjEzODYyYzc5NmEyZjQxODI4NThhMDZmYTFkNGZkNzhiL3RleHRyZWdpb246MTM4NjJjNzk2YTJmNDE4Mjg1OGEwNmZhMWQ0ZmQ3OGJfNjgwMw_70808e93-90a6-42e3-8445-dc76e324a881">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The following is a summary of significant accounting policies followed in the preparation of these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of consolidation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited interim financial information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company&#x2019;s Annual Report. In the opinion of the Company&#x2019;s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The preparation of the Company&#x2019;s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The full extent to which the ongoing COVID-19 pandemic will directly or indirectly impact the Company&#x2019;s business, results of operations and financial condition, including expenses, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered the impact of COVID-19 on estimates within its financial statements and there may be changes to those estimates in future periods. As of the date of issuance of these consolidated financial statements, the Company has not experienced material business disruptions or incurred impairment losses in the carrying value of its assets as a result of the pandemic and is not aware of any specific related event or circumstance that would require it to update its estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently issued accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company believes that no recently issued accounting standards will have a material impact on its consolidated financial statements, or apply to its operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNC9mcmFnOjEzODYyYzc5NmEyZjQxODI4NThhMDZmYTFkNGZkNzhiL3RleHRyZWdpb246MTM4NjJjNzk2YTJmNDE4Mjg1OGEwNmZhMWQ0ZmQ3OGJfNjgwNw_3b9e21e5-2ac5-4e5e-8a65-781a1acd44d4">Principles of consolidation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNC9mcmFnOjEzODYyYzc5NmEyZjQxODI4NThhMDZmYTFkNGZkNzhiL3RleHRyZWdpb246MTM4NjJjNzk2YTJmNDE4Mjg1OGEwNmZhMWQ0ZmQ3OGJfNjgwNQ_7c10910a-7703-43c9-b157-e9784be3855c">Use of estimates The preparation of the Company&#x2019;s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNC9mcmFnOjEzODYyYzc5NmEyZjQxODI4NThhMDZmYTFkNGZkNzhiL3RleHRyZWdpb246MTM4NjJjNzk2YTJmNDE4Mjg1OGEwNmZhMWQ0ZmQ3OGJfMjc0ODc3OTA4NTQ5Ng_11f67497-b9af-49e1-b5a1-ba311a3dc1fe">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently issued accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company believes that no recently issued accounting standards will have a material impact on its consolidated financial statements, or apply to its operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RleHRyZWdpb246YzcxMTc0ZWE1NTMxNDgxM2I4NDA3Zjc2MzY1ZDkzNGZfMTIwMQ_e23f73b3-5aa0-48d0-8040-7dd0dc5c5ff5">FAIR VALUE MEASUREMENTS&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Fair value measurements at March 31, 2022 using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;52,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;52,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;20,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;20,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;65,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;65,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;U.S. Government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;39,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;39,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;52,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;125,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;177,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Fair value measurements at December 31, 2021 using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;63,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;63,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;104,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;104,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;U.S. Government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;39,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;39,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;63,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;143,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;207,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;When developing fair value estimates, the Company maximizes the use of observable inputs and minimizes the use of unobservable inputs. When available, the Company uses quoted market prices to measure fair value. The valuation technique used to measure fair value for the Company's Level 1 and Level 2 assets is a market approach, using prices and other relevant information generated by market transactions involving identical or comparable assets. If market prices are not available, the fair value measurement is based on models that use primarily market-based parameters including yield curves, volatilities, credit ratings and currency rates. In certain cases where market rate assumptions are not available, the Company is required to make judgments about assumptions market participants would use to estimate the fair value of a financial instrument. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;There were no transfers in or out of Level 3 categories in the periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RleHRyZWdpb246YzcxMTc0ZWE1NTMxNDgxM2I4NDA3Zjc2MzY1ZDkzNGZfMTIwMg_4f19b1f6-3aa9-4b82-a3f9-d8bbabe853d5">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Fair value measurements at March 31, 2022 using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;52,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;52,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;20,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;20,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;65,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;65,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;U.S. Government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;39,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;39,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;52,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;125,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;177,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Fair value measurements at December 31, 2021 using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;63,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;63,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;104,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;104,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;U.S. Government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;39,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;39,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;63,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;143,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;207,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic7586d8f4b304a96a89edaf4e92faa9f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfNC0xLTEtMS0xNTQ2OA_238f7be6-563b-48a2-a792-a727c5c60b0f"
      unitRef="usd">52003000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i962aa1bfb86e483894de2bb2442985bc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfNC0zLTEtMS0xNTQ2OA_654845b7-b729-4578-9a13-160bcfc8cfc4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8d10b8beeaca440785de2cdb3d8eaf14_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfNC01LTEtMS0xNTQ2OA_d5c2baf8-5173-4b4f-ab64-d4ebca7405e7"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i42a51dbd5f584d6aa6a0cb3330f1fe5c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfNC03LTEtMS0xNTQ2OA_eb025307-7050-4dff-8da9-042b5ca96f29"
      unitRef="usd">52003000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="icadf51cb52294253943e014823f06afb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfNi0xLTEtMS0xNTQ2OA_a4a96283-db17-49fa-bf07-141e7af82a79"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i62ae75982324469693df81b6e1fc8c23_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfNi0zLTEtMS0xNTQ2OA_8fbb1faa-fff3-4b6e-b47c-0509f6be78de"
      unitRef="usd">20501000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i460915c867d24b099b0bf69feb2da59a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfNi01LTEtMS0xNTQ2OA_91f386f3-09f0-4776-bb35-f875871d7bee"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ibc6ba9d6b5064ee7aec84d28bbd1751d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfNi03LTEtMS0xNTQ2OA_6e73652c-cea6-4efd-b2d1-65a247b0294a"
      unitRef="usd">20501000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i34580173a0a9454eb268a5b3ec8b34eb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfNy0xLTEtMS0xNTQ2OA_e0328e1c-93aa-442c-bc6b-36ab20fdfa20"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i64edc7a1a2174b968d823d315842481f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfNy0zLTEtMS0xNTQ2OA_1c96709c-a871-4a60-badd-fd2b9861680e"
      unitRef="usd">65885000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i900b221b23fd4104a7f93150e16b1981_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfNy01LTEtMS0xNTQ2OA_a10e2651-188e-488b-86ce-5811b21a5cab"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i3ba3f44f3b104a51b92654a9c905ece2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfNy03LTEtMS0xNTQ2OA_1910ed5b-d129-4b60-b7c9-cc53e380e540"
      unitRef="usd">65885000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i83fb07b4cc0046609fb9c5c6324001ef_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfOC0xLTEtMS0xNTQ2OA_64b764d5-3bdc-4f95-a2a7-e9a81f7a707f"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i1cde33f4aa9549d797693a4f207e3ba3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfOC0zLTEtMS0xNTQ2OA_cba38f05-dbaf-4545-af81-17c2e205593a"
      unitRef="usd">39272000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i2cb17e460b95429b88a840c5224dd92a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfOC01LTEtMS0xNTQ2OA_b694d8d1-5f3f-4b53-bf17-cf8f301a95dc"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i29ce9fe315284e5abf314fcd5ed28b78_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfOC03LTEtMS0xNTQ2OA_163436cc-01ad-4aeb-9863-e27f3a1e3dd3"
      unitRef="usd">39272000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8fa4d5d4ec21402bb7f85adb8fb71d6a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfOS0xLTEtMS0xNTQ2OA_9cdff07d-7f3d-44a4-9e82-6f262b653509"
      unitRef="usd">52003000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id0e121bb40fd49258c14401a29e70859_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfOS0zLTEtMS0xNTQ2OA_b876d000-1380-4367-835c-df83409c3fe5"
      unitRef="usd">125658000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie054d218517947ee8d0e864d31140ce8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfOS01LTEtMS0xNTQ2OA_4062d8f7-469f-4aaa-a513-20818e6164ec"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i76fdf0838e4546cd851611fb3634158c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOjJkMDJhMmU4M2NhZjQyMzRiODRjMzMzMDEzMzgwMzYxL3RhYmxlcmFuZ2U6MmQwMmEyZTgzY2FmNDIzNGI4NGMzMzMwMTMzODAzNjFfOS03LTEtMS0xNTQ2OA_51c39fd7-6d0e-4557-a8e6-1bc66f9ef9d5"
      unitRef="usd">177661000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i62c67ae3c8ed44d39ed202dc3a02814d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfNC0xLTEtMS0xNTQ2OA_9cf440f7-8e09-4e0b-a489-b49b23c38a7e"
      unitRef="usd">63730000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic6469b9255c64b428aceb5e576c835e6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfNC0zLTEtMS0xNTQ2OA_f69b462c-29d0-4064-9a10-55a4573229cd"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i21a15014f6814669b4a982787c14c8ed_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfNC01LTEtMS0xNTQ2OA_e62b6112-c4b5-4870-a5ba-64a35f569ca2"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id6ef99d5dd434984929935c0f6dd1e3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfNC03LTEtMS0xNTQ2OA_fb21d03e-676d-44b5-8162-008b31db40bb"
      unitRef="usd">63730000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ib6472a833e63467aa7a16b853fed7648_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfNy0xLTEtMS0xNTQ2OA_44970fb9-7449-4625-823f-8fc0e8871550"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i421912da66f44fe09b19b8944d07a70d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfNy0zLTEtMS0xNTQ2OA_0e53ec4f-741a-4052-b1de-895e90d245d2"
      unitRef="usd">104066000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i9bf4c7e984404a6f86e23661b62cf071_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfNy01LTEtMS0xNTQ2OA_7db3bf09-83c4-4fe9-928b-c3eaf9f5a000"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ifd344bc37522487781fced407afc94fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfNy03LTEtMS0xNTQ2OA_9a83ae59-7823-41be-9be7-dbf21f715b36"
      unitRef="usd">104066000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i6c3b0ba2c8154adaaceee5c961ea1e9e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfOC0xLTEtMS0xNTQ2OA_3c8c31cc-2c27-4e19-bc7e-5c5d77a27591"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i7e34a2b0b44e4081b6b378a6828ca51b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfOC0zLTEtMS0xNTQ2OA_0de7df77-588e-43c7-8bb9-8c26c6caddde"
      unitRef="usd">39921000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i15df054aa48340d4a776ceb4901608d1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfOC01LTEtMS0xNTQ2OA_ce7d2fb1-1fe8-4f21-b58b-d90ed2421b9e"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i68881d5b14084f3c8c973338e687dea2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfOC03LTEtMS0xNTQ2OA_32bd507a-6948-49fe-9c97-e3d358323568"
      unitRef="usd">39921000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i131b634efed14bc78fcdf71e68e8a71e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfOS0xLTEtMS0xNTQ2OA_25476f48-0a10-44b3-97fe-218491959abc"
      unitRef="usd">63730000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9d2f217ac6a64e4788118680cfa194b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfOS0zLTEtMS0xNTQ2OA_552615ea-fa56-4ed2-9b3e-adac135352c9"
      unitRef="usd">143987000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i21ff474829e8485d8a14024ec03a39f1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfOS01LTEtMS0xNTQ2OA_280af784-efbd-45d5-9dc3-7d2302947181"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4941a960ea32475eb80b88d7de07c5ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN18zNy9mcmFnOmM3MTE3NGVhNTUzMTQ4MTNiODQwN2Y3NjM2NWQ5MzRmL3RhYmxlOmRjMjVkNDAyODhiOTRjMDNhZjA0NjYwOGQxNWY1ODZiL3RhYmxlcmFuZ2U6ZGMyNWQ0MDI4OGI5NGMwM2FmMDQ2NjA4ZDE1ZjU4NmJfOS03LTEtMS0xNTQ2OA_fa6922d3-f905-4591-afca-d2addd409943"
      unitRef="usd">207717000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RleHRyZWdpb246OTBlZGMxZGIyYTc0NDA4MDllNTE1YjRjMjRjZGU2NjlfNDYy_9ef9f0a3-a3d8-4b70-be0d-eebffe106b41">INVESTMENTS&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, investments were comprised of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;20,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;20,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;66,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(903)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;65,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;U.S. Government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;40,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(864)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;39,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;127,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(1,781)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;125,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, investments were comprised of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;104,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;104,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;U.S. Government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;40,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;39,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;144,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;143,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for U.S. government agencies, corporate bonds and commercial paper with a fair value of $65,238 that had maturities of one to three years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for  U.S. government agencies and corporate bonds with a fair value of $86,187 that had maturities of one to three years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the marketable securities in a loss position had a maturity of less than one year, except for U.S. government agencies, corporate bonds and commercial paper with a fair value of $65,238, that had maturities of one to three years. As of December&#160;31, 2021, the marketable securities in a loss position had a maturity of less than one year, except for U.S. government agencies and corporate bonds, with a fair value of $86,187, that had maturities of one to three years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the Company reviewed its investment portfolio to assess whether the unrealized losses on its available-for-sale investments were temporary. In determining whether the decline in fair value of these securities was temporary, the Company evaluated whether it intended to sell the security and whether it was more likely than not that the Company would be required to sell the security before recovering its amortized cost basis. There have been no impairments of the Company&#x2019;s assets measured and carried at fair value during the three months ended March&#160;31, 2022 and the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RleHRyZWdpb246OTBlZGMxZGIyYTc0NDA4MDllNTE1YjRjMjRjZGU2NjlfNDY0_48b1e06f-a437-4980-8b21-4fa961494b09">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, investments were comprised of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;20,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;20,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;66,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(903)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;65,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;U.S. Government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;40,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(864)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;39,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;127,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(1,781)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;125,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, investments were comprised of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;104,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;104,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;U.S. Government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;40,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;39,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;144,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;143,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib85e10885b3a4e9b8fb2f090569d6271_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfMS0xLTEtMS0xNTQ2OA_bb1489e3-4771-4a7f-88f1-7af9b76b29d8"
      unitRef="usd">20515000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib85e10885b3a4e9b8fb2f090569d6271_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfMS0zLTEtMS0xNTQ2OA_aca88031-40a6-40e5-9707-aa4eef80afc9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib85e10885b3a4e9b8fb2f090569d6271_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfMS01LTEtMS0xNTQ2OA_e19fcd95-fa0d-4533-bb4c-d8aabf4f3b6c"
      unitRef="usd">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib85e10885b3a4e9b8fb2f090569d6271_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfMS03LTEtMS0xNTQ2OA_9fa07776-994b-419d-b0d1-ce531d37ddf0"
      unitRef="usd">20501000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic8310139017c4117a15d446bef048a12_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfMi0xLTEtMS0xNTQ2OA_62353423-db14-46aa-8f52-75e4ac25af47"
      unitRef="usd">66782000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic8310139017c4117a15d446bef048a12_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfMi0zLTEtMS0xNTQ2OA_22a1e34b-3bcc-4b2e-b9cb-10f00dd38518"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic8310139017c4117a15d446bef048a12_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfMi01LTEtMS0xNTQ2OA_c2de8a6c-2706-4ce9-8a66-a542d8e48922"
      unitRef="usd">903000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic8310139017c4117a15d446bef048a12_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfMi03LTEtMS0xNTQ2OA_62f71680-dd98-410f-8e34-21b44c14f3f0"
      unitRef="usd">65885000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icd98783dea56424ba1c71b4e834b425a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfMy0xLTEtMS0xNTQ2OA_88d5a54d-c8f0-4148-82c7-3259cb9d0a24"
      unitRef="usd">40136000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icd98783dea56424ba1c71b4e834b425a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfMy0zLTEtMS0xNTQ2OA_ed66b528-006b-487b-8fd7-cb150089aa74"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icd98783dea56424ba1c71b4e834b425a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfMy01LTEtMS0xNTQ2OA_9f2ade40-3cb5-419f-ba78-0cab9ba4f236"
      unitRef="usd">864000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icd98783dea56424ba1c71b4e834b425a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfMy03LTEtMS0xNTQ2OA_7545d64f-a457-44cb-ab4d-ade386c4d1ed"
      unitRef="usd">39272000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfNC0xLTEtMS0xNTQ2OA_d3f1567a-58e7-47cb-a83e-5f98fa22904d"
      unitRef="usd">127433000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfNC0zLTEtMS0xNTQ2OA_a870be99-bfca-4ce6-a9cf-01172efdb567"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfNC01LTEtMS0xNTQ2OA_58c029ac-c305-47b5-9c72-434754d7a8e1"
      unitRef="usd">1781000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOmM3N2Y5MDZmOGIxYTRhMzU4YTY5NjQ2N2M5ZDU2Mjc5L3RhYmxlcmFuZ2U6Yzc3ZjkwNmY4YjFhNGEzNThhNjk2NDY3YzlkNTYyNzlfNC03LTEtMS0xNTQ2OA_52f03255-5b72-4859-a1cd-13330711d49d"
      unitRef="usd">125658000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6c17159b04ab4338b714552e7330de6e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOjNlMWE4NzIyMzY0MDQ3N2Q5Y2Y1MDkwZDY0ZmU3NTJlL3RhYmxlcmFuZ2U6M2UxYTg3MjIzNjQwNDc3ZDljZjUwOTBkNjRmZTc1MmVfMi0xLTEtMS0xNTQ2OA_1b9b0528-0207-4183-9160-7fe8ea9ae621"
      unitRef="usd">104261000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6c17159b04ab4338b714552e7330de6e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOjNlMWE4NzIyMzY0MDQ3N2Q5Y2Y1MDkwZDY0ZmU3NTJlL3RhYmxlcmFuZ2U6M2UxYTg3MjIzNjQwNDc3ZDljZjUwOTBkNjRmZTc1MmVfMi0zLTEtMS0xNTQ2OA_5ffda916-c9f3-4799-8712-f1283abcd51e"
      unitRef="usd">47000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6c17159b04ab4338b714552e7330de6e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOjNlMWE4NzIyMzY0MDQ3N2Q5Y2Y1MDkwZDY0ZmU3NTJlL3RhYmxlcmFuZ2U6M2UxYTg3MjIzNjQwNDc3ZDljZjUwOTBkNjRmZTc1MmVfMi01LTEtMS0xNTQ2OA_390e0795-e410-4049-a258-de60fc0edd9b"
      unitRef="usd">242000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6c17159b04ab4338b714552e7330de6e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOjNlMWE4NzIyMzY0MDQ3N2Q5Y2Y1MDkwZDY0ZmU3NTJlL3RhYmxlcmFuZ2U6M2UxYTg3MjIzNjQwNDc3ZDljZjUwOTBkNjRmZTc1MmVfMi03LTEtMS0xNTQ2OA_a7c1fb47-c5a2-4c64-b441-95f85cef6df7"
      unitRef="usd">104066000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib197786787854aa08e044a89989c79be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOjNlMWE4NzIyMzY0MDQ3N2Q5Y2Y1MDkwZDY0ZmU3NTJlL3RhYmxlcmFuZ2U6M2UxYTg3MjIzNjQwNDc3ZDljZjUwOTBkNjRmZTc1MmVfMy0xLTEtMS0xNTQ2OA_778b4bfc-5b61-442b-ab30-33f0e74c38f8"
      unitRef="usd">40140000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib197786787854aa08e044a89989c79be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOjNlMWE4NzIyMzY0MDQ3N2Q5Y2Y1MDkwZDY0ZmU3NTJlL3RhYmxlcmFuZ2U6M2UxYTg3MjIzNjQwNDc3ZDljZjUwOTBkNjRmZTc1MmVfMy0zLTEtMS0xNTQ2OA_e9621f6a-3956-42f2-850c-453cd451459e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib197786787854aa08e044a89989c79be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOjNlMWE4NzIyMzY0MDQ3N2Q5Y2Y1MDkwZDY0ZmU3NTJlL3RhYmxlcmFuZ2U6M2UxYTg3MjIzNjQwNDc3ZDljZjUwOTBkNjRmZTc1MmVfMy01LTEtMS0xNTQ2OA_f7661611-6a4b-4d3b-8b43-a25513b079e4"
      unitRef="usd">219000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib197786787854aa08e044a89989c79be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOjNlMWE4NzIyMzY0MDQ3N2Q5Y2Y1MDkwZDY0ZmU3NTJlL3RhYmxlcmFuZ2U6M2UxYTg3MjIzNjQwNDc3ZDljZjUwOTBkNjRmZTc1MmVfMy03LTEtMS0xNTQ2OA_d596c2e9-0f22-404a-8221-65ef074abaed"
      unitRef="usd">39921000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOjNlMWE4NzIyMzY0MDQ3N2Q5Y2Y1MDkwZDY0ZmU3NTJlL3RhYmxlcmFuZ2U6M2UxYTg3MjIzNjQwNDc3ZDljZjUwOTBkNjRmZTc1MmVfNC0xLTEtMS0xNTQ2OA_1175dcdb-7871-4371-88b2-e1de70a9a919"
      unitRef="usd">144401000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOjNlMWE4NzIyMzY0MDQ3N2Q5Y2Y1MDkwZDY0ZmU3NTJlL3RhYmxlcmFuZ2U6M2UxYTg3MjIzNjQwNDc3ZDljZjUwOTBkNjRmZTc1MmVfNC0zLTEtMS0xNTQ2OA_2660dd29-178d-47a5-959f-8ee286f4eb59"
      unitRef="usd">47000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOjNlMWE4NzIyMzY0MDQ3N2Q5Y2Y1MDkwZDY0ZmU3NTJlL3RhYmxlcmFuZ2U6M2UxYTg3MjIzNjQwNDc3ZDljZjUwOTBkNjRmZTc1MmVfNC01LTEtMS0xNTQ2OA_8c0eb649-8e32-49fd-9091-3ba190f6074e"
      unitRef="usd">461000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RhYmxlOjNlMWE4NzIyMzY0MDQ3N2Q5Y2Y1MDkwZDY0ZmU3NTJlL3RhYmxlcmFuZ2U6M2UxYTg3MjIzNjQwNDc3ZDljZjUwOTBkNjRmZTc1MmVfNC03LTEtMS0xNTQ2OA_abdaf1fa-47a4-4aee-9b42-e878f41a1ab9"
      unitRef="usd">143987000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <bdtx:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RleHRyZWdpb246OTBlZGMxZGIyYTc0NDA4MDllNTE1YjRjMjRjZGU2NjlfMTA5OTUxMTYzNjQwNQ_587baee2-e16b-4af0-b569-32156e49355f"
      unitRef="usd">65238000</bdtx:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree>
    <bdtx:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RleHRyZWdpb246OTBlZGMxZGIyYTc0NDA4MDllNTE1YjRjMjRjZGU2NjlfMTA5OTUxMTYzNTY3Mg_08544f15-0a65-4bc1-93be-49096c3cc7bd"
      unitRef="usd">86187000</bdtx:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RleHRyZWdpb246OTBlZGMxZGIyYTc0NDA4MDllNTE1YjRjMjRjZGU2NjlfMTA5OTUxMTY0MDI2Ng_0a0f0aac-36e6-47f4-b9ab-d5beb43050d2"
      unitRef="usd">65238000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RleHRyZWdpb246OTBlZGMxZGIyYTc0NDA4MDllNTE1YjRjMjRjZGU2NjlfMTA5OTUxMTYzNjQxNA_36c4ffd5-1910-452d-b635-40b183179582"
      unitRef="usd">86187000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RleHRyZWdpb246OTBlZGMxZGIyYTc0NDA4MDllNTE1YjRjMjRjZGU2NjlfMzU5_734e1caa-862c-4432-b1fa-38bc567c4785"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180MC9mcmFnOjkwZWRjMWRiMmE3NDQwODA5ZTUxNWI0YzI0Y2RlNjY5L3RleHRyZWdpb246OTBlZGMxZGIyYTc0NDA4MDllNTE1YjRjMjRjZGU2NjlfMzU5_b25ed3ff-ceb7-4861-bd27-40437ea72aa6"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RleHRyZWdpb246Y2U1OWE2YTc4Y2U2NDVkMjkyNzg3MmNhMTQ4M2VjMDZfMTcx_8696c602-29a4-4154-b669-fd66d99740bc">PROPERTY AND EQUIPMENT&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Computer and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Construction in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(494)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total Property and Equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Depreciation expense for the three months ended March&#160;31, 2022 and 2021 was $125 and $19, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RleHRyZWdpb246Y2U1OWE2YTc4Y2U2NDVkMjkyNzg3MmNhMTQ4M2VjMDZfMTcy_860b9377-b354-42e8-8e5e-cc776da28704">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Computer and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Construction in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(494)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total Property and Equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i592581da0c5c4d148c499857a0970854_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfMS0xLTEtMS0xNTQ2OA_bbc5bd40-24e0-4951-8260-571e8771cff4"
      unitRef="usd">689000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia34f847e770542fbb1c0526bcd0521db_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfMS0zLTEtMS0xNTQ2OA_f2feb1a6-cc0b-4dad-bfd9-278ef2c7d849"
      unitRef="usd">682000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2cf6dcdd2d6846acbcfd0f4697fbbd29_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfMi0xLTEtMS0xNTQ2OA_35b35b27-c663-4c5a-b30b-285efe178c92"
      unitRef="usd">17000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3c3fc5df5cff491cb5578febfa6291bf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfMi0zLTEtMS0xNTQ2OA_5ceb72b3-aa66-417a-873b-e3745ad4938d"
      unitRef="usd">17000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icee8d91286f54b40b3f46d39ea9f5b62_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfMy0xLTEtMS0xNTQ2OA_d7e59cc4-077b-4553-b309-167801e02bf9"
      unitRef="usd">120000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2a5f439d7d2246559ccab58abf38d308_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfMy0zLTEtMS0xNTQ2OA_2851370c-8360-4f84-b063-0cf6553dc76e"
      unitRef="usd">120000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2b03f59264e74ddaa03048707c7f0deb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfNC0xLTEtMS0xNTQ2OA_149f79e7-c705-4204-9ee2-3ccbe0fca592"
      unitRef="usd">2479000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8fa0e12ae93a4ef0b5f7c326a00d7970_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfNC0zLTEtMS0xNTQ2OA_fa0b09b2-82e5-4bca-ad65-ee357c905b5c"
      unitRef="usd">2437000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iae9953ec0cd04a469a57c8508f2c84ef_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfNS0xLTEtMS0xNTQ2OA_eed7a15e-5bf5-4f49-94de-f32670b10f39"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i601e1559c5444c6aadd65a73f7aba8dd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfNS0zLTEtMS0xNTQ2OA_1f1da6e7-6350-4f02-939a-98009088489d"
      unitRef="usd">148000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfNi0xLTEtMS0xNTQ2OA_f752d404-c65d-4a75-bf25-1737eb6c926a"
      unitRef="usd">3305000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfNi0zLTEtMS0xNTQ2OA_bed15293-da51-403e-9022-feeb923e5808"
      unitRef="usd">3404000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfNy0xLTEtMS0xNTQ2OA_4c5ead6d-4016-4873-ac5b-11efb4689d52"
      unitRef="usd">494000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfNy0zLTEtMS0xNTQ2OA_d089f07c-9365-49d2-9872-a02249752f76"
      unitRef="usd">369000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfOC0xLTEtMS0xNTQ2OA_e83caa91-11c9-43f1-88a5-45a8ddbf4a71"
      unitRef="usd">2811000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RhYmxlOjU1ODUyZGYwNjRiMTQ5YmFiYTU4ODNlZDIyZDMxN2YzL3RhYmxlcmFuZ2U6NTU4NTJkZjA2NGIxNDliYWJhNTg4M2VkMjJkMzE3ZjNfOC0zLTEtMS0xNTQ2OA_456375a6-3026-4de1-8825-c6de73d82b52"
      unitRef="usd">3035000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RleHRyZWdpb246Y2U1OWE2YTc4Y2U2NDVkMjkyNzg3MmNhMTQ4M2VjMDZfMTQ4_bcf82265-dd9a-450e-82a9-8c723492c6a7"
      unitRef="usd">125000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180My9mcmFnOmNlNTlhNmE3OGNlNjQ1ZDI5Mjc4NzJjYTE0ODNlYzA2L3RleHRyZWdpb246Y2U1OWE2YTc4Y2U2NDVkMjkyNzg3MmNhMTQ4M2VjMDZfMTU1_7d5206be-67be-4abc-9312-5f9f7fef9819"
      unitRef="usd">19000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RleHRyZWdpb246MzU3YzgwZDY1OGFiNDgxNGI4M2ExNGYwNjdhNWM1OTNfMTMx_ff10910c-0822-4c3d-93a5-689e262c4680">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES &lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Contracted research services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;12,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;12,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Payroll and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;5,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Professional and consulting fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfNS0wLTEtMS0xNTQ2OA_c195240d-53ce-44bf-b8a4-8e123e896ff6"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfNS0wLTEtMS0xNTQ2OA_fcf82e1a-149c-4590-8cc4-cc8f47ea4618"&gt;Current portion of operating lease liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;17,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;19,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RleHRyZWdpb246MzU3YzgwZDY1OGFiNDgxNGI4M2ExNGYwNjdhNWM1OTNfMTMy_e60bafb4-925f-4841-a490-9d9c80d31fe7">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Contracted research services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;12,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;12,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Payroll and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;5,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Professional and consulting fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfNS0wLTEtMS0xNTQ2OA_c195240d-53ce-44bf-b8a4-8e123e896ff6"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfNS0wLTEtMS0xNTQ2OA_fcf82e1a-149c-4590-8cc4-cc8f47ea4618"&gt;Current portion of operating lease liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;17,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;19,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <bdtx:AccruedContractResearchServiceFeesCurrent
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfMS0xLTEtMS0xNTQ2OA_16eebe7b-cf18-4cd6-8617-f0464fd4be2d"
      unitRef="usd">12571000</bdtx:AccruedContractResearchServiceFeesCurrent>
    <bdtx:AccruedContractResearchServiceFeesCurrent
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfMS0zLTEtMS0xNTQ2OA_f2407a26-0d71-4316-923c-29c7248ccd9a"
      unitRef="usd">12192000</bdtx:AccruedContractResearchServiceFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfMi0xLTEtMS0xNTQ2OA_cecf4c89-5f0c-4c74-a61b-f6cd77621a4f"
      unitRef="usd">2821000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfMi0zLTEtMS0xNTQ2OA_e94d8cd8-c799-4efb-b3b1-e6c72651ec9e"
      unitRef="usd">5088000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfMy0xLTEtMS0xNTQ2OA_34c2513c-ab73-4ced-abc3-98dbedf7eb32"
      unitRef="usd">1401000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfMy0zLTEtMS0xNTQ2OA_a2b1a984-20a0-4b86-a40e-70806b2557ab"
      unitRef="usd">1935000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfNS0xLTEtMS0xNTQ2OA_036a3369-4834-45b5-b0f6-abf23e6898e3"
      unitRef="usd">793000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfNS0zLTEtMS0xNTQ2OA_b0be2c6d-cb59-4f9e-80c3-eb288532daf3"
      unitRef="usd">320000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfNi0xLTEtMS0xNTQ2OA_5a40d9df-1355-460c-bd4a-57ce9b62a9f9"
      unitRef="usd">17586000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN180Ni9mcmFnOjM1N2M4MGQ2NThhYjQ4MTRiODNhMTRmMDY3YTVjNTkzL3RhYmxlOjYzZDM1Mjc1MjY4NjQyN2I5Y2FiNjU4MzE3YzkyNzJkL3RhYmxlcmFuZ2U6NjNkMzUyNzUyNjg2NDI3YjljYWI2NTgzMTdjOTI3MmRfNi0zLTEtMS0xNTQ2OA_64aee4a1-2e43-48b7-a617-f52497992737"
      unitRef="usd">19535000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfNDU0Mw_dff2dc75-13b6-40a6-a7a6-7ba0e9429881">STOCK-BASED COMPENSATION&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Stock Option and Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The 2020 Stock Option and Incentive Plan (the &#x201c;2020 Plan&#x201d;) was approved by the Company&#x2019;s board of directors on December 5, 2019, and the Company&#x2019;s stockholders on January 14, 2020 and became effective on the date immediately prior to the date on which the registration statement for the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;) was declared effective. The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company&#x2019;s officers, employees, directors and consultants. The 2020 Plan provides for an annual increase, to be added on the first day of each fiscal year, by up to 4% of the Company&#x2019;s outstanding shares of common stock as of the last day of the prior year. On January 1, 2022, 1,449,384 shares of common stock, representing 4% of the Company&#x2019;s outstanding shares of common stock as of December 31, 2021, were added to the 2020 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The 2020 Employee Stock Purchase Plan (the &#x201c;2020 ESPP&#x201d;) was approved by the Company&#x2019;s board of directors on December 5, 2019, and the Company&#x2019;s stockholders on January 14, 2020, and became effective on the date immediately prior to the date on which the registration statement for the Company&#x2019;s IPO was declared effective. The 2020 ESPP provides for an annual increase, to be added on the first day of each fiscal year, by up to 1% of the number of shares of the Company&#x2019;s common stock outstanding on the immediately preceding December 31. The number of authorized shares reserved for issuance under the 2020 ESPP was increased by 326,364 shares effective as of January 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based compensation expense &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense in the following award type categories included within the condensed consolidated statements of operations and comprehensive loss:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Employee Stock Purchase Plan and Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2022, the Company issued 13,038 shares of common stock out of our 2020 Plan under our policy where non-employee directors may elect to receive their compensation in the form of common stock in lieu of cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Options &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The following table summarizes the stock option activity under the Company&#x2019;s equity awards plans:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;(in Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Outstanding December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;4,903,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;17.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,366,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(3,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(347,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;16.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Outstanding March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;5,918,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;14.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Options vested or expected to vest at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;5,918,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;14.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Options exercisable at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2,082,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;16.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2022, total unrecognized compensation cost related to the unvested stock-options was $29,471, which is expected to be recognized over a weighted average period of 2.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted stock units &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The fair values of restricted stock units are based on the market value of the Company&#x2019;s stock on the date of the grant. Under terms of the time-based restricted stock agreements covering the common stock, shares of restricted common stock are subject to a vesting schedule. The following table summarizes time-based restricted stock activity since January 1, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Number&#160;of&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;grant&#160;date&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Unvested restricted common stock as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;30,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;29.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;20,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(5,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;28.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Unvested restricted common stock as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;45,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;18.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The total fair value of time-based restricted stock units vested during the three months ended March&#160;31, 2022 was $143. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2022, total unrecognized compensation cost related to the time-based unvested restricted stock units was $591, which is expected to be recognized over a weighted average period of 1.2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2022, the Company granted to its employees 193,000 performance restricted stock units related to the achievement of certain clinical development and/or financing milestones. As of March&#160;31, 2022, the Company had 212,000 performance restricted stock units outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Recognition of stock-based compensation expense associated with performance restricted stock units commences when the performance conditions are considered probable of achievement, using management&#x2019;s best estimates, which consider the inherent risk and uncertainty regarding the future outcomes of the milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, for performance-based restricted stock units that were outstanding, the achievement of the milestones that had not been met was considered not probable, and therefore no expense has been recognized related to these awards in the three months ended March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The 2020 ESPP enables eligible employees to purchase shares of the Company's common stock at the end of each six-month offering period at a price equal to 85% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Eligible employees generally included all employees. Offering periods begin on the first trading day of January and July of each year and end on the last trading day in June and December of each year, except for the first offering period which began on the first trading day in March and ended on the last trading day in June. Share purchases are funded through payroll deductions of up to 10% of an employee&#x2019;s eligible compensation for each payroll period, up to $25 each calendar year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2022 and 2021, there were 31,341 and no shares, respectively, issued under the 2020 ESPP.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding
      contextRef="i5aee93ec0e6140c1967b90030b644693_I20200114"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfODEy_d0e11451-f731-4522-95e3-edb7ac07c3c0"
      unitRef="number">0.04</bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i121d14ec620443948bfb2446cf6369a8_D20220101-20220101"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfOTI1_85afc236-1101-457b-b5c0-f5eccba9cb9d"
      unitRef="shares">1449384</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding
      contextRef="i6c5c649da96f4bf6a852cad3b98671b5_I20220101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfOTY1_d3f2d331-055b-46a5-b36c-ec83d7b4f987"
      unitRef="number">0.04</bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding>
    <bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding
      contextRef="i73e473532efc4938a233763c7ef748f4_I20200114"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfMTUzNw_15bf28ba-a4f2-4741-be89-d6dd790a86b1"
      unitRef="number">0.01</bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="ib84b1455b06c44f2b4f0df628ece6347_D20220101-20220101"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfMTY0OTI2NzQ0NjIxOQ_b3009c34-8ec7-4d3c-a741-55a731806ad3"
      unitRef="shares">326364</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfNDUzOQ_2b34d25d-5d41-43b8-8ba7-afdca9a1e635">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense in the following award type categories included within the condensed consolidated statements of operations and comprehensive loss:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Employee Stock Purchase Plan and Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9ced07d6335641afa9f14288d1f7a2e1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjY4Yzg2MTljNGM5MzQzMjQ4NjA1Njc2NWU1NzhmZjY5L3RhYmxlcmFuZ2U6NjhjODYxOWM0YzkzNDMyNDg2MDU2NzY1ZTU3OGZmNjlfMi01LTEtMS0xNTQ2OA_816d5997-1501-4f7e-b442-b95f092d3166"
      unitRef="usd">3193000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9e9380f128ab4b63b1d6e7a850a44abd_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjY4Yzg2MTljNGM5MzQzMjQ4NjA1Njc2NWU1NzhmZjY5L3RhYmxlcmFuZ2U6NjhjODYxOWM0YzkzNDMyNDg2MDU2NzY1ZTU3OGZmNjlfMi03LTEtMS0xNTQ2OA_67f87171-4b1f-4aa3-9d9f-262f5710fcfe"
      unitRef="usd">2794000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia65875741ae542c78ed7dd0c432423a4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjY4Yzg2MTljNGM5MzQzMjQ4NjA1Njc2NWU1NzhmZjY5L3RhYmxlcmFuZ2U6NjhjODYxOWM0YzkzNDMyNDg2MDU2NzY1ZTU3OGZmNjlfMy01LTEtMS0xNTQ2OA_5b3175e1-28b7-4450-b108-e902e0d2053c"
      unitRef="usd">121000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id260c31e9c0140f3a78bffba8953b169_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjY4Yzg2MTljNGM5MzQzMjQ4NjA1Njc2NWU1NzhmZjY5L3RhYmxlcmFuZ2U6NjhjODYxOWM0YzkzNDMyNDg2MDU2NzY1ZTU3OGZmNjlfMy03LTEtMS0xNTQ2OA_15ac4cff-0695-4b8a-a2a7-b3fec47265c8"
      unitRef="usd">270000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1f5c3ddf78054fd0ba9932327695ba3c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjY4Yzg2MTljNGM5MzQzMjQ4NjA1Njc2NWU1NzhmZjY5L3RhYmxlcmFuZ2U6NjhjODYxOWM0YzkzNDMyNDg2MDU2NzY1ZTU3OGZmNjlfNC01LTEtMS0xNTQ2OA_a115a993-6a0e-410b-be62-3b7e0574ce10"
      unitRef="usd">61000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibde6c6664ee5474ea71ce7b63f837206_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjY4Yzg2MTljNGM5MzQzMjQ4NjA1Njc2NWU1NzhmZjY5L3RhYmxlcmFuZ2U6NjhjODYxOWM0YzkzNDMyNDg2MDU2NzY1ZTU3OGZmNjlfNC03LTEtMS0xNTQ2OA_d6c9b531-74ed-46a4-834d-175b1cfbd712"
      unitRef="usd">30000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjY4Yzg2MTljNGM5MzQzMjQ4NjA1Njc2NWU1NzhmZjY5L3RhYmxlcmFuZ2U6NjhjODYxOWM0YzkzNDMyNDg2MDU2NzY1ZTU3OGZmNjlfNS01LTEtMS0xNTQ2OA_c37e6fc9-447f-4494-8632-5d80c5ae46be"
      unitRef="usd">3375000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjY4Yzg2MTljNGM5MzQzMjQ4NjA1Njc2NWU1NzhmZjY5L3RhYmxlcmFuZ2U6NjhjODYxOWM0YzkzNDMyNDg2MDU2NzY1ZTU3OGZmNjlfNS03LTEtMS0xNTQ2OA_85de25ef-f48f-4b5c-b955-02369893c78d"
      unitRef="usd">3094000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i83ac7265af3c4a80b9a2081786c15aec_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfMjA0OQ_788e4320-deb0-4ec6-b5b2-597772e27974"
      unitRef="shares">13038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ife37765db49e41bf81afa44e8728613a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjJhODBiNTFlMmQ2ZjRiZGY5ZDBlNjgxZDE1Yzg3MjY1L3RhYmxlcmFuZ2U6MmE4MGI1MWUyZDZmNGJkZjlkMGU2ODFkMTVjODcyNjVfMi01LTEtMS0xNTQ2OA_4cc630f0-9957-4bb6-a509-c9cd17bf2206"
      unitRef="usd">1528000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iab8781eeec934caf84183887064bbbca_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjJhODBiNTFlMmQ2ZjRiZGY5ZDBlNjgxZDE1Yzg3MjY1L3RhYmxlcmFuZ2U6MmE4MGI1MWUyZDZmNGJkZjlkMGU2ODFkMTVjODcyNjVfMi03LTEtMS0xNTQ2OA_21824ab0-9d25-47a4-a3c2-6c98c7a2fe71"
      unitRef="usd">1620000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifdd9e72b3a7b4336a10b4ac7dea8e88c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjJhODBiNTFlMmQ2ZjRiZGY5ZDBlNjgxZDE1Yzg3MjY1L3RhYmxlcmFuZ2U6MmE4MGI1MWUyZDZmNGJkZjlkMGU2ODFkMTVjODcyNjVfMy01LTEtMS0xNTQ2OA_900b2db0-cca9-4e06-a93b-788b1a53828f"
      unitRef="usd">1847000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7445afb88fcd42778b16246f068e465b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjJhODBiNTFlMmQ2ZjRiZGY5ZDBlNjgxZDE1Yzg3MjY1L3RhYmxlcmFuZ2U6MmE4MGI1MWUyZDZmNGJkZjlkMGU2ODFkMTVjODcyNjVfMy03LTEtMS0xNTQ2OA_80eb9a26-066a-437b-8e4e-678d295a333d"
      unitRef="usd">1474000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjJhODBiNTFlMmQ2ZjRiZGY5ZDBlNjgxZDE1Yzg3MjY1L3RhYmxlcmFuZ2U6MmE4MGI1MWUyZDZmNGJkZjlkMGU2ODFkMTVjODcyNjVfNC01LTEtMS0xNTQ2OA_e4e4857a-5e36-405a-a0fc-400f54d9ddf0"
      unitRef="usd">3375000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjJhODBiNTFlMmQ2ZjRiZGY5ZDBlNjgxZDE1Yzg3MjY1L3RhYmxlcmFuZ2U6MmE4MGI1MWUyZDZmNGJkZjlkMGU2ODFkMTVjODcyNjVfNC03LTEtMS0xNTQ2OA_f30d9b01-fb42-4984-bbcd-1a37a6e97b46"
      unitRef="usd">3094000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfNDU0NQ_194357ae-20a9-478c-a6ba-1465abedd5c2">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The following table summarizes the stock option activity under the Company&#x2019;s equity awards plans:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;(in Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Outstanding December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;4,903,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;17.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,366,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(3,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(347,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;16.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Outstanding March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;5,918,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;14.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Options vested or expected to vest at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;5,918,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;14.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Options exercisable at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2,082,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;16.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfMS0xLTEtMS0xNTQ2OA_0eea34f5-9be0-4a47-86bd-bc037ad51bf2"
      unitRef="shares">4903839</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfMS0zLTEtMS0xNTQ2OA_d72117e2-67c1-4b0c-beaa-e595bf9cd273"
      unitRef="usdPerShare">17.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="id953a840a46b432da2c79d8a575bc2a7_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfMS01LTEtMS0xNTQ2OA_67665312-b761-460e-a057-8b6d485096ce">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ib4b87c0a8eda41d88bf0d13971431e26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfMS03LTEtMS0xNTQ2OA_ad80821b-d033-4fc5-bd43-087998f24500"
      unitRef="usd">847000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfMi0xLTEtMS0xNTQ2OA_f5f8b0c3-7625-4cbc-b78f-9db05305bd60"
      unitRef="shares">1366350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfMi0zLTEtMS0xNTQ2OA_5937e11b-7572-4b74-bce4-2bd6d2a23875"
      unitRef="usdPerShare">3.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfMy0xLTEtMS0xNTQ2OA_fc96fc6e-b9e6-4929-9bef-11669b172ed2"
      unitRef="shares">3565</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfMy0zLTEtMS0xNTQ2OA_48227c87-7d3e-44ce-8940-411896b15bcf"
      unitRef="usdPerShare">3.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfNC0xLTEtMS0xNTQ2OA_19303e58-3694-4f93-b1c6-1ba85f844d42"
      unitRef="shares">347830</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfNC0zLTEtMS0xNTQ2OA_75a77a05-32de-42a0-a210-6418f522c222"
      unitRef="usdPerShare">16.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfNS0xLTEtMS0xNTQ2OA_8b8a80fb-bad5-4aa1-8384-14c349a023ac"
      unitRef="shares">5918794</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfNS0zLTEtMS0xNTQ2OA_e777e26e-419d-4f3e-9d2e-00f7c32d02ec"
      unitRef="usdPerShare">14.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfNS01LTEtMS0xNTQ2OA_a5150654-205a-4c47-b429-35e4d36483d9">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfNS03LTEtMS0xNTQ2OA_89e386a2-caf2-4168-ba00-0a936199eec5"
      unitRef="usd">56000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfNi0xLTEtMS0xNTQ2OA_a0a18f6f-a5e6-4145-9d83-4bfbb5d93a94"
      unitRef="shares">5918794</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfNi0zLTEtMS0xNTQ2OA_09da6e67-9716-4c02-a2c2-c5299999f965"
      unitRef="usdPerShare">14.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfNi01LTEtMS0xNTQ2OA_56c4b6dc-ecac-4759-9071-83a9beab3f6b">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfNi03LTEtMS0xNTQ2OA_91e7fe15-cc62-4e82-ae83-104416fe62a6"
      unitRef="usd">56000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfNy0xLTEtMS0xNTQ2OA_c23b3fa6-65e8-40a6-a752-391d8a63cd47"
      unitRef="shares">2082574</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfNy0zLTEtMS0xNTQ2OA_323cd41c-e4f4-4b40-b4d9-daf7daee0d90"
      unitRef="usdPerShare">16.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfNy01LTEtMS0xNTQ2OA_4af6b13f-adae-47b1-abd6-2ed65108bef7">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOmUzOTI3NTE0NTI3YjQxYTNhNTAxM2FiNzkxOWE2YzM1L3RhYmxlcmFuZ2U6ZTM5Mjc1MTQ1MjdiNDFhM2E1MDEzYWI3OTE5YTZjMzVfNy03LTEtMS0xNTQ2OA_1eb8c66a-4ec9-49ff-8119-b9f8cefab876"
      unitRef="usd">49000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfMjYxMg_d207098f-e964-4d20-b481-2dba9ee6a9d3"
      unitRef="usd">29471000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i9ced07d6335641afa9f14288d1f7a2e1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfMjY4NQ_c7d32ecc-0822-4d24-9aec-b031fca60c1c">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfNDU0MA_9c3f6c47-6c20-4f89-ae8a-6d7b2954342e">The following table summarizes time-based restricted stock activity since January 1, 2022:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Number&#160;of&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;grant&#160;date&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Unvested restricted common stock as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;30,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;29.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;20,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(5,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;28.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Unvested restricted common stock as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;45,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;18.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id3281f5219574c05b5edcdfcb8708b8f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjZjYjllMzNjYWE0MTQxODliOWNmMjlhNDI1MWRlOTcwL3RhYmxlcmFuZ2U6NmNiOWUzM2NhYTQxNDE4OWI5Y2YyOWE0MjUxZGU5NzBfNC0xLTEtMS0xNTQ2OA_2d154504-0260-4725-bcce-44b4d075939a"
      unitRef="shares">30667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="id3281f5219574c05b5edcdfcb8708b8f_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjZjYjllMzNjYWE0MTQxODliOWNmMjlhNDI1MWRlOTcwL3RhYmxlcmFuZ2U6NmNiOWUzM2NhYTQxNDE4OWI5Y2YyOWE0MjUxZGU5NzBfNC0zLTEtMS0xNTQ2OA_af9c3909-8682-4f80-9133-95d119533217"
      unitRef="usdPerShare">29.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i0604fd99be6c400cb46383e020232cc3_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjZjYjllMzNjYWE0MTQxODliOWNmMjlhNDI1MWRlOTcwL3RhYmxlcmFuZ2U6NmNiOWUzM2NhYTQxNDE4OWI5Y2YyOWE0MjUxZGU5NzBfNS0xLTEtMS0xNTQ2OA_5ae60243-2ba0-40f8-bd99-78012ee370a8"
      unitRef="shares">20075</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0604fd99be6c400cb46383e020232cc3_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjZjYjllMzNjYWE0MTQxODliOWNmMjlhNDI1MWRlOTcwL3RhYmxlcmFuZ2U6NmNiOWUzM2NhYTQxNDE4OWI5Y2YyOWE0MjUxZGU5NzBfNS0zLTEtMS0xNTQ2OA_19d72e77-8e4f-427b-8809-4d3024e4d768"
      unitRef="usdPerShare">3.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i0604fd99be6c400cb46383e020232cc3_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjZjYjllMzNjYWE0MTQxODliOWNmMjlhNDI1MWRlOTcwL3RhYmxlcmFuZ2U6NmNiOWUzM2NhYTQxNDE4OWI5Y2YyOWE0MjUxZGU5NzBfNi0xLTEtMS0xNTQ2OA_fe989578-6bf2-4fa5-9644-4a5d6f29a5d3"
      unitRef="shares">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0604fd99be6c400cb46383e020232cc3_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjZjYjllMzNjYWE0MTQxODliOWNmMjlhNDI1MWRlOTcwL3RhYmxlcmFuZ2U6NmNiOWUzM2NhYTQxNDE4OWI5Y2YyOWE0MjUxZGU5NzBfNi0zLTEtMS0xNTQ2OA_feb33bf1-0e08-4a28-91f2-8205851cf080"
      unitRef="usdPerShare">28.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="idfb5ec15550c48b5ba40e04db8d95d68_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjZjYjllMzNjYWE0MTQxODliOWNmMjlhNDI1MWRlOTcwL3RhYmxlcmFuZ2U6NmNiOWUzM2NhYTQxNDE4OWI5Y2YyOWE0MjUxZGU5NzBfOC0xLTEtMS0xNTQ2OA_98736610-9b00-4e8c-bc22-c754df18cd91"
      unitRef="shares">45742</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="idfb5ec15550c48b5ba40e04db8d95d68_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RhYmxlOjZjYjllMzNjYWE0MTQxODliOWNmMjlhNDI1MWRlOTcwL3RhYmxlcmFuZ2U6NmNiOWUzM2NhYTQxNDE4OWI5Y2YyOWE0MjUxZGU5NzBfOC0zLTEtMS0xNTQ2OA_d6601735-7be6-473c-937d-cb879a6b9b35"
      unitRef="usdPerShare">18.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ia65875741ae542c78ed7dd0c432423a4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfMzE0Ng_819c9477-0586-4988-87b6-55dd9aa49665"
      unitRef="usd">143000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i9607feb9fa2e47abb53ba9ad7befeaf9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfMzI2Nw_c360244a-f4d5-49bc-b58b-3843bd90e454"
      unitRef="usd">591000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ia65875741ae542c78ed7dd0c432423a4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfMzM0MA_11c9cb9f-04cf-4f3f-8d1f-404df8a5f4e6">P1Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i6bed481b20eb42c4b7b7f8e7b60c3743_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfMTA5OTUxMTYzNTMwMQ_db61a67f-ebc2-422a-87d6-76504c9aab06"
      unitRef="shares">193000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ic3cbdfd3eaf5479f8e2be722e19d3d35_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfMTA5OTUxMTYzNTA3NA_a65ddfcd-6f35-4459-8e25-1e90d5cf8698"
      unitRef="shares">212000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6bed481b20eb42c4b7b7f8e7b60c3743_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfMTA5OTUxMTYzNTE0OA_708a92da-fb17-4980-9e5f-55112f31252a"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod
      contextRef="i96258d5fc0c3444cbbfc78ce061c9bef_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfNDU0Nw_d744ebf8-03bc-4624-be5b-2d033854a534">P6M</bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i96258d5fc0c3444cbbfc78ce061c9bef_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfMzgwOA_31134c6c-6c4d-4168-8d74-b2c136b3663a"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="i1f60a8da3d204a1d84243bb405682e2e_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfNDMzNQ_9cabccda-35f3-4604-bad9-553b6f38c2ca"
      unitRef="number">0.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount
      contextRef="i96258d5fc0c3444cbbfc78ce061c9bef_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfNDQwOA_384e448f-8a8f-4a09-967e-6da59b23097e"
      unitRef="usd">25000</bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i96258d5fc0c3444cbbfc78ce061c9bef_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfNDQ4MA_002e66d2-914e-44f2-82c2-8eb438e7dc5d"
      unitRef="shares">31341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i9100305f99b146729261bbdc162cb093_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181Mi9mcmFnOjc3MDcwNWZhZTU4ODRjOWFhNWUxMzFjMjY3NzI5ZmM3L3RleHRyZWdpb246NzcwNzA1ZmFlNTg4NGM5YWE1ZTEzMWMyNjc3MjlmYzdfNDQ4Nw_e3d6d55c-6130-4f4d-94ca-4cec9f9debff"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RleHRyZWdpb246ODI0NmZmYjg1Yzc2NGUwMzg4YjQ5NmQ5YTVlMjllYjFfODY1_7775650f-03b4-43d6-bf77-6ae91d9ede27">NET LOSS PER SHARE&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net loss per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The following table summarizes the computation of basic and diluted net loss per share of the Company (in thousands, except share and per share amounts):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(25,507)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(30,301)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Weighted average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;36,271,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;36,123,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(0.70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(0.84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s potentially dilutive securities, which include options, unvested restricted stock and warrants to purchase common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;5,918,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;4,810,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Unvested restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;45,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;59,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Shares issuable under employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;27,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;10,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;10,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;6,002,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;4,880,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RleHRyZWdpb246ODI0NmZmYjg1Yzc2NGUwMzg4YjQ5NmQ5YTVlMjllYjFfODY2_562ae4cb-855d-4a5b-a9f4-1bb63cc19029">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The following table summarizes the computation of basic and diluted net loss per share of the Company (in thousands, except share and per share amounts):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(25,507)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(30,301)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Weighted average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;36,271,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;36,123,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(0.70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(0.84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOmM1NTk4MTQ4ZGIzZDQ3ZjFhNjdmYmIwYWY3N2RjYmE5L3RhYmxlcmFuZ2U6YzU1OTgxNDhkYjNkNDdmMWE2N2ZiYjBhZjc3ZGNiYTlfMi01LTEtMS0xNTQ2OA_61c9c85e-33e2-444c-aa13-f2542a696ca1"
      unitRef="usd">-25507000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOmM1NTk4MTQ4ZGIzZDQ3ZjFhNjdmYmIwYWY3N2RjYmE5L3RhYmxlcmFuZ2U6YzU1OTgxNDhkYjNkNDdmMWE2N2ZiYjBhZjc3ZGNiYTlfMi03LTEtMS0xNTQ2OA_c1d81fd2-4ff8-4d69-9dd8-00e5967edf85"
      unitRef="usd">-30301000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOmM1NTk4MTQ4ZGIzZDQ3ZjFhNjdmYmIwYWY3N2RjYmE5L3RhYmxlcmFuZ2U6YzU1OTgxNDhkYjNkNDdmMWE2N2ZiYjBhZjc3ZGNiYTlfMy01LTEtMS0xNTQ2OA_5ebbba76-d7fb-4c79-a64a-ea2b37cd100f"
      unitRef="shares">36271291</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOmM1NTk4MTQ4ZGIzZDQ3ZjFhNjdmYmIwYWY3N2RjYmE5L3RhYmxlcmFuZ2U6YzU1OTgxNDhkYjNkNDdmMWE2N2ZiYjBhZjc3ZGNiYTlfMy01LTEtMS0xNTQ2OA_c6c04341-468f-4f67-aee8-70279ddde08a"
      unitRef="shares">36271291</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOmM1NTk4MTQ4ZGIzZDQ3ZjFhNjdmYmIwYWY3N2RjYmE5L3RhYmxlcmFuZ2U6YzU1OTgxNDhkYjNkNDdmMWE2N2ZiYjBhZjc3ZGNiYTlfMy03LTEtMS0xNTQ2OA_52e8d0c4-e1b2-49d9-879c-7f2230c463c2"
      unitRef="shares">36123014</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOmM1NTk4MTQ4ZGIzZDQ3ZjFhNjdmYmIwYWY3N2RjYmE5L3RhYmxlcmFuZ2U6YzU1OTgxNDhkYjNkNDdmMWE2N2ZiYjBhZjc3ZGNiYTlfMy03LTEtMS0xNTQ2OA_a24b0f36-c667-44e3-81e3-11cbf2052b0c"
      unitRef="shares">36123014</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOmM1NTk4MTQ4ZGIzZDQ3ZjFhNjdmYmIwYWY3N2RjYmE5L3RhYmxlcmFuZ2U6YzU1OTgxNDhkYjNkNDdmMWE2N2ZiYjBhZjc3ZGNiYTlfNC01LTEtMS0xNTQ2OA_0c20e5ee-2483-47fb-a62e-7f75d22c093d"
      unitRef="usdPerShare">-0.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOmM1NTk4MTQ4ZGIzZDQ3ZjFhNjdmYmIwYWY3N2RjYmE5L3RhYmxlcmFuZ2U6YzU1OTgxNDhkYjNkNDdmMWE2N2ZiYjBhZjc3ZGNiYTlfNC01LTEtMS0xNTQ2OA_39d718c5-a936-41ff-8c4c-c6f81574f1bb"
      unitRef="usdPerShare">-0.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOmM1NTk4MTQ4ZGIzZDQ3ZjFhNjdmYmIwYWY3N2RjYmE5L3RhYmxlcmFuZ2U6YzU1OTgxNDhkYjNkNDdmMWE2N2ZiYjBhZjc3ZGNiYTlfNC03LTEtMS0xNTQ2OA_5a8e69bb-0987-4af9-98cb-ad94f9719400"
      unitRef="usdPerShare">-0.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOmM1NTk4MTQ4ZGIzZDQ3ZjFhNjdmYmIwYWY3N2RjYmE5L3RhYmxlcmFuZ2U6YzU1OTgxNDhkYjNkNDdmMWE2N2ZiYjBhZjc3ZGNiYTlfNC03LTEtMS0xNTQ2OA_6bd9508f-d25e-4267-a9f0-5a3b0694b3a4"
      unitRef="usdPerShare">-0.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RleHRyZWdpb246ODI0NmZmYjg1Yzc2NGUwMzg4YjQ5NmQ5YTVlMjllYjFfODY0_129f9cdc-979b-4ad7-a534-e4c5b2ed5aef">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;5,918,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;4,810,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Unvested restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;45,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;59,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Shares issuable under employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;27,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;10,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;10,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;6,002,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;4,880,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibe1143b3d4d645b7b96eb90d189b5d47_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOjNlZGI2ZWZjZjI0NjQ2NzI4MDIwZmI5Njg2YmVhZmFkL3RhYmxlcmFuZ2U6M2VkYjZlZmNmMjQ2NDY3MjgwMjBmYjk2ODZiZWFmYWRfMi0xLTEtMS0xNTQ2OA_5a2447a4-6ce9-40d9-addf-2e265c174c10"
      unitRef="shares">5918794</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iff2984996ead4b0a9658704d11ad854b_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOjNlZGI2ZWZjZjI0NjQ2NzI4MDIwZmI5Njg2YmVhZmFkL3RhYmxlcmFuZ2U6M2VkYjZlZmNmMjQ2NDY3MjgwMjBmYjk2ODZiZWFmYWRfMi0zLTEtMS0xNTQ2OA_2d9c06c4-e898-4121-b0c6-be4853b740b5"
      unitRef="shares">4810262</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i41ea06ffd4224202a713d2f339bde058_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOjNlZGI2ZWZjZjI0NjQ2NzI4MDIwZmI5Njg2YmVhZmFkL3RhYmxlcmFuZ2U6M2VkYjZlZmNmMjQ2NDY3MjgwMjBmYjk2ODZiZWFmYWRfMy0xLTEtMS0xNTQ2OA_6da18ea2-a92d-4e58-a14f-7a06a51a6369"
      unitRef="shares">45742</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6dcd8e4f8ad5440c98fd9db5a027ce37_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOjNlZGI2ZWZjZjI0NjQ2NzI4MDIwZmI5Njg2YmVhZmFkL3RhYmxlcmFuZ2U6M2VkYjZlZmNmMjQ2NDY3MjgwMjBmYjk2ODZiZWFmYWRfMy0zLTEtMS0xNTQ2OA_7d65132b-d2fe-48a7-85d8-164dd78d9678"
      unitRef="shares">59338</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9a5f037265fe4d04a7f18d30566bb541_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOjNlZGI2ZWZjZjI0NjQ2NzI4MDIwZmI5Njg2YmVhZmFkL3RhYmxlcmFuZ2U6M2VkYjZlZmNmMjQ2NDY3MjgwMjBmYjk2ODZiZWFmYWRfNC0xLTEtMS0xNTQ2OA_1fc83f55-59a7-4497-ab82-8d2c926ecf24"
      unitRef="shares">27572</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8b57788e875c480ba8c662e821360cb1_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOjNlZGI2ZWZjZjI0NjQ2NzI4MDIwZmI5Njg2YmVhZmFkL3RhYmxlcmFuZ2U6M2VkYjZlZmNmMjQ2NDY3MjgwMjBmYjk2ODZiZWFmYWRfNC0zLTEtMS0xNTQ2OA_1d98572e-702d-4564-be74-911c19419ed3"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icda07b5a5283444f941929ded278868b_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOjNlZGI2ZWZjZjI0NjQ2NzI4MDIwZmI5Njg2YmVhZmFkL3RhYmxlcmFuZ2U6M2VkYjZlZmNmMjQ2NDY3MjgwMjBmYjk2ODZiZWFmYWRfNS0xLTEtMS0xNTQ2OA_1d5a235c-4a47-4dc7-a4d3-563169eabe17"
      unitRef="shares">10757</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i11c8ad192542472fae54a22841a0002f_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOjNlZGI2ZWZjZjI0NjQ2NzI4MDIwZmI5Njg2YmVhZmFkL3RhYmxlcmFuZ2U6M2VkYjZlZmNmMjQ2NDY3MjgwMjBmYjk2ODZiZWFmYWRfNS0zLTEtMS0xNTQ2OA_15d238f3-d330-405e-bbdb-6fcc5e2c08fb"
      unitRef="shares">10757</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOjNlZGI2ZWZjZjI0NjQ2NzI4MDIwZmI5Njg2YmVhZmFkL3RhYmxlcmFuZ2U6M2VkYjZlZmNmMjQ2NDY3MjgwMjBmYjk2ODZiZWFmYWRfNi0xLTEtMS0xNTQ2OA_0e00d041-c4d5-4eeb-b382-5e85dc21af5e"
      unitRef="shares">6002865</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181NS9mcmFnOjgyNDZmZmI4NWM3NjRlMDM4OGI0OTZkOWE1ZTI5ZWIxL3RhYmxlOjNlZGI2ZWZjZjI0NjQ2NzI4MDIwZmI5Njg2YmVhZmFkL3RhYmxlcmFuZ2U6M2VkYjZlZmNmMjQ2NDY3MjgwMjBmYjk2ODZiZWFmYWRfNi0zLTEtMS0xNTQ2OA_54f885a5-f481-4b47-b7b5-993bcdb7201d"
      unitRef="shares">4880357</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfMjYyMg_0bb7a267-0d21-4e47-a967-03721ee6bc57">LEASES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company has historically entered into lease arrangements for its facilities. As of March&#160;31, 2022, the Company had two operating leases with required future minimum payments. The Company determined the classification of these leases to be operating leases and recorded right-of-use assets and lease liabilities as of the effective dates. The Company&#x2019;s leases generally do not include termination or purchase options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;In July 2020, the Company entered into a seven-year agreement with an option to extend for &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfNTgy_c161a703-7086-4d07-92a4-b87f9bfb15b3"&gt;five&lt;/span&gt; additional years to lease two floors totaling approximately 25,578 square feet of office space for its principal office, which is located in Cambridge, MA. The lease on the first floor commenced on August 1, 2020 and the lease on the second floor commenced March 9, 2021. The Company recognized the respective lease balances on the condensed consolidated balance sheets when the lease of each floor commenced. Under the terms of the lease, the Company was required to issue a $1,168 letter of credit as security for the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company previously leased an office space in Cambridge, MA under a lease that commenced in February 2019 for approximately 2,357 square feet of office space, which was set to expire on April 30, 2022, subject to an option to extend the lease for &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfMTM1MQ_fb0605bf-86e1-4515-94ea-01a6d35b03a5"&gt;three&lt;/span&gt; additional years. Effective June 15, 2021, the lease was terminated, and the remaining right-of-use asset and lease liability were derecognized. A gain of $5 was recognized for the termination of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company entered into an eleven-year agreement to lease approximately 18,120 square feet of office and laboratory space in New York, NY. The Company has an option to extend the lease for &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfMTc1MA_0ef0df9a-0a44-47d0-a64e-d0e4a8dda2cf"&gt;five&lt;/span&gt; additional years. The lease commenced August 26, 2021 and the related lease balance was recognized on the condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#x2019;s operating lease for the three months ended March 31, 2022 and 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.681%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Other Operating Lease Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The variable lease costs for the three months ended March&#160;31, 2022 and 2021 include common area maintenance and other operating charges. As the Company&#x2019;s leases do not provide an implicit rate, the Company utilized its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under the Company&#x2019;s operating leases as of March&#160;31, 2022 were as follows: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;As of March 31, 2022&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2022 (excluding the three months ended March&#160;31, 2022)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;4,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;4,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;4,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;4,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;16,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;35,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Less: interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(7,646)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;28,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <bdtx:LesseeOperatingLeaseNumberOfContracts
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfMTIz_8a97dd46-1be3-4a30-ae04-7d70653bd004"
      unitRef="contract">2</bdtx:LesseeOperatingLeaseNumberOfContracts>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i698d38b82399483e9b66aecdbb49ea01_I20200731"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfMjYyMw_66e6c3a9-d4c9-4bbd-a773-77ba78213560">P7Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <bdtx:LesseeOperatingLeaseArea
      contextRef="i698d38b82399483e9b66aecdbb49ea01_I20200731"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfNjQ1_f5c9277b-313c-401f-9fae-232da6a90602"
      unitRef="sqft">25578</bdtx:LesseeOperatingLeaseArea>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i698d38b82399483e9b66aecdbb49ea01_I20200731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfMTA1Nw_3e73a624-0b01-422d-a5e9-1f59abaf0956"
      unitRef="usd">1168000</us-gaap:LettersOfCreditOutstandingAmount>
    <bdtx:LesseeOperatingLeaseArea
      contextRef="i2fb5e46658e2428a9f4d40e61ba2085a_I20190228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfMTIzMQ_11fd87a2-4384-4e58-b524-62bdf02a279a"
      unitRef="sqft">2357</bdtx:LesseeOperatingLeaseArea>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="ia1bcd124beab438caab6f8c9006bed30_D20210615-20210615"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfMTA5OTUxMTYzMDQxMw_98a6ff6e-8c14-446d-9de9-507be38fb963"
      unitRef="usd">5000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i54692e00a6974fcd89b396554614c7ad_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfMjYyOQ_85310468-aa27-42c0-9098-cc0c16859a47">P11Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <bdtx:LesseeOperatingLeaseArea
      contextRef="i54692e00a6974fcd89b396554614c7ad_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfMTYzNw_34b37162-2c32-4530-87a1-ffc674353511"
      unitRef="sqft">18120</bdtx:LesseeOperatingLeaseArea>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfMjYyNA_738d4b24-6219-47c8-8646-e85405353837">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#x2019;s operating lease for the three months ended March 31, 2022 and 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.681%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Other Operating Lease Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjYxYmU4MTg3ODYxNTQ1NTA5NDE2ODc3MGUxNWE2OWE1L3RhYmxlcmFuZ2U6NjFiZTgxODc4NjE1NDU1MDk0MTY4NzcwZTE1YTY5YTVfMy01LTEtMS0xNjc4NA_d77f2afc-de7e-4670-b0eb-2ef8a68db99d"
      unitRef="usd">1059000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjYxYmU4MTg3ODYxNTQ1NTA5NDE2ODc3MGUxNWE2OWE1L3RhYmxlcmFuZ2U6NjFiZTgxODc4NjE1NDU1MDk0MTY4NzcwZTE1YTY5YTVfMy03LTEtMS0xNjc4NA_d6dc84e1-c2b0-47fa-9c83-2a1ff70fb69c"
      unitRef="usd">462000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjYxYmU4MTg3ODYxNTQ1NTA5NDE2ODc3MGUxNWE2OWE1L3RhYmxlcmFuZ2U6NjFiZTgxODc4NjE1NDU1MDk0MTY4NzcwZTE1YTY5YTVfNC01LTEtMS0xNjc4NA_379b5536-bd12-4198-8685-e55ff02cab9f"
      unitRef="usd">19000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjYxYmU4MTg3ODYxNTQ1NTA5NDE2ODc3MGUxNWE2OWE1L3RhYmxlcmFuZ2U6NjFiZTgxODc4NjE1NDU1MDk0MTY4NzcwZTE1YTY5YTVfNC03LTEtMS0xNjc4NA_b027b74f-81bb-485c-8dab-200ca83492d8"
      unitRef="usd">287000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjYxYmU4MTg3ODYxNTQ1NTA5NDE2ODc3MGUxNWE2OWE1L3RhYmxlcmFuZ2U6NjFiZTgxODc4NjE1NDU1MDk0MTY4NzcwZTE1YTY5YTVfNS01LTEtMS0xNjc4NA_565674cc-5fe3-4ea0-ae1e-fbefa7182f5d"
      unitRef="usd">257000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjYxYmU4MTg3ODYxNTQ1NTA5NDE2ODc3MGUxNWE2OWE1L3RhYmxlcmFuZ2U6NjFiZTgxODc4NjE1NDU1MDk0MTY4NzcwZTE1YTY5YTVfNS03LTEtMS0xNjc4NA_7c180f90-80fd-4ea5-9101-3f8b4cf0b8cb"
      unitRef="usd">33000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjYxYmU4MTg3ODYxNTQ1NTA5NDE2ODc3MGUxNWE2OWE1L3RhYmxlcmFuZ2U6NjFiZTgxODc4NjE1NDU1MDk0MTY4NzcwZTE1YTY5YTVfNi01LTEtMS0xNjc4NA_f143447b-128e-45a6-9ba0-4e1710abe27e"
      unitRef="usd">1335000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjYxYmU4MTg3ODYxNTQ1NTA5NDE2ODc3MGUxNWE2OWE1L3RhYmxlcmFuZ2U6NjFiZTgxODc4NjE1NDU1MDk0MTY4NzcwZTE1YTY5YTVfNi03LTEtMS0xNjc4NA_5da745c1-2006-4fcd-9a58-953fd245c59d"
      unitRef="usd">782000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjkwZDhmYzVmN2IyZTQ5ZTVhNzU1MDkwMzcyZjRhZjNkL3RhYmxlcmFuZ2U6OTBkOGZjNWY3YjJlNDllNWE3NTUwOTAzNzJmNGFmM2RfMi0xLTEtMS0xNTQ2OA_1984fcc0-be7a-414d-8251-a792bdbe1feb"
      unitRef="usd">702000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjkwZDhmYzVmN2IyZTQ5ZTVhNzU1MDkwMzcyZjRhZjNkL3RhYmxlcmFuZ2U6OTBkOGZjNWY3YjJlNDllNWE3NTUwOTAzNzJmNGFmM2RfMi0zLTEtMS0xNjc2Mw_4c683829-f2dd-4a30-86c6-aa4f3f3ac83c"
      unitRef="usd">370000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjkwZDhmYzVmN2IyZTQ5ZTVhNzU1MDkwMzcyZjRhZjNkL3RhYmxlcmFuZ2U6OTBkOGZjNWY3YjJlNDllNWE3NTUwOTAzNzJmNGFmM2RfMy0xLTEtMS0xNTQ2OA_0ec6254d-9125-4d56-8570-ba6969c4b78e">P8Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i5c8a085e141b45ee84f490448563d1f1_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjkwZDhmYzVmN2IyZTQ5ZTVhNzU1MDkwMzcyZjRhZjNkL3RhYmxlcmFuZ2U6OTBkOGZjNWY3YjJlNDllNWE3NTUwOTAzNzJmNGFmM2RfMy0zLTEtMS0xNjc2Mw_f63f7abc-d6c0-4046-8c75-6587c42bb74c">P7Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjkwZDhmYzVmN2IyZTQ5ZTVhNzU1MDkwMzcyZjRhZjNkL3RhYmxlcmFuZ2U6OTBkOGZjNWY3YjJlNDllNWE3NTUwOTAzNzJmNGFmM2RfNC0xLTEtMS0xNTQ2OA_ec8ebb6c-3734-4035-a998-408fa246e08e"
      unitRef="number">0.053</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i5c8a085e141b45ee84f490448563d1f1_I20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjkwZDhmYzVmN2IyZTQ5ZTVhNzU1MDkwMzcyZjRhZjNkL3RhYmxlcmFuZ2U6OTBkOGZjNWY3YjJlNDllNWE3NTUwOTAzNzJmNGFmM2RfNC0zLTEtMS0xNjc2Mw_5189c020-4b65-45c7-b07c-1b6fdd532781"
      unitRef="number">0.053</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RleHRyZWdpb246MDYwNzljMTlhNWI1NDJjN2I4ZTE5MGUyMWJiOGZmZThfMjYyNQ_97274787-3071-4e1c-a61f-120724a0edb2">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under the Company&#x2019;s operating leases as of March&#160;31, 2022 were as follows: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;As of March 31, 2022&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2022 (excluding the three months ended March&#160;31, 2022)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;4,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;4,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;4,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;4,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;16,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;35,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Less: interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(7,646)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;28,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjI4ZWVkZWE4YWYwOTQzNjc5MzdlODU0MDMxMWU1ODJhL3RhYmxlcmFuZ2U6MjhlZWRlYThhZjA5NDM2NzkzN2U4NTQwMzExZTU4MmFfMS0xLTEtMS0xNTQ2OA_ce023e34-4c3a-44b0-a3c5-d8b7832c3909"
      unitRef="usd">1241000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjI4ZWVkZWE4YWYwOTQzNjc5MzdlODU0MDMxMWU1ODJhL3RhYmxlcmFuZ2U6MjhlZWRlYThhZjA5NDM2NzkzN2U4NTQwMzExZTU4MmFfMi0xLTEtMS0xNTQ2OA_5b12ca85-eec8-46a8-aab0-269b2b9a27e7"
      unitRef="usd">4244000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjI4ZWVkZWE4YWYwOTQzNjc5MzdlODU0MDMxMWU1ODJhL3RhYmxlcmFuZ2U6MjhlZWRlYThhZjA5NDM2NzkzN2U4NTQwMzExZTU4MmFfMy0xLTEtMS0xNTQ2OA_75241fd4-95ab-482e-a1b2-cc3fa55f0631"
      unitRef="usd">4359000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjI4ZWVkZWE4YWYwOTQzNjc5MzdlODU0MDMxMWU1ODJhL3RhYmxlcmFuZ2U6MjhlZWRlYThhZjA5NDM2NzkzN2U4NTQwMzExZTU4MmFfNC0xLTEtMS0xNTQ2OA_13c8e75a-bdfe-4195-b0ce-2155427e2266"
      unitRef="usd">4477000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjI4ZWVkZWE4YWYwOTQzNjc5MzdlODU0MDMxMWU1ODJhL3RhYmxlcmFuZ2U6MjhlZWRlYThhZjA5NDM2NzkzN2U4NTQwMzExZTU4MmFfNS0xLTEtMS0xNTQ2OA_37021e35-7ee6-4f7e-b5a3-ba2726df3c6a"
      unitRef="usd">4599000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <bdtx:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjI4ZWVkZWE4YWYwOTQzNjc5MzdlODU0MDMxMWU1ODJhL3RhYmxlcmFuZ2U6MjhlZWRlYThhZjA5NDM2NzkzN2U4NTQwMzExZTU4MmFfNi0xLTEtMS0xNTQ2OA_c9233ae9-cd5a-4bb3-8528-4c702eb7d60d"
      unitRef="usd">16972000</bdtx:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjI4ZWVkZWE4YWYwOTQzNjc5MzdlODU0MDMxMWU1ODJhL3RhYmxlcmFuZ2U6MjhlZWRlYThhZjA5NDM2NzkzN2U4NTQwMzExZTU4MmFfNy0xLTEtMS0xNTQ2OA_b72808c3-b370-4b32-9c2e-06e34c96925a"
      unitRef="usd">35892000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjI4ZWVkZWE4YWYwOTQzNjc5MzdlODU0MDMxMWU1ODJhL3RhYmxlcmFuZ2U6MjhlZWRlYThhZjA5NDM2NzkzN2U4NTQwMzExZTU4MmFfOC0xLTEtMS0xNTQ2OA_76e6e2ea-0fa3-4ae8-ba02-dcd659ccdace"
      unitRef="usd">7646000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN181OC9mcmFnOjA2MDc5YzE5YTViNTQyYzdiOGUxOTBlMjFiYjhmZmU4L3RhYmxlOjI4ZWVkZWE4YWYwOTQzNjc5MzdlODU0MDMxMWU1ODJhL3RhYmxlcmFuZ2U6MjhlZWRlYThhZjA5NDM2NzkzN2U4NTQwMzExZTU4MmFfOS0xLTEtMS0xNTQ2OA_3c466d58-50aa-44b7-833e-8879355e2aeb"
      unitRef="usd">28246000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN182MS9mcmFnOmU0YjJmZWE4NDlkNzQ3YzNiNzk5YTQ5MmI5ZDU4YzUyL3RleHRyZWdpb246ZTRiMmZlYTg0OWQ3NDdjM2I3OTlhNDkyYjlkNThjNTJfMjU3Ng_cdbe2b72-f37e-4f15-90e8-73385894f754">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;We enter into contracts in the normal course of business with contract research organizations ("CROs"), contract manufacturing organizations ("CMOs") and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts do not contain minimum purchase commitments and are cancelable upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of service providers, up to the date of cancellation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;License agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company is party to license agreements, which include contingent payments. These payments will become payable if and when certain development, regulatory and commercial milestones are achieved. As of March&#160;31, 2022, the satisfaction and timing of the contingent payments is uncertain and not reasonably estimable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnification agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of March&#160;31, 2022 or December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company is not currently party to and is not aware of any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN182NC9mcmFnOjM0NmZmOWRmNmQ0NDQzZjVhOTc5ZGIwMmNjY2JhMTI3L3RleHRyZWdpb246MzQ2ZmY5ZGY2ZDQ0NDNmNWE5NzlkYjAyY2NjYmExMjdfNzMz_ee5c6815-e292-4a3e-93a7-8e92d1ffaeb7">BENEFIT PLANSThe Company has a tax-qualified 401(k) and Profit Sharing defined contribution plan (the &#x201c;401(k) Plan&#x201d;). Under the 401(k) Plan, the Company provides an employer safe harbor matching contribution equal to 100% of a participant&#x2019;s eligible contributions of up to 6% of eligible compensation, subject to limits established by the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the &#x201c;Code&#x201d;). All matching contributions are fully vested when made. During the three months ended March&#160;31, 2022 and 2021 the Company contributed $558 and $345 to the 401(k) Plan, respectively.</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN182NC9mcmFnOjM0NmZmOWRmNmQ0NDQzZjVhOTc5ZGIwMmNjY2JhMTI3L3RleHRyZWdpb246MzQ2ZmY5ZGY2ZDQ0NDNmNWE5NzlkYjAyY2NjYmExMjdfMzI1_e3d31346-7c5d-40dd-bedf-ba73dc27b088"
      unitRef="number">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN182NC9mcmFnOjM0NmZmOWRmNmQ0NDQzZjVhOTc5ZGIwMmNjY2JhMTI3L3RleHRyZWdpb246MzQ2ZmY5ZGY2ZDQ0NDNmNWE5NzlkYjAyY2NjYmExMjdfMzc5_84db80ae-8ba3-427a-ae1b-8d82c8594dd1"
      unitRef="number">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN182NC9mcmFnOjM0NmZmOWRmNmQ0NDQzZjVhOTc5ZGIwMmNjY2JhMTI3L3RleHRyZWdpb246MzQ2ZmY5ZGY2ZDQ0NDNmNWE5NzlkYjAyY2NjYmExMjdfNjY4_0bd7d25b-9760-4813-9caa-d60ed0625e0c"
      unitRef="usd">558000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i0b790ba85e34465f8dbbbc972aea6c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliNThhZmQ3YzgxNTQ1MGY5ZWY5YWNjMzY3M2ZlMDI3L3NlYzo5YjU4YWZkN2M4MTU0NTBmOWVmOWFjYzM2NzNmZTAyN182NC9mcmFnOjM0NmZmOWRmNmQ0NDQzZjVhOTc5ZGIwMmNjY2JhMTI3L3RleHRyZWdpb246MzQ2ZmY5ZGY2ZDQ0NDNmNWE5NzlkYjAyY2NjYmExMjdfNzAx_60ad13f6-58ac-4c31-8adc-69732e726417"
      unitRef="usd">345000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>53
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M&0!3[9>%]J&6>W,YOY9U+0O3W'&6<:4-X/\;*>N7!SU!]WWGYC]02P,$%
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MU;BE&H]2_<JDTM4*3"%$JN*I/JE[MKN2J\D QC:GY3)QDTI:4LDHJ;I_S[4
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MV<?PZH4?4FN=^1A4'+I.A_UKT_K=RZ.SH_'!)[MI$CTX>?6BUQNS-.FG_F/
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MVD\*-&:&G3^ 2FSURI=LX$*#@E.1J+04/G%IQSS);%]3-;*K03(B(",JNLR
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M[N:]EEQ59+RR1C@JSB?+XY\O3_E\//"[HKT?70N.9&OM+=^L\_/)$3M$FK+
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M;0BVBI<E5DQR? #O>07O;MA _\7JXK]02P,$%     @ *8*K5*_FV37J!
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MVE'O[(<%?:R@X0.TO]#:;2>LH/_\.?L+4$L#!!0    ( "F"JU3$)HEH\P(
M $T&   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;*55;4_;,!#^*Z<,
M34RJR&NA96TE7HJ&!*SC9=,T[8.;7!H+QPZV0^'?[^RTI4B##YO4VC[[[KD7
M^YZ,EDK?FPK1PE,MI!D'E;7-81B:O,*:F3W5H*234NF:61+U(C2-1E9XHUJ$
M213MAS7C,IB,_-Y,3T:JM8)+G&DP;5TS_7R,0BW'01RL-Z[YHK)N(YR,&K;
M&[1WS4R3%&Y0"EZC-%Q)T%B.@Z/X\#AS^E[A.\>EV5J#RV2NU+T3SHMQ$+F
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MS)4E^O'+BO@>M5.@\U(INQ:<@\T79/('4$L#!!0    ( "F"JU0ABT8?R0(
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M21,POBP*5[_0!LU/KR>_ 5!+ P04    "  I@JM4N?0\A \$  !["0  &0
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M'0UFTUXXZFP?G*[],7VI'0[]?IGC+TL:%L#W3&NW?6 'W7_;Q;]02P,$%
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M3B2]]8>,".DJ8NS&&$U+*192NRZ])AH0 _KLVXG:] 0*I&W*5/!83CQN:][
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MA3R.O- [':SX+C?VP!\/]VR':S1/^Z6BG=^@I+S 4G-9@L)LY$W"P;1MXUW
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M*AM ]YF4YK2Q!,V '_\!4$L#!!0    ( "F"JU1 9;7_U00  -@+   9
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MSB.ZJBV:!XQ"]>QSC'L&[E5)M=HA<>;R=0YB""C*Q\Q?@17X^[1/_LO\ '>
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MHBHU_5CL-TZW813=:4>#+2QK^I- XP7H^UI3 >XVWL#P;[+X%U!+ P04
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MFJ%8CJQ/<-*R[T(O3J 6-T9-BD.<5V6,2HK+L11#J7,#^WRDE/FXR<^%JG/
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M$-G=*&LHOK&WA0>N]-W#/J[U?1*$"=#OEYRK7<,4*&ZHD]]02P,$%     @
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MV_Q""X=Z6E_ 8F'^@DV^=S#J@" 3DB6%L$*01&G^GSP7@:@(0+]! !4"Z(T
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M1P[$+HXQ_[@F$3M<C>#H^.")KC<R?6#,IEN\)DLB7[:/7-T9I9>0QB01E"6
MD]75: Z_+Y"3&F0S?E%R$+4Q2%-Y9>PMO;D+KT9FBHA$))"I"ZPN>[(@491Z
M4CC^*YR.RIBI87U\]/Y7EKQ*YA4+LF#1;QK*S=7('X&0K/ NDD_L\ \I$LH
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M[*GP//]XD=](MLW._Z],2A9GPPW!(>'I!/7_BC%YO$D#E)^09O\#4$L#!!0
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MR-=VAQZ)]DJ+I "C!PE/\W]V5R3B"!#0!D!0 (+'@* !T"D G4< VF\ = M
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MO<Q#!2Q(S?2S6#_ )E!L]>:"*?>/ULW:-/'0O%9:5)MBXZ"BO+F2C\V+V"G
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M76">+X30VXGMYNUA//D#4$L#!!0    ( "F"JU06OPK,B@(  '$&   9
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M"505TX8]P3B291@"O>COT31%LI/"QU\?["E)DBSS(X#Y%20)AL#3B".8 M"
M(4EBS\&#\RC:G%/1]E>2R6]02P,$%     @ *8*K5)>*NQS     $P(   L
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ME<W1GW7_2>:?4$L! A0#%     @ *8*K5 =!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  I@JM4V,EG
MNNX    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    "  I@JM4F5R<(Q &  "<)P  $P              @ ', 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( "F"JU3C8HFIO 4  $X9
M   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    "  I@JM4=+1K)V,%    %0  &               @('_#0
M>&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ *8*K5.#7QL'E
M @  UPD  !@              ("!F!,  'AL+W=O<FMS:&5E=',O<VAE970S
M+GAM;%!+ 0(4 Q0    ( "F"JU21BA66400  /8/   8              "
M@;,6  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  I@JM4
MUFU:=DD&  #K&0  &               @($Z&P  >&PO=V]R:W-H965T<R]S
M:&5E=#4N>&UL4$L! A0#%     @ *8*K5!_;#VQ%!0  .Q<  !@
M     ("!N2$  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (
M "F"JU1K+R(1IPP  &L@   8              " @30G  !X;"]W;W)K<VAE
M971S+W-H965T-RYX;6Q02P$"% ,4    "  I@JM4;(&_P&<'  "]$@  &
M            @($1-   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#
M%     @ *8*K5*_FV37J!   KPL  !@              ("!KCL  'AL+W=O
M<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( "F"JU0)AOP7KP0   H-
M   9              " @<Y   !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL
M4$L! A0#%     @ *8*K5,0FB6CS @  308  !D              ("!M$4
M 'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  I@JM4(8M&
M'\D"   D!@  &0              @('>2   >&PO=V]R:W-H965T<R]S:&5E
M=#$R+GAM;%!+ 0(4 Q0    ( "F"JU0>Z3[X\ D  (8=   9
M  " @=Y+  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @
M*8*K5+GT/(0/!   >PD  !D              ("!!58  'AL+W=O<FMS:&5E
M=',O<VAE970Q-"YX;6Q02P$"% ,4    "  I@JM47A+IE,L%  ###0  &0
M            @(%+6@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4
M Q0    ( "F"JU2NE0G * 8  )(.   9              " @4U@  !X;"]W
M;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ *8*K5"9VQ/0R P
MQP8  !D              ("!K&8  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX
M;6Q02P$"% ,4    "  I@JM4=$55+*@(   E&   &0              @($5
M:@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( "F"JU2P
M+1/9D0,  #X(   9              " @?1R  !X;"]W;W)K<VAE971S+W-H
M965T,3DN>&UL4$L! A0#%     @ *8*K5#7K>Z = P  Q 8  !D
M     ("!O'8  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "F"JU2H=:5HO0,  ,8(   9              "
M@4&)  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ *8*K
M5$2I)W9= @  [00  !D              ("!-8T  'AL+W=O<FMS:&5E=',O
M<VAE970R-BYX;6Q02P$"% ,4    "  I@JM4=FR9C!(%   3'   &0
M        @(')CP  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0
M   ( "F"JU1L?VO,U@,  )X/   9              " @1*5  !X;"]W;W)K
M<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ *8*K5 CR1XF: @  X 8
M !D              ("!'YD  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q0
M2P$"% ,4    "  I@JM4D#('ML4#  "M#@  &0              @('PFP
M>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( "F"JU0#VT*^
M*P,  ,@(   9              " @>R?  !X;"]W;W)K<VAE971S+W-H965T
M,S$N>&UL4$L! A0#%     @ *8*K5(NG<F!7!0  )QD  !D
M ("!3J,  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  I
M@JM4RBQN<(P#  "(#0  &0              @('<J   >&PO=V]R:W-H965T
M<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( "F"JU0EY/_(@00  $X2   9
M          " @9^L  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#
M%     @ *8*K5$X^7$P= P  N0D  !D              ("!5[$  'AL+W=O
M<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  I@JM4KH* V>P"  !<
M"   &0              @(&KM   >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM
M;%!+ 0(4 Q0    ( "F"JU3.3;+P60,  &H,   9              " @<ZW
M  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ *8*K5(I-
M4T2F P  Z0T  !D              ("!7KL  'AL+W=O<FMS:&5E=',O<VAE
M970S."YX;6Q02P$"% ,4    "  I@JM4P'=U=D,#   '"@  &0
M    @($[OP  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (
M "F"JU1B"K( MP(  )@'   9              " @;7"  !X;"]W;W)K<VAE
M971S+W-H965T-# N>&UL4$L! A0#%     @ *8*K5!:_"LR* @  <08  !D
M             ("!H\4  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"
M% ,4    "  I@JM4IA_5\A #   R$0  #0              @ %DR   >&PO
M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( "F"JU27BKL<P    !,"   +
M      "  9_+  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( "F"JU1AMT5VW@,
M )\;   /              "  8C,  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    "  I@JM4*5V(H),!  #B&   &@              @ &3T   >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  I@JM4B(RI-Z4!   O
M&0  $P              @ %>T@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    ,0 Q $X-   TU      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>122</ContextCount>
  <ElementCount>207</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>38</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION</Role>
      <ShortName>NATURE OF BUSINESS AND BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2108104 - Disclosure - INVESTMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/INVESTMENTS</Role>
      <ShortName>INVESTMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2112105 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2115106 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2118107 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2124108 - Disclosure - NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE</Role>
      <ShortName>NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2128109 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2133110 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2134111 - Disclosure - BENEFIT PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS</Role>
      <ShortName>BENEFIT PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - INVESTMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables</Role>
      <ShortName>INVESTMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/INVESTMENTS</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2316304 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2319305 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2325306 - Disclosure - NET LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables</Role>
      <ShortName>NET LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2329307 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/LEASES</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails</Role>
      <ShortName>NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - INVESTMENTS - Schedule of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails</Role>
      <ShortName>INVESTMENTS - Schedule of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - INVESTMENTS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/INVESTMENTSAdditionalInformationDetails</Role>
      <ShortName>INVESTMENTS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2414405 - Disclosure - PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2417406 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2420407 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2421408 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2422409 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2423410 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Schedule of Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2426411 - Disclosure - NET LOSS PER SHARE - Computation of Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails</Role>
      <ShortName>NET LOSS PER SHARE - Computation of Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2427412 - Disclosure - NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails</Role>
      <ShortName>NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2430413 - Disclosure - LEASES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails</Role>
      <ShortName>LEASES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2431414 - Disclosure - LEASES - Summary of Lease Cost and Other Operating Lease Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails</Role>
      <ShortName>LEASES - Summary of Lease Cost and Other Operating Lease Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2432415 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>LEASES - Schedule of Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="bdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2435416 - Disclosure - BENEFIT PLANS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails</Role>
      <ShortName>BENEFIT PLANS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS</ParentRole>
      <Position>41</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="bdtx-20220331.htm">bdtx-20220331.htm</File>
    <File>bdtx-20220331.xsd</File>
    <File>bdtx-20220331_cal.xml</File>
    <File>bdtx-20220331_def.xml</File>
    <File>bdtx-20220331_lab.xml</File>
    <File>bdtx-20220331_pre.xml</File>
    <File>bdtx-nonxemployeedirectorc.htm</File>
    <File>exhibit311_q12022.htm</File>
    <File>exhibit312_q12022.htm</File>
    <File>exhibit321_q12022.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="422">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="34">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>59
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bdtx-20220331.htm": {
   "axisCustom": 0,
   "axisStandard": 14,
   "contextCount": 122,
   "dts": {
    "calculationLink": {
     "local": [
      "bdtx-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bdtx-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "bdtx-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bdtx-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bdtx-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bdtx-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 332,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 5,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 10
   },
   "keyCustom": 10,
   "keyStandard": 197,
   "memberCustom": 8,
   "memberStandard": 27,
   "nsprefix": "bdtx",
   "nsuri": "http://www.blackdiamondtherapeutics.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.blackdiamondtherapeutics.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108104 - Disclosure - INVESTMENTS",
     "role": "http://www.blackdiamondtherapeutics.com/role/INVESTMENTS",
     "shortName": "INVESTMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112105 - Disclosure - PROPERTY AND EQUIPMENT",
     "role": "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115106 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "role": "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118107 - Disclosure - STOCK-BASED COMPENSATION",
     "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124108 - Disclosure - NET LOSS PER SHARE",
     "role": "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE",
     "shortName": "NET LOSS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128109 - Disclosure - LEASES",
     "role": "http://www.blackdiamondtherapeutics.com/role/LEASES",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133110 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134111 - Disclosure - BENEFIT PLANS",
     "role": "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS",
     "shortName": "BENEFIT PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "role": "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - INVESTMENTS (Tables)",
     "role": "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables",
     "shortName": "INVESTMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "role": "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316304 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "role": "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319305 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325306 - Disclosure - NET LOSS PER SHARE (Tables)",
     "role": "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables",
     "shortName": "NET LOSS PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329307 - Disclosure - LEASES (Tables)",
     "role": "http://www.blackdiamondtherapeutics.com/role/LEASESTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i377d263c6d38493ca25e90aa73fd3701_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails",
     "shortName": "NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i377d263c6d38493ca25e90aa73fd3701_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i76fdf0838e4546cd851611fb3634158c_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i76fdf0838e4546cd851611fb3634158c_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410403 - Disclosure - INVESTMENTS - Schedule of Marketable Securities (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails",
     "shortName": "INVESTMENTS - Schedule of Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "bdtx:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411404 - Disclosure - INVESTMENTS - Additional Information (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSAdditionalInformationDetails",
     "shortName": "INVESTMENTS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "bdtx:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414405 - Disclosure - PROPERTY AND EQUIPMENT (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails",
     "shortName": "PROPERTY AND EQUIPMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "bdtx:AccruedContractResearchServiceFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417406 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "bdtx:AccruedContractResearchServiceFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420407 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421408 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails",
     "shortName": "STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "ife37765db49e41bf81afa44e8728613a_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "ib4b87c0a8eda41d88bf0d13971431e26_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422409 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails",
     "shortName": "STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "id3281f5219574c05b5edcdfcb8708b8f_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423410 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Restricted Stock Activity (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails",
     "shortName": "STOCK-BASED COMPENSATION - Schedule of Restricted Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "id3281f5219574c05b5edcdfcb8708b8f_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426411 - Disclosure - NET LOSS PER SHARE - Computation of Net Loss per Share (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails",
     "shortName": "NET LOSS PER SHARE - Computation of Net Loss per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427412 - Disclosure - NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails",
     "shortName": "NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bdtx:LesseeOperatingLeaseNumberOfContracts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "contract",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430413 - Disclosure - LEASES - Narrative (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails",
     "shortName": "LEASES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bdtx:LesseeOperatingLeaseNumberOfContracts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "contract",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431414 - Disclosure - LEASES - Summary of Lease Cost and Other Operating Lease Information (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails",
     "shortName": "LEASES - Summary of Lease Cost and Other Operating Lease Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432415 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails",
     "shortName": "LEASES - Schedule of Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "id0aaa27bb3be4aaeb9e6a0b78f8eee6f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435416 - Disclosure - BENEFIT PLANS (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails",
     "shortName": "BENEFIT PLANS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i9079e499652941b491fb8e9ed7ce1958_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i9079e499652941b491fb8e9ed7ce1958_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION",
     "role": "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION",
     "shortName": "NATURE OF BUSINESS AND BASIS OF PRESENTATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - FAIR VALUE MEASUREMENTS",
     "role": "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20220331.htm",
      "contextRef": "i2de83412714b43ca9f1b17fd070e6c44_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 38,
   "tag": {
    "bdtx_A2020EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Employee Stock Purchase Plan",
        "label": "2020 Employee Stock Purchase Plan [Member]",
        "terseLabel": "2020 ESPP"
       }
      }
     },
     "localname": "A2020EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20220331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdtx_A2020StockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Stock Option Plan",
        "label": "2020 Stock Option Plan [Member]",
        "terseLabel": "2020 Stock Option Plan"
       }
      }
     },
     "localname": "A2020StockOptionPlanMember",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20220331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdtx_AccruedContractResearchServiceFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Contract Research Service Fees, Current",
        "label": "Accrued Contract Research Service Fees, Current",
        "terseLabel": "Contracted research services"
       }
      }
     },
     "localname": "AccruedContractResearchServiceFeesCurrent",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20220331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Three",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Three",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20220331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdtx_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Operating Lease Liabilities",
        "label": "Increase (Decrease) in Operating Lease Liabilities",
        "terseLabel": "Non-current operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20220331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdtx_LeaseOtherInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Other Information [Abstract]",
        "label": "Lease, Other Information [Abstract]",
        "terseLabel": "Other Operating Lease Information"
       }
      }
     },
     "localname": "LeaseOtherInformationAbstract",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20220331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdtx_LesseeOperatingLeaseArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Area",
        "label": "Lessee, Operating Lease, Area",
        "terseLabel": "Area leased (square feet)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseArea",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20220331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Due after Year Four",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20220331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdtx_LesseeOperatingLeaseNumberOfContracts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Contracts",
        "label": "Lessee, Operating Lease, Number Of Contracts",
        "terseLabel": "Number of leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfContracts",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20220331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bdtx_OpenMarketSaleMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Open Market Sale",
        "label": "Open Market Sale [Member]",
        "terseLabel": "Open Market Sale"
       }
      }
     },
     "localname": "OpenMarketSaleMember",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20220331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Office and Laboratory Space, NY",
        "label": "Operating Lease, Office and Laboratory Space, NY [Member]",
        "terseLabel": "Operating Lease, Office and Laboratory Space, NY"
       }
      }
     },
     "localname": "OperatingLeaseOfficeAndLaboratorySpaceNYMember",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20220331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdtx_OperatingLeasePrincipalOfficeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Principal Office, One",
        "label": "Operating Lease, Principal Office, One [Member]",
        "terseLabel": "Principal office, lease one"
       }
      }
     },
     "localname": "OperatingLeasePrincipalOfficeOneMember",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20220331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdtx_OperatingLeasePrincipalOfficeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Principal Office, Two",
        "label": "Operating Lease, Principal Office, Two [Member]",
        "terseLabel": "Principal office, lease two"
       }
      }
     },
     "localname": "OperatingLeasePrincipalOfficeTwoMember",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20220331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdtx_OtherAwardTypeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Award Type",
        "label": "Other Award Type [Member]",
        "terseLabel": "Employee Stock Purchase Plan and Other"
       }
      }
     },
     "localname": "OtherAwardTypeMember",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20220331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdtx_PerformanceRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Restricted Stock Units",
        "label": "Performance Restricted Stock Units [Member]",
        "terseLabel": "Performance Restricted Stock Units"
       }
      }
     },
     "localname": "PerformanceRestrictedStockUnitsMember",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20220331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdtx_RentExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rent Expense",
        "label": "Rent Expense",
        "terseLabel": "Noncash rent expense"
       }
      }
     },
     "localname": "RentExpense",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20220331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Authorized Shares, Percent of Common Stock Outstanding",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Authorized Shares, Percent of Common Stock Outstanding",
        "terseLabel": "Increase of authorized shares, percent of common stock outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20220331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount",
        "terseLabel": "Maximum employee subscription amount"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20220331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period",
        "terseLabel": "Award purchase period (in months)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20220331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]",
        "terseLabel": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]",
        "terseLabel": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Addresses [Line Items]",
        "terseLabel": "Entity Addresses [Line Items]"
       }
      }
     },
     "localname": "EntityAddressesLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressesTable": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container of address information for the entity",
        "label": "Entity Addresses [Table]",
        "terseLabel": "Entity Addresses [Table]"
       }
      }
     },
     "localname": "EntityAddressesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_FormerAddressMember": {
     "auth_ref": [
      "r354",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former address for entity",
        "label": "Former Address [Member]",
        "terseLabel": "Former Address"
       }
      }
     },
     "localname": "FormerAddressMember",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r171",
      "r177",
      "r192",
      "r194",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r310",
      "r333",
      "r334",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r171",
      "r177",
      "r183",
      "r192",
      "r194",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r310",
      "r333",
      "r334",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r171",
      "r177",
      "r183",
      "r192",
      "r194",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r310",
      "r333",
      "r334",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r82",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r82",
      "r87",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r82",
      "r87",
      "r158",
      "r193",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r26",
      "r278"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails",
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r28"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional and consulting fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r24",
      "r149"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r16",
      "r36",
      "r37",
      "r38",
      "r325",
      "r339",
      "r340"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r35",
      "r38",
      "r44",
      "r45",
      "r46",
      "r74",
      "r75",
      "r76",
      "r235",
      "r335",
      "r336",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r14",
      "r224",
      "r278"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r221",
      "r222",
      "r223",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r196",
      "r198",
      "r226",
      "r227"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustment to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r198",
      "r217",
      "r225"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r71",
      "r110",
      "r112",
      "r116",
      "r134",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r232",
      "r236",
      "r250",
      "r276",
      "r278",
      "r314",
      "r324"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r32",
      "r71",
      "r134",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r232",
      "r236",
      "r250",
      "r276",
      "r278"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r242"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r123",
      "r141"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r119",
      "r124",
      "r141",
      "r316"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r121",
      "r141"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r199",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Principles of consolidation and unaudited interim financial information"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r2",
      "r73",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "NATURE OF BUSINESS AND BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r66",
      "r67",
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of equipment included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r22",
      "r65"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r60",
      "r65",
      "r69"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Cash, cash equivalents and restricted cash, end of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r60",
      "r251"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r184",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r30",
      "r157",
      "r317",
      "r329"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note\u00a010)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r159",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r74",
      "r75",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r13",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r13",
      "r278"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock; $0.0001 par value; 500,000,000 shares authorized at March\u00a031, 2022 and 500,000,000 shares authorized at December\u00a031, 2021; 36,287,568 shares issued and outstanding at March\u00a031, 2022 and 36,234,624 shares issued and outstanding at December\u00a031, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r181",
      "r182",
      "r195",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "BENEFIT PLANS"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r40",
      "r42",
      "r43",
      "r48",
      "r319",
      "r331"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r70",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in process"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r129",
      "r143",
      "r146"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "Loss position fair value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Schedule of Marketable Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employer contribution amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer contribution, percent of each participant's salary"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Employer contribution, matching contribution percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r63",
      "r147"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r49",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r88",
      "r90",
      "r92",
      "r93",
      "r94",
      "r98",
      "r99",
      "r240",
      "r241",
      "r320",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic (in dollars per share)",
        "verboseLabel": "Net loss per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r49",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r90",
      "r92",
      "r93",
      "r94",
      "r98",
      "r99",
      "r240",
      "r241",
      "r320",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted (in dollars per share)",
        "verboseLabel": "Net loss per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation cost, recognition period (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost, options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Shares issuable under employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options to purchase common stock",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r44",
      "r45",
      "r46",
      "r74",
      "r75",
      "r76",
      "r78",
      "r84",
      "r86",
      "r101",
      "r135",
      "r179",
      "r180",
      "r221",
      "r222",
      "r223",
      "r230",
      "r231",
      "r239",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r335",
      "r336",
      "r337",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r172",
      "r174",
      "r175",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r243",
      "r283",
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r242",
      "r243",
      "r245",
      "r246",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r172",
      "r184",
      "r185",
      "r190",
      "r191",
      "r243",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r172",
      "r174",
      "r175",
      "r184",
      "r185",
      "r190",
      "r191",
      "r243",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r172",
      "r174",
      "r175",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r243",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r172",
      "r174",
      "r175",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r283",
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r247",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r127",
      "r128",
      "r131",
      "r132",
      "r133",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r142",
      "r144",
      "r145",
      "r146",
      "r173",
      "r178",
      "r238",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnTerminationOfLease": {
     "auth_ref": [
      "r258"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.",
        "label": "Gain (Loss) on Termination of Lease",
        "terseLabel": "Gain on lease termination"
       }
      }
     },
     "localname": "GainLossOnTerminationOfLease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r151",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in current assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "negatedTerseLabel": "Amortization of premium on investments"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNonoperating": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.",
        "label": "Investment Income, Nonoperating",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r242"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investments:"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r130",
      "r313",
      "r322",
      "r341",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "INVESTMENTS"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r272",
      "r274"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease Cost"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Lease Cost and Other Operating Lease Information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r273"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r273"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r273"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r273"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r273"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r273"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022 (excluding the three months ended March\u00a031, 2022)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r273"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease term, optional extension (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of credit outstanding"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r27",
      "r71",
      "r113",
      "r134",
      "r160",
      "r161",
      "r162",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r233",
      "r236",
      "r237",
      "r250",
      "r276",
      "r277"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r19",
      "r71",
      "r134",
      "r250",
      "r278",
      "r315",
      "r327"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r29",
      "r71",
      "r134",
      "r160",
      "r161",
      "r162",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r233",
      "r236",
      "r237",
      "r250",
      "r276",
      "r277",
      "r278"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r60",
      "r61",
      "r64"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r39",
      "r41",
      "r46",
      "r47",
      "r64",
      "r71",
      "r77",
      "r79",
      "r80",
      "r81",
      "r82",
      "r85",
      "r86",
      "r91",
      "r110",
      "r111",
      "r114",
      "r115",
      "r117",
      "r134",
      "r160",
      "r161",
      "r162",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r241",
      "r250",
      "r318",
      "r330"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently issued accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Activity"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Computer and office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r110",
      "r111",
      "r114",
      "r115",
      "r117"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r265",
      "r274"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "ASC 842"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r260"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r260"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r260"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r262",
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liability"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r259"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r271",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r270",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": {
     "auth_ref": [
      "r33",
      "r34"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized loss on investments",
        "verboseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other non-cash items"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other (expense) income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": {
     "auth_ref": [
      "r122"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale",
        "terseLabel": "Impairment of fair value assets"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedTerseLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r199",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r12",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r12",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r12",
      "r278"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares and 10,000,000 shares authorized at March\u00a031, 2022 and December\u00a031, 2021, respectively; no shares issued or outstanding at March\u00a031, 2022 and December\u00a031, 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r20",
      "r21"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r59",
      "r220"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from exercise of common stock options and ESPP"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r55",
      "r56",
      "r120"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sales and maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r24",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r152",
      "r344",
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r23",
      "r148"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r9",
      "r10",
      "r150",
      "r278",
      "r323",
      "r328"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r9",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r9",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r229",
      "r311",
      "r349"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r6",
      "r11",
      "r69",
      "r342"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Unvested restricted stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r15",
      "r180",
      "r224",
      "r278",
      "r326",
      "r338",
      "r340"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r74",
      "r75",
      "r76",
      "r78",
      "r84",
      "r86",
      "r135",
      "r221",
      "r222",
      "r223",
      "r230",
      "r231",
      "r239",
      "r335",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r269",
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease obligation"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds from stock issuance, net"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Computation of Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r198",
      "r216",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r198",
      "r216",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r242",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r24",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r199",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r202",
      "r211",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested restricted common stock, ending balance (in shares)",
        "periodStartLabel": "Unvested restricted common stock, beginning balance (in shares)",
        "terseLabel": "Units outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number\u00a0of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested restricted common stock, ending balance (in dollars per share)",
        "periodStartLabel": "Unvested restricted common stock, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted average grant\u00a0date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r212"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of units vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum employee subscription rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Life and Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Canceled or forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled or forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r204",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Options vested or expected to vest, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options vested or expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options vested or expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Shares issued under share-based compensation plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r197",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable, intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, remaining life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding, remaining life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options vested or expected to vest, remaining life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Maximum percent of fair market value of common stock"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r266",
      "r274"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r31",
      "r44",
      "r45",
      "r46",
      "r74",
      "r75",
      "r76",
      "r78",
      "r84",
      "r86",
      "r101",
      "r135",
      "r179",
      "r180",
      "r221",
      "r222",
      "r223",
      "r230",
      "r231",
      "r239",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r335",
      "r336",
      "r337",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r101",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r12",
      "r13",
      "r179",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock related to ESPP (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r12",
      "r13",
      "r179",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r12",
      "r13",
      "r179",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r12",
      "r13",
      "r179",
      "r180",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)",
        "verboseLabel": "Exercise of common stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r12",
      "r13",
      "r179",
      "r180"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock related to ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r31",
      "r179",
      "r180"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of common stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r13",
      "r17",
      "r18",
      "r71",
      "r118",
      "r134",
      "r250",
      "r278"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r127",
      "r128",
      "r131",
      "r132",
      "r133",
      "r173",
      "r178",
      "r238",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r72",
      "r184",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. Government agencies"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r267",
      "r274"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants to purchase common stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r89",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r88",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123386189&loc=SL77918607-209975"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r350": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r351": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r352": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r353": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r354": {
   "Name": "Form 10-Q",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r355": {
   "Name": "Form 8-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "308"
  },
  "r356": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r357": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r358": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r359": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r360": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r361": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r362": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r363": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r364": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r365": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r366": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0001701541-22-000018-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001701541-22-000018-xbrl.zip
M4$L#!!0    ( "F"JU2N$;K/ND<! ,':#0 1    8F1T>"TR,#(R,#,S,2YH
M=&WL?>E7&\F2[_?Y*_2X\V:ZSZ%P[I7I[LL[M%DN/99D@[!'?/')%0IKX6IA
M^^M?9%4)Q&9C6X $U>>XD51569D9$;]8,C+RS_]WUNW43OQ@F/5[_US"*VBI
M]O]6__P_2?*_?^V\KZWW[;CK>Z/:NX'7(^]JI]GHL/;9^>'76ACTN[7/_<'7
M[$0G2?[,N_[Q^2 [.!S5""+DQL7!6Y$RSZDC"98!)2QU(3%8\80*@ET04II
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M>1MTPM]'P"1LO[7!ZUM[Y_7/?T,[H)U:AP$(?PX (;!.$4U2<.% 7Z T400
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M6#Y*978N8%+ ['@Y]91I NS,F&<H[IHV-)5:2")M3'U^';S\JBW0%\/+F+N
M )%UK+F('--I&D\K9 IA@:2KC-&7;XR^&%X64DKLN,$ RBQ0*ZU**:72"YDZ
MKQ?@>)9YY.57PSZ8@B:GS ?O,+@WJ0S6A10#]WBIX>]"L<]K,E'GA8&4(X'@
M5%NA!5B&*: 1ED(B&W0\QIZ^#@9:0+MP7AB(X!!8RB117C+)G=0QZ9AYBZBF
M:A&.?IM'!3;WN7XS7!M1#&LED->4L)1[(Y&1TH'U@U++C:X8:/YH9B3W&$G)
M#=7,J[BU@ 2D$!?*"9(NPM;_5UPZQTJ*$:;@+J>685#^X% S)HP/B %\+\*^
M]WD,/,^00$[)5%+P_[A@A!F-;8H-\Y+&]$2^"#MXYMP#FV':L\4IYLH@I@T#
MQ]VDF'%./'CQR'FQ"![8/ K3#'455FDJ\U-48\P028\8TU(IJ6RJS$L@T(L)
M9_"XVPP[C2RWS&$F+0,Z\50C%7>>+4"9]@^#/HQW=/ZA U, %D*T#HYC&W^=
MM\Z/_76Z75Y<$*S3E 7)4I^FB#,2C,$6<2*,=? 'NP581)I#\LS0%;=!..L<
M<4(RH:VQP:' A$J!5(XLP+[-'R+/YGC0RT;@0L&-F]E9_+0H1@.U-%CN K<A
M,!4+MO-4!F^"%D1A$UZ8(#TYI6:X-RCN7E682!$X&-_(4!"HN+E-J\"-6 !?
MZ8<HU0P!AKQH>HEH'AA5+G6$,,&YLE8;+F/A#.DH6H#\\+DET@RUDT$T@($G
MF$^9<V")4\1DBE*;!O"4%J!@[P\1Z;W70W_8[[CM[O$ K//N @6(9-"Q!(3V
ML1R8#\CPD%I*A$8H5@E#+TR>GIY4LY,JH)'BU%L$-CC38.MIGEK)D0S$2K8(
M]0A_B%3O^KD+;.,QO]L]>/0 3(E%$2N!L,=1.W'&F!5:.R=X/(PTU49+MP Y
MR/-.JQE&(K0'] .Y\B+6+,%*I$8A4%E&Q+-GBG5QF&/,YI960*.&[OJILU77
M8I_S U>;QY$J\99'I0>*1]%C]G/T&(//D!.C-XY]N9SG;K%PMEJV 1\G#4RN
M3+['%NZD+B;88>:M((B!X<BD"?$42P$.- 4(E>7!P'AR,#!\J,C\G8-T\<,/
MTIV^]1<.TA6Q\"Y33BL1F E"2TZL=M0H*5)\>6)Z1;SOZ;=I>OQ*CCGU+*6<
M$A\L4U1J0FDJJ$U]2)D,;'$Q<Z-[W.F?>Y_3Y<-X8 _!8IQO]+RQ7L],7)8R
M2%C& C$,7*X@B/0V;JE.7P#>/2&)GA_YE/4.I4Y0R@7#.F@5,"-2.@RV)/'X
M)CWGV/Q?.]4#=T?L?9J<!1+.%2&G78)?(208F1(%3*0VS AJL!,^!46&-&/:
MN)R0>$)(7!'R 83$#R<DGADAM> RY2D(H^>,V%1ZESJ'+*.$$:K9XDODC@=O
M+K,C[W)2[H%M/=S9W7N)4NF(0)9BKRP"YR]0G8*#$,!'5QPD5*C%E\KG(>:S
M2"8.W%+G0BH19\$AHY6BA))4*&XTM8LKF;GQTQP=^L'EA9<HC<9Y886(QT9R
MEC*O4VQ]"LHR2)H2)!97&I^>@,\B@9)JFQ+!=:"6:8F,T@1)G$IA,==^D21P
M-@[[XME4SR+XP=,T%=P9ICS#)LCHZ3#F94JDP%0O$-]L]VR_"_2"F8A/ON];
M':EV2RG[N,-C#:8L[N#HYZ'UC;-C:.U%(KLV,I78>V\5958'R;"D4J9(,&.,
MU0N$['-/X&=!_N"<\BDQ8$''Y&BA,3(,E('S6GHI%PGY'T3@+=_S ]T!^JZY
M;M;+P,B&NT[\"Y;AE#%0[$;&G<>,I. I84&8"$A(SP0W+TV&GY?$SR+%#MS>
M>)J69@*DF#A-;*J<U#SEQA*=WB#Q4RQ@/^J\75M#_I5YHT2"]TFPXBFSB!ON
MG77!@M9#TL@%R/)\6/1@09;TD4#@_RMEP)UD"%G#!)74@_5.*+&6+I R>BZZ
M/+^Z<0&D"-Q&SI%ETG"C&?*(.2,!I9Q8@*-EYD"F9G@&N$!I\$8%33Q+M3&<
M&JVT2XT/7H<%V'+PW '2Q\DT,]XQB0U!WC!BF4GC(7 Q:(8L3=D"0UT><OG@
M!Z$_Z.J>]7?1Z27BGJ76N. H"!5GJ0)B$@.>%?%8.>HH7SA!>QY"/A(($BX=
M#Q:$*V9V&A-L*JU' ENP-L("2=NLLRM^%8:OO?<ERC4. FGI-'4$,8V=9(31
M>/0B%Y)XXN=?KE\9RSP.@N"86LP#.">8B90H(K QSF)!K$&*+E 0Y96QP_-'
M9XS'&""#.N8$XV#I*0$&.7)8*L/=[=R^.>:=-6C!99UQC*==U2[8."OJ[FP.
M^MUW_>[Q>)2'Y9IA0P]Z6>]@"%;$[J$>^+_.[V[@=2Z>!1*/50)FT(X9I%5,
M4 )'&6/M)&>+%)=]H6SQ+&C!L-=(A. 8(0Q:UBD&TR-0JHSSB-_:^?#:V>(5
MA-1BS0CI69#:<<:053(XY0S7B*36TYOA_8HEGI0EG@4EE.8!T9BS$SR+&TO3
M@.-.>BZ$,4"S"B5>F9LJ#4]3*;U,N642&2VM$,1+@JE UN *(UZ9UV&=1BGH
M"$YDC'D%Q; B"B:0 )L(:2J$N,X0G_5@H!^C5L?S8P/&%DP'(#]GA*4DQ!T0
MFA#)L :"D5!APW.PPE.APN4N[?C[0-O1K7W:>0QH<G72RH.W:@L%AH<TDE"E
MF*1>&2&TM\[$K%"-<+FI-)U?ILK+B[PKQS_6G98?=*?SOV%^@9]Z!_E]'P99
MSV;'NE,4^6F=]A][BVGZTR',2](/_QUNDWT\&KR-%WZ8XB0N\3,AN/3@HDJM
M G,LUF$P,6V\J'Z+%2"8?(D4;_8>(8?LBN)8)8@D1,X@:*VQL0X39GRL?"NM
MUD8$:15"<?F9HA+W!>;)Y,,<IH6)!/,'@N3TK;^@+SD3BGB$M% I"^![*T.5
MX/ S9C;511D8-,]I83_$WP5;K_7<>VUB%>'^X'SW6%O?:#\RLOU4WMB;[.SM
MP _[XX'UP^+KH=<N[X_+3E;_A/]-CL3E4@>7YJ=#<A24#TI;2T5*@T<D_1+)
M=_7,<'3> 4)ULUYRZ+.#P]%;QH]'?YQF;G3X%B/T?Y>NWZ<'!W#KJ'_\%I/C
MB*[#8]V;7+7]3G_P]A] 713"'P$ZGP3=S3KG;_^[!>0:UAK^M+;3[^K>?R\/
M=6^8#&&XY8W#[,*_Q1C>G7\]+3N#T!^=K.<GG<-4_=\_XI0DSMM(-F  @&R8
MB'@7=$?/35]JAP,?_KGTCP=0!"VMMK3I^%H_U"+_ B\-_WRC@4YQ=B?DND6T
M_-VZDQWTWEIX)*]%<P\YH.L_,P7BQA2D-Z> 1 ;9:VRW-M9KNZVUUL;N]3[/
M86]W-][M[6RWMC=V:VN-]=K&_[[[UUIC:Z/VKEFO;^_N;C<;SSB$FSQW]Q ^
MK^W^:[NQU6HVEFOK*^]6:@1QIN:^VU\>_M_<<]%F<Z=>^Q-@N-?O-<9=:,36
M2K3>B6*?$1?/1< DQ0S,$!M+81B<!H=2%!-][]QY7^OIJ#6=S]ZN]VU>43VN
M'"]-\K8_G9OU_LE[LG/2IO6Q.]HXV=]21\VC3M9H'1[N=S_2]L7!6:/U$=>W
MVGS_<YNW/S>.ZA=P-]GOU->WZ7O:Z+0O^KQ]M,?:G_>_-DB=U5M[J-'ZJ]O\
M_ G^;1ZU+^JD<='H[K?6SAM8GKTG^^?MSU;4C^JL3?;8_KH]:[;V6&-KCS2Z
MFX?-K?VC^GK[=/]H[VS_:.VL?71PXK8^,?>OOSO[I'-BCOKG]8O#H_W6X=?&
MQ09OM [0?JM-VI\WV'ZW?MHX^JO;:&UVZ^N;67-3GM6/VE\<LTKIP!*P1F@2
M:XDD)DB?&!)-<$M2ZMS2*D;)QUP77A%A]25*P2A7#F4_P5H!%9- =SOZ>.C?
M3C[\X;+A<4>?@TV1OS1_Z(]289O^:-3OOHVJ_<0/1IG5G7(N\FDI+E]I_154
M:/X1V!<C-WES<1FMX'CIS<C=OD96.%'W7OW6DW@%W7M-B16<WO_H=+-O\AX7
MO8:)B=/WSR6Z-'G@6#L'!N!;<GQ6B]2:XHF.#[?GIG_\<";Y# W'QH<_;4_D
M[/$$F/)Q#/X$6"GG._ZX/Q@MU?)DQQ&\X&ST-F1GWB6CP7@Q86<S,UM[8K^U
M?=;HUFG[:..\N?7W86/KXUF=_-VI'^UT]X]VCIKK'_E^=P^@:*-\YA.\B_?V
M6\=PSP9I7[BLWMIF[>X&VE_?N&AW]\X;6_O=QE:=-=8[T,>ON/Y)GKYOK8WJ
MN^CL?6L#-];;[$NL*.:U=8GWQB;1;TJDIS:QJ1,I5@%YKY96_^L?X&*)/^Z%
MKI++GYB!9XIR'_?6=EH;.^_;M9V-#\V=5NW#WL[NWEJC56LU:V""M<#.JF%:
M:^[4,/_-_5YK;M9:_]JH35EGEY;9VKM6O(P59=>F*!?V-SG./0?>JX<:"OG
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MLQT=\LRBU(!,")S^?MO9>3RFB$=<=#X<]GN+G(*QN(S17/M".4VY1B$1E%'
M?(43PX5/!$M3)"WXS2E@/N$D09+)%P#[5UD.__4/27#ZQ[ V\AU_')FPULNY
M<#E&2COC"/$U#9 %+/]<:N+Y]0+FW]$+-"C#A%%(><FT(]HZ&83E 3/'O/=5
MG.RQL !-80&K7^Q=W++_NO">"[#SUC^29FL[8@'?W]J$YS]>-.-\=6&>/G_$
M[>XG< /7.(SOK-YJGS?7P7T\_:(QLT9RDU!".6"#"(FAX!\*"6XBPB3 +W?%
MS=!]<;,Y#IL]*9M78;/Y8/+SQMJ7N' :R]0FG"N5,&-]HCS!B6<ZQ8$HC"7Y
MZ3#:+)FF"J,M%&LU/WXQU ?#B4Q8&O,)A4H3\+#!RG*2:\4D7!+?B:H]&7=5
MH9>Y89V+^ND7J8S2C(4$!0L,XRU)-'(XD7%_*;%!>V-^-!3S_!9XKF1_VP3<
M\H.<$9=S$(,ON@S%ZIZ;_!2R(=C&M;A-$0SR$#-/>P?>U881_6H=/1S5!OGF
MHWLM\\FNCH5)V50_G%LYN:&<89I7ZKD[.ET._,HEJPW[G<S5)@2?>"LH^BJ%
M%U+PQ^J?9O#F9HF:']TZ<S>O$8P=]C^5-(\>E-5V50.Q3&SV V"AX_%@.(X9
MSJ-^#>[(4R$P^<W\'I<"1H>^MF9';Q<NX9>2%2'8S!-^L5R1#]P[^4-YQ'P%
M"SZ+/.*2)M&E?HMOL75Y-2]D=2_//W.&YBUFOF<_7#8J2D=YL!=J%B!P^( L
MU-<S/0.=AVQVS[NFW_EM:N'N%R=G4+SD)<]=H]S]D7.6/RMT;0U@\?0P@U^N
ML/-'4D=?(.<]>>YTJ<#.,3&Y^"^P:=ZX^/NH';=CP?W[G[?AF8WS^M;?L4]L
MO_7I:+^UQ^M;8#BO[]W<4$WC2F5SZR.&L76@3=1N;9^VN_6+QM%AI_&YT0$3
M_[1-VJ>-3]#'FXG^A&KEJ,4)9QZ,:7#K$\5H2(@0AEMN/4L5N/C];K<?6:=O
MOR[7CO6@=J([8U_[SUPAW[_W\54A[Y/S?PGJ!:97S/\ YK^Q5T!+SR0/+'%
MJX2I0!)%C$^P3(F31"!,R-+J7^NM_WTL#G]1ZO/9%,!&J92+O;DW8W]192]\
MV._I9&3[NHRDW@="J$V<0: @%/6)=M@FP1KNB D&JUBY%1S#AAXZ_>_:5J=O
M= =\QPYXC[6Z'GSUHX=LLKGAKJM?<-<?)#T37_[[(KR [_GU\,.CX\)VS\6M
M%KYFSFOVT-NO->C65S"J?;[!*(8:IO9;_X9_+^I-'>IA+60=[VJZTRFC7#&
M\>]Q%L,7HW[-^/(&:+B,8!2/8AHW]A354,I@QE0,9 (B,< 1+\=J*#4'5\%M
MBK<>#[SUN1.%22TO%S:L_0;M =S4AF-P!(:'_;C]NU:4KX9G].CF*$[U]:[&
M?A8/EP/Y?3D/\_U&ID9K +G@)G,4Y0D>RN^')V-7RL9BW:%AWI.\IS'^IU#-
MZ?/A2M'.[?\_>M[BN_%@ -TJBB!%,V6D1^/A0D+P3Y=.8'#/%X]%\*DU27"Q
MD C1,51-26*<,E@ M)(@EU;;_M8"QS5RE8@YJW)9#Y/1RQJ-/_3RF<+$??S;
MZ']O>AYC0AY8.&@A(#5B"\!*-QN- (UR=3WH]Z+9V#FO>3 ASVO;T9K4-D_Y
M7M<C78L5@6Z"[54;T['CG3'<R1"/4+KC#\:=8E?=;M*J_19IEOY!*%DI;Q@=
M9GGYC.-8/N.Q0;?H[R6,^N'OSP>24Q,<Y[?$S-<%DF?UUE?V)3CF9<#@BZ5(
M) Q3E"CE1:*\#EXQ*U40%4I6*/G4* G I&L=Z+>O:6L!)0<Z0ET$CD$TUN[\
MM0;\F=QY8=@%>(6W#"9F$8!*%R;A?#G:IM <V')QC@YJ!X/^Z>AP<GD%3%6?
M]\WYD/7R^I+Y[IR8J4E@F/?T,+^,_YC<]MT;[N_?Y,9HGY8WW]/7R9U9K] "
MF)B$3"SN:3-[9>'6$;%:07CVZX@,K_"4S+Q92E<(_;F*L=^N0RO2F:Q._DRU
MS?>1T0LXFV+FXH><HY^KO.<LE0G[XP$!QCFH5?JP(:W=0Z=G'>$CDNO'\T]^
M/+_DI;;SC"6F%R7J?56;=? .9.J@/SB_(^B=WY0+FBUO6NCX=W-]I[-_9"_@
M7MY<WT"-=7C/UC;<6Z?[W;V+QM%>S"F$]K[>C']#^Y^ZC8LZ^"!?H8\?$8R)
MM<$'J5\XZ!OTL=4YJA]M\.:GV[O'OW@M4X&=2"CQ<7<85XF*)_$P[*0"#P6)
MU"ZM-NZR]^:L_O3C>#LO04'M%D9OH9PN+=_B:VG3O@S:/3HJY3/YUW@(;QX.
M;Z.2Z?<[!N[HCTS_K$*C!Z!1_3H:,6VQ!Q(ES,4MB1REB4E3FR@O"77>BI2(
MAQVM4QDICVZD3#7XT%IH2[,:P=.\<.Z1?>/N"$6%Y@]"\\GL;>63]ZZ8NQ=X
M4MH3P3FZ!>= #>VIP4DP6B2,2)IHHD(21/!2B@CJ[ ?@_"$+_O3YXJ[A&_'-
MN*_\SK!L%NY:M\I7J\#.[O7SQ:;QL(B- OO[GHO+/)>'\$Q6AN**47Q7YSR^
M_#2#5\-K:ST86S^&.T^R86ZW]W3/9KH30ZFQQG2\.9Y.[?3 #6MQ!V'F[MLE
M07_3O]\9YJP]S[K$X^/#V=5A1\4!:R_KL*.?7]("%+GX0E-/P2##2:J=!^DV
M+%'.T,0ID0KC4?!8??^PHINR/'U"^7&_F/RW Q_75T_\O6>6EP8 NGI$FV&_
M,Q[=_\C=QYS?92G\U$/3_S\<7*G= Y^8@==?$QU&?O!6=T[U^7#I3752^Z*?
MU+ZHBW_#0]_I3/14[3?0/OD27''NQ[<7N.[/+&C[X?,O7#]^."!.W3?LQE>I
M&EIU^L4Z1WQP+*%QQP5SRB6&1M6@O1>,NI1*_EW5L%B)!D\?F9Q+ %K+5^WK
M^KR8*5*<GKI\V\AUD_H&FWF"$!B8XUY6".?P4 _\<.FZP,I L E*4($TP\HI
M8G7P(DAN!6.I^;*=RRE'9 D S&9=D+U_+J$[$C?SS3Z[<:_/;OZBYGB4F\!
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MNM.P7[Z6LOBUUS_ME6F*Q><\<7'Y>M;B5#Y0S)&- ?8\P2#&:ZV.D;\< 8H
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MJ=:WA8C;?+@E0TQZ'%/S_ "8J-R"$$6BE[-8-Z;ZE',5,?42.2/[W9T<'O6
M'Y3EUN]5%GG /8<7-Q'],EUX#-QN\]AGIP_SX8L<^*OKN2<*=TQ._[C,D'=]
M.RXW1 PF@EP>!E(LZ425,NAEP\.B;S=V:\2!7&["B-L@BRS1Y>N;03;>36]<
MB1@P1?8RRS%.9?R6&XTW; N@3Z[D8C#Q4K&!B5 $"6\ET5[&K5=JN_WNU.Z
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M"JXH4J\[EV8&\/-)-NCW(FM>:N9RB:44F5)8RVS?:UNR[ENBN=S26(O34(A
M] $G[4[>,WD^RI>-&KI<AP.]?:([$^MATH-N5.;3-E"^\_1JX#F@@SP8G?O%
MO>EIBXGH8)6/KL_@\F0QZ3)<$\&YY,JNATZ[N'<RBG,6L?DP]]@[Y]/'K-UP
M^7+#KL"$(FBQ?$,5QKTJX^A]7IO)"8R4*=53$S"XS!HI^QJG=/E;WD2Q_^IJ
M7DI[XQO*:J6VU^ODV_HB-YU&6Z8,,,2Q1NWD<FNH2)^(T'68S\>$LRZY:>JU
MEW,;M^(M3X]HNF]7+)SOV,O[7YKKRU=4 ;5^XL^'R]=V[UVB1WP0FC_6I>UV
MDZ8ABTAX]2;H_,#%*AD%Q:Z&,6&P>.M$4 IC8Y(1<A"3+')A*8<UW9$AB)LM
M6IS:#IUO-#N?2&,>?;JRZLJ]B[IS/LRN0C++U^WRY=)5*XL87BF+(B-A] UW
MNUKA6F6SJ P2EU>J9;%YZ<O3E@9Y'F:^NS1(:^VO]QNUYB:XXXW6=.F/A3D9
M29$5S-*9'V'$5P2GLSQK:!YJ9.<9I4]T2/?#+-4/ 'EWE8>?477LR[']P*S_
MB&P^(ES- 4#V^C^&C13HN;;3JFU'0*PEM<WMQEHCKSRTW=AL[M376MO-QH/Y
M^&>/HG\H']R4BZ>G<E$+\RFI'!>[9T!E<8?&>USAK23PH;0IEC]CU"CF<T3'
M%3[EPI/[Q9N7D?_=JR#A;WL]#7X07/_]'LH^&AH_OQ0N+*6?7@IO-%'DRPCT
M3,[% E)-+*W>(Y=_Z4Z^_+I[Z/V='L4+E\+%U(6BDL(%E$)UKQ3N7JMLV+Q<
M L_#:G&A8N /X;&8-/&^/ZS$=$'$% B>5F*Z8&)*R /%])T>'M8V._W32AX7
M0QXC964ECXLFC_R!\IA7\#_L=YPO$FYQ^D=MX]_C;'1>R>=BR"=06E7RN6CR
M*>-QT'GMPG[M,J#S(W&@2CP70SR!T!@]FWP^<-6J$M?OG V"RE@M6:G5\UH
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MEUC2F.#A#QQB!1 +("X HO#:8BTBX<1Q$:/FB1O,N1:2!9)J/7>%^&@!Q.8
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M$_(DE8!UB<\\3F6KQ&<: NG+I4\L"8DGZ9"0SH-&EB*R$O.J"(K-)WY &I>
M=0'$ H@E8/TT 7%!QV6@Y J,#3+>$,19SL&6H.,:;6(,H)4:JIY&P/IF]2-+
MP/J9!*RO-C,.QV=GW9C+]=MN*W2&OML?C@=5C4%@ %39'W.%R\'06%^-R55/
M6C[D,YZ\M_KJ#L! \WPH$BS,3@_H[&&&8'R>V?/<3:K:!O#A8 S?QZ^YJAG<
M?AL7P%/3I*Z:XI-1EM9> >F5/>L _.SDG10Z(X"?7!LO._["[^/1?G_T(8[^
MM)UP64%*G:\QH&]QT"^ZT0UTH_WMY;I(/A%)1=3(,AYR=K-'F@2+/&?!T62-
M-6$#E"!-"?VM0:=6UJ1 %*1ZHDBU]H)-JR-50:2;(=)B8D-P3"IC$-')(.X$
M0R9XC!P6GB9)HJ1Q8Y/I6V<UW-\9NB=0%+.YQLTUF1CY=]1/:#P$I74XC*##
M]MW(PH658ALG!3^R7M'*K=MM9>5TJY)3?0>CKZKUKJ[:WB8I[I$(C)_*BWLL
M F/MJFVU P_2^V'<RMOO8++Y=GO36C.O^X.#Z<;[(^^[/SK6=;J=T7F1(3>2
M(<MG]E1,7$O)D4DZ@0PA$FGL0;\E3L0H&;8N1[7)PV;&/4B(HP!4D^;VD!KM
MK0"JQ"O6B%X+&G B5 =O%4K,Y+"MB,@"<"&J,WY1RT6N&2/:BJ@&X==3TX$;
M.N!?1]D/"_^&SN?-_X$?TSM.[>"XTZM#3O0RI.>>%''P0!!W=!(K-_(IO#N?
M#6CU^B-XNAUD9S*HXJ-X/+#=UID=C+(?>G0200,?]^P8K.R<YM3OA>QEKGZK
MXF@V?SP)1<"-PQ%\4#4=?C';]HMK,QD0Q2^H@$&?]8>=S"TO![%K<[>.W[YT
MPNCD)<$5)L_=6&_QE_CB%NM@$./1];<TD [,P!CUY=69_YE'7R&U<4+;%)37
M1'"!DXG) .W 'F<I8JK^H6)C>M/)+/AX9H\C<H-H/R&;8((O;?>+/1]N_'IY
M76!1IG0P-1U67,+K%RRE.UNPFFX@TOJ#RA)\.<[]7?)5,!S;F+&T3@99._BO
M'Y,N)_T<53$<X+)76;.H"BC;S:OVQ1PQKMJ_%09=\$@56(6EZ-JS87PY_>6W
M*89U>M6$JIM^F]!VPEAY%RSZ#/+[ZJ\G&\20%UCRO$<F:#UY\63[O*BVSX*H
MJ[_C_ 5G_-JO\0MR[7??>ZQZH>CUWW[OJ=__CO*?N[.,M8SUZ8P5R]6>>K7^
M)F<JU$_Y*G\ ? ^1I_%[%]3VUG;'GH(JU )U:F#/XAB&/FRW=GO^1>M:M:<I
M,W@UT^%>S>MPAS/-+8NDJA7:2;\+LF3X?ULY.6YTWOKE_501_%?C9_E+IP?:
M:W\,SPBYZ,-7'W/J5^X"UX()VX49?">-B\GOY'$M.GZ6]::);,W*YYPF=:%(
M;?Z/&_RZ*/8731&S"A_5ZWT_'A6S6A6.N>ZH*V0FW=-BP@L'_2^+I\5N"%"S
M9;U:4[X76^.'1*A,C2V85]93;?=:IEU>W8:,_<QV JIZCE3QWA\3MN$[J7DL
MNN7]^'3<K41 '\S]06YI?#:()R BP!;/^6?]T]CZI=L?#I=*O:^P\D]]S4),
M'=\9%71[((0XZB_APGUJ(ZL-<CBG35796^JWQX?%<:($3G;\Z@H4^5XB_/UQ
MQ64'R4J' 9H-0W6GXU4ROE>9<B' C0GPIQVTJN(ZC4+_IKSP8<9V3^<$[BA.
MC5?S06S]L;7_:J>%6MO1QU,'2ALC[5;N67 GS82;U0UB<8UN&,NO7 ##A7"^
MP<I$;HP4U.2CAX8DIZ.)0?E(C-!7-X3 2VFIE;U;^4YJ<#X8CX8CV\N+MUJ4
M'C]PE'[_<!*E_PC/_;;[]</1)_SAXR[]^^@MWM_^]\G?VY^^'1SMGQS\]1;>
M_8%^.'W_Y2)*OW6^]^8_G;VC_=/];^\^PG\G>W^]ZWPX.CG]^\W[;Q].X1EO
M=NG>FQV^&*6'\7[Y^Z_=KWOT ]M_LP?_[7S]^\V_3P[>_/WI[Z/]SM_;;V$<
M'[[ L](L0G^(\_SIP=8_DJI(I::(8TD05U8BYQ)!.G+'HG3"1KZQR60;*]UF
M^L[["C^FK/I;L/T#(N.:\NU7G/PCQ;KEO*6? [KE=*5Y_W#M'6Y,HM$C@;!O
M"Q#F>-" 7@R)( ''F(M($^R0\]$S+07!TFULKBO/OB!70:X&S/H&R$6H9R;
MS DQW$EOJ%6>6!<CX2%I>QOD>@SYDX\$UL@"K!&=I!52(RL#SR7-$C+".T2M
MLP0G3:24&YN<BC:312TKX/8\P0UKK9T,U@O.N+?>!<:$D8!O\%G4M*AE]X5?
M; &_,*6>6^>1M[GAE! >&1T88C$0H(RF5M*-34EN7;RK8%?!KN;,^B9-YET"
M&]))ZV3T(,BYCLQ**8!5)#>>B.O!ZYK>\D5%NU.($PL0EXACTAA0T:QVB#O
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MF9IZ'IU90K!F-G'LN/+)<B6IXH$:%:7 ; 6U[IJ#Z0>Y0/JK^?KHNU5Y]#]
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M[7F>1OP^()8K'^>590,\\RO+!GCF5Y8-\,RO+!O@F5]9-L SO[)L@&=^9=D
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M<K%_SMJ:X@)*!92:;Y@Y[K3RV.H8+"<!MG3"@3"C"&<D4ED,LV9 T=[D4#;
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MDT6;O'QHNWE1%LSP!0VQ<<!PT&N]CFY0P7M=#HU<7H34Z69!"89>[*:\OSO
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M?8N#?L&GF^'3MP5\DH)K+IQ"3E&#N% :&4L8 N!Q/GD-__&-S2J$1W\K %4
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M+2<L:4ZMBM@ZE9S02I:"^K5UOCG!CN'S4?PD0'F3F+>[EWE?QY'+VO#D*-9
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M]U6U6MQ[R7#"R!BA$'=.(BNP0=[X0)1+L(PRTT(*.N\6E[14H0+ "@ ?J5S
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M$\J4&8B#<9ZT%8E'";@]3QE?&MJ%Y6+W.2?!F')@K#$9=^-$3 >UQ0) TL7
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M#/YL>W4'H+>#0<^W"TT^;@_W[S(;^50FPOM@]N_',2O.Q6^!TH7VF)DM4]3
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MUM5J;7,>"7_$;NS;3N<$MC7?&>5=#/XZ_\!J;?ORE?,^"5!_>:C#OBT\Q,F
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M^ CC#K#[MI8/:3SA8LXX ;NXM*M1Y'Q,TL\=X^QCTS7&#%-K\FQY;YYYBI6
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M#XK;')CNP)$23-W!I#\8C)VA[9L!(VF;+>OLG766E7DPM(.1<+VN/_1P:O0
M6,<;.=VA,QYY \MU1P-0YJ.>?2WK//D@SHH2]</,PTB. <0K-XJ1[ZR%(:;Y
M4\]NKU4K8_X&6WY)3ARKVW@'E_%6IABR+:W\KM5*AALEP]G+%:4JO;%TW:'7
MM4?V "2#[73%9#*&_QH'PAH,91^5JM/[YG+ NVEMV <C_.>M[(>V_VE[X;&+
M7=$*C_T)CV6SPC''$Z]O@47A#L$B=[Q1U^V/O*[I#@/?=VQK-#9;X;%L034K
M()8-KNLJ(O92FCR5QN5JJU5V([1H<[)FB2]:3A1$G%^0#"*5PD#[/Y<Q0?)6
MT*<5F*DWA:-0DSO7P9ZJ"7YJ9N$\32Y#'Y]DA+-Y%'HA&W!-//@B#R-"7@TY
M4<=I.1$9;I*F#.6*/T*DU=(,Y/WK88]ZH$8J@TAZ>:8&.7W!.8WX2Y&K+]1?
M"P^*?/4.!"D6!I6RY#AVD9;CBBSD1W$6L8D;J]^M,XH92$##*])4QMZBP\E'
M(PN!$$1*,9\.?K/Z$TZ*2F;@V,GX,DR3&!^VA'_<S@^_=G[X>//\\'84^-[7
MLH]1X&L',V\Q:/GA1WG_H4L-3D5.T[-:$/(__YF,K-%@-!YU[?X(YWN;7E<,
MS: +^F]D#41?^JZU D*^#U7\NCES>$DA%.50O1M P?5LX'5:FH8!B4S!F6<O
MRJ&XCZ88<^3T!N/-']^VOM&R>K:UW6-O")/M$%&^;>"X-M^\5GOWX"$\DIS[
M8!0BY>?R"QJ:!):_M9GZXY+P;PL8V@*&Y0*&VX4ZU_507*.@=1D#YT;@?-\$
MKT,,5WRD),C3[U0#E?W7OS[__=<K>-_'JS?G?WX]^^0YIU_]Z,WQA_[I\>F7
MT[\^F&^.?Y\N!S5./TVCO_]Z%WW$O7W"+@Y<U^>O9]:' ;S[ZO3KJR]_GW\8
MG,Y>!QC,6(J(>F =VA*#H9XMNH.!V^\*VW.Z_ABNV+8\>]*?8*>:-3#;TH=#
MR-H M]FWRLU\%X ,#RJMC@MY!F\^OY+1I>1!$:VLNC-9M5IMZKBFY0D$C)/>
MN#L8"IRA!P++&DY<RYW O4MP- <@JP8MG,.#2J1!FRT^%(F$%M/Y5=(*HCL3
M1*NU62,'S*' 'W0GCD"$/$MVA>E:7<^S ^$X07\(MPF"R/YVJ/$6(V\G0>2T
MIM%!"2(,0[2BZ*Y$T9J*%M/VQG+DB*[K!Q(Q=9VNV_=DUS(=9P &D64-ARB*
M!J-# J+['FRB86L3'9(H>IT4;23I[B31:B3)'O4M4]I.=P17V!T$(]EU'6%W
M7;AI:^@'MC<4*(F<26L4/6Q%2RHI*]^:1O<ECUP__[*U,#K"NV@ETIU+I-5X
MD3>Q;%O(2=?SP4 :P/5VQXXU[@X\$%72'?G#/DZ$&G8FHW8VRT.*I!K^IT[H
M?XNQ] WYR.]:;.UJ1K7"ZLZ$U6I,R1U9X_[8 WL)#"D05K;5G7B6[/:'TAYX
MD^'$<L!\LIW.>/(XT!2>O&6%;//"P%+>5%X#8OPTK:OGAR:G/L2Z;EGZK[YX
M\-4C*BANA=9=":TWJ]&GT5 .I25%MQ^ IS<0<@SN7M_J^IX_=":>YPM//OME
MU!D.ABLRZ\?6MKIGV^I;H;9:I-T6:?=A)/L&F=[*[CN3W6OB==Y@./2=<=>!
M2\3*KU%W;-NR.QZ/)K;C2$L@=I<U[EAKA/=CA^-=[OM?:0(J&R&8!W_Y+S?]
M::E7 KLDB/!N;+X8FL^V:JW8!WRKV>\9]]R;\3*9S<*<O,BCV'])YWPA8R^4
M&?:I1@FB1!Y(6X9U^EYQ\^Q#_^.GWV?(F6?'T>>SK_B^LQ X#+C[3^=T=N+\
M?0S/_?IAL=R6\??YN_!T]C=PYD7_S5]_VF?'_J=3Z\1^@VT:QY\7'S_!\\ZG
MG\[.?P]./WVPSR[^\7Q76N #=@,;IY<'IM.=],&<&MGVV!E/!L'(&;#P!1J5
M_E%.=#>9>,BL$WN"OYA8PTG?=KR^ZX],)S"7VSA>OCD]/3D_?75V_MXX.CLV
M7KXY.S\Y^^W5V<N35^\W8F$0V:YM^KGQ_7LE]TV@%P;UTZ'?EM!YHD@K&PQC
MU#<1MBVF&;5*N44&S\@RXRK,I^7W#?#X)#4<).F%B,.O="J9\?S9RW=OLF<_
M=JIOPHJ+ /ZC2+$V?^7KI_CU6A=H/@U3WY@+D&22NT[GJ?1@'RC8JM=F>>'#
M%^ ]^J,\#4&YTI-R<$?Q9?C?S=?#H5V&'K:6GD\E];;J_:MF4OR#@+/073?S
M M[&7; E#]-S10I_PP[6B%IEBCD0Q3P-8;U7:9CG,L;'P:MZA@X@&7ZAOL>_
MBYB2X(U9F.5&$D<+//"RPP?WKM>KFUSAE%)#?IG+&!M[PIA:0?V.ZK+%'0(%
MUY:5N* )U&'#L]7C]--2.+]BCBVO>/4^-K'"E^JKZZU*_(>F9GKBBQ"L^M#;
M0IS_ ?N#PS'$12IE,[*Z;_VSN>-:=PN'&5'^ J\D6MF(;D"N6JJ5(LE+HM%T
M71+151A%ABN!>NF/1!1A0!1\-04B]<!D0'KWY:6,DCG^J -<=E' _2?I@KZ(
MI"]3#]@+V"("WDIB["K#UC%O&L(/?>K47M]CUE%]RWF8!<J>)A8-9R0.N-EY
MS4[P+(I8+P]_@NR9@GF<Q+"+A8$\/L/]/#X:/8E].8O# .06'\ACH=435A)@
MIX:Q2!=KU$2SZ7XF%F5[?KBT:?C1)3R#I+*7S*62W.DL0^J_E+&?H'P">LOH
M/TI%A!P2@^RJ*0VM+DA'@8Z82U \J-X4^8 +E>,O2C&)C\N)HB(@Q!SD:I[
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M"+$!7Q%(O464E]2VM JU\YJ^P(>**Q3&24 /75EWF@I%A>H2>/]3 =<OJC6
M?XI<@[8M&A\APG/@WS6&0T<MC6A+]1B369'B&4R- #N(.T1>85[N%]Q ,+UY
MNW5J( P)/GG:9]U0"7D):!BA"TS?J]:#5*)VL[FQ&19U+#WBA<8G9L_8OXC=
MU:*1%RQ6/"E1=AVZDEA#H(Q8DH/6+LT;HI,UY%O28[2\;3 R<H-$<2KG24H6
M_BJCR4L1@8^&RF J&5<FY;?4Y 0*^E)8I(V/B%EH6@-^)R3+VR6S"5>\SOZH
MM>*3KLNTM4V@+D4^3< A(, 4XZ( <D;4&^)#$/FI9(WC4>(&=X16?VD.>:%<
MXOC2]A>5^:],*!0ARVRU>H@M^,L.X"^3S> O.P2_!F7PJT6,V?M:]H$8LY>P
MIOD084T41G3"1['_:C:/DH64O\I8!F'^-H+5'TI0\ZQ,49SVX:_PG7>SL]F?
M_;/C/[_^_>E?TS?GGO/W;R=7I[.S3Q^MWZ>GY_B>):R9KW]:?\]@3;]]M/X^
MQM^>S<[^>N6<?8T^?_QTM/AHP6]GK[Z<?O*#LZ^G7_^1TO&&0%U=:4TLQ-27
MW8DM1MVQG%B^&01"NJ/ED*88VR*P)T"2YF1@C\835XZE+4U_TI\XOCU<#FG^
M^NKLU>N3<^/M'T=G-X0P#\Y06!]4O?$$&@;&E(SF7'SI_AN<+[!Z0?D-^N;S
MSQQ3?)LF0(K&^ZF@\)\/A!E+G\-^(;B ^-8Y$*KQ''4H0NA8_9_5[Y& Z2_F
MSS_VC ^EDJ]]W#0]E*>++I8AF1E WHM PBI3%_0ZV#;>E #NZN^7N'+4V+NA
M:'[CA*#^,C<?\]F\K"T-MZBX.CU5:V]\SL":;P+Z\&#P-1^<VT^_GIC_2-NW
M37LP[(X\Q^\.^K[?=:4?=%TQLGW/&KG]\1BS3:L3-/Z3;%^.!G@AD%)>8CE)
M,()"5$%UBB'CDN.V#THRUMV1S/=,*Y[SSWC@N^.^D-VQBV5#UDATA33=[M@?
M6][8F0Q\WWSVRVK6F2BE1A.5_NV O>]^4F$O"D5DZ*& ^1)F4X29I B-<8+6
M= SBYIV\E*!T0';Y9-^8D_&P0Q&(&:$EL2./4DT%@XGN0,+-BNB"70SLJV#7
MIRX\\8&5U#R*HO52C^/'01&!)W4)"Y4J'HT!LIYQS-F:V^"--@,]ZH7PHQ_V
M.7SM!D;!)' J\:\B7=2_I"OX#J/0X^&MJ$\?!_]@,M6W'+<[&0W[W<'8M+L3
M3XBN/^Q+OS^T'-GWGOWB..,5;B&BV.7>[WQ657OOM[2>C[[\,^P+W[2#81?<
M- _1F<SN6/A>=S@9V98<6<.!.7KVBSUP5N]=)30;AIK*"H27,EKTUM6[;#"5
MO_L@B-6_BR#(J-\&0=H@R$,'04YR.3.L'E@,L> 42&E9H^PMLDSGHX_ *%H@
M$C=L\W69:X -<U:.OO.NRG^\*?,?^_>Q-Z83-H?G&>^5/.+F,0A]#-FT2I()
M&F@,XO)3$;,.I50CBM@B%H5/^5/XV,?(M+]-WH8BZ1RICI-<UB8GRRB35VA9
M<D$2K.3/ OPBH-L%G#^&_3GM6Z1&[<T[OX^,5U 3&M4>9TTIZU+GC<I1W(VQ
MSOCBHS@NR(2FY<!QO$[2F6'VN_^SU?-T&<<5 N^&$5J^^CC?OWJ)SV,H5W/$
MMBTF ,)LXTTUL^ J\;#NW'1I$ZSQ2J1^-TJ2SY1]KP[*%7B!7*/$*1N@@"B4
M0=:A,(G.'J,F52X!93+"^#*)+H%6PNPS)4-5 IA2?;3:+"MF<_I%1Z71L_J+
MP<D0J<])]Y1?U3$2<FA S<)_U]_9H81[K-P(>#JX)?1-RH^^0=+@5+Q.6%)E
M ?H29=%))C%=C_1V2>_GE*@?!H%,RQ04'!VE]_-I@G4X,7OG>3G?.Y/7G>5R
M-E?B8)+(P"(8JF>H2K;X^9G,\7'Y= LRH^19K*X=B0;H:$UV9P?U;!]N@>Z;
M2ZP&D%?[E[0W%5922135*U(2$.X,7WZQ,&;2!]J)V66G4"%\+&7IY%+G%FR3
MZZUJM5B<WP;W./T?21Y\*N:4$X2WY3@D(\?L8UI<7&!I(+SN0L:A9_@I< T0
M<I%7*76@W+"J$X'O2:H5!R(OHZ*8FM3%%0&6KY>5.DB/7I73=8L0J)KDA("?
MRSGG0('Z8U]Q&#],OP?E1PJ2-\1K20N/BC-PKX%2*1QO4.>$%1%3.0OAJPMF
M:"RJ24.98]%1+KUIS.<*@B+'#HE2I**Z0A;&!'-&JSY59] ] I6'![GHOIV*
M=";X:CJ8_ST]>MLQ\!1K%R%CH"G9P=WZ,@,KG+.J A6G462<P@81_%4:\V2N
M(B3="*].;QI8^M\%)G$Y42W*V2)X-]5E5;=$LA1C+'!2^@"%EV(B.B]FJ%H6
M<ZE$W$4"IQ32.D(?A6$ T@KI&D4NG/_24^%IJ,S#>!JZI#6)"M:0%JM&5T>S
M<>UK"!K>>@&& =81<Z0QX]+5FTB,MI$=0A'&3;Q,Y3'ES2=,@SY0+AZE3]9&
M0XC_>GS^OUW3L1TB9/K78&+;5"7%U041<S>K'O)#]74T+FX=83!U)YY7E 0A
MJDJ%!FU4ZT#[HDZZ;AC[VC46M (#?%.I*Q5>I>ZO7=.0<RP,QAKPBS2Y@FMD
MA05\Y<DY_ <QS*O?7K\CGL,A 7/.K7#E.'U\%8(RQ?70%XWG?YUW\3]^Y->&
M^:)B5S(O8"54>1;.D.A4D30I[.0+CO,A8D13B0Y(6R;T;+Y^?9")EEYNBI;.
M'"F0[71=EJ<.N3JEK)B3?J7RC;(*)$?BU@+XMU]/Z>;.WK_\X^42D=-N08$7
MN7HG,#BV</4J$EBYB'6W_C("$\DXZ1@G)_2N$_A?(+2$:]NY_#7N5G\I::-1
M/$C7+*GTW9@"/</)E.3&EA+ML#JN3FV9XC()?2JO%#Z>.[X7?RE*!P@E?_U@
MX[P:"U4_L!N.2 L!K3&C+#$B,H\NM 4($GF]0&[(.[9_ZL>XX9!0_UT*[2,H
M#I-E034F$9?N/T&+4]N-90$HJUP5_%::&([_"'13I,8NL%S;4FB]A#6Y:;A)
M6%E;":O.CB^]4TF)/"SB.$&3WZ]LF5I25XF7):.&&7 \,<@)\[#LDWCT BNB
M2C\@G,N(+GV:)L7%% 4$\"K273$'<P2_5ZM(1UK<((;1&KB2(&)$5B>I  WN
M=5;S06FC]R&6C.&!X'_,.54> [V9@PZ>OU)5EPE29E:X:(;E[+_ _]'FF]HL
M6UVEEPS'#1]BAPE<A&K.T:TS\)P@T'?AZ4K@J@X;O+28:JF!J^G./&")''6
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MPW1>FKA5"4Q;)["Q3L!JZP3:.H&]*ZW-"F@E>[1B#724F^&A%YXMP J<D0Q
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M+FQ-(%484QV#K#(%<I9A*P<_.]-VVKI9OW>@5!^0OW=%XU%A/K)IGZL3_O'
M%>OZ16M=FC65*94]2VZ>PN\#2<95>]8-(QX,%U1Q[.D*<*!6'&'MJT*B\I]8
M8@P205F:WJ(^4<>X(.!9_(4>=MSZ_1O]?F>SW[\#'-[D61LL.)BU/+U@P29
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MQWX=T_IY?]=T1R[>X0KM\R2ORM+6S4';A=#4YK<.:CT2*K2<SG TN9W)NDN
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M-D7P!E@ K'M0H6RXA."7(Z"41F<P""XP*V8JVDE&%FI85*>DH%U899J@=E?
M(%Y21+X!^IQU*D8?+D484;IJ!:W&R)(DEHA)!#=9QF5H21A+HIBJY+=>J>-0
M6VOH$/58CAYMLAXWQX?X;@):_31),JD@.+("D_Q=$")\VFA\>O!V3@1SP$G#
M9JV&G.AY"I=B[7JT,7M-]GM-J*H>8%HC$S5EU.H<](,;,K6S8I^MF&,=%4U2
MD)574\SQ-\ZH83\=.N?^*CU1< 29"D,*6#KB?Z1A]EGA/\0>"",48!1B7(%@
M9=S03B.BL%XU<?QZW76*%-%?-&A6R6<,%@.7LQ3KNTK2SWC^%>=4C-TSWL W
M@H(X/E@356Z$!%4!"[-G%;:MJ(G#KW7PN!E2)U),DM;#(VT,\=ZT*&4A/1#T
M'8Y+4;4,7X@&T\E8=VAJ+!F7:9)X]9I2&@1'4Y ]&P,E-WG);2'-N"VD:0MI
M6CGW;7).89#6TEQ)D1.T(XFWTEY"G"Y8RD8KJ8T'// U5=G$>C!^DVVMW'U,
M1M:]?78+UV=IEAW[-G[[X!=.V,%L6=:3];5X3AW#<B6TVPS[KL1RFE[&C7Y0
M,\"K7:K5Z&Y+& ]#&,T+K;R?[D4J?%E>((.28CX&\34Q]A&30*\% &O)M4B
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M>:/EC5MYVBUOM+SQ/?#&;3SUEC=:WO@>>.-6GO[C9X[[&939LEC+8G<4;S@
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M;$B].9M3;S^YB;^ _YGFL^B7_P=02P,$%     @ *8*K5.M8^!UI"P  J6D
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M$62RT7J3'&=]]@'>CFM(/KD-6VX.B[?62],(^&H,<!T\9GGQV@?(@7(!A5E
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M]_;?_&OWY9.]_W[[['4-S[8(-&_[NAXQY=KP&X6/MUYHGYE 1GH&2C-$W0]
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M>]Z@>LXR+3.MG?[RZ*S(?WSX'9K81QN@1S555*9,F(F42)L#<48;8KT(@=+
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MD91QQ@57$2!4$H"HQ #'"0=2(44S;<%GQ,I-=.CA8Z/64KZ@%#"H)+1CUH/
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M0B*4E!%WVORV#S<ZJE]+>Q$8><M*#F4]CC/Z$[8#;LG"WF#LFU7/0]"=(*V
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MH!T)SU4)C@PV<$F"=I7WZQ&<N+[K:?65-,^<W<R%_/&_Y?-$(1XSFDF@<,H
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M.@.B<&5E44X!SUVRC=V>&)07FJ=> ?$QA1K;BE6*F'RK97258*V092KFUS+
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M:;OZ@[EG(]9$N+I3V)-]&U7HQ/_Y+K$:N+,AJT-4DL0NX,5F30R286@:Q2X
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M>0%9)4^6<@<<D/F![G&^&!W*GNW"912[I/7ZP1EP[A@=UH'.'Z^8I&''CT$
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M(W)1K5VH#(-:OHX '5K!KLUTLXB_3N=\+J=\MBOW?O_G=#6A.E<(YCG0&4&
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MG<ZIC)L"Y?799)9IPX5P?!/&.M%<&\"@4"#%DBJ4XZ*@08>_1SV,;>EZU?F
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MKE=K)WNU=3Y@O/Z[;7_]FJ_U-BMEHD4AM8#"6EJB #$R TR9 A@.B5$00OM
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MU/BYA$$@135-?CT/:I>"P#@T2F$O=\TTGJ\6LZFJ8J_LO^3+CO6+%QE),6<
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M"/(-!LC0_^3ZV#+K->CTPG:#)[#TV]I=AU#/2W%#N!X.WL^K'G7;=**;0?=
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M>,ZE:'YM;^V__O5?-C^Q?SCY_O5?_A]02P,$%     @ *8*K5'MT.K<<5P
M<@T$ !4   !B9'1X+3(P,C(P,S,Q7W!R92YX;6SLO5F36TER)OH^OZ)NS^OU
MKM@7F:2Q+"XMVK!(#LEJ2?<%%HL'B=N9  4@V:1^_7@@]Y5(X 1.@))9%9D)
M9I[CR^<>[AX>'O_XO[Z='/_R%1?+Z7SV3W_B?V9_^@5G:9ZGLT__]*<_/KX$
M]Z?_]<__XW_\X_\#\&^_O7_]R_-Y.CW!V>J79PL,*\R__'VZ^OS+OV9<_NV7
MLIB?_/*O\\7?IE\#P#^O?^G9_,OWQ?33Y]4O@@EQ^U\7_V"L0BVS .X* V5S
M@<B]!FD$S\4X%XO\?S_]0XB8N:9_I,\TJ,@CN, +\&1]B849P^7ZH<?3V=_^
MH?X1PQ)_(>9FR_6W__2GSZO5EW_X]=>___WO?_X6%\=_GB\^_2H8D[]>_/2?
MSG_\VYV?_[M<_S3WWO^Z_M?+'UU.[_M!>BS_]=]^?_TA?<:3 -/9<A5FJ;Y@
M.?V'Y?K#U_,45FN9_Y"N7Q[\B?H=7/P8U(^ "Y#\S]^6^4___#]^^>5,'(OY
M,;['\DO]^X_WKVZ\,AZ']+<\#2?S65Y]QD7X@J>K:5K^.<U/?JV_\.NS.<'C
M7?A4R5\_;O7]"_[3GY;3DR_'EY]]7F#YIS_%O/H&5<],GA'Q/Z]^^=<K>KXL
M<$D06O/_FCXX?T9]VS"TX;<5SC*>R>#BK<?S=..'CJL&YHN+WSPFB!VO/YUD
MG$[63SZ*R]4BI-7$"E-"D :\8!Y4T!%\J%\5H470I2 +-T51V5@2'VN%+3']
M^=/\ZZ_T8%*<X/^AZI=P]N5:3G=>>2:O[6A_,5M-5]^/<B8Y+W'Y,<1CG/B<
M/+/%$$*4 "6< )^"@LRR]=:YHHO?F87[WGR3D^NZ/UJD7^:+C MR/!>O#HMT
M!P<W07_^$[]^"0MZ$*3/T^-\\=O5 PVAP]5\0&F>J8S(_M,OQ'W!Q0+SZS.-
M/<CDFL,5N65<_^2 :#C_XB/]YM&WZ7(2HV6YV (EY;58 @2T$NAC';1W&D49
M&A>W:!@/(;OK]F&@["+HD2%SC?3G\Y,PG4V4(C/)&B&(D$!YK4@FU@$*DX,W
MV>4@=D;)G==V XR==#D?2K CH^+E?'%"_O2,A=_Q).)B(CTZY6T&5#R 8D)!
M-%F"%-X4Y5U2C.V,BWM>/!XR=E3A?#AY]K6N4""'KU9XLIPP9T3F*4!<&X=!
M!]Y:!J'X(!-SWA@[](IR^?:-@"$.;2W93K@C ^0B5:RF,LE:&JV=I!0O11($
M1W!%6A#&(',,O7%J9U!<?V,W:\>6NIL/(,A. /!_3L."GGC\_3U^F2]6$^^%
M#XE2>.%H"56!43*O:D;/4H@^J<*T' P+MU[>C7\8#A:[B+<3A+S#Q72>7\SR
M\[!"6@2ST85+P"@SX;PP<#)IP,1"=)$R-=P]V[[WU1NA0QX4.K87;2?8^+@(
ML^6TZN <W\ZXE(22P#&01"@.)V&0@(1':8LWDI?=<Y&'WKX10M1!(60G 7<1
MA+Z<'N.;TW4 ';+FAC .TGD">)$>0O8&C(K6!EMDB'&@X//JK1N!0A\$*'82
M:!=@>(^?IK7D-UN]"2<U J>T25,*)1S7H+0HX$P(ZV\Y_9]$V#WPO._-&X'"
M'! H=A!L%\!X-4OS!3FXM0X^D"KPV?QTMEI\?S;/.%$2,^7QE*1QCX1S)B$P
M5*"5U;9DH[#H@7#R*"$;P<8>$&R&$WL7*/H8OKW*),EIF9[MX)W[2:FEDRP5
MD)F1.2!%W5&B!G*=-F&)69FA_,P#)&R$''= R!E"U%U@YEPRYW]5\?")S%'D
M$AA%XH& [\ESAD#K*A,F&H8Z(0X5J-SS^HVPX@\(*[N*N"></*,OWRX^SO\^
MFT1*S'Q"0^NKKT+AB?*U8L!'Z5 K<I)A]U+) R_?K(+&#@\D6\JW)XBLU]&W
MBW>+^=?I+.'$<:LR8@%;E"-F3()@68'D<V*FB!S$[OLPCU&P&5@.H]XZF*1[
M0LR[^7(5CO^_Z9=UV.54L3G&!+$$16%70G!6>Y JL^10&NL&WO6_\?[-T'(8
M9=B!I#PR5JI//%I@6-.=1522: .I,U;72$&YT B&Q:2,S.0FS<[HN/[&S?!P
M&(77K24Y,@)J1^+QN\_SV67EQT=!5%,NYHEBI0I"5#Z"YP*Y8EZ9L#L*;K]U
M,R0<1H%U)XF.C(8/F$X7) XNXL?IZA@G)NB8:X\NPT1)E^3$/S.4MT?ZQ<@#
MD[@[&FZ_=3,T'$9E=2>)CHR&CXM0.\(_?#^)\^-)MD2Y41PDPPPJ123"90%O
MN.,J.292VAD*-UZY&0X.HYBZO2P[<0DOOJ7/8?8)UU5@JU@4@0?(41.(C380
M3+:@<DI>ZYR1[9Z@WO?FS2!Q&(72G27;1:+Q['11)7>VB5@13NHX74X4T]$Y
M'6K,4ZJ;(X2G;" SI04&5.3]!DHU[J=@,Z0<4F%T $EW@9A7,WI:2*OI5WP>
M5N&<K4G(Y!$9E\"*CA0T<PY1RP12IJ YI4U9[;Z^/$;!9H@YI/+H )+N C%U
M8WKQ+*SPTWSQ?<*YLS&Y0.3GV@OG-#@?B'SN$M.Z2&N& LJ-%V_61'9(E='M
MY=H%+#Z<A./CWTZ7)(WE<B)<3"()#Z)$"J=ED%"S<,@2A98Y8BI#;:W<>/%F
ML#BD&NCV<NT"%B].</&)UL>_+.9_7WU^-C_Y$F;?)U8&I8WD4'+MH%6>0104
M?%ON1%0V&^Z'VE.YEX#-8')(Q<_=Y=P'7+Y=M<*=M4U.-$7AF*,%3MDZI6=6
M@-/TK1""\2!<XBD/A94[;]\,*(=1%1U$PEV@Y,-G/#Z^P'BT-@G-%'!I JA8
M1#V7+L%8;5(QFB4YU*G:Z^_=#!F'427=4:I=8(((/ZG-3?/TMP^?283+MZ>K
M>N:_%GHFJ'50WB-8SRE]5P+K.4%%P95"7:*TP^W-/D;'9I@YC%KJP%(?^[CM
M"<YR[<1^>1P^3:(0SL3"R0VFVI<0"D3I.05=7ADN*,8:(*FY\<K-D'$8U=7M
M9=G)<8>7TV7=-5HOCB_IL^5$%C0Z!@NT5)(HF&'@ZI:B,2A]CDD-46)]\/6;
M@>,PZJS#R+@KH/P[AL49"UQP8Y.5P)DCAQ?1$.J# QDC2JN<"WYWO_' RS<#
MR6&46(>0;Q]!"3&Q",>O9AF__6_\/G&R\$CJ!,$Y"81\(ZV(.0']KG+*2/*5
M@\4A-U^]&3P.J9ZZBVS'[O0YJ_U>P?OB;&!)UI84:;%,V8'RIDXT4!$REBR9
M\#)(OC,^'GK[9B<O#Z.D.HB$!T/)/_YZ1Z3$XM^&&P]&-C!;8J8OEO/C::Y3
MX7X+QW7@&25UN%K^,0NG>4J?WF1MTP%BFS^^T8BQ+?G;<0C9Z1(^A?!ELNX_
MK>O1V_)R.J.W3BERF9^54"YG6R$/6A<"*>K:Z:ZMA5BB!F8R8TX(R_"Q=LX2
MEG&-HO.7KNWW5SQ>+2\^69LQ,'X^7.Y_/H6Z;9W5Q3N.R"I7RTM>4W+)"*X@
M"5_WQ9F%H%B&Z"T3!5/4X;']Y.UYO4G'./,EFJ'BPG\-(/01U[>;U)_[X4LF
M#/<H$W>@$W(*\C4Q(:( 8TE(FIDD'\VL=T7.+7+&!= N^KT7*KL(NP/$/ O+
MST>S7/]Z\1^GTZ_AF)A9'JV>A<7B^W3VZ:_A^!0GW$BCO)!@=:IA7JSCF;@!
MHXW6J)1(CXXVVAY!&Y'7 Z)V@L&\M4XZ -K1US ]KK.A7LX7'XBC\]ZO*2Z?
M8UQ=?7?1HB$L+[904J&K["B92."+EI!UE)SQ'+EO [DG$CK.8)UVX&NIIPY@
M^&Z!7\(TO_CVI0:W9&5O:_A[0XP3%%%G:VE1B":#DCJ PU#[A+P-UFC%PF.;
M6]M#;P/BQIG4TPYN0^NC XC=)#[(B(I9#@4+D<R\J1620+DOA1[)9*WC8T.=
M!@J^QAG?T]!+;2WC[0$R7X7C@7S0_ LN5M_?43*](LC71?Y+36K>X&JBT#.E
M0@$A4STK0V"/R 0IV'J+P=?Y\(V<S\-4];#(#1*S#R;Z#OS,>R2!3-,*UY'B
MF_DLG9M#)LO) ADMQ,'4XU8>O,8"M!QS8;7UP;9Q.0]1U,.B-0A\!A%Y!]!Y
M2T80:@?]:PQ+?%_OJ7A;_J#UMXIJPK-!*QU",,919E$W!9.GD"Z%7!2IWF";
M>L&C9/6PA T"HN&$WP.2KL*U:^80/2WI-I(GU:Y.(*D'/DLVP.E+XW5D*+$-
M@NXC9YPQ=2V0L[.P.T#,&?T3K0V3P67@B$2UDPH<*140G6>6\4B":!@7CS.E
MKED5\DGB[" $?CT-<7J\+B10%+9N9?L\/R:A+VM$MOI^*1K%'>=H)$1.VE0J
M)_!<:= ^:@R&N2#:E($VI7#<T+CY?D@3177@A:[Q=3LO]887SE2=$"Q<G?Q9
M**J+&5PINF"6PKHVGNEAFL:M<+?!P,- VT4A'4#K**4ZZ''Y+GRO==3+0FE,
M3"9%M.NL0#%:J[U$XB**8(K6FK-&NW#WTM,-I';2]NW%<'?1]P&@Q2F]]8Z,
M)HF".<\S@LLQ@I*Q3H"4EN(&9PLJAEH_-@)\)PS=3]*XRU\[& V@@ Z0= \'
M@N6"+!DPK%X\B;E X)1I)LR8RGI,S[Y6MW'+0HVPLZ/(.XC-;]8G+OCY?BWC
M3"P'46\K];9NPP3*,T(,&@ICJ(P/W(?'.FJ'*A#=0UHW[JA=H#2L>OIR4A,=
M8G*J'D7PI=XI%@6X1/Y5>UD2>N3RT6G2@WBG;MS27H+M)XF\ ^]4#[]-5R?K
MCIA9;4ZMIH"4^!(KT46O$#F$.OUXO8'CG,V@>52>H9.LM-D[>X2H<<O6>T'3
M4"KIP!<](B'&K+*IUDY2+<RG1!+R=5'/6$+T1LA'KWS<I==XI]I3L\+V7K U
MD$(Z@-:[B_>N63KKX;,^%>E2O05>!%#"! @2/3 OO.;&9&5:;?;?(6;LQNYA
M]'RWO6@GH7> FVNGO<_HS[E8;0H1+)FB!5MD",ES\#)D<K<Y1]NFD'2;DK%+
MWTT0LY.X.X#+4<[KZG\X?A>F^=7L6?@RI=AK(HU6SI/7C=K4;BN5(# 6ZQ C
MF0.7T3;:2'F H'&C[$;@&4+X/6 HI=.3T^-ZXFN]Y5SGDRSP,\Z6TZ]8[S4Z
MP=?SY?(-KMZ6C^';).K$99 )$FI*(8Q"<$A_<,Y*T5E1Q->L+/D40L>-Q5MA
MKJ&R.L#B>UR%Z0SSB["845JQO,;N<RS3-%U-DL^6\R)!8+VJC[$$L<X8Y\E)
M$Q(W(;>)HGY,V[@1>B/$#:R2#D!V5U 3JT)BU5'+FKDH4P0E+;$ RQB*4#%H
MT::%Z2XMX_:J- +1CB+OH!+UH_R7$@TO420$&Q(E&JS4R#$39T499(+I(!X;
M+-"N=V5<0.V[PKF[<@8#6S\S"=ZM5?49Z0$4B]_@<_ !!3??-?:T@D<XW^?H
M@BS65_$Q,"F1[^11 .62II8B1$I98VP4,^]C=,'-L@M)_.UB_=J\3JG?X6(]
MMVX2A)'*%0VY\-KK+ 6$G#AP0_P'PAI]M(?RUT/TC5T1&QA%C]?&!E%2!Z'<
M3:[.YB,>G:X^SQ?3_\0\D:S$Q(,"JTLA;K0$'S,#%W1ES6C&W!X@=YNNL4MI
M>X7:3DKI%&+71W 6;[Q1-?G1EC+LS!!"< A1>TJ'6)(BMMG$_@%A8Y?<1@#9
MMFKI%&6OELM3LA=D%* ZQR%SI^L%OPD<6@=&46ZMM:*8>7].[(RFL4MK(V!K
M"V5T *MK^QL/+OG>.0S64R*>ZGU]TE(BGJT&&4J)3 3G\V,720RRP[134-:P
MHM88:$.KIR_$W5GYO5!.&I,@RD(IOB2F8@P9>!!"<(5*Z#89P"-$C5UNVQ_"
M=E)'C\@Z=\FZ7C!;QU9J3S)2S!DR$%00&4;Z/V7'V@QP>8"@C1 U^"CI\1"U
MA1IZ1-/UX-%F%-9K"T:7>@>0KX=LG0*-K'B.+EFW)T@]-: ??/KT>+C:5B$'
M/5/V4LS+>3GO_:9_#;71\MI&;]WB'7[@[#;OWE]]=V?)#%_O/=MO/[I%POFG
M%S:AB[)2!0NI: \J* \A&@^<NXA1<HZIS1&<)Q(ZV$&2\^E>5P?>L41$6PH(
M'VLJKB+0!PJXTH85CEEAF^+W@R1U4^L='$$/GA_922L=K-?O24=$0!V5^1R_
MXO%\/<CIG*M)$EFENM(PS*)>'LS UYE@,=4AY$DD9]OLWS]*UK@P&TCU=X<B
M#:2'#D#U%YR1C(Z)EZ-\,IU-JWSJ[;$7[# OLF=!@HE)@E+UM(SF]=8#$V7D
MSO#0IC3R \+&W4!H ZPA==$!M.X(:2**3;%8RJ]3J,+)#IQ:-Z9CIL LAB#-
M?I;!<;<&VL!G-WEWT&!TR<!5%^>$\N8@@Z6EWLL(RFDD%B@&2"86J97R.;?)
M0^\AIIM-R_W%3%MJH@<PU<3J4E!W#,U(':2L6["ISH^JIQPB$X:2=5ZO?(F.
MI3:%V,?IZF;+LCW$AM-/!VO=J]E77*Z/A)ZQ]&8^FU_8T*2@$2R4""A$/"O=
M^.0<H%>2G'*4R;2YR>0QJD:.S ?4_KR1*CJ U5I,UQDX8^DB(+3HA<@F@I"U
MZ]PZ!HZ+NGW!I7*.> V-XJE'Z1HY-F\'K0'5T0&X'F:$"QE+=)1CR#JIO%[3
M[9*/8)WRVE$,JK#-T>_=(-4N7F\'J6&4T$&\]097UX+%5(H*.0O(D@2AD(S"
MERPA1S($+HS.CUY2N@."KI/139-.\VAJ>^EW )V+<U47#1^_A>4T31+74CBB
M7W-DH))5X'E6$(5B6=5*B&V3^=U+3C=M.,VAM+LV.EC;;C/Q?'I\NL(\$5$+
M1_ '*:2M6_0:0J%,EM9G\JA6>I[:E#,?(*B;WIN]PVH;C70 K'_%.K\>\]%7
M6K0_X9O3DXB+M^7.?OVYU;"D3:[EO"AH(8^T? >;.0C%K1,Z1-OHT,N3R.RF
M7:<Y"-MIKU]HGAO:W8Z2&)S2DM7]@WHB$(,''PU%L4:*HG-,++0YKOE$0KOI
M^AD+GH-HL . WB.VBRD-E^*C7)FO+R'BSD6RN9+!&PI=*88-*3F5<R./N0%Q
M&P%Q\-OMQP#BT)KJ 'PW,R179'&H&"1=AQRAKQ..<ZI'K8LVB?[5-*IP/#D_
M;5:#'5S)C^:D3Y%X!W#99+3,N_EBK:O5:C&-IZLZ@?WC_.RX]:4 '4HE-7.0
M7:A5'!U(@!(A$?.^,+1&M#D;-Q #X]9R6T-T#"UW#NZ'[\,]RO__Z=G&RF]8
MY@M\C^DX+)?3,DUG@+C\]ZOA2YIL.WNI(:=Z!M&E C$)#8IK3-&22PAM6C_W
MQF('^VC[!O 3C&@\-'5@9H]XKXDO6L>4/"2O,JCB'43//!A+?UICF [-1C<_
M1-2XFRRM??U0VCCHX3C7CQ#4*SU?'L__WO@<Q3VO&>?(Q(_X'?YTQ.4;K_K[
M%*><C&E @BHH)0(X931$I7@N009LU*7]&%4#I%;UF>\6\Z]3DM]OW_\@+;R:
M73:1':75].N9T[^00W'<I*0""$4VK#@&B%$S$$B&J"2J()OM#SZ1UFY.2NR&
MIGNRLY9*ZV#YO9E_*E%,JJ//3$BB7A@I(*AZB6@I7&@A$\GQ9\_X6^O\T0+
M4Q30 7JNQ9\?YQ2<SF=I>HPW6/HX?ZHTN>19DB! &Z2P-5"L[9248'7F09)(
M%2]-0-B"FW%+ WO&\NAPZ, D+MH!<%UWIEAKK>R)X%9%60R8F"DH3Y&"9YXT
M%(6,1?1:LS:3UN^G9UP7.SY.;L^=W5UI'4#O.=*;T_2,]L1#E%$Y\+$>DN$I
M@DL\T\+BB])*LM"HG_HZ%>-ZO^Y@MK6".@#7G8YQ7!V=U*+9?Z[9J1NPR_4]
MJT>S_&Z!)]/3DXDH**)6" 6#J\<\$S%K-?BL$MF/45&U26"V(';<NDYW4&VM
M[J<CVI\A>H:?:LWBX\[ KE6:R?MKAY*=*HS^(X-DG)&X<H!@@X$DI-,ZN%!N
MWQAPM]!S^Z'C-M=V@ZJ=9-V!\[LXTY!(5C<;T)-0JO!,;CN% HI9#S$5"I<-
M^7">?(JV35SW($GC-N%V [EA53>^N[IRS&E1[WA]CF=_7Y/<^<5"5ZF<I7S-
M8 $98JBS30VXH!ADKR6SI2CEV[0);4[CN*V]W8&UD7([\*!W.:.HX4N8ULMA
MUO2<6R6%$VN+/5HN<;6<V"29#CH S]J<W?80'&5@P5MC=5$1>9M6].WH'3>M
M;H6>'X)T<%7NZFY;>=J+M>3\:O@SQHK,(6B7ZF59)$N=! 0N/>2$,:)&9AI=
M,+PA@>,FX:.!<G=E];SH'Z5U]K5\%[ZO>U46(>,DH \V.PE9)PZJ3C[T6BA@
M,HM@M-/*M=DXW8R^<5/LT8"XLZJZ7+Z)J\4IT7'C2J6US5V*]?J%\@99%ISX
M%9'7;04KR?$S^M:4))&+Y!K5OW>E?-P,?DS0ME+OB'!>UR$>D>GK^OUUOH@)
M;URF]-"P7%O^*)C/%-L;%DLJF**1MUHS'Z@)/>&EXR;PC1'75 ,=.,K-=UPG
M% +;6,\(,U.'(!:5(;IZ'ETYHRM\T+29KK0YC>.NV/OOQ&BAN@YF!SS V5F-
M_P9GS^8S^N"4/KN:G7PUMIO;D%3AD$HMVB9E(7*"5V"%:V%XT:7-#3/#T-_-
M9+J]]*BU5&X'?I:"Z?.ZW5'ZC]/I HE_8FKU_=UQ6&]*U1L]US-G)\K2JF2L
M@^)#!%77JN!IF4(EC)?&,92-;M[:F,8N.]Z:(NCV54IMU-E/!D_\),2\?$G2
MKV<\B*7?PZH>\_C^MCQ\ &3B4XS""0<B%TDQEJ65IG;>2VNQJ/45+&VFEVU)
M<)?];GM%\AX4W:/_O6H86$ZXXRH95T KY>I4+@<1/:<0GB)WX71*L<U4HL>H
MZC*6'=7';JNR?KSJYE*=",N#9ME3R(X48D533R])!<D7+[*0Q&6;0Y:;TSAN
MJ:D#A#929[\9V/D521L+U_N< W,,>/**TELEP9GUJ+%<N(D8?-DKB)](?S>#
MF_>2@;54;@\1P+5 I][M1KSBQ92H/V9Y/0N4A#W]6D.@^QNL:W"_I!\[/JV3
M>M9W>KW]LA;*)$<>;"3GP70B87AI(20GP,B4L6016:/;^IJRU66>UQ2GCT3'
MXX*F PO:7!\33>MF\DP DYJ27B8%N)+J8!C4S&(,>'L?8N^.O\O,;Y_8;J3.
M#J*7RE;]OQ9AOE+:2@G#>XK(%M-$T7S]!S+6FQ]<^\EWN)C.\]TMGW,#?O$M
M?0ZS3_B>%N<7I2 I(;HL!5<<T%& IX1SX'UA()'T87*.QC<:^[!7/KL9O#QL
M--0Q6 [=E";,4-ZCE ;+&#DEZ33IQ7MP6B<L)CGIVQR-W8GL;L9"=P3T)ZER
M:]Q^69L326"QZ@"]%D-T)82:I/-Z-1N'$) L-UM>"F7LF-O,4FV/WGU,G^X)
MO4]1Y8[H?3$;IIUW)X:ORELN.D%)!AAOZ@PP1Q;K:XJ16$[TCUKP-GO@@Y#?
MS1#KCK"\E6H[R![/^;K-#>4@B\5WBI7^&HY/D<(C#)2T4&24ZW4[.5"FH7B=
MX>4C1V=$M&V.X&Y$WLBS7?</FWN .ZP..P#F39%==>!/DBZ,S)P"'2R!DNNL
MP-74-R<N$DE/%&RSE_T012//;1T=?H-HJ@/$[1;+%,&CRLB TL9Z%EFQ.@-<
M$8Z\+-P9&1J=FF@?EK:;0SDZ=O>G\TZJ!C5<NCS'?+$A.LOWE!?K:(;C^?)T
M<37GOFAODI"Q+AR1##I*"))YB$59BT(;$QK=&+ CY=W<:S%\Q+HWA7;AH=='
M!]8G0_-T19S4+9RZVN3?3E=OYJM_Q]6[,,T3F9@LMI EENQ F5#[4#" Y2[5
M0I]DK:ZVV)#"\4/6_>'F#F@;*+$#<+ZO%\J\+7\L<7U(]&U<A>FL;MU<E)M?
MSA?W'U#Y/I$.407-P&0*E\CR&3@;$F#((6FIA?%M[LC8@>CQP][1(+PO50^&
MZK'G7Z_WUS_/CPD3RQI K;ZW'83]V/O&F8B]L02&'XU]]]671I"4,SDX"]IZ
M"4J0GW44<4"R3$4=>"S8IB%@(_)V'J)Y\9*/M5EZPH@6GY, FZ,!LG()408)
M%&9I3$S'V&C"PDTZNAER/1 N[DS!W%[J':SBE]2?2:2V#,UGZW3SVW0Y\:4D
MZY('D92BA"]%\%;5RW]]#BPKID2;?K)'R>H$45OH^R'H["S\#I!TBX?G\Q,*
M$B8E2I92O66<U:OB#!(3*@B*/5#9DASR1F6B>\GI!#F[J_OV#;@[R[X# !'Y
M%'"LO?3O6*^GG*#S2>@2@"E%,6NA*#(F9T!2+(G,)9)4F^7Z#BGC F< ]=Z]
ML68'67< EJ-,L22)/QS7W/G5[#S+/F?&FYQ]0@O9^CJ"6B&$(FE1MT9*M+S9
MW6"/DC5N!CD\B(;300^ 2NGTY/2XYC$/W3IVSEB)AH4@:)TO@E;\P 7QY#4D
M+(R)D#*F-A,H-B9QW%V.!D!KHIL.0/<>SRHI%S?8GW.1#!;OBZK'6.ME=+J
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MD#Q+XL6;8-NTA6Y/\[B93#?0W9/2NX#WXLM\$5;XV[S*_.)6K7-F0D)7O/+
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MPQ["=M&[/B_K:L0=B0P^FVW3%^YQ9-M6,NACDIM!:74=7I%X<J!LO9*% G]
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MBRV#8.*V1QM&_(=R9O66Z:Y;;[<ZBGK_@_;A;NZCN;73D<IJ9T,$^M^#(@2
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MT>E \X!3Q9GVP#+(,%4&K47X+&^2>ZTV-@#3@1PQL)\H@M%$)1^M((P.\>4
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MU_;HSC"H^0WJ[_W' R<K8.[Z:#,-^>=").+2B-OY6SNUQ.Q/!#.CEE>M_EI
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MF8C_E0IP'UDGC7V\2=GZ_T'R1XB<=@AR%.2Q -#98[R]$/ %!Y1D0F5VH)L
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M,#(R,#,S,5]D968N>&UL4$L! A0#%     @ *8*K5/^IA1V[E0  I'P& !4
M             ( !@I8! &)D='@M,C R,C S,S%?;&%B+GAM;%!+ 0(4 Q0
M   ( "F"JU1[=#JW'%<  '(-!  5              "  7 L @!B9'1X+3(P
M,C(P,S,Q7W!R92YX;6Q02P$"% ,4    "  I@JM404!1>:D*  "$0P  '@
M            @ &_@P( 8F1T>"UN;VYX96UP;&]Y965D:7)E8W1O<F,N:'1M
M4$L! A0#%     @ *8*K5%T)=00D"0  6S   !4              ( !I(X"
M &5X:&EB:70S,3%?<3$R,#(R+FAT;5!+ 0(4 Q0    ( "F"JU3",KQI#PD
M +4O   5              "  ?N7 @!E>&AI8FET,S$R7W$Q,C R,BYH=&U0
M2P$"% ,4    "  I@JM4V5C<.8<%  !&)   %0              @ $]H0(
K97AH:6)I=#,R,5]Q,3(P,C(N:'1M4$L%!@     *  H GP(  />F @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
